Appendix A. Literature Search Strategies

Last search date: 3/16/12

Search Strategy: PubMed

1. "Menopause"[Mesh] OR menopause OR menopausal OR "post-menopause" OR postmenopause OR "post-menopausal" OR postmenopausal OR climacteri* OR perimenopause OR "peri-menopause" OR "peri-menopausal" OR perimenopausal

2. "therapy" [Subheading] OR "Therapeutics"[Mesh] OR "Estrogen Replacement Therapy"[Mesh] OR "Drug Therapy"[Mesh] OR "drug therapy" [Subheading] OR "therapeutic use" [Subheading] OR "Hormone Replacement Therapy"[Mesh] OR "Complementary Therapies"[Mesh] OR "Estrogens"[Mesh] OR "Progestins"[Mesh] OR estrogen* OR progestin* OR "hormone replacement" OR antidepressant* OR eszopiclone OR clonidine OR methyldopa OR bellergal OR gabapentin OR pregabalin OR isoflavone* OR "red clover" OR "black cohosh" OR cimicifuga OR "st. johns wort" OR ginseng OR flaxseed OR "vitamin E" OR "dong quai" OR "Dehydroepiandrosterone"[Mesh] OR "Androgens"[Mesh] OR DHEA OR dehydroepiandrosterone OR "androgenic agents" OR "androgenic compounds" OR androgen*

3. Subset: Systematic Review OR Publication Type: Meta-analysis OR (“meta-analysis” OR metaanalysis OR “systematic review”)

4. Limits: English, Human
Added - (1 AND 2) AND (“meta-analysis” OR metaanalysis OR “systematic review”) NOT in previous set and in English and relevant = 31 additional nonindexed records

Vasomotor symptoms
("Hyperhidrosis"[Mesh]) OR "Hot Flashes"[Mesh] OR "vasomotor symptoms" OR "hot flashes" OR "night sweats" OR sweats OR flushes - + (1 AND 2) AND RCT(pt)/Eng/Human

Sleep disturbance
("Dyssomnias"[Mesh]) OR "Sleep Initiation and Maintenance Disorders"[Mesh] OR insomnia OR sleeplessness OR "early awakening" OR "somatic complaints" - +(1 AND 2) AND RCT(pt)/Eng/Human

Psychological symptoms
("Behavioral Symptoms"[Mesh]) OR "Mood Disorders"[Mesh] OR irritability OR depression OR despair OR anxiety OR “difficulty concentrating” OR “over-reacting” OR forgetfulness OR “reminiscence lapses” OR “mood swings” OR “temper swings” OR “emotional flare-ups” OR weepiness - +(1 AND 2) AND RCT(pt)/Eng/Human

Urogenital atrophy
"Female Urogenital Diseases"[Mesh] OR "Urogenital System/pathology"[Mesh] OR "urogenital disorders" OR ((vulva* OR vagina* OR vulvovaginal OR urinary OR genital OR urogenital) AND atrophy) OR "atrophic vaginitis" +(1 AND 2) AND RCT(pt)/Eng/Human

Sexual function
"Sexual Dysfunction, Physiological"[Mesh] OR "Sexual Dysfunctions, Psychological"[Mesh] OR "Libido"[Mesh] OR "female sexual dysfunction" OR "female sexual dysfunctions" OR "hypoactive sexual desire disorder" OR "sexual function" OR "sexual desire" OR "sexual satisfaction" +(1 AND 2) AND RCT(pt)/Eng/Human

Quality of Life
"Quality of Life"[Mesh] OR "quality of life" OR "well-being" +(1 AND 2) AND RCT(pt)/Eng/Human

Harms Search

1. "Menopause"[Mesh] OR menopause OR menopausal OR "post-menopause" OR postmenopause OR "post-menopausal" OR postmenopausal OR climacteri* OR perimenopause OR "peri-menopause" OR "peri-menopausal" OR perimenopausal

2. ((("adverse effects" [Subheading]) OR "complications" [Subheading]) OR ("poisoning" [Subheading] OR "Poisoning"[Mesh])) OR "drug effects" [Subheading]) OR "Drug Toxicity"[Mesh]

3. "Estrogen Replacement Therapy"[Mesh] OR "Hormone Replacement Therapy"[Mesh] OR "Estrogens"[Mesh] OR "Progestins"[Mesh] OR estrogen* OR progestin* OR "hormone replacement" OR antidepressant* OR eszopiclone OR clonidine OR methyldopa OR bellergal OR gabapentin OR pregabalin OR isoflavone* OR "red clover" OR "black cohosh" OR cimicifuga OR "st. johns wort" OR ginseng OR flaxseed OR "vitamin E" OR "dong quai" OR ("Dehydroepiandrosterone"[Mesh]) OR "Androgens"[Mesh] OR DHEA OR dehydroepiandrosterone OR "androgenic agents" OR "androgenic compounds" OR androgen*)

4. Subset: Systematic Review OR Publication Type: Randomized controlled trial OR ("placebo-controlled" OR (placebo AND (control OR controlled))) OR (observational OR cohort OR "case-control" OR "cross-sectional")

5. Limits: English, Human
(((1 AND 2) AND 3) AND 4)/English/Human

EMBASE

1. 'menopause'/exp OR menopausal OR 'post-menopause'/exp OR 'postmenopause'/exp OR 'post-menopausal' OR postmenopausal OR climacteri* OR 'perimenopause'/exp OR 'peri-menopause' OR 'peri-menopausal' OR perimenopausal AND [humans]/lim AND [english]/lim AND [embase]/lim =60511

2. 'estrogen replacement therapy'/exp OR 'drug therapy'/exp OR 'hormone replacement therapy'/exp OR estrogen* OR progestin* OR 'hormone replacement'/exp OR antidepressant* OR 'eszopiclone'/exp OR 'clonidine'/exp OR 'methyldopa'/exp OR 'bellergal'/exp OR 'gabapentin'/exp OR 'pregabalin'/exp OR isoflavone* OR 'red clover'/exp OR 'black cohosh'/exp OR 'cimicifuga'/exp OR 'st johns wort'/exp OR 'ginseng'/exp OR 'flaxseed'/exp OR 'vitamin e'/exp OR 'dong quai'/exp OR (DHEA OR dehydroepiandrosterone OR "androgenic agents" OR "androgenic compounds" OR androgen*)
(1 AND 2) AND [humans]/lim AND [english]/lim AND [embase]/lim

Cochrane searches were also performed for menopause/post-menopausal/climacteric to detect new references since the main search.

Appendix B. List of Excluded Studies

Abbreviations
DES: date earlier than systematic review
DUP: duplicate patient population or duplicate article
NCT: not clinical trial, MA, or SR
NOP: number of patients (too few)
NRC: not relevant comparator
NRD: not relevant design
NRF: not relevant followup
NRO: not relevant outcome
NRP: not relevant population
NRQ: not relevant question
PTU: prior to USPSTF report

H. O. Adami, I. Persson, R. Hoover, C. Schairer and L. Bergkvist. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 1989 44(5): 833-9. PMID: . Reason for Exclusion: DES

Y. AinMelk. Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomized trial. Fertil Steril 1996 66(6): 962-8. PMID: . Reason for Exclusion: NRO

S. Akhavan, F. Zandvakili, M. Arab, H. Karimi and F. Gharibi. Comparison of the therapeutic effects of fluoxetine, citalopram, estrogen and progesterone and placebo in the treatment of hot flushes in perimenopausal women. Scientific Journal of Kurdistan University of Medical Scien Reason for Exclusion: NCT

F. Al-Azzawi, M. Wahab, J. Thompson, M. Whitehead and W. Thompson. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study. Hum Reprod 1999 14(3): 636-41. PMID: . Reason for Exclusion: NRO

P. Albertazzi, S. A. Steel and M. Bottazzi. Effect of pure genistein on bone markers and hot flushes. Climacteric 2005 8(4): 371-9. PMID: . Reason for Exclusion: NRF

I. M. Alexander and A. Moore. Treating vasomotor symptoms of menopause: the nurse practitioner's perspective. J Am Acad Nurse Pract 2007 19(3): 152-63. PMID: . Reason for Exclusion: NRD

J. L. Alexander, K. Kotz, L. Dennerstein, S. J. Kutner, K. Wallen and M. Notelovitz. The effects of postmenopausal hormone therapies on female sexual functioning: a review of double-blind, randomized controlled trials. Menopause 2004 11(6 Pt 2): 749-65. PMID: . Reason for Exclusion: NRD

J. L. Alexander, L. Dennerstein, H. Burger and A. Graziottin. Testosterone and libido in surgically and naturally menopausal women. Women's Health 2006 2(3): 459-477. PMID: . Reason for Exclusion: NRD

K. P. Alexander, L. K. Newby, A. S. Hellkamp, R. A. Harrington, E. D. Peterson, S. Kopecky, A. Langer, P. O'Gara, C. M. O'Connor, R. N. Daly, R. M. Califf, S. Khan and V. Fuster. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more ca Reason for Exclusion: DES

P. Alexandersen, L. B. Tanko, Y. Z. Bagger, G. Qin and C. Christiansen. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric 2006 9(2): 108-18. PMID: . Reason for Exclusion: DES

M. A. Allison and J. E. Manson. Age, hormone therapy use, coronary heart disease, and mortality. Menopause 2011 18(3): 243-245. PMID: . Reason for Exclusion: NRD

D. G. Altman. A meta-analysis of hormone replacement therapy for fracture prevention. JAMA 2001 286(17): 2096-7. PMID: . Reason for Exclusion: NCT

G. L. Anderson, H. L. Judd, A. M. Kaunitz, D. H. Barad, S. A. Beresford, M. Pettinger, J. Liu, S. G. McNeeley and A. M. Lopez. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003 Reason for Exclusion: DES

G. L. Anderson, P. Autier, V. Beral, M. C. Bosland, E. Fernandez, S. Z. Haslam, D. G. Kaufman, C. La Vecchia, A. A. Molinolo, P. A. Newcomb, F. F. Parl, J. Peto, G. Rosano, D. Roy, F. Z. Stanczyk, D. B. Thomas, L. Vatten, T. Junghans, S. Olin, S. Shapiro, R. S. Stafford, C. W. Jam Reason for Exclusion: NCT

G. L. Anderson, R. T. Chlebowski, J. E. Rossouw, R. J. Rodabough, A. McTiernan, K. L. Margolis, A. Aggerwal, J. David Curb, S. L. Hendrix, F. Allan Hubbell, J. Khandekar, D. S. Lane, N. Lasser, A. M. Lopez, J. Potter and C. Ritenbaugh. Prior hormone therapy and breast cancer risk Reason for Exclusion: DES

C. M. Antunes, P. D. Strolley, N. B. Rosenshein, J. L. Davies, J. A. Tonascia, C. Brown, L. Burnett, A. Rutledge, M. Pokempner and R. Garcia. Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med 1979 300(1): 9-13. PMID: . Reason for Exclusion: DES

A. M. Arana, C. Varas, A. Gonzalez-Perez, L. Gutierrez, L. Bjerrum and L. A. Garcia Rodriguez. Hormone therapy and cerebrovascular events: a population-based nested case-control study. Menopause 2006 13(5): 730-6. PMID: . Reason for Exclusion: DES

D. F. Archer, D. W. Sturdee, R. Baber, T. J. De Villiers, A. Pines, R. R. Freedman, A. Gompel, M. Hickey, M. S. Hunter, R. A. Lobo, M. A. Lumsden, A. H. MacLennan, P. Maki, S. Palacios, D. Shah, P. Villaseca and M. Warren. Menopausal hot flushes and night sweats: Where are we now? Reason for Exclusion: NRD

D. F. Archer, I. H. Thorneycroft, M. Foegh, V. Hanes, M. D. Glant, P. Bitterman and R. L. Kempson. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005 12(6): 716-27. PMID: . Reason for Exclusion: NRO

D. F. Archer, J. L. Shifren, R. F. J. Cheng, W. Bao and C. J. Guico-Pabia. Tolerability of desvenlafaxine 100 mg in women with vasomotor symptoms (VMS) associated with menopause: A pooled analysis of 5 trials. Fertility and Sterility 2011 96(3): S4-S5. PMID: . Reason for Exclusion: NRD

D. F. Archer, L. A. Fischer, D. Rich, G. H. Schade, S. Schwartz, H. Wittcoff, C. S. Clark Sr, K. Maloney and F. O. Smith. Estrace(registered trademark) vs Premarin(registered trademark) for treatment of menopausal symptoms: Dosage comparison study. Advances in Therapy 1992 9(1): 2 Reason for Exclusion: NOP

D. F. Archer. Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric 2007 10 Suppl 1(): 3-10. PMID: . Reason for Exclusion: NRD

D. F. Archer. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001 8(4): 245-51. PMID: . Reason for Exclusion: NCT

B. H. Ascott-Evans, E. W. W. Sonnendecker and T. de Villiers. Hormone therapy in postmenopausal osteoporosis: 2008. Journal of Endocrinology, Metabolism and Diabetes of South Africa 2008 13(1): 8-12. PMID: . Reason for Exclusion: NCT

F. Atsma, M. L. Bartelink, D. E. Grobbee and Y. T. van der Schouw. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006 13(2): 265-79. PMID: . Reason for Exclusion: NRO

G. K. Au. Evaluation of the benefits and risks of hormone replacement therapy. Hong Kong Med J 2000 6(4): 381-9. PMID: . Reason for Exclusion: PTU

M. Aylward, F. Holly and R. J. Parker. An evaluation of clinical response to piperazine oestrone sulphate ('Harmogen') in menopause patients. Curr Med Res Opin 1974 2(7): 417-23. PMID: . Reason for Exclusion: NOP

C. N. B. Merz. Hormone therapy and cardiovascular risk: Why the new focus on perimenopausal women?. Advanced Studies in Medicine 2006 6(6): 267-274. PMID: . Reason for Exclusion: NCT

G. Bachmann, J. Bobula and S. Mirkin. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric 2010 13(2): 132-40. PMID: . Reason for Exclusion: NRC

G. A. Bachmann. Menopausal vasomotor symptoms: a review of causes, effects and evidence-based treatment options. J Reprod Med 2005 50(3): 155-65. PMID: . Reason for Exclusion: NRD

Y. Z. Bagger, L. B. Tanko, P. Alexandersen, H. B. Hansen, A. Mollgaard, P. Ravn, P. Qvist, J. A. Kanis and C. Christiansen. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF stud Reason for Exclusion: DES

W. Bai, H. H. Henneicke-von Zepelin, S. Wang, S. Zheng, J. Liu, Z. Zhang, L. Geng, L. Hu, C. Jiao and E. Liske. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, Reason for Exclusion: NRC

K. Bakken, A. Fournier, E. Lund, M. Waaseth, V. Dumeaux, F. Clavel-Chapelon, A. Fabre, B. Hemon, S. Rinaldi, V. Chajes, N. Slimani, N. E. Allen, G. K. Reeves, S. Bingham, K. T. Khaw, A. Olsen, A. Tjonneland, L. Rodriguez, M. J. Sanchez, P. A. Etxezarreta, E. Ardanaz, M. J. Tormo, Reason for Exclusion: PTU

D. Barad, C. Kooperberg, J. Wactawski-Wende, J. Liu, S. L. Hendrix and N. B. Watts. Prior oral contraception and postmenopausal fracture: a Women's Health Initiative observational cohort study. Fertil Steril 2005 84(2): 374-83. PMID: . Reason for Exclusion: NRQ

D. H. Barlow. HRT and the risk of deep vein thrombosis. Int J Gynaecol Obstet 1997 59 Suppl 1(): S29-33. PMID: . Reason for Exclusion: NCT

D. H. Barlow. Menopause and HRT--the state of the art in Europe. Maturitas 2005 51(1): 40-7. PMID: . Reason for Exclusion: NCT

V. M. Barnabei, B. B. Cochrane, A. K. Aragaki, I. Nygaard, R. S. Williams, P. G. McGovern, R. L. Young, E. C. Wells, M. J. O'Sullivan, B. Chen, R. Schenken and S. R. Johnson. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiati Reason for Exclusion: DUP

V. M. Barnabei, D. Grady, D. W. Stovall, J. A. Cauley, F. Lin, C. A. Stuenkel, M. L. Stefanick and J. H. Pickar. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002 100(6): 1209-18. PMID: . Reason for Exclusion: NRP

E. Barrett-Connor and D. Grady. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998 19(): 55-72. PMID: . Reason for Exclusion: NCT

E. Barrett-Connor, R. Young, M. Notelovitz, J. Sullivan, B. Wiita, H. M. Yang and J. Nolan. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med Reason for Exclusion: NRO

E. Barrett-Connor. The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence. Maturitas 1996 23(2): 227-34. PMID: . Reason for Exclusion: NCT

D. Barton and C. L. Loprinzi. Making sense of the evidence regarding nonhormonal treatments for hot flashes. Clin J Oncol Nurs 2004 8(1): 39-42. PMID: . Reason for Exclusion: NCT

S. Basaria and A. S. Dobs. Clinical review: Controversies regarding transdermal androgen therapy in postmenopausal women. J Clin Endocrinol Metab 2006 91(12): 4743-52. PMID: . Reason for Exclusion: NRD

R. Basson. Androgen replacement for women. Can Fam Physician 1999 45(): 2100-7. PMID: . Reason for Exclusion: NCT

P. M. Bath and L. J. Gray. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005 330(7487): 342. PMID: . Reason for Exclusion: PTU

J. W. Bea, Q. Zhao, J. A. Cauley, A. Z. LaCroix, T. Bassford, C. E. Lewis, R. D. Jackson, F. A. Tylavsky and Z. Chen. Effect of hormone therapy on lean body mass, falls, and fractures: 6-year results from the Women's Health Initiative hormone trials. Menopause 2011 18(1): 44-52. P Reason for Exclusion: PTU

C. M. Beard, T. E. Kottke, J. F. Annegers and D. J. Ballard. The Rochester Coronary Heart Disease Project: effect of cigarette smoking, hypertension, diabetes, and steroidal estrogen use on coronary heart disease among 40- to 59-year-old women, 1960 through 1982. Mayo Clin Proc 19 Reason for Exclusion: DES

S. Becker and R. Kaaks. Exogenous and endogenous hormones, mammographic density and breast cancer risk: can mammographic density be considered an intermediate marker of risk?. Recent Results Cancer Res 2009 181(): 135-57. PMID: . Reason for Exclusion: NRO

M. J. Beckermann. Estrogen-progestin hormone replacement therapy: Evaluation of epidemiological studies. HeartDrug 2001 1(4): 215-224. PMID: . Reason for Exclusion: NRO

S. Belisle, J. Blake, R. Basson, S. Desindes, G. Graves, S. Grigoriadis, S. Johnston, A. Lalonde, C. Mills, L. Nash, R. Reid, T. Rowe, V. Senikas and M. Turek. Canadian Consensus Conference on menopause, 2006 update. J Obstet Gynaecol Can 2006 28(2 Suppl 1): S7-94. PMID: . Reason for Exclusion: NRD

V. Beral, E. Banks and G. Reeves. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002 360(9337): 942-4. PMID: . Reason for Exclusion: PTU

V. Beral, G. Reeves and E. Banks. Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women. BJOG 2005 112(6): 692-5. PMID: . Reason for Exclusion: PTU

S. A. Beresford, N. S. Weiss, L. F. Voigt and B. McKnight. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997 349(9050): 458-61. PMID: . Reason for Exclusion: DES

L. Bergkvist, H. O. Adami, I. Persson, R. Hoover and C. Schairer. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989 321(5): 293-7. PMID: . Reason for Exclusion: DES

L. Bergkvist, I. Persson, H. O. Adami and C. Schairer. Risk factors for breast and endometrial cancer in a cohort of women treated with menopausal oestrogens. Int J Epidemiol 1988 17(4): 732-7. PMID: . Reason for Exclusion: DES

L. Bernstein. The risk of breast, endometrial and ovarian cancer in users of hormonal preparations. Basic Clin Pharmacol Toxicol 2006 98(3): 288-96. PMID: . Reason for Exclusion: PTU

B. R. Bhavnani and R. C. Strickler. Menopausal hormone therapy. J Obstet Gynaecol Can 2005 27(2): 137-62. PMID: . Reason for Exclusion: NCT

K. Bibbins-Domingo, F. Lin, E. Vittinghoff, E. Barrett-Connor, S. B. Hulley, D. Grady and M. G. Shlipak. Predictors of heart failure among women with coronary disease. Circulation 2004 110(11): 1424-30. PMID: . Reason for Exclusion: DES

N. Biglia, A. Gadducci, R. Ponzone, R. Roagna and P. Sismondi. Hormone replacement therapy in cancer survivors. Maturitas 2004 48(4): 333-46. PMID: . Reason for Exclusion: NRP

N. Biglia, L. Sgro, E. Defabiani, G. De Rosa, R. Ponzone, D. Marenco and P. Sismondi. The influence of hormone replacement therapy on the pathology of breast cancer. Eur J Surg Oncol 2005 31(5): 467-72. PMID: . Reason for Exclusion: DES

N. Biglia, P. Sgandurra, E. Peano, D. Marenco, G. Moggio, V. Bounous, N. Tomasi Cont, R. Ponzone and P. Sismondi. Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E. Climacteric 2009 12(4): 310-8. PMID: . Reason for Exclusion: NRP

A. M. Billeci, M. Paciaroni, V. Caso and G. Agnelli. Hormone replacement therapy and stroke. Curr Vasc Pharmacol 2008 6(2): 112-23. PMID: . Reason for Exclusion: NCT

A. M. R. Billeci, V. Caso, M. Paciaroni, F. Palmerini and G. Agnelli. Hormone-replacement therapy, dementia and stroke. Women's Health 2007 3(6): 699-710. PMID: . Reason for Exclusion: NCT

J. Bitzer, P. Kenemans and A. O. Mueck. Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy. Maturitas 2008 59(3): 209-18. PMID: . Reason for Exclusion: PTU

K. Bjarnason, A. Cerin, R. Lindgren and T. Weber. Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas 1999 32(3): 161-70. PMID: . Reason for Exclusion: DES

I. Bjorn, M. Bixo, K. S. Nojd, S. Nyberg and T. Backstrom. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am J Obstet Gynecol 2000 183(6): 1419-26. PMID: . Reason for Exclusion: NOP

R. D. Blank and R. S. Bockman. A review of clinical trials of therapies for osteoporosis using fracture as an end point. J Clin Densitom 1999 2(4): 435-52. PMID: . Reason for Exclusion: PTU

J. J. Body, P. Bergmann, S. Boonen, Y. Boutsen, J. P. Devogelaer, S. Goemaere, J. M. Kaufman, S. Rozenberg and J. Y. Reginster. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int Reason for Exclusion: NRD

R. Bolanos, A. Del Castillo and J. Francia. Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: systematic review and meta-analysis. Menopause 2010 17(3): 660-6. PMID: . Reason for Exclusion: NRD

R. Bolanos-Diaz, J. C. Zavala-Gonzales, E. Mezones-Holguin and J. Francia-Romero. Soy extracts versus hormone therapy for reduction of menopausal hot flushes: Indirect comparison. Menopause 2011 18(7): 825-829. PMID: . Reason for Exclusion: NRD

S. Bolour and G. Braunstein. Testosterone therapy in women: a review. Int J Impot Res 2005 17(5): 399-408. PMID: . Reason for Exclusion: NCT

L. A. Boothby, P. L. Doering and S. Kipersztok. Bioidentical hormone therapy: a review. Menopause 2004 11(3): 356-67. PMID: . Reason for Exclusion: NRD

K. S. Bora and A. Sharma. Phytochemical and pharmacological potential of Medicago sativa: A review. Pharmaceutical Biology 2011 49(2): 211-220. PMID: . Reason for Exclusion: NRQ

S. Borgquist, L. Anagnostaki, K. Jirstrom, G. Landberg and J. Manjer. Breast tumours following combined hormone replacement therapy express favourable prognostic factors. Int J Cancer 2007 120(10): 2202-7. PMID: . Reason for Exclusion: NRF

F. Borrelli and E. Ernst. Alternative and complementary therapies for the menopause. Maturitas 2010 66(4): 333-43. PMID: . Reason for Exclusion: NRD

F. Borrelli and E. Ernst. Black cohosh (Cimicifuga racemosa) for menopausal symptoms: a systematic review of its efficacy. Pharmacol Res 2008 58(1): 8-14. PMID: . Reason for Exclusion: NRD

F. Borrelli and E. Ernst. Cimicifuga racemosa: a systematic review of its clinical efficacy. Eur J Clin Pharmacol 2002 58(4): 235-41. PMID: . Reason for Exclusion: NRD

F. Bottiglione, A. Volpe, G. Esposito and D. D. Aloysio. Transvaginal estriol administration in postmenopausal women: a double blind comparative study of two different doses. Maturitas 1995 22(3): 227-32. PMID: . Reason for Exclusion: NRF

N. F. Boyd, O. Melnichouk, L. J. Martin, G. Hislop, A. M. Chiarelli, M. J. Yaffe and S. Minkin. Mammographic density, response to hormones, and breast cancer risk. J Clin Oncol 2011 29(22): 2985-92. PMID: . Reason for Exclusion: PTU

C. M. Brandao, M. G. Lima, A. L. Silva, G. D. Silva, A. A. Guerra, Jr. and A. Acurcio Fde. Treatment of postmenopausal osteoporosis in women: a systematic review. Cad Saude Publica 2008 24 Suppl 4(): s592-606. PMID: . Reason for Exclusion: NRO

G. D. Braunstein. Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies. J Sex Med 2007 4(4 Pt 1): 859-66. PMID: . Reason for Exclusion: NRD

G. D. Braunstein. Safety of testosterone treatment in postmenopausal women. Fertil Steril 2007 88(1): 1-17. PMID: . Reason for Exclusion: NRQ

M. Brincat, A. Magos, J. W. Studd, L. D. Cardozo, T. O'Dowd, P. J. Wardle and D. Cooper. Subcutaneous hormone implants for the control of climacteric symptoms. A prospective study. Lancet 1984 1(8367): 16-8. PMID: . Reason for Exclusion: NOP

L. A. Brinton and C. Schairer. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 1993 15(1): 66-79. PMID: . Reason for Exclusion: PTU

L. A. Brinton and R. N. Hoover. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol 1993 81(2): 265-71. PMID: . Reason for Exclusion: DES

L. A. Brinton, D. R. Brogan, R. J. Coates, C. A. Swanson, N. Potischman and J. L. Stanford. Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause 1998 5(3): 145-51. PMID: . Reason for Exclusion: DES

L. A. Brinton, D. Richesson, M. F. Leitzmann, G. L. Gierach, A. Schatzkin, T. Mouw, A. R. Hollenbeck and J. V. Lacey, Jr.. Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev 2008 17(11): 3150-60. PMID: . Reason for Exclusion: PTU

L. A. Brinton, R. Hoover and J. F. Fraumeni, Jr.. Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 1986 54(5): 825-32. PMID: . Reason for Exclusion: DES

L. A. Brinton, R. N. Hoover, M. Szklo and J. F. Fraumeni, Jr.. Menopausal estrogen use and risk of breast cancer. Cancer 1981 47(10): 2517-22. PMID: . Reason for Exclusion: DES

S. E. Bromley, C. S. de Vries, D. Thomas and R. D. Farmer. Hormone replacement therapy and risk of acute myocardial infarction : a review of the literature. Drug Saf 2005 28(6): 473-93. PMID: . Reason for Exclusion: PTU

J. N. Brown and B. R. Wright. Use of gabapentin in patients experiencing hot flashes. Pharmacotherapy 2009 29(1): 74-81. PMID: . Reason for Exclusion: NRD

S. Brown. Soy isoflavones fail to prevent bone loss or menopausal symptoms. Menopause International 2011 17(4): 117. PMID: . Reason for Exclusion: NCT

R. L. Brunner, A. Aragaki, V. Barnabei, B. B. Cochrane, M. Gass, S. Hendrix, D. Lane, J. Ockene, N. F. Woods, S. Yasmeen and M. Stefanick. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial Reason for Exclusion: NRQ

K. Buck, A. K. Zaineddin, A. Vrieling, J. Linseisen and J. Chang-Claude. Meta-analyses of lignans and enterolignans in relation to breast cancer risk. Am J Clin Nutr 2010 92(1): 141-53. PMID: . Reason for Exclusion: NRP

N. Burbos and E. P. Morris. Menopausal symptoms. Clin Evid (Online) 2011 2011(): . PMID: . Reason for Exclusion: PTU

J. E. Buring, C. H. Hennekens, R. J. Lipnick, W. Willett, M. J. Stampfer, B. Rosner, R. Peto and F. E. Speizer. A prospective cohort study of postmenopausal hormone use and risk of breast cancer in US women. Am J Epidemiol 1987 125(6): 939-47. PMID: . Reason for Exclusion: DES

C. Bushnell. Hormone therapy and stroke: Is it all about timing?. Current Treatment Options in Cardiovascular Medicine 2009 11(3): 241-250. PMID: . Reason for Exclusion: NCT

J. E. Buster. Transdermal menopausal hormone therapy: delivery through skin changes the rules. Expert Opin Pharmacother 2010 11(9): 1489-99. PMID: . Reason for Exclusion: PTU

J. P. Buyon, M. A. Petri, M. Y. Kim, K. C. Kalunian, J. Grossman, B. H. Hahn, J. T. Merrill, L. Sammaritano, M. Lockshin, G. S. Alarcon, S. Manzi, H. M. Belmont, A. D. Askanase, L. Sigler, M. A. Dooley, J. Von Feldt, W. J. McCune, A. Friedman, J. Wachs, M. Cronin, M. Hearth-Holmes Reason for Exclusion: NRP

E. E. Calle, H. S. Feigelson, J. S. Hildebrand, L. R. Teras, M. J. Thun and C. Rodriguez. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer 2009 115(5): 936-45. PMID: . Reason for Exclusion: PTU

L. Calvocoressi, M. H. Stowe, D. Carter and E. B. Claus. Postmenopausal hormone therapy and ductal carcinoma in situ: A population-based case-control study. Cancer Epidemiology 2012 (): . PMID: . Reason for Exclusion: PTU

S. T. Cameron, A. F. Glasier, A. Gebbie, H. Dewart and D. T. Baird. Comparison of a transdermal continuous combined and an interrupted progestogen HRT. Maturitas 2006 53(1): 19-26. PMID: . Reason for Exclusion: NRO

C. Campagnoli, C. Abba, S. Ambroggio, C. Peris, M. Perona and P. Sanseverino. Polyunsaturated fatty acids (PUFAs) might reduce hot flushes: an indication from two controlled trials on soy isoflavones alone and with a PUFA supplement. Maturitas 2005 51(2): 127-34. PMID: . Reason for Exclusion: NOP

C. Campagnoli, S. Ambroggio, M. R. Lotano and C. Peris. Progestogen use in women approaching the menopause and breast cancer risk. Maturitas 2009 62(4): 338-42. PMID: . Reason for Exclusion: NRQ

S. Campbell and M. Whitehead. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977 4(1): 31-47. PMID: . Reason for Exclusion: NRF

P. T. Campbell, P. Newcomb, S. Gallinger, M. Cotterchio and J. R. McLaughlin. Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer. Cancer Causes Control 2007 18(7): 723-33. PMID: . Reason for Exclusion: PTU

A. J. Canchola, E. T. Chang, L. Bernstein, J. A. Largent, P. Reynolds, D. Deapen, G. Ursin and P. L. Horn-Ross. Body size and the risk of endometrial cancer by hormone therapy use in postmenopausal women in the California Teachers Study cohort. Cancer Causes Control 2010 21(9): 14 Reason for Exclusion: PTU

A. J. Canchola, E. T. Chang, L. Bernstein, J. A. Largent, P. Reynolds, D. Deapen, K. D. Henderson, G. Ursin and P. L. Horn-Ross. Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort. Cancer Causes Control 2010 21(12): 2241-8. PMID Reason for Exclusion: PTU

R. Canderelli, L. A. Leccesse, N. L. Miller and J. Unruh Davidson. Benefits of hormone replacement therapy in postmenopausal women. J Am Acad Nurse Pract 2007 19(12): 635-41. PMID: . Reason for Exclusion: NCT

A. Cano, M. A. Garcia-Perez and J. J. Tarin. Isoflavones and cardiovascular disease. Maturitas 2010 67(3): 219-26. PMID: . Reason for Exclusion: NCT

M. Canonico, A. Fournier, L. Carcaillon, V. Olie, G. Plu-Bureau, E. Oger, S. Mesrine, M. C. Boutron-Ruault, F. Clavel-Chapelon and P. Y. Scarabin. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb V Reason for Exclusion: PTU

M. Canonico, E. Oger, G. Plu-Bureau, J. Conard, G. Meyer, H. Levesque, N. Trillot, M. T. Barrellier, D. Wahl, J. Emmerich and P. Y. Scarabin. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the Reason for Exclusion: PTU

M. Canonico, E. Oger, J. Conard, G. Meyer, H. Levesque, N. Trillot, M. T. Barrellier, D. Wahl, J. Emmerich and P. Y. Scarabin. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The EST Reason for Exclusion: DES

M. Canonico, G. Plu-Bureau, G. D. Lowe and P. Y. Scarabin. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008 336(7655): 1227-31. PMID: . Reason for Exclusion: PTU

L. Cardozo, G. Bachmann, D. McClish, D. Fonda and L. Birgerson. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998 92(4 Pt 2): 722-7. PMID: . Reason for Exclusion: NRD

L. O. Carmignani, A. O. Pedro, L. H. Costa-Paiva and A. M. Pinto-Neto. The effect of dietary soy supplementation compared to estrogen and placebo on menopausal symptoms: a randomized controlled trial. Maturitas 2010 67(3): 262-9. PMID: . Reason for Exclusion: NOP

J. Casagrande, V. Gerkins, B. E. Henderson, T. Mack and M. C. Pike. Exogenous estrogens and breast cancer in women with natural menopause. J Natl Cancer Inst 1976 56(4): 839-41. PMID: . Reason for Exclusion: DES

J. Castellsague, S. Perez Gutthann and L. A. Garcia Rodriguez. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review. Drug Saf 1998 18(2): 117-23. PMID: . Reason for Exclusion: NCT

C. Castelo-Branco and M. J. Cancelo Hidalgo. Isoflavones: effects on bone health. Climacteric 2011 14(2): 204-11. PMID: . Reason for Exclusion: NRO

C. Castelo-Branco and M. J. Cancelo. Compounds for the treatment of atropic vaginitis. Expert Opinion on Therapeutic Patents 2008 18(12): 1385-1394. PMID: . Reason for Exclusion: NRD

J. A. Cauley, D. G. Seeley, K. Ensrud, B. Ettinger, D. Black and S. R. Cummings. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995 122(1): 9-16. PMID: . Reason for Exclusion: DES

J. A. Cauley, D. M. Black, E. Barrett-Connor, F. Harris, K. Shields, W. Applegate and S. R. Cummings. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med 2001 110(6): 442-50. PMID: . Reason for Exclusion: DES

J. A. Cauley, J. Robbins, Z. Chen, S. R. Cummings, R. D. Jackson, A. Z. LaCroix, M. LeBoff, C. E. Lewis, J. McGowan, J. Neuner, M. Pettinger, M. L. Stefanick, J. Wactawski-Wende and N. B. Watts. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the W Reason for Exclusion: DES

C. Chang and C. H. Lin. Hormone replacement therapy and menopause: a review of randomized, double-blind, placebo-controlled trials. Kaohsiung J Med Sci 2003 19(6): 257-70. PMID: . Reason for Exclusion: NRO

S. C. Chang, J. V. Lacey, Jr., L. A. Brinton, P. Hartge, K. Adams, T. Mouw, L. Carroll, A. Hollenbeck, A. Schatzkin and M. F. Leitzmann. Lifetime weight history and endometrial cancer risk by type of menopausal hormone use in the NIH-AARP diet and health study. Cancer Epidemiol Bi Reason for Exclusion: NRF

R. D. Chapurlat, D. C. Bauer, M. Nevitt, K. Stone and S. R. Cummings. Incidence and risk factors for a second hip fracture in elderly women. The Study of Osteoporotic Fractures. Osteoporos Int 2003 14(2): 130-6. PMID: . Reason for Exclusion: DES

M. A. Checa, A. Garrido, M. Prat, M. Conangla, C. Rueda and R. Carreras. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, Reason for Exclusion: NRC

P. Chedraui, L. Hidalgo, G. San Miguel, N. Morocho and S. Ross. Red clover extract (MF11RCE) supplementation and postmenopausal vaginal and sexual health. Int J Gynaecol Obstet 2006 95(3): 296-7. PMID: . Reason for Exclusion: DUP

D. Cheema, A. Coomarasamy and T. El-Toukhy. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. Arch Gynecol Obstet 2007 276(5): 463-9. PMID: . Reason for Exclusion: NRD

W. Y. Chen, G. A. Colditz, B. Rosner, S. E. Hankinson, D. J. Hunter, J. E. Manson, M. J. Stampfer, W. C. Willett and F. E. Speizer. Use of postmenopausal hormones, alcohol, and risk for invasive breast cancer. Ann Intern Med 2002 137(10): 798-804. PMID: . Reason for Exclusion: DES

W. Y. Chen, J. E. Manson, S. E. Hankinson, B. Rosner, M. D. Holmes, W. C. Willett and G. A. Colditz. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006 166(9): 1027-32. PMID: . Reason for Exclusion: DES

W. Y. Chen, S. E. Hankinson, S. J. Schnitt, B. A. Rosner, M. D. Holmes and G. A. Colditz. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004 101(7): 1490-500. PMID: . Reason for Exclusion: DES

H. Y. Chen, W. C. Cho, S. C. Sze and Y. Tong. Treatment of menopausal symptoms with Er-xian decoction: a systematic review. Am J Chin Med 2008 36(2): 233-44. PMID: . Reason for Exclusion: NRD

L. C. Chen, Y. T. Tsao, K. Y. Yen, Y. F. Chen, M. H. Chou and M. F. Lin. A pilot study comparing the clinical effects of Jia-Wey Shiau-Yau San, a traditional Chinese herbal prescription, and a continuous combined hormone replacement therapy in postmenopausal women with climacteric Reason for Exclusion: NOP

L. M. Chiechi and L. Micheli. Utility of dietary phytoestrogens in preventing postmenopausal osteoporosis. Current Topics in Nutraceutical Research 2005 3(1): 15-28. PMID: . Reason for Exclusion: NRO

R. T. Chlebowski, G. Anderson, J. E. Manson, M. Pettinger, S. Yasmeen, D. Lane, R. D. Langer, F. A. Hubbell, A. McTiernan, S. Hendrix, R. Schenken and M. L. Stefanick. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J C Reason for Exclusion: NRQ

R. T. Chlebowski, G. L. Anderson, M. Gass, D. S. Lane, A. K. Aragaki, L. H. Kuller, J. E. Manson, M. L. Stefanick, J. Ockene, G. E. Sarto, K. C. Johnson, J. Wactawski-Wende, P. M. Ravdin, R. Schenken, S. L. Hendrix, A. Rajkovic, T. E. Rohan, S. Yasmeen and R. L. Prentice. Estrogen Reason for Exclusion: PTU

R. T. Chlebowski, J. Wactawski-Wende, C. Ritenbaugh, F. A. Hubbell, J. Ascensao, R. J. Rodabough, C. A. Rosenberg, V. M. Taylor, R. Harris, C. Chen, L. L. Adams-Campbell and E. White. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004 350(10): Reason for Exclusion: DES

R. T. Chlebowski, L. H. Kuller, R. L. Prentice, M. L. Stefanick, J. E. Manson, M. Gass, A. K. Aragaki, J. K. Ockene, D. S. Lane, G. E. Sarto, A. Rajkovic, R. Schenken, S. L. Hendrix, P. M. Ravdin, T. E. Rohan, S. Yasmeen and G. Anderson. Breast cancer after use of estrogen plus pr Reason for Exclusion: PTU

R. T. Chlebowski, S. L. Hendrix, R. D. Langer, M. L. Stefanick, M. Gass, D. Lane, R. J. Rodabough, M. A. Gilligan, M. G. Cyr, C. A. Thomson, J. Khandekar, H. Petrovitch and A. McTiernan. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausa Reason for Exclusion: DES

M. S. Christensen, C. Hagen, C. Christiansen and I. Transbol. Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol 1982 144(8): 873-9. PMID: . Reason for Exclusion: NOP

J. Chubak, J. A. Doherty, K. L. Cushing-Haugen, L. F. Voigt, B. S. Saltzman, D. A. Hill, S. A. Beresford and N. S. Weiss. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy. Cancer Causes Control 2007 18(9): 1001-7. PMID: . Reason for Exclusion: PTU

M. Cirigliano. Bioidentical hormone therapy: a review of the evidence. J Womens Health (Larchmt) 2007 16(5): 600-31. PMID: . Reason for Exclusion: NRC

D. J. Cirillo, R. B. Wallace, R. J. Rodabough, P. Greenland, A. Z. LaCroix, M. C. Limacher and J. C. Larson. Effect of estrogen therapy on gallbladder disease. JAMA 2005 293(3): 330-9. PMID: . Reason for Exclusion: DES

S. C. Clarke, J. Kelleher, H. Lloyd-Jones, M. Slack and P. M. Schofiel. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002 109(9): 1056-62. PMID: . Reason for Exclusion: DES

Clonidine, gabapentin, and some SSRIs effective for hot ashes. South African Family Practice 2006 48(6): 13. PMID: . Reason for Exclusion: NRD

Clonidine, gabapentin, and some SSRIs effective for hot flashes. Journal of Family Practice 2006 55(8): 662. PMID: . Reason for Exclusion: NRD

N. F. Col, L. A. Bowlby and K. McGarry. The role of menopausal hormone therapy in preventing osteoporotic fractures: a critical review of the clinical evidence. Minerva Med 2005 96(5): 331-42. PMID: . Reason for Exclusion: NRD

G. A. Colditz, M. J. Stampfer, W. C. Willett, C. H. Hennekens, B. Rosner and F. E. Speizer. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 1990 264(20): 2648-53. PMID: . Reason for Exclusion: DES

G. A. Colditz, M. J. Stampfer, W. C. Willett, D. J. Hunter, J. E. Manson, C. H. Hennekens, B. A. Rosner and F. E. Speizer. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 1992 3(5): 433-9. PMID: . Reason for Exclusion: DES

G. A. Colditz, S. E. Hankinson, D. J. Hunter, W. C. Willett, J. E. Manson, M. J. Stampfer, C. Hennekens, B. Rosner and F. E. Speizer. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995 332(24): 1589-93. PMID: . Reason for Exclusion: DES

G. A. Colditz, W. C. Willett, M. J. Stampfer, B. Rosner, F. E. Speizer and C. H. Hennekens. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987 316(18): 1105-10. PMID: . Reason for Exclusion: DES

J. A. Collins, J. M. Blake and P. G. Crosignani. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 2005 11(6): 545-60. PMID: . Reason for Exclusion: PTU

J. E. Compston and N. B. Watts. Combination therapy for postmenopausal osteoporosis. Clin Endocrinol (Oxf) 2002 56(5): 565-9. PMID: . Reason for Exclusion: NRO

E. Conaway. Bioidentical hormones: an evidence-based review for primary care providers. J Am Osteopath Assoc 2011 111(3): 153-64. PMID: . Reason for Exclusion: NCT

N. R. Cook, B. A. Rosner, S. E. Hankinson and G. A. Colditz. Mammographic screening and risk factors for breast cancer. Am J Epidemiol 2009 170(11): 1422-32. PMID: . Reason for Exclusion: NRQ

J. T. Coon, M. H. Pittler and E. Ernst. Trifolium pratense isoflavones in the treatment of menopausal hot flushes: a systematic review and meta-analysis. Phytomedicine 2007 14(2-3): 153-9. PMID: . Reason for Exclusion: NRD

W. Cooper, M. Marnie and E. Daw. A clinical trial of piperazine oestrone sulphate ('Harmogen') in the treatment of menopausal symptoms. Curr Med Res Opin 1974 2(5): 260-3. PMID: . Reason for Exclusion: NOP

G. Corrao, A. Zambon, V. Conti, F. Nicotra, C. La Vecchia, C. Fornari, G. Cesana, P. Contiero, G. Tagliabue, R. E. Nappi and L. Merlino. Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. Ann Oncol 2008 19(1): 150-5. PMID: . Reason for Exclusion: PTU

J. Cortes-Prieto and P. Juez-Martel. Incidences of breast cancer throughout long-term hormone replacement therapy. J Steroid Biochem Mol Biol 2007 104(3-5): 180-9. PMID: . Reason for Exclusion: NOP

C. J. Crandall, A. K. Aragaki, R. T. Chlebowski, A. McTiernan, G. Anderson, S. L. Hendrix, B. B. Cochrane, L. H. Kuller and J. A. Cauley. New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk. Arch Intern Med 2009 169(18): 1684-91. Reason for Exclusion: PTU

A. Cranney, G. Guyatt, L. Griffith, G. Wells, P. Tugwell and C. Rosen. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews 2002 23(4): 570-578. PMID: . Reason for Exclusion: PTU

M. D. Cravioto, M. Durand-Carbajal, L. Jimenez-Santana, P. Lara-Reyes, A. H. Seuc and J. Sanchez-Guerrero. Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: a randomized, double-blind, controlled trial. Arthritis Care Res (Hobok Reason for Exclusion: NRP

W. T. Creasman. Is there an association between hormone replacement therapy and breast cancer?. J Womens Health 1998 7(10): 1231-46. PMID: . Reason for Exclusion: NCT

M. H. Criqui, L. Suarez, E. Barrett-Connor, J. McPhillips, D. L. Wingard and C. Garland. Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community. Am J Epidemiol 1988 128(3): 606-14. PMID: . Reason for Exclusion: DES

E. J. Crosbie, M. Zwahlen, H. C. Kitchener, M. Egger and A. G. Renehan. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010 19(12): 3119-30. PMID: . Reason for Exclusion: NRO

J. D. Curb, R. L. Prentice, P. F. Bray, R. D. Langer, L. Van Horn, V. M. Barnabei, M. J. Bloch, M. G. Cyr, M. Gass, L. Lepine, R. J. Rodabough, S. Sidney, G. I. Uwaifo and F. R. Rosendaal. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med Reason for Exclusion: DES

K. L. Cushing, N. S. Weiss, L. F. Voigt, B. McKnight and S. A. Beresford. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstet Gynecol 1998 91(1): 35-9. PMID: . Reason for Exclusion: DES

M. Cushman, L. H. Kuller, R. Prentice, R. J. Rodabough, B. M. Psaty, R. S. Stafford, S. Sidney and F. R. Rosendaal. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004 292(13): 1573-80. PMID: . Reason for Exclusion: DES

F. S. Dalais, G. E. Rice, M. L. Wahlqvist, M. Grehan, A. L. Murkies, G. Medley, R. Ayton and B. J. Strauss. Effects of dietary phytoestrogens in postmenopausal women. Climacteric 1998 1(2): 124-9. PMID: . Reason for Exclusion: NOP

E. Daly, M. P. Vessey, M. M. Hawkins, J. L. Carson, P. Gough and S. Marsh. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996 348(9033): 977-80. PMID: . Reason for Exclusion: DES

T. M. Dando and C. M. Perry. 17 beta-estradiol/levonorgestrel transdermal system. Treat Endocrinol 2004 3(5): 319-24. PMID: . Reason for Exclusion: DUP

K. N. Danforth, S. S. Tworoger, J. L. Hecht, B. A. Rosner, G. A. Colditz and S. E. Hankinson. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer 2007 96(1): 151-6. PMID: . Reason for Exclusion: PTU

C. Daniele, J. Thompson Coon, M. H. Pittler and E. Ernst. Vitex agnus castus: a systematic review of adverse events. Drug Saf 2005 28(4): 319-32. PMID: . Reason for Exclusion: NRP

R. D'Anna, M. L. Cannata, M. Atteritano, F. Cancellieri, F. Corrado, G. Baviera, O. Triolo, F. Antico, A. Gaudio, N. Frisina, A. Bitto, F. Polito, L. Minutoli, D. Altavilla, H. Marini and F. Squadrito. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal Reason for Exclusion: DUP

S. R. Davis, M. Panjari and F. Z. Stanczyk. DHEA replacement for postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2011 96(6): 1642-1653. PMID: . Reason for Exclusion: NRD

D. De Aloysio, A. G. Fabiani, M. Mauloni and F. Bottiglioni. Use of Org OD 14 for the treatment of climacteric complaints. Maturitas 1987 Suppl 1(): 49-65. PMID: . Reason for Exclusion: NRC

M. A. de Lecinana, J. A. Egido, C. Fernandez, E. Martinez-Vila, S. Santos, A. Morales, E. Martinez, A. Pareja, J. Alvarez-Sabin and I. Casado. Risk of ischemic stroke and lifetime estrogen exposure. Neurology 2007 68(1): 33-8. PMID: . Reason for Exclusion: NRD

V. De Leo, A. la Marca, G. Morgante, D. Lanzetta, P. Florio and F. Petraglia. Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety. Maturitas 2001 39(2): 185-8. PMID: . Reason for Exclusion: NOP

B. de Lignieres, F. de Vathaire, S. Fournier, R. Urbinelli, F. Allaert, M. G. Le and F. Kuttenn. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 2002 5(4): 332-40. PMID: . Reason for Exclusion: DES

C. S. de Vries, S. E. Bromley and R. D. Farmer. Myocardial infarction risk and hormone replacement: differences between products. Maturitas 2006 53(3): 343-50. PMID: . Reason for Exclusion: DES

A. Delaune, K. Landreneau, K. Hire, B. Dillard, M. Cox, K. Payne and C. Powell. Credibility of a meta-analysis: evidence-based practice concerning soy intake and breast cancer risk in premenopausal women. Worldviews Evid Based Nurs 2009 6(3): 160-6. PMID: . Reason for Exclusion: NRQ

M. Delgado-Rodriguez, M. Sillero-Arenas, R. Rodriguez-Contreras, R. Lopez Gigosos and R. Galvez Vargas. Oral contraceptives and breast cancer. A meta-analysis. Rev Epidemiol Sante Publique 1991 39(2): 165-81. PMID: . Reason for Exclusion: NRQ

H. F. D'Elia, A. Larsen, L. A. Mattsson, E. Waltbrand, G. Kvist, D. Mellstrom, T. Saxne, C. Ohlsson, E. Nordborg and H. Carlsten. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 2003 30(7): 1456-63. PMID Reason for Exclusion: NRO

L. Dennerstein and G. D. Burrows. Hormone replacement therapy and sexuality in women. Clin Endocrinol Metab 1982 11(3): 661-79. PMID: . Reason for Exclusion: NRD

L. R. DeRogatis, A. Graziottin, J. Bitzer, S. Schmitt, P. E. Koochaki and C. Rodenberg. Clinically relevant changes in sexual desire, satisfying sexual activity and personal distress as measured by the profile of female sexual function, sexual activity log, and personal distress s Reason for Exclusion: DUP

E. Diamanti-Kandarakis. Hormone replacement therapy and risk of malignancy. Curr Opin Obstet Gynecol 2004 16(1): 73-8. PMID: . Reason for Exclusion: NCT

S. E. Dick, D. E. DeWitt and B. D. Anawalt. Postmenopausal hormone replacement therapy and major clinical outcomes: a focus on cardiovascular disease, osteoporosis, dementia, and breast and endometrial neoplasia. Am J Manag Care 2002 8(1): 95-104; quiz 105-6. PMID: . Reason for Exclusion: NCT

C. Dimitrakakis, R. A. Jones, A. Liu and C. A. Bondy. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004 11(5): 531-5. PMID: . Reason for Exclusion: DES

E. L. Ding, S. Mehta, W. W. Fawzi and E. L. Giovannucci. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial. Int J Cancer 2008 122(8): 1690-4. PMID: . Reason for Exclusion: PTU

A. S. Dobs, T. Nguyen, C. Pace and C. P. Roberts. Differential effects of oral estrogen versus oral estrogen-androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab 2002 87(4): 1509-16. PMID: . Reason for Exclusion: NOP

J. A. Doherty, K. L. Cushing-Haugen, B. S. Saltzman, L. F. Voigt, D. A. Hill, S. A. Beresford, C. Chen and N. S. Weiss. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007 197(2): 139 e1-7. PMID: . Reason for Exclusion: PTU

J. Y. Dong and L. Q. Qin. Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies. Breast Cancer Res Treat 2011 125(2): 315-23. PMID: . Reason for Exclusion: NRD

M. Dooley, C. M. Spencer and D. Ormrod. Estradiol-intranasal: a review of its use in the management of menopause. Drugs 2001 61(15): 2243-62. PMID: . Reason for Exclusion: NRD

M. Doren, F. A. Azzawi, J. Donnez, M. J. Van der Mooren, J. Villero and A. Gompel. Therapeutic value and long-term safety of pulsed estrogen therapy. Maturitas 2001 38 Suppl 1(): S23-30. PMID: . Reason for Exclusion: DUP

J. D. Douketis, J. A. Julian, C. Kearon, D. R. Anderson, M. A. Crowther, S. M. Bates, M. Barone, F. Piovella, A. G. Turpie, S. Middeldorp, P. van Nguyen, P. Prandoni, P. S. Wells, M. J. Kovacs, M. R. MacGillavry, L. Costantini and J. S. Ginsberg. Does the type of hormone replaceme Reason for Exclusion: DES

J. Drife. Evidence-based hormone replacement therapy for the well woman at menopause. Current Obstetrics and Gynaecology 2005 15(4): 244-250. PMID: . Reason for Exclusion: PTU

G. P. Dubey, G. V. Rajamanickam and A. Aruna Agrawal. Neuropsycho-cardiologic risks associated with menopausal women - Benefits of a plant based formulation. Planta Medica 2009 75(4): 453-454. PMID: . Reason for Exclusion: NRO

W. D. Dupont and D. L. Page. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991 151(1): 67-72. PMID: . Reason for Exclusion: PTU

A. Dupont, P. Dupont, L. Cusan, M. Tremblay, J. Rioux, D. Cloutier, J. Mailloux, B. De Lignieres, J. Gutkowska, H. Boucher and et al.. Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women. Maturitas 1991 13(4): 297-311. PMID: . Reason for Exclusion: NOP

S. Eberhardt, W. Kulp, J. M. von der Schulenburg, S. N. Willich, T. Keil and W. Greiner. Hormones for therapy of climacteric afflictions. GMS Health Technol Assess 2007 3(): Doc03. PMID: . Reason for Exclusion: NRD

R. F. Edington, J. P. Chagnon and W. M. Steinberg. Clonidine (Dixarit) for menopausal flushing. Can Med Assoc J 1980 123(1): 23-6. PMID: . Reason for Exclusion: NOP

S. F. Eichner, K. B. Lloyd and E. M. Timpe. Comparing therapies for postmenopausal osteoporosis prevention and treatment. Ann Pharmacother 2003 37(5): 711-24. PMID: . Reason for Exclusion: PTU

A. Eisen, J. Lubinski, J. Gronwald, P. Moller, H. T. Lynch, J. Klijn, C. Kim-Sing, S. L. Neuhausen, L. Gilbert, P. Ghadirian, S. Manoukian, G. Rennert, E. Friedman, C. Isaacs, E. Rosen, B. Rosen, M. Daly, P. Sun and S. A. Narod. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008 100(19): 1361-7. PMID: . Reason for Exclusion: PTU

A. Elfituri, F. Sherif, M. Elmahaishi and H. Chrystyn. Two hormone replacement therapy (HRT) regimens for middle-eastern postmenopausal women. Maturitas 2005 52(1): 52-9. PMID: . Reason for Exclusion: NRC

B. Elhelw. Non-hormonal therapies for the treatment of menopausal symptoms. Middle East Fertility Society Journal 2006 11(1): 1-17. PMID: . Reason for Exclusion: NRD

L. Elit. Endometrial cancer. Prevention, detection, management, and follow up. Can Fam Physician 2000 46(): 887-92. PMID: . Reason for Exclusion: NRQ

P. Engel, A. Fabre, A. Fournier, S. Mesrine, M. C. Boutron-Ruault and F. Clavel-Chapelon. Risk of osteoporotic fractures after discontinuation of menopausal hormone therapy: results from the E3N cohort. Am J Epidemiol 2011 174(1): 12-21. PMID: . Reason for Exclusion: PTU

E. Epstein, P. G. Lindqvist and H. Olsson. A population-based cohort study on the use of hormone treatment and endometrial cancer in southern Sweden. Int J Cancer 2009 125(2): 421-5. PMID: . Reason for Exclusion: PTU

R. Erkkola, S. Vervarcke, S. Vansteelandt, P. Rompotti, D. De Keukeleire and A. Heyerick. A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts. Phytomedicine 2010 17(6): 389-96. PMID: . Reason for Exclusion: NOP

M. Espie, P. Mares, P. de Reilhac, T. Chevallier and J. P. Daures. Breast cancer in postmenopausal women with and without hormone replacement therapy: preliminary results of the MISSION study. Gynecol Endocrinol 2006 22(8): 423-31. PMID: . Reason for Exclusion: DES

Oestrogen plus progestin hormone replacement therapy increases venous thrombosis in postmenopausal women. Evidence-Based Healthcare and Public Health 2005 9(2): 159-160. PMID: . Reason for Exclusion: DES

B. Ettinger. Use of low-dosage 17 beta-estradiol for the prevention of osteoporosis. Clin Ther 1993 15(6): 950-62; discussion 949. PMID: . Reason for Exclusion: NOP

B. Ettinger. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage. Am J Med 2005 118 Suppl 12B(): 74-8. PMID: . Reason for Exclusion: NCT

M. Ewertz, L. Mellemkjaer, A. H. Poulsen, S. Friis, H. T. Sorensen, L. Pedersen, J. K. McLaughlin and J. H. Olsen. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 2005 92(7): 1293-7. PMID: . Reason for Exclusion: DES

A. Fabre, A. Fournier, S. Mesrine, J. Desreux, A. Gompel, M. C. Boutron-Ruault and F. Clavel-Chapelon. Oral progestagens before menopause and breast cancer risk. Br J Cancer 2007 96(5): 841-4. PMID: . Reason for Exclusion: PTU

C. Farquhar, J. Marjoribanks, A. Lethaby, J. A. Suckling and Q. Lamberts. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009 (2): CD004143. PMID: . Reason for Exclusion: PTU

E. Fernandez, C. La Vecchia, C. Braga, R. Talamini, E. Negri, F. Parazzini and S. Franceschi. Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev 1998 7(4): 329-33. PMID: . Reason for Exclusion: DES

E. Fernandez, C. La Vecchia, S. Franceschi, C. Braga, R. Talamini, E. Negri and F. Parazzini. Oral contraceptive use and risk of colorectal cancer. Epidemiology 1998 9(3): 295-300. PMID: . Reason for Exclusion: DES

E. Fernandez, S. Gallus, C. Bosetti, S. Franceschi, E. Negri and C. La Vecchia. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003 105(3): 408-12. PMID: . Reason for Exclusion: NRD

J. C. Figueiredo, R. W. Haile, L. Bernstein, K. E. Malone, J. Largent, B. Langholz, C. F. Lynch, L. Bertelsen, M. Capanu, P. Concannon, A. Borg, A. L. Borresen-Dale, A. Diep, S. Teraoka, T. Torngren, S. Xue and J. L. Bernstein. Oral contraceptives and postmenopausal hormones and r Reason for Exclusion: PTU

A. Finckh, I. C. Berner, B. Aubry-Rozier and A. K. So. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. J Rheumatol 2005 32(7): 1336-40. PMID: . Reason for Exclusion: NRP

A. Floter, J. Nathorst-Boos, K. Carlstrom and B. von Schoultz. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being. Climacteric 2002 5(4): 357-65. PMID: . Reason for Exclusion: NOP

A. R. Folsom, J. P. Anderson and J. A. Ross. Estrogen replacement therapy and ovarian cancer. Epidemiology 2004 15(1): 100-4. PMID: . Reason for Exclusion: DES

A. R. Folsom, S. A. Kaye, J. D. Potter and R. J. Prineas. Association of incident carcinoma of the endometrium with body weight and fat distribution in older women: early findings of the Iowa Women's Health Study. Cancer Res 1989 49(23): 6828-31. PMID: . Reason for Exclusion: DES

A. Fournier, F. Berrino and F. Clavel-Chapelon. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008 107(1): 103-11. PMID: . Reason for Exclusion: PTU

A. Fournier, F. Berrino, E. Riboli, V. Avenel and F. Clavel-Chapelon. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005 114(3): 448-54. PMID: . Reason for Exclusion: DES

A. Fournier, S. Mesrine, M. C. Boutron-Ruault and F. Clavel-Chapelon. Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?. J Clin Oncol 2009 27(31): 5138-43. PMID: . Reason for Exclusion: PTU

A. L. Franks, J. S. Kendrick and C. W. Tyler, Jr.. Postmenopausal smoking, estrogen replacement therapy, and the risk of endometrial cancer. Am J Obstet Gynecol 1987 156(1): 20-3. PMID: . Reason for Exclusion: DES

D. I. Fraser, A. Parsons, M. I. Whitehead, J. Wordsworth, G. Stuart and J. Pryse-Davies. The optimal dose of oral norethindrone acetate for addition to transdermal estradiol: a multicenter study. Fertil Steril 1990 53(3): 460-8. PMID: . Reason for Exclusion: NRO

S. E. Fugate and C. O. Church. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause. Ann Pharmacother 2004 38(9): 1482-99. PMID: . Reason for Exclusion: NRD

S. Furness, H. Roberts, J. Marjoribanks, A. Lethaby, M. Hickey and C. Farquhar. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2009 (2): CD000402. PMID: . Reason for Exclusion: PTU

S. R. Gabriel, L. Carmona, M. Roque, G. L. Sanchez and X. Bonfill. Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2005 (2): CD002229. PMID: . Reason for Exclusion: PTU

S. Gallus, E. Negri, L. Chatenoud, C. Bosetti, S. Franceschi and C. La Vecchia. Post-menopausal hormonal therapy and gallbladder cancer risk. Int J Cancer 2002 99(5): 762-3. PMID: . Reason for Exclusion: DES

M. Gambacciani, G. Rosano, B. Cappagli, A. Pepe, C. Vitale and A. R. Genazzani. Clinical and metabolic effects of drospirenone-estradiol in menopausal women: a prospective study. Climacteric 2011 14(1): 18-24. PMID: . Reason for Exclusion: NOP

R. D. Gambrell, Jr.. Hormone replacement therapy and breast cancer risk. Arch Fam Med 1996 5(6): 341-8. PMID: . Reason for Exclusion: NRD

S. M. Gapstur, M. Morrow and T. A. Sellers. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 1999 281(22): 2091-7. PMID: . Reason for Exclusion: DES

E. Garbe, L. Levesque and S. Suissa. Variability of breast cancer risk in observational studies of hormone replacement therapy: a meta-regression analysis. Maturitas 2004 47(3): 175-83. PMID: . Reason for Exclusion: PTU

P. P. Garg, K. Kerlikowske, L. Subak and D. Grady. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998 92(3): 472-9. PMID: . Reason for Exclusion: PTU

S. E. Geller, L. P. Shulman, R. B. van Breemen, S. Banuvar, Y. Zhou, G. Epstein, S. Hedayat, D. Nikolic, E. C. Krause, C. E. Piersen, J. L. Bolton, G. F. Pauli and N. R. Farnsworth. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. Menopause 2009 16(6): 1156-66. Reason for Exclusion: NOP

M. Gerhardsson de Verdier and S. London. Reproductive factors, exogenous female hormones, and colorectal cancer by subsite. Cancer Causes Control 1992 3(4): 355-60. PMID: . Reason for Exclusion: DES

D. M. Gertig, A. S. Fletcher, D. R. English, R. J. Macinnis, J. L. Hopper and G. G. Giles. Hormone therapy and breast cancer: what factors modify the association?. Menopause 2006 13(2): 178-84. PMID: . Reason for Exclusion: DES

B. Gigliotti, A. Multinu and V. R. Lai. Role of pivagabine in the treatment of climacteric syndrome. Arzneimittelforschung 1997 47(11A): 1317-21. PMID: . Reason for Exclusion: NRC

P. D. Gikas and K. Mokbel. Phytoestrogens and the risk of breast cancer: a review of the literature. Int J Fertil Womens Med 2005 50(6): 250-8. PMID: . Reason for Exclusion: NRD

E. Glud, S. K. Kjaer, B. L. Thomsen, C. Hogdall, L. Christensen, E. Hogdall, J. E. Bock and J. Blaakaer. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 2004 164(20): 2253-9. PMID: . Reason for Exclusion: DES

H. H. Goh, T. G. McCarthy, V. Dramusic, A. Costales, W. Junge and S. S. Ratnam. Endocrine effects in Asian postmenopausal women, treated with SH D 461 M and Prempak-C. Maturitas 1995 21(1): 17-25. PMID: . Reason for Exclusion: NRO

M. T. Goodman, J. B. Cologne, H. Moriwaki, M. Vaeth and K. Mabuchi. Risk factors for primary breast cancer in Japan: 8-year follow-up of atomic bomb survivors. Prev Med 1997 26(1): 144-53. PMID: . Reason for Exclusion: NRQ

S. Gordon, B. W. Walsh, A. V. Ciaccia, S. Siddhanti, A. S. Rosen and L. Plouffe, Jr.. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms. Obstet Gynecol 2004 103(2): 267-73. PMID: . Reason for Exclusion: NRQ

S. F. Gordon, K. A. Thompson, G. E. Ruoff, J. R. Imig, P. J. Lane and C. E. Schwenker. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: comparison with conjugated estrogens and placebo. The Transdermal Estradiol Patch Study Group. Int J Fertil Menopa Reason for Exclusion: NRF

A. Gordon. Red clover extracts not effective for hot flushes. Journal of Family Practice 2003 52(11): 846-848. PMID: . Reason for Exclusion: NCT

D. M. Grabrick, L. C. Hartmann, J. R. Cerhan, R. A. Vierkant, T. M. Therneau, C. M. Vachon, J. E. Olson, F. J. Couch, K. E. Anderson, V. S. Pankratz and T. A. Sellers. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000 284(Reason for Exclusion: NRC

D. Grady, D. Herrington, V. Bittner, R. Blumenthal, M. Davidson, M. Hlatky, J. Hsia, S. Hulley, A. Herd, S. Khan, L. K. Newby, D. Waters, E. Vittinghoff and N. Wenger. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Stu Reason for Exclusion: DES

D. Grady, N. K. Wenger, D. Herrington, S. Khan, C. Furberg, D. Hunninghake, E. Vittinghoff and S. Hulley. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000 132(9): 689-96. PMID: Reason for Exclusion: DES

D. Grady, T. Gebretsadik, K. Kerlikowske, V. Ernster and D. Petitti. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995 85(2): 304-13. PMID: . Reason for Exclusion: PTU

S. Graff-Iversen, N. Hammar, D. S. Thelle and S. Tonstad. Hormone therapy and mortality during a 14-year follow-up of 14 324 Norwegian women. J Intern Med 2004 256(5): 437-45. PMID: . Reason for Exclusion: DES

T. Graser, A. Muller, R. Druckman and M. Oettel. Effects of a combination of 2 MG estradiol valerate and 3 MG dienogest on coagulation, lipid profile, and glucose metabolism in postmenopausal women. Drugs of Today 2001 37(SUPPL. G): 87-99. PMID: . Reason for Exclusion: NRO

T. Graser, A. Muller, U. Mellinger, A. O. Muck, T. H. Lippert and M. Oettel. Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest - a dose-ranging study. Maturitas 2000 35(3): 253-61. PMID: . Reason for Exclusion: NOP

T. Graser, T. Romer, K. D. Wiedey and A. Janaud. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints. Climacteric 2001 4(4): 332-42. PMID: . Reason for Exclusion: NRP

A. Graziottin and A. Serafini. Depression and the menopause: why antidepressants are not enough?. Menopause Int 2009 15(2): 76-81. PMID: . Reason for Exclusion: NRD

J. Green, G. Czanner, G. Reeves, J. Watson, L. Wise, A. Roddam and V. Beral. Menopausal hormone therapy and risk of gastrointestinal cancer: Nested case-control study within a prospective cohort, and meta-analysis. International Journal of Cancer 2011 7(6): . PMID: . Reason for Exclusion: NRD

G. A. Greendale, B. A. Reboussin, P. Hogan, V. M. Barnabei, S. Shumaker, S. Johnson and E. Barrett-Connor. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998 92(6): 982-8. PMID: . Reason for Exclusion: NRO

P. Greenwald, T. A. Caputo and P. E. Wolfgang. Endometrial cancer after menopausal use of estrogens. Obstet Gynecol 1977 50(2): 239-43. PMID: . Reason for Exclusion: DES

C. M. Greiser, E. M. Greiser and M. Doren. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Hum Reprod Update 2005 11(6): 561-73. PMID: . Reason for Exclusion: PTU

C. M. Greiser, E. M. Greiser and M. Doren. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 2007 13(5): 453-63. PMID: . Reason for Exclusion: PTU

H. Griesser, S. Skonietzki, T. Fischer, K. Fielder and M. Suesskind. Low dose estriol pessaries for the treatment of vaginal atrophy: A double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas 2012 71(4): 360-36 Reason for Exclusion: NRO

D. A. Grimes and R. A. Lobo. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Obstet Gynecol 2002 100(6): 1344-53. PMID: . Reason for Exclusion: NCT

F. Grodstein and M. J. Stampfer. Estrogen for women at varying risk of coronary disease. Maturitas 1998 30(1): 19-26. PMID: . Reason for Exclusion: NCT

F. Grodstein, G. A. Colditz and M. J. Stampfer. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994 83(1): 5-11. PMID: . Reason for Exclusion: DES

F. Grodstein, J. E. Manson and M. J. Stampfer. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006 15(1): 35-44. PMID: . Reason for Exclusion: DES

F. Grodstein, J. E. Manson, M. J. Stampfer and K. Rexrode. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008 168(8): 861-6. PMID: . Reason for Exclusion: PTU

F. Grodstein, M. J. Stampfer, M. Falkeborn, T. Naessen and I. Persson. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology 1999 10(5): 476-80. PMID: . Reason for Exclusion: DES

F. Grodstein, M. J. Stampfer, S. Z. Goldhaber, J. E. Manson, G. A. Colditz, F. E. Speizer, W. C. Willett and C. H. Hennekens. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996 348(9033): 983-7. PMID: . Reason for Exclusion: DES

F. Guidozzi and A. Daponte. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer 1999 86(6): 1013-8. PMID: . Reason for Exclusion: DES

M. Gupta and K. Kohli. Current status of hormone replacement therapy in post menopausal women. Current Drug Therapy 2007 2(1): 11-15. PMID: . Reason for Exclusion: NCT

D. H. Gutteridge, M. L. Holzherr, R. W. Retallack, R. I. Price, R. K. Will, S. S. Dhaliwal, D. L. Faulkner, G. O. Stewart, B. G. Stuckey, R. L. Prince, R. A. Criddle, P. J. Drury, L. Tran, C. I. Bhagat, G. N. Kent and K. Jamrozik. A randomized trial comparing hormone replacement t Reason for Exclusion: DES

T. Guttuso Jr. Effective and clinically meaningful non-hormonal hot flash therapies. Maturitas 2012 (): . PMID: . Reason for Exclusion: NRD

C. Hagen, M. S. Christensen, C. Christiansen, K. E. Stocklund and I. Transbol. Effects of two years' estrogen-gestagen replacement on climacteric symptoms and gonadotropins in the early postmenopausal period. Acta Obstet Gynecol Scand 1982 61(3): 237-41. PMID: . Reason for Exclusion: NOP

D. Hailey, L. Sampietro-Colom, D. Marshall, R. Rico, A. Granados and J. Asua. The effectiveness of bone density measurement and associated treatments for prevention of fractures. An international collaborative review. Int J Technol Assess Health Care 1998 14(2): 237-54. PMID: . Reason for Exclusion: NRO

R. Haimov-Kochman and D. Hochner-Celnikier. Hot flashes revisited: pharmacological and herbal options for hot flashes management. What does the evidence tell us?. Acta Obstet Gynecol Scand 2005 84(10): 972-9. PMID: . Reason for Exclusion: NRD

C. Haines and M. I. Harwood. Gabapentin helpful for hot flushes in postmenopausal women. Journal of Family Practice 2003 52(7): 513-514. PMID: . Reason for Exclusion: DUP

C. J. Haines, S. M. Xing, K. H. Park, C. F. Holinka and M. K. Ausmanas. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) stud Reason for Exclusion: DUP

E. Hall, B. N. Frey and C. N. Soares. Non-hormonal treatment strategies for vasomotor symptoms: a critical review. Drugs 2011 71(3): 287-304. PMID: . Reason for Exclusion: NRD

R. Hardy. Vasomotor menopausal symptoms and risk of coronary heart disease: A life course perspective. Menopause 2011 18(2): 127-128. PMID: . Reason for Exclusion: NRQ

R. E. Harris, K. K. Namboodiri and E. L. Wynder. Breast cancer risk: effects of estrogen replacement therapy and body mass. J Natl Cancer Inst 1992 84(20): 1575-82. PMID: . Reason for Exclusion: DES

H. J. Hauselmann and R. Rizzoli. A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 2003 14(1): 2-12. PMID: . Reason for Exclusion: PTU

L. P. Hayes, D. G. Carroll and K. W. Kelley. Use of gabapentin for the management of natural or surgical menopausal hot flashes. Ann Pharmacother 2011 45(3): 388-94. PMID: . Reason for Exclusion: NRD

The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society. Menopause 2000 7(4): 215-29. PMID: . Reason for Exclusion: NCT

The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. Menopause 2005 12(5): 496-511; quiz 649. PMID: . Reason for Exclusion: NRD

S. R. Heckbert, N. S. Weiss, T. D. Koepsell, R. N. Lemaitre, N. L. Smith, D. S. Siscovick, D. Lin and B. M. Psaty. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch Intern Med 1997 157(12): 1330-6. PMID: . Reason for Exclusion: DES

B. Hedblad, J. Merlo, J. Manjer, G. Engstrom, G. Berglund and L. Janzon. Incidence of cardiovascular disease, cancer and death in postmenopausal women affirming use of hormone replacement therapy. Scand J Public Health 2002 30(1): 12-9. PMID: . Reason for Exclusion: DES

M. Hedelin, M. Lof, M. Olsson, H. Adlercreutz, S. Sandin and E. Weiderpass. Dietary phytoestrogens are not associated with risk of overall breast cancer but diets rich in coumestrol are inversely associated with risk of estrogen receptor and progesterone receptor negative breast t Reason for Exclusion: NRD

J. E. Heikkinen, R. T. Vaheri, S. M. Ahomaki, P. M. Kainulainen, A. T. Viitanen and U. M. Timonen. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: a comparison of six different treatment regimens. Am J Obstet Gynecol 2000 182(3): 560-7. Reason for Exclusion: NRO

J. Heikkinen, R. Vaheri and U. Timonen. A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: Update of safety and quality-of-life findings. J Br Menopause Soc 2006 12(3): 115-25. PMID: . Reason for Exclusion: NRC

J. Heikkinen, R. Vaheri and U. Timonen. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses. J Br Menopause Soc 2004 10(3): 95-102. PMID: . Reason for Exclusion: DES

A. B. Heinrich and O. T. Wolf. Investigating the effects of estradiol or estradiol/progesterone treatment on mood, depressive symptoms, menopausal symptoms and subjective sleep quality in older healthy hysterectomized women: a questionnaire study. Neuropsychobiology 2005 52(1): 17 Reason for Exclusion: NOP

E. Hemminki, P. Veerus, H. Pisarev, S. L. Hovi, P. Topo and H. Karro. The effects of postmenopausal hormone therapy on social activity, partner relationship, and sexual life - experience from the EPHT trial. BMC Womens Health 2009 9(): 16. PMID: . Reason for Exclusion: NRO

R. E. Hempling, C. Wong, M. S. Piver, N. Natarajan and C. J. Mettlin. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. Obstet Gynecol 1997 89(6): 1012-6. PMID: . Reason for Exclusion: DES

S. L. Hendrix. Hormone therapy: evolving concepts. Curr Opin Rheumatol 2003 15(4): 464-8. PMID: . Reason for Exclusion: NCT

J. B. Henrich, P. J. Kornguth, C. M. Viscoli and R. I. Horwitz. Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 1998 51(12): 1277-83. PMID: . Reason for Exclusion: DES

J. B. Henrich. The postmenopausal estrogen/breast cancer controversy. JAMA 1992 268(14): 1900-2. PMID: . Reason for Exclusion: PTU

D. Henry, J. Robertson, D. O'Connell and W. Gillespie. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. I. An assessment of the quality of randomized trials published between 1977 and 1995. Climacteric 1998 1(2): 92-111. PMID: . Reason for Exclusion: PTU

D. M. Herrington. Effects of oestrogen on cardiovascular events in postmenopausal women. European Heart Journal, Supplement 2001 3(M): M7-M11. PMID: . Reason for Exclusion: NCT

A. Heyerick, S. Vervarcke, H. Depypere, M. Bracke and D. De Keukeleire. A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. Maturitas 2006 54(2): 164-75. PMID: . Reason for Exclusion: NOP

N. G. Hildreth, J. L. Kelsey, V. A. LiVolsi, D. B. Fischer, T. R. Holford, E. D. Mostow, P. E. Schwartz and C. White. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 1981 114(3): 398-405. PMID: . Reason for Exclusion: DES

D. A. Hill, N. S. Weiss, S. A. Beresford, L. F. Voigt, J. R. Daling, J. L. Stanford and S. Self. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000 183(6): 1456-61. PMID: . Reason for Exclusion: DES

E. Hirvonen, N. Crona, T. Wahlstrom and A. C. Backstrom. Effect of an estradiol gel with monthly or quarterly progestogen on menopausal symptoms and bleeding. Climacteric 2000 3(4): 262-70. PMID: . Reason for Exclusion: NRD

M. A. Hlatky, D. Boothroyd, E. Vittinghoff, P. Sharp and M. A. Whooley. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002 287(5): 591-7. PMID: . Reason for Exclusion: NRP

H. N. Hodis and W. J. Mack. A "window of opportunity": The reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Research 2011 1379(): 244-252. PMID: . Reason for Exclusion: NCT

H. N. Hodis and W. J. Mack. Postmenopausal hormone therapy in clinical perspective. Menopause 2007 14(5): 944-57. PMID: . Reason for Exclusion: NCT

M. Hoffmeister, E. Raum, A. Krtschil, J. Chang-Claude and H. Brenner. No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy. Clin Pharmacol Ther 2009 86(4): 416-24. PMID: . Reason for Exclusion: PTU

C. W. Hogue, Jr., R. Fucetola, T. Hershey, A. Nassief, S. Birge, V. G. Davila-Roman, B. Barzilai, B. Thomas, K. B. Schechtman and K. Freedland. The role of postoperative neurocognitive dysfunction on quality of life for postmenopausal women 6 months after cardiac surgery. Anesth A Reason for Exclusion: NRP

E. Hoibraaten, E. Qvigstad, H. Arnesen, S. Larsen, E. Wickstrom and P. M. Sandset. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). T Reason for Exclusion: DES

R. J. Honkanen, K. Honkanen, H. Kroger, E. Alhava, M. Tuppurainen and S. Saarikoski. Risk factors for perimenopausal distal forearm fracture. Osteoporos Int 2000 11(3): 265-70. PMID: . Reason for Exclusion: DES

Hormone therapy. An update on risks and benefits. Mayo Clin Womens Healthsource 2009 Suppl(): 1-8. PMID: . Reason for Exclusion: NRD

P. L. Horn-Ross, E. M. John, A. J. Canchola, S. L. Stewart and M. M. Lee. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst 2003 95(15): 1158-64. PMID: . Reason for Exclusion: NRD

R. I. Horwitz and K. R. Stewart. Effect of clinical features on the association of estrogens and breast cancer. Am J Med 1984 76(2): 192-8. PMID: . Reason for Exclusion: DES

L. G. Howes, J. B. Howes and D. C. Knight. Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis. Maturitas 2006 55(3): 203-11. PMID: . Reason for Exclusion: NRD

A. J. Huang, G. F. Sawaya, E. Vittinghoff, F. Lin and D. Grady. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause 2009 16(4): 639-43. PMID: . Reason for Exclusion: NRP

Z. Hubayter and J. A. Simon. Testosterone therapy for sexual dysfunction in postmenopausal women. Climacteric 2008 11(3): 181-91. PMID: . Reason for Exclusion: NRD

T. Hudson. Latest study shows red clover relieves hot flashes. Alternative and Complementary Therapies 2003 9(3): 137. PMID: . Reason for Exclusion: NRD

B. S. Hulka. Links between hormone replacement therapy and neoplasia. Fertil Steril 1994 62(6 Suppl 2): 168S-175S. PMID: . Reason for Exclusion: NCT

S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs and E. Vittinghoff. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA Reason for Exclusion: DES

L. L. Humphrey, B. K. Chan and H. C. Sox. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002 137(4): 273-84. PMID: . Reason for Exclusion: PTU

L. L. Humphrey, L. M. A. Takano and B. K. S. Chan. Postmenopausal Hormone Replacement Therapy and Cardiovascular Disease [Internet].. 2002 (): . PMID: . Reason for Exclusion: PTU

K. H. Humphries and J. McElhaney. Hormone replacement therapy in the older adult. Geriatrics and Aging 2006 9(2): 114-118. PMID: . Reason for Exclusion: NCT

Y. A. Hundrup, S. Hoidrup, O. Ekholm, M. Davidsen and E. B. Obel. Risk of low-energy hip, wrist, and upper arm fractures among current and previous users of hormone replacement therapy: The Danish Nurse Cohort Study. Eur J Epidemiol 2004 19(12): 1089-95. PMID: . Reason for Exclusion: DES

K. Hunt, M. Vessey, K. McPherson and M. Coleman. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987 94(7): 620-35. PMID: . Reason for Exclusion: DES

A. L. Huntley and E. Ernst. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause 2003 10(5): 465-76. PMID: . Reason for Exclusion: NRD

A. L. Huntley and E. Ernst. Soy for the treatment of perimenopausal symptoms--a systematic review. Maturitas 2004 47(1): 1-9. PMID: . Reason for Exclusion: NRD

A. L. Huntley. Compounded or confused? Bioidentical hormones and menopausal health. Menopause Int 2011 17(1): 16-8. PMID: . Reason for Exclusion: NRQ

T. A. Hutchinson, S. M. Polansky and A. R. Feinstein. Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study. Lancet 1979 2(8145): 705-9. PMID: . Reason for Exclusion: DES

Y. Ishida and S. Kawai. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. Am J Med 2004 117(8): 549-55. PMID: . Reason for Exclusion: DES

N. Ishiwata, M. K. Melby, S. Mizuno and S. Watanabe. New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause 2009 16(1): 141-8. PMID: . Reason for Exclusion: NOP

J. Iwamoto, Y. Sato, T. Takeda and H. Matsumoto. High-dose vitamin K supplementation reduces fracture incidence in postmenopausal women: a review of the literature. Nutr Res 2009 29(4): 221-8. PMID: . Reason for Exclusion: NRQ

S. Jaakkola, H. K. Lyytinen, T. Dyba, O. Ylikorkala and E. Pukkala. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer 2011 128(7): 1644-51. PMID: . Reason for Exclusion: PTU

S. Jaakkola, H. Lyytinen, E. Pukkala and O. Ylikorkala. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol 2009 114(6): 1197-204. PMID: . Reason for Exclusion: PTU

R. D. Jackson, J. Wactawski-Wende, A. Z. LaCroix, M. Pettinger, R. A. Yood, N. B. Watts, J. A. Robbins, C. E. Lewis, S. A. Beresford, M. G. Ko, M. J. Naughton, S. Satterfield and T. Bassford. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal wome Reason for Exclusion: DES

A. Jacobs, U. Wegewitz, C. Sommerfeld, R. Grossklaus and A. Lampen. Efficacy of isoflavones in relieving vasomotor menopausal symptoms - A systematic review. Mol Nutr Food Res 2009 53(9): 1084-97. PMID: . Reason for Exclusion: NRD

O. E. Jaschevatzky, S. Anderman, A. Shalit, D. Kampf and S. Grunstein. The treatment of postmenopausal syndrome by monthly oral doses of quinestrol. Acta Obstet Gynecol Scand 1979 58(2): 175-8. PMID: . Reason for Exclusion: NRO

P. B. Jensen, J. Jensen, B. J. Riis, P. Rodbro, V. Strom and C. Christiansen. Climacteric symptoms after oral and percutaneous hormone replacement therapy. Maturitas 1987 9(3): 207-15. PMID: . Reason for Exclusion: NOP

S. S. Jick, K. W. Hagberg, J. A. Kaye and H. Jick. Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer. Obstet Gynecol 2009 113(1): 74-80. PMID: . Reason for Exclusion: PTU

H. Jick, L. E. Derby, M. W. Myers, C. Vasilakis and K. M. Newton. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996 348(9033): 981-3. PMID: . Reason for Exclusion: DES

M. M. Joffe, C. Byrne and G. A. Colditz. Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias. Epidemiology 2001 12(4): 429-38. PMID: . Reason for Exclusion: DES

E. Johannisson, C. F. Holinka and S. Arrenbrecht. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium. Int J Fertil Womens Med 1997 42 Suppl 2(): 388-98. PMID: . Reason for Exclusion: DES

O. E. Johansen and E. Qvigstad. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg. Adv Ther 2008 25(6): 525-51. PMID: . Reason for Exclusion: NCT

E. D. Johnson and D. G. Carroll. Venlafaxine and desvenlafaxine in the management of menopausal hot flashes. Pharmacy Practice 2011 9(3): 117-122. PMID: . Reason for Exclusion: NRD

R. G. Josse. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women. CMAJ 1996 155(7): 929-34. PMID: . Reason for Exclusion: NCT

H. J. Jou, P. Y. Ling and S. C. Wu. Comparison of 70 mg and 35 mg isoflavone soya supplement for menopause symptoms. Int J Gynaecol Obstet 2005 90(2): 159-60. PMID: . Reason for Exclusion: NOP

D. Kalogirou, G. Antoniou, P. Karakitsos, O. Kalogirou, D. Antoniou and L. Giannikos. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical finding Reason for Exclusion: NRO

S. Kapil K, T. O. Lawal, T. D. Locklear and G. B. Mahady. Black cohosh for menopause: Safety and efficacy issues and future perspectives. Drug Information Journal 2011 45(1): 37-44. PMID: . Reason for Exclusion: NRD

R. C. Kaplan, S. R. Heckbert, N. S. Weiss, P. W. Wahl, N. L. Smith, K. M. Newton and B. M. Psaty. Postmenopausal estrogens and risk of myocardial infarction in diabetic women. Diabetes Care 1998 21(7): 1117-21. PMID: . Reason for Exclusion: DES

J. Karlberg, L. A. Mattsson and I. Wiklund. A quality of life perspective on who benefits from estradiol replacement therapy. Acta Obstet Gynecol Scand 1995 74(5): 367-72. PMID: . Reason for Exclusion: DUP

N. G. Kase. Impact of hormone therapy for women aged 35 to 65 years, from contraception to hormone replacement. Gend Med 2009 6 Suppl 1(): 37-59. PMID: . Reason for Exclusion: NRO

M. Kaszkin-Bettag, B. M. Ventskovskiy, A. Kravchenko, R. Rettenberger, A. Richardson, P. W. Heger and M. Heger. The special extract ERr 731 of the roots of Rheum rhaponticum decreases anxiety and improves health state and general well-being in perimenopausal women. Menopause 2007 Reason for Exclusion: DUP

D. W. Kaufman, J. P. Kelly, W. R. Welch, L. Rosenberg, P. D. Stolley, M. E. Warshauer, J. Lewis, J. Woodruff and S. Shapiro. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 1989 130(6): 1142-51. PMID: . Reason for Exclusion: DES

D. W. Kaufman, J. R. Palmer, J. de Mouzon, L. Rosenberg, P. D. Stolley, M. E. Warshauer, A. G. Zauber and S. Shapiro. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 1991 134(12): 1375-85; discussion 1396 Reason for Exclusion: DES

K. W. Kelley and D. G. Carroll. Evaluating the evidence for over-the-counter alternatives for relief of hot flashes in menopausal women. J Am Pharm Assoc (2003) 2010 50(5): e106-15. PMID: . Reason for Exclusion: NRD

J. L. Kelsey, D. B. Fischer, T. R. Holford, V. A. LiVoisi, E. D. Mostow, I. S. Goldenberg and C. White. Exogenous estrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst 1981 67(2): 327-33. PMID: . Reason for Exclusion: DES

J. L. Kelsey, T. H. Keegan, M. M. Prill, C. P. Quesenberry, Jr. and S. Sidney. Risk factors for fracture of the shafts of the tibia and fibula in older individuals. Osteoporos Int 2006 17(1): 143-9. PMID: . Reason for Exclusion: DES

J. L. Kelsey, V. A. LiVolsi, T. R. Holford, D. B. Fischer, E. D. Mostow, P. E. Schwartz, T. O'Connor and C. White. A case-control study of cancer of the endometrium. Am J Epidemiol 1982 116(2): 333-42. PMID: . Reason for Exclusion: DES

S. K. Khoo and P. Chick. Sex steroid hormones and breast cancer: is there a link with oral contraceptives and hormone replacement therapy?. Med J Aust 1992 156(2): 124-32. PMID: . Reason for Exclusion: PTU

S. K. Khoo, M. Coglan, D. Battistutta, V. Tippett and B. Raphael. Hormonal treatment and psychological function during the menopausal transition: an evaluation of the effects of conjugated estrogens/cyclic medroxyprogesterone acetate. Climacteric 1998 1(1): 55-62. PMID: . Reason for Exclusion: NRP

D. P. Kiel, D. T. Felson, J. J. Anderson, P. W. Wilson and M. A. Moskowitz. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987 317(19): 1169-74. PMID: . Reason for Exclusion: DES

S. A. Kingsberg, J. A. Simon and I. Goldstein. The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2008 5 Suppl 4(): 182-93; quiz 193. PMID: . Reason for Exclusion: NRD

S. Kingsberg, J. Shifren, K. Wekselman, C. Rodenberg, P. Koochaki and L. Derogatis. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2007 4(4 Pt 1): 1001-8. Reason for Exclusion: DUP

V. Kirsh and N. Kreiger. Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control 2002 13(6): 583-90. PMID: . Reason for Exclusion: DES

S. J. Kittner and M. G. Bousser. Post-menopausal hormone replacement therapy and stroke risk. Cephalalgia 2000 20(3): 208-13. PMID: . Reason for Exclusion: NCT

D. C. Knight and J. A. Eden. A review of the clinical effects of phytoestrogens. Obstet Gynecol 1996 87(5 Pt 2): 897-904. PMID: . Reason for Exclusion: NRD

T. Kocjan and G. M. Prelevic. Hormone replacement therapy update: who should we be prescribing this to now?. Curr Opin Obstet Gynecol 2003 15(6): 459-64. PMID: . Reason for Exclusion: NCT

P. R. Koninckx, J. M. Lauweryns and F. J. Cornillie. Endometrial effects during hormone replacement therapy with a sequential oestradiol valerate/cyproterone acetate preparation. Maturitas 1993 16(2): 97-110. PMID: . Reason for Exclusion: NOP

J. Kotsopoulos, J. Lubinski, S. L. Neuhausen, H. T. Lynch, B. Rosen, P. Ainsworth, P. Moller, P. Ghadirian, C. Isaacs, B. Karlan, P. Sun and S. A. Narod. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 2006 100(1): 83- Reason for Exclusion: DES

K. Kotz, J. L. Alexander and L. Dennerstein. Estrogen and androgen hormone therapy and well-being in surgically postmenopausal women. J Womens Health (Larchmt) 2006 15(8): 898-908. PMID: . Reason for Exclusion: NRD

E. E. Krebs, K. E. Ensrud, R. MacDonald and T. J. Wilt. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol 2004 104(4): 824-36. PMID: . Reason for Exclusion: NRD

N. Kreiger, J. L. Kelsey, T. R. Holford and T. O'Connor. An epidemiologic study of hip fracture in postmenopausal women. Am J Epidemiol 1982 116(1): 141-8. PMID: . Reason for Exclusion: DES

N. Krieger. Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: critical reflections. Int J Epidemiol 2008 37(3): 627-37. PMID: . Reason for Exclusion: NRD

S. R. Kristensen, B. Abrahamsen, J. S. Madsen, J. Gram, L. Rejnmark, B. Rud and J. Jespersen. Venous thrombosis is not increased in younger women on genuine oestrogen postmenopausal hormonal replacement therapy: results from the Danish Osteoporosis Prevention Study (DOPS). Thromb. Reason for Exclusion: DES

D. Kritz-Silverstein, D. Von Muhlen, E. Barrett-Connor and M. A. Bressel. Isoflavones and cognitive function in older women: the SOy and Postmenopausal Health In Aging (SOPHIA) Study. Menopause 2003 10(3): 196-202. PMID: . Reason for Exclusion: NRO

F. Kronenberg and A. Fugh-Berman. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002 137(10): 805-13. PMID: . Reason for Exclusion: NRD

M. L. Krychman. Vaginal estrogens for the treatment of dyspareunia. Journal of Sexual Medicine 2011 8(3): 666-674. PMID: . Reason for Exclusion: NRD

C. Kupfersztain, C. Rotem, R. Fagot and B. Kaplan. The immediate effect of natural plant extract, Angelica sinensis and Matricaria chamomilla (Climex) for the treatment of hot flushes during menopause. A preliminary report. Clin Exp Obstet Gynecol 2003 30(4): 203-6. PMID: . Reason for Exclusion: NOP

M. S. Kurzer. Soy consumption for reduction of menopausal symptoms. Inflammopharmacology 2008 16(5): 227-9. PMID: . Reason for Exclusion: NRD

C. La Vecchia and S. Franceschi. Reproductive factors and colorectal cancer. Cancer Causes Control 1991 2(3): 193-200. PMID: . Reason for Exclusion: NRQ

C. La Vecchia, L. A. Brinton and A. McTiernan. Menopause, hormone replacement therapy and cancer. Maturitas 2001 39(2): 97-115. PMID: . Reason for Exclusion: NCT

C. La Vecchia, S. Franceschi, A. Decarli, G. Gallus and G. Tognoni. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst 1984 73(3): 667-71. PMID: . Reason for Exclusion: DES

C. La Vecchia, S. Franceschi, G. Gallus, A. Decarli, E. Colombo, C. Mangioni and G. Tognoni. Oestrogens and obesity as risk factors for endometrial cancer in Italy. Int J Epidemiol 1982 11(2): 120-6. PMID: . Reason for Exclusion: DES

C. La Vecchia, S. Gallus and E. Fernandez. Hormone replacement therapy and colorectal cancer: an update. J Br Menopause Soc 2005 11(4): 166-72. PMID: . Reason for Exclusion: PTU

C. La Vecchia. Sex hormones and cardiovascular risk. Hum Reprod 1992 7(2): 162-7. PMID: . Reason for Exclusion: NCT

F. Labrie, D. Archer, C. Bouchard, M. Fortier, L. Cusan, J. L. Gomez, G. Girard, M. Baron, N. Ayotte, M. Moreau, R. Dube, I. Cote, C. Labrie, L. Lavoie, L. Berger, C. Martel and J. Balser. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecol End Reason for Exclusion: NRO

F. Labrie, D. Archer, C. Bouchard, M. Fortier, L. Cusan, J. L. Gomez, G. Girard, M. Baron, N. Ayotte, M. Moreau, R. Dube, I. Cote, C. Labrie, L. Lavoie, L. Berger, L. Gilbert, C. Martel and J. Balser. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly eff Reason for Exclusion: DUP

F. Labrie, D. Archer, C. Bouchard, M. Fortier, L. Cusan, J. L. Gomez, G. Girard, M. Baron, N. Ayotte, M. Moreau, R. Dube, I. Cote, C. Labrie, L. Lavoie, R. Berube, P. Belanger, L. Berger, L. Gilbert, C. Martel and J. Balser. Serum steroid levels during 12-week intravaginal dehydro Reason for Exclusion: NRO

F. Labrie, D. F. Archer, C. Bouchard, M. Fortier, L. Cusan, J. L. Gomez, G. Girard, M. Baron, N. Ayotte, M. Moreau, R. Dube, I. Cote, C. Labrie, L. Lavoie, L. Berger, L. Gilbert, C. Martel and J. Balser. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatmen Reason for Exclusion: NRO

J. V. Lacey, Jr., L. A. Brinton, J. H. Lubin, M. E. Sherman, A. Schatzkin and C. Schairer. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005 14(7): 1724-31. P Reason for Exclusion: DES

J. V. Lacey, Jr., L. A. Brinton, M. F. Leitzmann, T. Mouw, A. Hollenbeck, A. Schatzkin and P. Hartge. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 2006 98(19): 1397-405. PMID: . Reason for Exclusion: NRF

A. Z. LaCroix, R. T. Chlebowski, J. E. Manson, A. K. Aragaki, K. C. Johnson, L. Martin, K. L. Margolis, M. L. Stefanick, R. Brzyski, J. D. Curb, B. V. Howard, C. E. Lewis and J. Wactawski-Wende. Health outcomes after stopping conjugated equine estrogens among postmenopausal women Reason for Exclusion: PTU

A. Z. LaCroix. Estrogen with and without progestin: benefits and risks of short-term use. Am J Med 2005 118 Suppl 12B(): 79-87. PMID: . Reason for Exclusion: NCT

F. W. Lafferty and M. E. Fiske. Postmenopausal estrogen replacement: a long-term cohort study. Am J Med 1994 97(1): 66-77. PMID: . Reason for Exclusion: DES

P. H. Lahmann, K. Hoffmann, N. Allen, C. H. van Gils, K. T. Khaw, B. Tehard, F. Berrino, A. Tjonneland, J. Bigaard, A. Olsen, K. Overvad, F. Clavel-Chapelon, G. Nagel, H. Boeing, D. Trichopoulos, G. Economou, G. Bellos, D. Palli, R. Tumino, S. Panico, C. Sacerdote, V. Krogh, P. H. Reason for Exclusion: DES

F. Laliberte, K. Dea, M. S. Duh, K. H. Kahler, M. Rolli and P. Lefebvre. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause 2011 18(10): 1052-9. Reason for Exclusion: PTU

. F laxseed consumption reduces menopausal symptoms. Oncology Report 2005 (SPRING): 133. PMID: . Reason for Exclusion: NCT

G. Le Gal, M. J. Kovacs, M. Carrier, K. Do, S. R. Kahn, P. S. Wells, D. A. Anderson, I. Chagnon, S. Solymoss, M. Crowther, M. Righini, K. Lacut, R. H. White, L. Vickars and M. Rodger. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from th Reason for Exclusion: PTU

M. J. Leach and V. Moore. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database of Systematic Reviews 2008 (3): . PMID: . Reason for Exclusion: NRD

Y. Lee, K. Dharmala and C. H. Lee. An intelligent data mining model approach for adverse effects of hormone replacement therapy. Methods Inf Med 2007 46(1): 5-18. PMID: . Reason for Exclusion: NRQ

S. Lee, L. Kolonel, L. Wilkens, P. Wan, B. Henderson and M. Pike. Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort. Int J Cancer 2006 118(5): 1285-91. PMID: . Reason for Exclusion: DES

S. A. Lee, R. K. Ross and M. C. Pike. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 2005 92(11): 2049-58. PMID: . Reason for Exclusion: PTU

R. N. Lemaitre, N. S. Weiss, N. L. Smith, B. M. Psaty, T. Lumley, E. B. Larson and S. R. Heckbert. Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. Arch Intern Med 2006 166(4): 399-404. PMID: . Reason for Exclusion: DES

R. N. Lemaitre, S. R. Heckbert, B. M. Psaty, N. L. Smith, R. C. Kaplan and W. T. Longstreth, Jr.. Hormone replacement therapy and associated risk of stroke in postmenopausal women. Arch Intern Med 2002 162(17): 1954-60. PMID: . Reason for Exclusion: DES

A. E. Lethaby, J. Brown, J. Marjoribanks, F. Kronenberg, H. Roberts and J. Eden. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007 (4): CD001395. PMID: . Reason for Exclusion: NRD

A. Lethaby, J. Suckling, D. Barlow, C. M. Farquhar, R. G. Jepson and H. Roberts. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004 (3): CD000402. PMID: . Reason for Exclusion: PTU

P. C. Leung, K. F. Cheng and Y. H. Chan. An innovative herbal product for the prevention of osteoporosis. Chin J Integr Med 2011 17(10): 744-9. PMID: . Reason for Exclusion: NRO

F. Levi, F. Lucchini, C. Pasche and C. La Vecchia. Oral contraceptives, menopausal hormone replacement treatment and breast cancer risk. Eur J Cancer Prev 1996 5(4): 259-66. PMID: . Reason for Exclusion: DES

D. W. Levine, M. E. Dailey, B. Rockhill, D. Tipping, M. J. Naughton and S. A. Shumaker. Validation of the Women's Health Initiative Insomnia Rating Scale in a multicenter controlled clinical trial. Psychosom Med 2005 67(1): 98-104. PMID: . Reason for Exclusion: NRQ

R. Li, F. D. Gilliland, K. Baumgartner and J. Samet. Hormone replacement therapy and breast carcinoma risk in Hispanic and non-Hispanic women. Cancer 2002 95(5): 960-8. PMID: . Reason for Exclusion: DES

C. Li, G. Engstrom, B. Hedblad, G. Berglund and L. Janzon. Risk of stroke and hormone replacement therapy. A prospective cohort study. Maturitas 2006 54(1): 11-8. PMID: . Reason for Exclusion: DES

C. I. Li, K. E. Malone and J. R. Daling. Interactions between body mass index and hormone therapy and postmenopausal breast cancer risk (United States). Cancer Causes Control 2006 17(5): 695-703. PMID: . Reason for Exclusion: DES

C. I. Li, K. E. Malone, P. L. Porter, T. J. Lawton, L. F. Voigt, K. L. Cushing-Haugen, M. G. Lin, X. Yuan and J. R. Daling. Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev 2008 17(1 Reason for Exclusion: PTU

C. I. Li, N. S. Weiss, J. L. Stanford and J. R. Daling. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000 88(11): 2570-7. PMID: . Reason for Exclusion: DES

C. I. Li. Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist. Maturitas 2004 49(1): 44-50. PMID: . Reason for Exclusion: NCT

E. Y. Liao, X. H. Luo, X. G. Deng, X. P. Wu, H. J. Liao, P. F. Wang, J. P. Mao, X. P. Zhu, G. Huang and Q. Y. Wei. The effect of low dose nylestriol-levonorgestrel replacement therapy on bone mineral density in women with postmenopausal osteoporosis. Endocr Res 2003 29(2): 217-26. Reason for Exclusion: DES

M. A. Limouzin-Lamothe, N. Mairon, C. R. Joyce and M. Le Gal. Quality of life after the menopause: influence of hormonal replacement therapy. Am J Obstet Gynecol 1994 170(2): 618-24. PMID: . Reason for Exclusion: NRC

K. K. Limpaphayom and S. Bunyavejchevin. Clinical effects of 17 beta-estradiol and norethisterone acetate in postmenopausal Thai women. J Med Assoc Thai 2000 83(4): 407-16. PMID: . Reason for Exclusion: NOP

T. J. Lin, J. L. So-Bosita, H. K. Brar and B. V. Roblete. Clinical and cytologic responses of postmenopausal women to estrogen. Obstet Gynecol 1973 41(1): 97-107. PMID: . Reason for Exclusion: DES

K. J. Lin, W. Y. Cheung, J. Y. Lai and E. L. Giovannucci. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer 2012 130(2): 419-30. PMID: . Reason for Exclusion: PTU

L. Lindh-Astrand, M. Bixo, A. L. Hirschberg, I. Sundstrom-Poromaa and M. Hammar. A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms. Menopause 2010 17(1): 72-9. PMID: . Reason for Exclusion: NRQ

R. Lindsay and D. M. Hart. Failure of response of menopausal vasomotor symptoms to clonidine. Maturitas 1978 1(1): 21-5. PMID: . Reason for Exclusion: NOP

L. Lipworth, K. Katsouyanni, S. Stuver, E. Samoli, S. E. Hankinson and D. Trichopoulos. Oral contraceptives, menopausal estrogens, and the risk of breast cancer: a case-control study in Greece. Int J Cancer 1995 62(5): 548-51. PMID: . Reason for Exclusion: DES

J. H. Liu and K. N. Muse. The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. Am J Obstet Gynecol 2005 192(4): 1316-23; discussion 1323-4. PMID: . Reason for Exclusion: DES

B. Liu, V. Beral, A. Balkwill, J. Green, S. Sweetland and G. Reeves. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 2008 337(): a386. PMID: . Reason for Exclusion: PTU

J. H. Liu. Therapeutic effects of progestins, androgens, and tibolone for menopausal symptoms. Am J Med 2005 118 Suppl 12B(): 88-92. PMID: . Reason for Exclusion: NRD

R. A. Lobo, J. V. Pinkerton, M. L. Gass, M. H. Dorin, S. Ronkin, J. H. Pickar and G. Constantine. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009 92(3): 1025 Reason for Exclusion: NRC

R. A. Lobo, S. Belisle, W. T. Creasman, N. R. Frankel, N. E. Goodman, J. E. Hall, S. L. Ivey, S. Kingsberg, R. Langer, R. Lehman, D. B. McArthur, V. Montgomery-Rice, M. Notelovitz, G. S. Packin, R. W. Rebar, M. Rousseau, R. S. Schenken, D. L. Schneider, K. Sherif and S. Wysocki. S Reason for Exclusion: NCT

R. A. Lobo. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. Arch Intern Med 2004 164(5): 482-4. PMID: . Reason for Exclusion: DES

R. A. Lobo. The risk of stroke in postmenopausal women receiving hormonal therapy. Climacteric 2009 12 Suppl 1(): 81-5. PMID: . Reason for Exclusion: PTU

D. M. Lochner and K. L. Brubaker. Incidence of malignancy in hormone therapy users with indeterminate calcifications on mammogram. Am J Obstet Gynecol 2006 194(1): 82-5. PMID: . Reason for Exclusion: DES

E. Lokkegaard, Z. Jovanovic, B. L. Heitmann, N. Keiding, B. Ottesen, Y. A. Hundrup, E. B. Obel and A. T. Pedersen. Increased risk of stroke in hypertensive women using hormone therapy: analyses based on the Danish Nurse Study. Arch Neurol 2003 60(10): 1379-84. PMID: . Reason for Exclusion: DES

S. London. HRT doesn't worsen breast cancer risk following oophorectomy. Oncology Report 2011 (JULY-AUGUST): 13. PMID: . Reason for Exclusion: NCT

M. P. Longnecker, L. Bernstein, A. Paganini-Hill, S. M. Enger and R. K. Ross. Risk factors for in situ breast cancer. Cancer Epidemiol Biomarkers Prev 1996 5(12): 961-5. PMID: . Reason for Exclusion: DES

W. T. Longstreth, L. M. Nelson, T. D. Koepsell and G. van Belle. Subarachnoid hemorrhage and hormonal factors in women. A population-based case-control study. Ann Intern Med 1994 121(3): 168-73. PMID: . Reason for Exclusion: DES

P. Lopes, H. M. Merkus, J. Nauman, F. Bruschi, J. M. Foidart and J. Calaf. Randomized comparison of intranasal and transdermal estradiol. Obstet Gynecol 2000 96(6): 906-12. PMID: . Reason for Exclusion: DUP

C. L. Loprinzi, D. L. Barton, J. A. Sloan, P. J. Novotny and S. Wolf. Newer antidepressants for hot flashes--should their efficacy still be up for debate?. Menopause 2009 16(1): 184-7. PMID: . Reason for Exclusion: NRD

C. L. Loprinzi, R. Qin, E. P. Balcueva, K. A. Flynn, K. M. Rowland, Jr., D. L. Graham, N. K. Erwin, S. R. Dakhil, D. J. Jurgens and K. N. Burger. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 2010 Reason for Exclusion: NRP

C. L. Loprinzi, V. Stearns and D. Barton. Centrally active nonhormonal hot flash therapies. Am J Med 2005 118 Suppl 12B(): 118-23. PMID: . Reason for Exclusion: NRD

T. Low Dog. Menopause: a review of botanical dietary supplements. Am J Med 2005 118 Suppl 12B(): 98-108. PMID: . Reason for Exclusion: NRD

G. Lowe, M. Woodward, M. Vessey, A. Rumley, P. Gough and E. Daly. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb Haemost 2000 83(4): 530-5. PMID: . Reason for Exclusion: DES

F. Lowry, K. Wachter and S. Worcester. Citalopram reduces hot flashes in randomized phase III trial. Oncology Report 2008 (FALL): 104. PMID: . Reason for Exclusion: NCT

E. G. Lufkin, H. W. Wahner, W. M. O'Fallon, S. F. Hodgson, M. A. Kotowicz, A. W. Lane, H. L. Judd, R. H. Caplan and B. L. Riggs. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992 117(1): 1-9. PMID: . Reason for Exclusion: DES

F. Lumachi, A. C. Frigo, U. Basso, V. Tombolan and M. Ermani. Estrogen therapy and risk of breast cancer in postmenopausal women: a case-control study and results of a multivariate analysis. Menopause 2010 17(3): 524-8. PMID: . Reason for Exclusion: PTU

E. Lund, K. Bakken, V. Dumeaux, V. Andersen and M. Kumle. Hormone replacement therapy and breast cancer in former users of oral contraceptives--The Norwegian Women and Cancer study. Int J Cancer 2007 121(3): 645-8. PMID: . Reason for Exclusion: PTU

H. K. Lyytinen, T. Dyba, O. Ylikorkala and E. I. Pukkala. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer 2010 126(2): 483-9. PMID: . Reason for Exclusion: PTU

P. H. M. Van De Weijer. Long-term adherence to continuous combined HRT: Seven-year update on the Heikkinen study. Journal of the British Menopause Society 2003 9(SUPPL. 1): 8-9. PMID: . Reason for Exclusion: NRO

A. H. MacLennan, A. MacLennan, S. Wenzel, H. M. Chambers and K. Eckert. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Med J Aust 1993 159(2): 102-6. PMID: . Reason for Exclusion: NRO

A. H. Maclennan, J. L. Broadbent, S. Lester and V. Moore. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004 (4): CD002978. PMID: . Reason for Exclusion: NRD

A. MacLennan, S. Lester and V. Moore. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 2001 4(1): 58-74. PMID: . Reason for Exclusion: NRD

D. J. Magliano, S. L. Rogers, M. J. Abramson and A. M. Tonkin. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 2006 113(1): 5-14. PMID: . Reason for Exclusion: PTU

C. Magnusson, J. A. Baron, N. Correia, R. Bergstrom, H. O. Adami and I. Persson. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999 81(3): 339-44. PMID: . Reason for Exclusion: DES

A. L. Magos, E. Brewster, R. Singh, T. O'Dowd, M. Brincat and J. W. Studd. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol 1986 93(12): 1290-6. PMID: . Reason for Exclusion: NOP

G. B. Mahady, D. Fabricant, L. R. Chadwick and B. Dietz. Black cohosh: an alternative therapy for menopause?. Nutr Clin Care 2002 5(6): 283-9. PMID: . Reason for Exclusion: NRD

R. Maheux, F. Naud, M. Rioux, R. Grenier, A. Lemay, J. Guy and M. Langevin. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994 170(2): 642-9. PMID: . Reason for Exclusion: NRO

P. M. Maki and E. Sundermann. Hormone therapy and cognitive function. Hum Reprod Update 2009 15(6): 667-81. PMID: . Reason for Exclusion: NRO

H. Mallmin, S. Ljunghall, I. Persson and R. Bergstrom. Risk factors for fractures of the distal forearm: a population-based case-control study. Osteoporos Int 1994 4(6): 298-304. PMID: . Reason for Exclusion: DES

M. M. Mamdani, K. Tu, C. van Walraven, P. C. Austin and C. D. Naylor. Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. CMAJ 2000 162(10): 1421-4. PMID: . Reason for Exclusion: DES

J. Manjer, J. Malina, G. Berglund, L. Bondeson, J. P. Garne and L. Janzon. Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer 2001 92(6): 919-22. PMID: . Reason for Exclusion: DES

J. Manonai, A. Chittacharoen, U. Theppisai and H. Theppisai. Effect of Pueraria mirifica on vaginal health. Menopause 2007 14(5): 919-24. PMID: . Reason for Exclusion: NOP

J. Manonai, S. Songchitsomboon, K. Chanda, J. H. Hong and S. Komindr. The effect of a soy-rich diet on urogenital atrophy: a randomized, cross-over trial. Maturitas 2006 54(2): 135-40. PMID: . Reason for Exclusion: NOP

J. Manonai, U. Theppisai, S. Suthutvoravut, U. Udomsubpayakul and A. Chittacharoen. The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. J Obstet Gynaecol Res 2001 27(5): 255-60. PMID: . Reason for Exclusion: NOP

J. E. Manson, J. Hsia, K. C. Johnson, J. E. Rossouw, A. R. Assaf, N. L. Lasser, M. Trevisan, H. R. Black, S. R. Heckbert, R. Detrano, O. L. Strickland, N. D. Wong, J. R. Crouse, E. Stein and M. Cushman. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003 349(6): 523-34. Reason for Exclusion: DES

P. A. Marchbanks, J. A. McDonald, H. G. Wilson, S. G. Folger, M. G. Mandel, J. R. Daling, L. Bernstein, K. E. Malone, G. Ursin, B. L. Strom, S. A. Norman, P. A. Wingo, R. T. Burkman, J. A. Berlin, M. S. Simon, R. Spirtas and L. K. Weiss. Oral contraceptives and the risk of breast Reason for Exclusion: NRC

D. Marchesoni, B. Mozzanega, T. Maggino and G. B. Nardelli. Postmenopausal hot flushes: Endocrine correlations and progestinic treatment. Double blind crossed clinical trial using MPA versus placebo. Journal of Gynaecological Endocrinology 1985 1(1-2): 63-69. PMID: . Reason for Exclusion: NOP

U. Marslew, B. J. Riis and C. Christiansen. Bleeding patterns during continuous combined estrogen-progestogen therapy. Am J Obstet Gynecol 1991 164(5 Pt 1): 1163-8. PMID: . Reason for Exclusion: NOP

U. Marslew, B. J. Riis and C. Christiansen. Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Eur J Clin Invest 1991 21(6): 601-7. PMID: . Reason for Exclusion: NOP

U. Marslew, B. Riis and C. Christiansen. Progestogens: therapeutic and adverse effects in early post-menopausal women. Maturitas 1991 13(1): 7-16. PMID: . Reason for Exclusion: NOP

U. Marslew, K. Overgaard, B. J. Riis and C. Christiansen. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Obstet Gynecol 1992 79(2): 202-10. PM Reason for Exclusion: NOP

U. Marslew, N. Munk-Nielsen, L. Nilas, B. J. Riis and C. Christiansen. Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use. Maturitas 1994 19(3): 225-37. PMID: . Reason for Exclusion: NOP

P. Marx, G. Schade, S. Wilbourn, S. Blank, D. L. Moyer and R. Nett. Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis. Maturitas 2004 47(1): 47-54. PMID: . Reason for Exclusion: NRO

G. Maskarinec. Soy foods and cancer risk: How does the relation vary in individuals with different ethnicity, diet, and lifestyle?. Cancer Prevention Research 2010 3(12): . PMID: . Reason for Exclusion: NRD

P. Mason. Isoflavones. Pharmaceutical Journal 2001 266(7129): 16-19. PMID: . Reason for Exclusion: NCT

L. A. Mattsson, S. O. Skouby, J. Heikkinen, R. Vaheri, J. Maenpaa and U. Timonen. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen. Climacteric 2004 7(1): 59-69. PMID Reason for Exclusion: NRO

P. Maxim, B. Ettinger and G. M. Spitalny. Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995 5(1): 23-9. PMID: . Reason for Exclusion: DES

T. W. McDonald, J. F. Annegers, W. M. O'Fallon, M. B. Dockerty, G. D. Malkasian, Jr. and L. T. Kurland. Exogenous estrogen and endometrial carcinoma: case-control and incidence study. Am J Obstet Gynecol 1977 127(6): 572-80. PMID: . Reason for Exclusion: DES

J. A. McDonald, N. S. Weiss, J. R. Daling, A. M. Francis and L. Polissar. Menopausal estrogen use and the risk of breast cancer. Breast Cancer Res Treat 1986 7(3): 193-9. PMID: . Reason for Exclusion: DES

A. McKay. Alexander, J.L., Kotz, K., Dennerstein, L. et al. (2004). The effects of postmenopausal hormone therapies on female sexual functioning: A review of double-blind, randomized controlled trials. Menopause, 11, 749-765. Canadian Journal of Human Sexuality 2004 13(2): 126. PM Reason for Exclusion: NRD

V. A. McKeon. Hormone replacement therapy: evaluating the risks and benefits. J Obstet Gynecol Neonatal Nurs 1994 23(8): 647-57. PMID: . Reason for Exclusion: NCT

T. L. McMillan and S. Mark. Complementary and alternative medicine and physical activity for menopausal symptoms. J Am Med Womens Assoc 2004 59(4): 270-7. PMID: . Reason for Exclusion: NRD

N. Mendoza, J. A. Pison, M. Fernandez, M. C. Sanchez, J. Malde and J. A. Miranda. Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus. Maturitas 2002 41(4): 289-98. PMID: . Reason for Exclusion: NRC

C. N. Mhurchu, C. Anderson, K. Jamrozik, G. Hankey and D. Dunbabin. Hormonal factors and risk of aneurysmal subarachnoid hemorrhage: an international population-based, case-control study. Stroke 2001 32(3): 606-12. PMID: . Reason for Exclusion: DES

R. G. Miller and B. H. Ashar. Managing menopause: Current therapeutic options for vasomotor symptoms. Advanced Studies in Medicine 2004 4(9): 484-492+494. PMID: . Reason for Exclusion: NRD

J. Miller, B. K. Chan and H. D. Nelson. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002 136(9): 680-90. PMID: . Reason for Exclusion: PTU

J. Miller, B. K. S. Chan and H. Nelson. Hormone Replacement Therapy and Risk of Venous Thromboembolism [Internet].. 2002 (): . PMID: . Reason for Exclusion: PTU

P. K. Mills, W. L. Beeson, R. L. Phillips and G. E. Fraser. Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer 1989 64(3): 591-7. PMID: . Reason for Exclusion: DES

H. Mizunuma, H. Honjo, T. Aso, M. Urabe, H. Ohta, S. Kobayashi, Y. Sagara, M. Sanada, K. Tanaka, K. Dobashi, K. Hayashi and K. Ohama. Postmenopausal hormone replacement therapy use and risk of endometrial cancer in Japanese women. Climacteric 2001 4(4): 293-8. PMID: . Reason for Exclusion: DES

K. Modelska and S. Cummings. Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. Am J Obstet Gynecol 2003 188(1): 286-93. PMID: . Reason for Exclusion: NRD

F. Modugno, K. E. Kip, B. Cochrane, L. Kuller, T. L. Klug, T. E. Rohan, R. T. Chlebowski, N. Lasser and M. L. Stefanick. Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. Int J Cancer 2006 118(5): 1292-301. PMID: . Reason for Exclusion: DES

K. E. Moe. Hot flashes and sleep in women. Sleep Med Rev 2004 8(6): 487-97. PMID: . Reason for Exclusion: NCT

B. Mohandas and J. L. Mehta. Lessons from hormone replacement therapy trials for primary prevention of cardiovascular disease. Curr Opin Cardiol 2007 22(5): 434-42. PMID: . Reason for Exclusion: NCT

J. C. Montgomery, L. Appleby, M. Brincat, E. Versi, A. Tapp, P. B. Fenwick and J. W. Studd. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet 1987 1(8528): 297-9. PMID: . Reason for Exclusion: NOP

P. G. Moorman, H. Kuwabara, R. C. Millikan and B. Newman. Menopausal hormones and breast cancer in a biracial population. Am J Public Health 2000 90(6): 966-71. PMID: . Reason for Exclusion: DES

P. G. Moorman, J. M. Schildkraut, B. Calingaert, S. Halabi and A. Berchuck. Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol 2005 193(1): 76-82. PMID: . Reason for Exclusion: DES

L. S. Morch, E. Lokkegaard, A. H. Andreasen, S. Kruger-Kjaer and O. Lidegaard. Hormone therapy and ovarian cancer. JAMA 2009 302(3): 298-305. PMID: . Reason for Exclusion: PTU

L. M. Morimoto, P. A. Newcomb, J. M. Hampton and A. Trentham-Dietz. Cholecystectomy and endometrial cancer: a marker of long-term elevated estrogen exposure?. Int J Gynecol Cancer 2006 16(3): 1348-53. PMID: . Reason for Exclusion: PTU

E. P. Morris and J. Rymer. Menopausal symptoms. Clin Evid (Online) 2007 2007(): . PMID: . Reason for Exclusion: DUP

L. Mosca. The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Intern Med 2000 160(15): 2263-72. PMID: . Reason for Exclusion: NCT

M. J. Mourits and D. E. B. GH. Exogenous steroids for menopausal symptoms and breast/endometrial cancer risk. Int J Gynecol Cancer 2006 16 Suppl 2(): 494-6. PMID: . Reason for Exclusion: NCT

A. O. Mueck, H. Seeger and T. Rabe. Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer 2010 17(4): R263-71. PMID: . Reason for Exclusion: NRQ

L. Nachtigall, P. Casson, J. Lucas, V. Schofield, C. Melson and J. A. Simon. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol 2011 27(1): 39-48. PMID: . Reason for Exclusion: NRO

L. E. Nachtigall, R. H. Nachtigall, R. D. Nachtigall and E. M. Beckman. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979 54(1): 74-9. PMID: . Reason for Exclusion: DES

L. E. Nachtigall, R. J. Baber, R. Barentsen, N. Durand, N. Panay, J. Pitkin, P. H. van de Weijer and S. Wysocki. Complementary and hormonal therapy for vasomotor symptom relief: a conservative clinical approach. J Obstet Gynaecol Can 2006 28(4): 279-89. PMID: . Reason for Exclusion: NRD

L. E. Nachtigall. Clinical trial of the estradiol vaginal ring in the U.S. Maturitas 1995 22 Suppl(): S43-7. PMID: . Reason for Exclusion: NRO

G. V. Nair, L. A. Chaput, E. Vittinghoff and D. M. Herrington. Pulse pressure and cardiovascular events in postmenopausal women with coronary heart disease. Chest 2005 127(5): 1498-506. PMID: . Reason for Exclusion: DES

K. Nanda, L. A. Bastian, V. Hasselblad and D. L. Simel. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999 93(5 Pt 2): 880-8. PMID: . Reason for Exclusion: PTU

R. E. Nappi and F. Polatti. The use of estrogen therapy in women's sexual functioning (CME). J Sex Med 2009 6(3): 603-16; quiz 618-9. PMID: . Reason for Exclusion: NRD

J. Nathorst-Boos, I. Wiklund, L. A. Mattsson, K. Sandin and B. von Schoultz. Is sexual life influenced by transdermal estrogen therapy? A double blind placebo controlled study in postmenopausal women. Acta Obstet Gynecol Scand 1993 72(8): 656-60. PMID: . Reason for Exclusion: NRO

K. Nazeri, A. Khatibi, P. Nyberg, C. D. Agardh, J. Lidfeldt and G. Samsioe. Colorectal cancer in middle-aged women in relation to hormonal status: a report from the Women's Health in the Lund Area (WHILA) study. Gynecol Endocrinol 2006 22(8): 416-22. PMID: . Reason for Exclusion: DES

A. Nedrow, J. Miller, M. Walker, P. Nygren, L. H. Huffman and H. D. Nelson. Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 2006 166(14): 1453-65. PMID: . Reason for Exclusion: NRD

E. Negri, A. Tzonou, V. Beral, P. Lagiou, D. Trichopoulos, F. Parazzini, S. Franceschi, M. Booth and C. La Vecchia. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer 1999 80(6): 848-51. PMID: . Reason for Exclusion: DES

H. D. Nelson, E. Haney, L. Humphrey, J. Miller, A. Nedrow, C. Nicolaidis, K. Vesco, M. Walker, C. Bougatsos and P. Nygren. Management of menopause-related symptoms. Evid Rep Technol Assess (Summ) 2005 (120): 1-6. PMID: . Reason for Exclusion: NRD

H. D. Nelson, J. Rizzo, E. Harris, J. Cauley, K. Ensrud, D. C. Bauer and E. Orwoll. Osteoporosis and fractures in postmenopausal women using estrogen. Arch Intern Med 2002 162(20): 2278-84. PMID: . Reason for Exclusion: DES

H. D. Nelson, K. K. Vesco, E. Haney, R. Fu, A. Nedrow, J. Miller, C. Nicolaidis, M. Walker and L. Humphrey. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006 295(17): 2057-71. PMID: . Reason for Exclusion: NRD

H. D. Nelson, L. L. Humphrey, P. Nygren, S. M. Teutsch and J. D. Allan. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002 288(7): 872-81. PMID: . Reason for Exclusion: PTU

H. D. Nelson. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004 291(13): 1610-20. PMID: . Reason for Exclusion: NRD

H. D. Nelson. Hormone Replacement Therapy and Osteoporosis [Internet].. 2002 (): . PMID: . Reason for Exclusion: PTU

B. I. Nesheim and T. Saetre. Reduction of menopausal hot flushes by methyldopa. A double blind crossover trial. Eur J Clin Pharmacol 1981 20(6): 413-6. PMID: . Reason for Exclusion: NOP

R. B. Ness, J. D. Albano, A. McTiernan and J. A. Cauley. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med 2009 169(1): 41-6. PMID: . Reason for Exclusion: NRF

P. A. Newcomb and A. Trentham-Dietz. Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control 2003 14(2): 195-201. PMID: . Reason for Exclusion: DES

P. A. Newcomb, J. O. Taylor and A. Trentham-Dietz. Interactions of familial and hormonal risk factors for large bowel cancer in women. Int J Epidemiol 1999 28(4): 603-8. PMID: . Reason for Exclusion: DES

P. A. Newcomb, L. Titus-Ernstoff, K. M. Egan, A. Trentham-Dietz, J. A. Baron, B. E. Storer, W. C. Willett and M. J. Stampfer. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002 11(7): 593-600. PMID: . Reason for Exclusion: DES

P. A. Newcomb, M. P. Longnecker, B. E. Storer, R. Mittendorf, J. Baron, R. W. Clapp, G. Bogdan and W. C. Willett. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995 142(8): 788-95. PMID: . Reason for Exclusion: DES

L. M. Newcomer, P. A. Newcomb, A. Trentham-Dietz and B. E. Storer. Hormonal risk factors for endometrial cancer: modification by cigarette smoking (United States). Cancer Causes Control 2001 12(9): 829-35. PMID: . Reason for Exclusion: DES

L. M. Newcomer, P. A. Newcomb, J. D. Potter, Y. Yasui, A. Trentham-Dietz, B. E. Storer, M. P. Longnecker, J. A. Baron and J. R. Daling. Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 2003 14(3): 225-33. PMID: . Reason for Exclusion: DES

W. K. Nicholson, A. F. Brown, J. Gathe, K. Grumbach, A. E. Washington and E. J. Perez-Stable. Hormone replacement therapy for African American women: missed opportunities for effective intervention. Menopause 1999 6(2): 147-55. PMID: . Reason for Exclusion: NRQ

E. Nikander, E. M. Rutanen, P. Nieminen, T. Wahlstrom, O. Ylikorkala and A. Tiitinen. Lack of effect of isoflavonoids on the vagina and endometrium in postmenopausal women. Fertil Steril 2005 83(1): 137-42. PMID: . Reason for Exclusion: NRO

A. Nomura, T. Hirohata, L. Kolonel and J. Hankin. Diet and exogenous estrogens in three populations at different levels of risk for breast cancer. Natl Cancer Inst Monogr 1977 47(): 165-7. PMID: . Reason for Exclusion: DES

B. E. Nordin, M. M. Jones, R. G. Crilly, D. H. Marshall and R. Brooke. A placebo-controlled trial of ethinyl oestradiol and norethisterone in climacteric women. Maturitas 1980 2(3): 247-51. PMID: . Reason for Exclusion: NOP

S. A. Norman, A. L. Weber, A. R. Localio, P. A. Marchbanks, G. Ursin, B. L. Strom, L. K. Weiss, R. T. Burkman, L. Bernstein, D. M. Deapen, S. G. Folger, M. S. Simon and M. R. Nadel. Hormone therapy and fatal breast cancer. Pharmacoepidemiol Drug Saf 2010 19(5): 440-7. PMID: . Reason for Exclusion: PTU

S. A. Norman, J. A. Berlin, A. L. Weber, B. L. Strom, J. R. Daling, L. K. Weiss, P. A. Marchbanks, L. Bernstein, L. F. Voigt, J. A. McDonald, G. Ursin, J. M. Liff, R. T. Burkman, K. E. Malone, M. S. Simon, S. G. Folger, D. Deapen, P. A. Wingo and R. Spirtas. Combined effect of ora Reason for Exclusion: DES

G. D. O. Lowe. Update on the cardiovascular risks of hormone replacement therapy. Women's Health 2007 3(1): 87-97. PMID: . Reason for Exclusion: NCT

E. B. Obel, N. Munk-Jensen, B. Svenstrup, P. Bennett, S. Micic, R. Henrik-Nielsen, S. P. Nielsen, H. Gydesen and B. M. Jensen. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism durin Reason for Exclusion: DUP

N. Obi, J. Chang-Claude, J. Berger, W. Braendle, T. Slanger, M. Schmidt, K. Steindorf, W. Ahrens and D. Flesch-Janys. The use of herbal preparations to alleviate climacteric disorders and risk of postmenopausal breast cancer in a German case-control study. Cancer Epidemiol Biomark Reason for Exclusion: NRD

D. O'Connell, J. Robertson, D. Henry and W. Gillespie. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects. Climacteric 1998 1(2): 112-23. PMID: . Reason for Exclusion: NRO

R. R. Odem, M. H. Moniz, J. E. Allsworth, C. R. Bleckman, V. A. Omicioli, L. T. Lawrence and P. H. Thaker. Long-term postmenopausal hormone therapy and endometrial cancer risk: a study by Doherty et al. Am J Obstet Gynecol 2007 197(2): 213-4; discussion e1-5. PMID: . Reason for Exclusion: DUP

I. S. Odmark, T. Backstrom, B. Jonsson and M. Bixo. Long-term effects of two different continuous combined regimens of hormone replacement therapy on well-being. Gynecol Endocrinol 2004 18(6): 305-17. PMID: . Reason for Exclusion: NRC

Oestrogen increases the risk of stroke but has no effect on coronary heart disease in healthy post-menopausal women. Evidence-Based Healthcare and Public Health 2004 8(5): 308-309. PMID: . Reason for Exclusion: DES

K. J. Oh, M. J. Chae, H. S. Lee, H. D. Hong and K. Park. Effects of Korean red ginseng on sexual arousal in menopausal women: placebo-controlled, double-blind crossover clinical study. J Sex Med 2010 7(4 Pt 1): 1469-77. PMID: . Reason for Exclusion: NOP

T. Ohira, A. R. Folsom, M. Cushman, R. H. White, P. J. Hannan, W. D. Rosamond and S. R. Heckbert. Reproductive history, hormone replacement, and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology. Br J Haematol 2010 149(4): 606-12. PMID Reason for Exclusion: PTU

V. Olie, M. Canonico and P. Y. Scarabin. Postmenopausal hormone therapy and venous thromboembolism. Thromb Res 2011 127 Suppl 3(): S26-9. PMID: . Reason for Exclusion: PTU

V. Olie, M. Canonico and P. Y. Scarabin. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 2010 17(5): 457-63. PMID: . Reason for Exclusion: PTU

H. Olsson, A. Bladstrom and C. Ingvar. Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy?. Obstet Gynecol 2003 102(3): 565-70. PMID: . Reason for Exclusion: DES

H. Olsson, A. Bladstrom, C. Ingvar and T. R. Moller. A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer 2001 85(5): 674-7. PMID: . Reason for Exclusion: DES

H. L. Olsson, C. Ingvar and A. Bladstrom. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003 97(6): 1387-92. PMID: . Reason for Exclusion: DES

Conjugated equine estradiol and 17(beta)-estradiol effectively relieve hot flashes in menopausal women. Evidence-Based Healthcare and Public Health 2004 8(5): 310-311. PMID: . Reason for Exclusion: NRD

Conjugated equine oestrogen increases the risk of venous thrombosis in post-menopausal women. Evidence-Based Healthcare and Public Health 2005 9(2): 161-162. PMID: . Reason for Exclusion: DES

L. Opatrny, S. Dell'Aniello, S. Assouline and S. Suissa. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 2008 115(2): 169-75; discussion 175. PMID: . Reason for Exclusion: PTU

Hormone replacement best for women < 60 years. South African Family Practice 2005 47(1): 20. PMID: . Reason for Exclusion: DUP

Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002 137(10): 834-9. PMID: . Reason for Exclusion: NCT

Postmenopausal hormone therapy: cardiovascular risks. Prescrire Int 2003 12(64): 65-9. PMID: . Reason for Exclusion: DES

M. L. Padwick, N. C. Siddle, G. Lane, J. A. Endacott, H. Cooper, J. Pryse-Davies and M. I. Whitehead. Oestriol with oestradiol verses oestradiol alone: a comparison of endometrial, symptomatic and psychological effects. Br J Obstet Gynaecol 1986 93(6): 606-12. PMID: . Reason for Exclusion: NOP

A. Paganini-Hill, R. K. Ross and B. E. Henderson. Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer 1989 59(3): 445-7. PMID: . Reason for Exclusion: DES

A. Paganini-Hill, R. K. Ross and B. E. Henderson. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 1988 297(6647): 519-22. PMID: . Reason for Exclusion: DES

A. Paganini-Hill. Estrogen replacement therapy in the elderly. Zentralbl Gynakol 1996 118(5): 255-61. PMID: . Reason for Exclusion: DES

L. Pal, S. M. Hailpern, N. F. Santoro, R. Freeman, D. Barad, S. Kipersztok, V. M. Barnabei and S. Wassertheil-Smoller. Increased incident hip fractures in postmenopausal women with moderate to severe pelvic organ prolapse. Menopause 2011 18(9): 967-973. PMID: . Reason for Exclusion: PTU

C. Palacio, G. Masri and A. D. Mooradian. Black cohosh for the management of menopausal symptoms : a systematic review of clinical trials. Drugs Aging 2009 26(1): 23-36. PMID: . Reason for Exclusion: NRD

S. Palacios. Managing urogenital atrophy. Maturitas 2009 63(4): 315-8. PMID: . Reason for Exclusion: NRD

N. Panay, K. Toth, C. Pelissier and J. Studd. Dose-ranging studies of a novel intranasal estrogen replacement therapy. Maturitas 2001 38 Suppl 1(): S15-22. PMID: . Reason for Exclusion: NOP

N. Panay. Taking an integrated approach: managing women with phytoestrogens. Climacteric 2011 14 Suppl 2(): 2-7. PMID: . Reason for Exclusion: NCT

M. Panjari and S. R. Davis. DHEA for postmenopausal women: a review of the evidence. Maturitas 2010 66(2): 172-9. PMID: . Reason for Exclusion: NRD

M. Panjari and S. R. Davis. DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update 2007 13(3): 239-48. PMID: . Reason for Exclusion: NRD

M. Panjari and S. R. Davis. Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas 2011 70(1): 22-5. PMID: . Reason for Exclusion: NRD

M. Panjari, R. J. Bell, F. Jane, J. Adams, C. Morrow and S. R. Davis. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas 2009 63(3): 240-5. PMID: . Reason for Exclusion: NRO

F. Parazzini, E. Negri, C. La Vecchia, P. Bruzzi and A. Decarli. Population attributable risk for endometrial cancer in northern Italy. Eur J Cancer Clin Oncol 1989 25(10): 1451-6. PMID: . Reason for Exclusion: DES

B. D. Park, S. Lookinland, R. L. Beckstrand and S. Chasson. Factor V Leiden and venous thromboembolism: risk associated with hormone replacement therapy. J Am Acad Nurse Pract 2003 15(10): 458-66. PMID: . Reason for Exclusion: PTU

B. L. Parry, C. J. Meliska, L. F. Martinez, N. Basavaraj, G. G. Zirpoli, D. Sorenson, E. L. Maurer, A. Lopez, K. Markova, A. Gamst, T. Wolfson, R. Hauger and D. F. Kripke. Menopause: neuroendocrine changes and hormone replacement therapy. J Am Med Womens Assoc 2004 59(2): 135-45. Reason for Exclusion: NOP

J. A. Pasco, M. A. Kotowicz, M. J. Henry, K. M. Sanders and G. C. Nicholson. Health outcomes associated with hormone therapy in Australian women. Curr Drug Saf 2009 4(3): 169-72. PMID: . Reason for Exclusion: PTU

C. L. Pearce, K. Chung, M. C. Pike and A. H. Wu. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 2009 115(3): 531-9. PMID: . Reason for Exclusion: PTU

S. H. Pedersen, E. Lokkegaard and B. Ottesen. Hormone theraphy and cardiovascular risk markers and disease: Focus on progestagens. Future Cardiology 2006 2(6): 677-686. PMID: . Reason for Exclusion: NCT

K. Peeyananjarassri and R. Baber. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric 2005 8(1): 13-23. PMID: . Reason for Exclusion: NRO

K. Pentti, R. Honkanen, M. T. Tuppurainen, L. Sandini, H. Kroger and S. Saarikoski. Hormone replacement therapy and mortality in 52- to 70-year-old women: the Kuopio Osteoporosis Risk Factor and Prevention Study. Eur J Endocrinol 2006 154(1): 101-7. PMID: . Reason for Exclusion: PTU

J. L. Perez-Castrillon, D. De Luis, G. Hernandez and A. Duenas-Laita. Isoflavones and bone health. Current Women's Health Reviews 2009 5(3): 125-129. PMID: . Reason for Exclusion: NRO

F. R. Perez-Lopez, P. Chedraui, J. J. Gilbert and G. Perez-Roncero. Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women's Health Initiative era. Fertil Steril 2009 92(4): 1171-86. PMID: . Reason for Exclusion: NCT

J. A. Perlman, P. H. Wolf, R. Ray and G. Lieberknecht. Cardiovascular risk factors, premature heart disease, and all-cause mortality in a cohort of northern California women. Am J Obstet Gynecol 1988 158(6 Pt 2): 1568-74. PMID: . Reason for Exclusion: DES

I. Persson, H. O. Adami, B. S. Lindberg, E. D. Johansson and P. Manell. Characteristics of estrogen-treated women. A descriptive epidemiological study of a Swedish population. Part II. Acta Obstet Gynecol Scand 1983 62(4): 297-302. PMID: . Reason for Exclusion: DES

I. R. Persson, H. O. Adami, G. Eklund, E. D. Johansson, B. S. Lindberg and A. Lindgren. The risk of endometrial neoplasia and treatment with estrogens and estrogen-progestogen combinations. First results of a cohort study after one to four completed years of observation. Acta Obst. Reason for Exclusion: DES

I. Persson. The risk of endometrial and breast cancer after estrogen treatment. A review of epidemiological studies. Acta Obstet Gynecol Scand Suppl 1985 130(): 59-66. PMID: . Reason for Exclusion: NCT

B. Pesch, Y. Ko, H. Brauch, U. Hamann, V. Harth, S. Rabstein, C. Pierl, H. P. Fischer, C. Baisch, C. Justenhoven, U. Ranft and T. Bruning. Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 2005 20(8): 699-711. PMID: . Reason for Exclusion: DES

G. M. Peterson, M. Naunton, L. K. Tichelaar and L. Gennari. Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Ann Pharmacother 2011 45(4): 499-509. PMID: . Reason for Exclusion: NRQ

D. B. Petitti, S. Sidney and C. P. Quesenberry, Jr.. Hormone replacement therapy and the risk of myocardial infarction in women with coronary risk factors. Epidemiology 2000 11(5): 603-6. PMID: . Reason for Exclusion: DES

D. B. Petitti, S. Sidney and J. A. Perlman. Increased risk of cholecystectomy in users of supplemental estrogen. Gastroenterology 1988 94(1): 91-5. PMID: . Reason for Exclusion: DES

D. B. Petitti, S. Sidney, C. P. Quesenberry, Jr. and A. Bernstein. Ischemic stroke and use of estrogen and estrogen/progestogen as hormone replacement therapy. Stroke 1998 29(1): 23-8. PMID: . Reason for Exclusion: DES

B. Pettersson, H. O. Adami, I. Persson, R. Bergstrom, A. Lindgren and E. D. Johansson. Climacteric symptoms and estrogen replacement therapy in women with endometrial carcinoma. Acta Obstet Gynecol Scand 1986 65(1): 81-7. PMID: . Reason for Exclusion: DES

R. E. Peverill. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab 2003 17(1): 149-64. PMID: . Reason for Exclusion: NCT

R. I. Pfeffer and S. Van Den Noort. Estrogen use and stroke risk in postmenopausal women. Am J Epidemiol 1976 103(5): 445-56. PMID: . Reason for Exclusion: DES

R. I. Pfeffer, G. H. Whipple, T. T. Kurosaki and J. M. Chapman. Coronary risk and estrogen use in postmenopausal women. Am J Epidemiol 1978 107(6): 479-97. PMID: . Reason for Exclusion: DES

L. S. Phillips and R. D. Langer. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 2005 83(3): 558-66. PMID: . Reason for Exclusion: NCT

M. C. Pike and R. K. Ross. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids 2000 65(10-11): 659-64. PMID: . Reason for Exclusion: DES

M. C. Pike, R. K. Peters, W. Cozen, N. M. Probst-Hensch, J. C. Felix, P. C. Wan and T. M. Mack. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997 89(15): 1110-6. PMID: . Reason for Exclusion: DES

J. V. Pinkerton and R. Santen. Use of alternatives to estrogen for treatment of menopause. Minerva Endocrinol 2002 27(1): 21-41. PMID: . Reason for Exclusion: NCT

J. V. Pinkerton, D. W. Stovall and R. S. Kightlinger. Advances in the treatment of menopausal symptoms. Womens Health (Lond Engl) 2009 5(4): 361-384; quiz 383-4. PMID: . Reason for Exclusion: NRD

J. V. Pinkerton, W. H. Utian, G. D. Constantine, S. Olivier and J. H. Pickar. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009 16(6): 1116-24. PMID: . Reason for Exclusion: NRC

J. Pitkin. Alternative and complementary therapies for the menopause. Menopause Int 2012 18(1): 20-7. PMID: . Reason for Exclusion: NCT

V. A. Place, M. Powers, P. E. Darley, L. Schenkel and W. R. Good. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol 1985 152(8): 1092-9. PMID: . Reason for Exclusion: NRF

P. Polo-Kantola, E. Rauhala, H. Helenius, R. Erkkola, K. Irjala and O. Polo. Breathing during sleep in menopause: a randomized, controlled, crossover trial with estrogen therapy. Obstet Gynecol 2003 102(1): 68-75. PMID: . Reason for Exclusion: DUP

P. Polo-Kantola, R. Erkkola, H. Helenius, K. Irjala and O. Polo. When does estrogen replacement therapy improve sleep quality?. Am J Obstet Gynecol 1998 178(5): 1002-9. PMID: . Reason for Exclusion: DUP

A. Polychronopoulou, A. Tzonou, C. C. Hsieh, G. Kaprinis, A. Rebelakos, N. Toupadaki and D. Trichopoulos. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer 1993 55(3): 402-7. PMID: . Reason for Exclusion: DES

B. Pornel, A. R. Genazzani, D. Costes, M. P. Dain, L. Lelann and C. Vandepol. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study. Maturitas 1995 22(3): 207-18. PMID: . Reason for Exclusion: NRC

B. Pornel. Efficacy and safety of Menorest in two positive-controlled studies. Eur J Obstet Gynecol Reprod Biol 1996 64 Suppl(): S35-7. PMID: . Reason for Exclusion: DUP

R. L. Prentice, J. E. Manson, R. D. Langer, G. L. Anderson, M. Pettinger, R. D. Jackson, K. C. Johnson, L. H. Kuller, D. S. Lane, J. Wactawski-Wende, R. Brzyski, M. Allison, J. Ockene, G. Sarto and J. E. Rossouw. Benefits and risks of postmenopausal hormone therapy when it is init Reason for Exclusion: PTU

R. L. Prentice, R. T. Chlebowski, M. L. Stefanick, J. E. Manson, M. Pettinger, S. L. Hendrix, F. A. Hubbell, C. Kooperberg, L. H. Kuller, D. S. Lane, A. McTiernan, M. Jo O'Sullivan, J. E. Rossouw and G. L. Anderson. Estrogen plus progestin therapy and breast cancer in recently pos Reason for Exclusion: PTU

R. L. Prentice, R. T. Chlebowski, M. L. Stefanick, J. E. Manson, R. D. Langer, M. Pettinger, S. L. Hendrix, F. A. Hubbell, C. Kooperberg, L. H. Kuller, D. S. Lane, A. McTiernan, M. J. O'Sullivan, J. E. Rossouw and G. L. Anderson. Conjugated equine estrogens and breast cancer risk Reason for Exclusion: PTU

B. M. Psaty, S. R. Heckbert, D. Atkins, D. S. Siscovick, T. D. Koepsell, P. W. Wahl, W. T. Longstreth, Jr., N. S. Weiss, E. H. Wagner, R. Prentice and et al.. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern M Reason for Exclusion: NCT

D. M. Purdie, C. J. Bain, V. Siskind, P. Russell, N. F. Hacker, B. G. Ward, M. A. Quinn and A. C. Green. Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 1999 81(3): 559-63. PMID: . Reason for Exclusion: DES

L. Q. Qin, J. Y. Xu, P. Y. Wang and K. Hoshi. Soyfood intake in the prevention of breast cancer risk in women: a meta-analysis of observational epidemiological studies. J Nutr Sci Vitaminol (Tokyo) 2006 52(6): 428-36. PMID: . Reason for Exclusion: PTU

A. Ratanawichitrasin, W. Reansuwan, S. Ratanawichitrasin, K. Bhodhisuwan and S. Kongpatanakul. Risk of breast cancer in post-menopausal women using hormone replacement therapy. J Med Assoc Thai 2002 85(5): 583-9. PMID: . Reason for Exclusion: DES

P. Razavi, M. C. Pike, P. L. Horn-Ross, C. Templeman, L. Bernstein and G. Ursin. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev 2010 19(2): 475-83. PMID: . Reason for Exclusion: PTU

T. D. Rea, B. M. Psaty, S. R. Heckbert, M. Cushman, E. Meilahn, J. L. Olson, R. N. Lemaitre, N. L. Smith, N. Sotoodehnia and P. H. Chaves. Hormone replacement therapy and the risk of incident congestive heart failure: the Cardiovascular Health Study. J Womens Health (Larchmt) 2003 Reason for Exclusion: DES

. B reast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997 350(9084): 1047-59. P Reason for Exclusion: PTU

. T reatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004 11(1): 11-33. PMID: . Reason for Exclusion: NRD

S. D. Reed, K. M. Newton, A. Z. LaCroix, L. C. Grothaus, V. S. Grieco and K. Ehrlich. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternative Reason for Exclusion: NRO

S. D. Reed, L. F. Voigt, S. A. Beresford, D. A. Hill, J. A. Doherty and N. S. Weiss. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer. Am J Obstet Gynecol 2004 191(4): 1146-51. PMID: . Reason for Exclusion: DES

G. K. Reeves, V. Beral, J. Green, T. Gathani and D. Bull. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. Lancet Oncol 2006 7(11): 910-8. PMID: . Reason for Exclusion: DES

J. Y. Reginster, F. Richy and O. Bruyere. A critical analysis of the efficacy of estrogens on spinal and non-spinal fracture reduction. Reproduction Humaine et Hormones 2004 17(5): 419-423. PMID: . Reason for Exclusion: PTU

C. Renoux, S. Dell'Aniello and S. Suissa. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010 8(5): 979-86. PMID: . Reason for Exclusion: PTU

C. Renoux, S. Dell'aniello, E. Garbe and S. Suissa. Hormone replacement therapy use and the risk of stroke. Maturitas 2008 61(4): 305-9. PMID: . Reason for Exclusion: PTU

C. Renoux, S. Dell'aniello, E. Garbe and S. Suissa. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010 340(): c2519. PMID: . Reason for Exclusion: PTU

T. Riman, P. W. Dickman, S. Nilsson, N. Correia, H. Nordlinder, C. M. Magnusson and I. R. Persson. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 2002 156(4): 363-73. PMID: . Reason for Exclusion: DES

T. Riman, P. W. Dickman, S. Nilsson, N. Correia, H. Nordlinder, C. M. Magnusson, E. Weiderpass and I. R. Persson. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002 94(7): 497-504. PMID: . Reason for Exclusion: DES

H. A. Risch and G. R. Howe. Menopausal hormone usage and breast cancer in Saskatchewan: a record-linkage cohort study. Am J Epidemiol 1994 139(7): 670-83. PMID: . Reason for Exclusion: DES

H. Roberts. Hormone therapy for menopausal symptoms. BMJ 2012 344(): e815. PMID: . Reason for Exclusion: NCT

D. Robinson and L. Cardozo. Urogenital effects of hormone therapy. Best Practice and Research in Clinical Endocrinology and Metabolism 2003 17(1): 91-104. PMID: . Reason for Exclusion: NRD

C. Rodriguez, A. V. Patel, E. E. Calle, E. J. Jacob and M. J. Thun. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001 285(11): 1460-5. PMID: . Reason for Exclusion: DES

C. Rodriguez, E. E. Calle, A. V. Patel, L. M. Tatham, E. J. Jacobs and M. J. Thun. Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol 2001 153(2): 145-52. PMID: . Reason for Exclusion: NRD

Progestagen-only treatment before menopause: increased risk of breast cancer. Prescrire Int 2008 17(98): 243. PMID: . Reason for Exclusion: PTU

T. E. Rohan and A. J. McMichael. Non-contraceptive exogenous oestrogen therapy and breast cancer. Med J Aust 1988 148(5): 217-21. PMID: . Reason for Exclusion: DES

G. M. Rosano, C. Vitale, A. Silvestri and M. Fini. Hormone replacement therapy and cardioprotection: the end of the tale?. Ann N Y Acad Sci 2003 997(): 351-7. PMID: . Reason for Exclusion: NCT

L. U. Rosenberg, C. Magnusson, E. Lindstrom, S. Wedren, P. Hall and P. W. Dickman. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 2006 8(1): R11. P Reason for Exclusion: DES

L. U. Rosenberg, F. Granath, P. W. Dickman, K. Einarsdottir, S. Wedren, I. Persson and P. Hall. Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study. Breast Cancer Res 2008 10(5): R78. PMID: . Reason for Exclusion: PTU

R. K. Ross, A. Paganini-Hill, P. C. Wan and M. C. Pike. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000 92(4): 328-32. PMID: . Reason for Exclusion: DES

R. K. Ross, A. Paganini-Hill, T. M. Mack and B. E. Henderson. Cardiovascular benefits of estrogen replacement therapy. Am J Obstet Gynecol 1989 160(5 Pt 2): 1301-6. PMID: . Reason for Exclusion: NCT

R. K. Ross, A. Paganini-Hill, V. R. Gerkins, T. M. Mack, R. Pfeffer, M. Arthur and B. E. Henderson. A case-control study of menopausal estrogen therapy and breast cancer. JAMA 1980 243(16): 1635-9. PMID: . Reason for Exclusion: DES

S. M. Ross. Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms. Holist Nurs Pract 2012 26(1): 58-61. PMID: . Reason for Exclusion: NCT

M. A. Rossing, K. L. Cushing-Haugen, K. G. Wicklund, J. A. Doherty and N. S. Weiss. Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007 16(12): 2548-56. PMID: . Reason for Exclusion: PTU

J. E. Rossouw, G. L. Anderson, R. L. Prentice, A. Z. LaCroix, C. Kooperberg, M. L. Stefanick, R. D. Jackson, S. A. Beresford, B. V. Howard, K. C. Johnson, J. M. Kotchen and J. Ockene. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2003 288(3): 321-33. Reason for Exclusion: DES

J. E. Rossouw, R. L. Prentice, J. E. Manson, L. Wu, D. Barad, V. M. Barnabei, M. Ko, A. Z. LaCroix, K. L. Margolis and M. L. Stefanick. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007 297(13): 1465-77. PMID: . Reason for Exclusion: PTU

C. Rotem and B. Kaplan. Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. Gynecol Endocrinol 2007 23(2): 117-22. PMID: . Reason for Exclusion: NOP

M. Y. Roth and J. K. Amory. Testosterone for low libido in postmenopausal women?. Expert Review of Endocrinology and Metabolism 2009 4(2): 131-133. PMID: . Reason for Exclusion: DUP

L. C. Rovati, K. Schmid, G. Giacovelli, M. Bonn, I. Setnikar, F. Wolff and A. R. Genazzani. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group Reason for Exclusion: NRC

J. P. Rowan, J. A. Simon, L. Speroff and H. Ellman. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. Clin Ther 2006 28(6): 921-32. PMID: . Reason for Exclusion: NRD

J. A. Roy, C. A. Sawka and K. I. Pritchard. Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?. J Clin Oncol 1996 14(3): 997-1006. PMID: . Reason for Exclusion: PTU

H. Rozenbaum, M. Birkhauser, C. De Nooyer, R. Lambotte, B. Pornel, H. Schneider and J. Studd. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy. Maturitas 1996 25(3): 161-73. PMID: . Reason for Exclusion: NRC

S. Rozenberg, P. Caubel and P. C. Lim. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms. Int J Gynaecol Obstet 2001 72(3): 235-43. PMID: . Reason for Exclusion: NRO

J. S. Rudic, G. Poropat, M. N. Krstic, G. Bjelakovic and C. Gluud. Hormone replacement for osteoporosis in women with primary biliary cirrhosis. Cochrane Database Syst Rev 2011 12(): CD009146. PMID: . Reason for Exclusion: NRP

A. Ruiz, J. Carson, R. Peddaiahgari, R. K. Hummel, K. Daniels and C. Frei. Bioidentical hormone replacement therapy: An epidemiological study in six community pharmacies. Journal of the American Pharmacists Association 2010 50(2): 222. PMID: . Reason for Exclusion: NRD

A. D. Ruiz, K. R. Daniels, J. C. Barner, J. J. Carson and C. R. Frei. Effectiveness of Compounded Bioidentical Hormone Replacement Therapy: An Observational Cohort Study. BMC Women's Health 2011 11(): . PMID: . Reason for Exclusion: NRD

A. D. Ruiz, K. R. Daniels, J. C. Barner, J. J. Carson and C. R. Frei. Impact of conventional and bioidentical hormone replacement therapy on cardiovascular & breast health: A review. International Journal of Pharmaceutical Compounding 2011 15(4): 290-300. PMID: . Reason for Exclusion: NCT

R. Russo and R. Corosu. The clinical use of a preparation based on phyto-oestrogens in the treatment of menopausal disorders. Acta Biomed 2003 74(3): 137-43. PMID: . Reason for Exclusion: NOP

T. Ryan-Borchers, B. Chew, J. S. Park, M. McGuire, L. Fournier and K. Beerman. Effects of dietary and supplemental forms of isoflavones on thyroid function in healthy postmenopausal women. Topics in Clinical Nutrition 2008 23(1): 13-22. PMID: . Reason for Exclusion: NOP

F. M. Sacks, A. Lichtenstein, L. Van Horn, W. Harris, P. Kris-Etherton and M. Winston. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 2006 113(7): 1034-44. PMID: . Reason for Exclusion: NCT

T. Saeki, M. Sano, Y. Komoike, H. Sonoo, H. Honjyo, K. Ochiai, T. Kobayashi, K. Aogi, N. Sato, S. Sawai, Y. Miyoshi, M. Takeuchi and S. Takashima. No increase of breast cancer incidence in Japanese women who received hormone replacement therapy: overview of a case-control study of Reason for Exclusion: PTU

U. Salagame, K. Canfell and E. Banks. An epidemiological overview of the relationship between hormone replacement therapy and breast cancer. Expert Review of Endocrinology and Metabolism 2011 6(3): 397-409. PMID: . Reason for Exclusion: NCT

S. R. Salpeter, J. M. E. Walsh, E. Greyber and E. E. Salpeter. Brief rport: Cronary heart disease events associated with hormone therapy in younger and older women - A meta-analysis. Journal of General Internal Medicine 2006 21(4): 363-366. PMID: . Reason for Exclusion: PTU

S. R. Salpeter, J. M. Walsh, E. Greyber and E. E. Salpeter. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006 21(4): 363-6. PMID: . Reason for Exclusion: PTU

S. R. Salpeter, J. M. Walsh, E. Greyber, T. M. Ormiston and E. E. Salpeter. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004 19(7): 791-804. PMID: . Reason for Exclusion: NRO

G. Samsioe, E. Boschitsch, H. Concin, C. De Geyter, A. Ehrenborg, J. Heikkinen, R. Hobson, M. Arguinzoniz, P. Ibarra de Palacios, C. Scheurer and G. Schmidt. Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 Reason for Exclusion: DES

J. E. Sanderson, C. J. Haines, L. Yeung, G. W. Yip, K. Tang, S. F. Yim, L. N. Jorgensen and J. Woo. Anti-ischemic action of estrogen-progestogen continuous combined hormone replacement therapy in postmenopausal women with established angina pectoris: a randomized, placebo-controlled, double-blind, parallel-group trial. J Cardiovasc Pharmacol 2001 38(3): 372-83. Reason for Exclusion: NRP

R. J. Santen, D. C. Allred, S. P. Ardoin, D. F. Archer, N. Boyd, G. D. Braunstein, H. G. Burger, G. A. Colditz, S. R. Davis, M. Gambacciani, B. A. Gower, V. W. Henderson, W. N. Jarjour, R. H. Karas, M. Kleerekoper, R. A. Lobo, J. E. Manson, J. Marsden, K. A. Martin, L. Martin, J. Reason for Exclusion: NCT

R. J. Santen. Risk of breast cancer with progestins: critical assessment of current data. Steroids 2003 68(10-13): 953-64. PMID: . Reason for Exclusion: NCT

N. Santoro. Symptoms of menopause: hot flushes. Clin Obstet Gynecol 2008 51(3): 539-48. PMID: . Reason for Exclusion: NRD

G. M. Sare, L. J. Gray and P. M. Bath. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 2008 29(16): 2031-41. PMID: . Reason for Exclusion: PTU

T. Saxena, E. Lee, K. D. Henderson, C. A. Clarke, D. West, S. F. Marshall, D. Deapen, L. Bernstein and G. Ursin. Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev 2010 19(9) Reason for Exclusion: PTU

P. Y. Scarabin, E. Oger and G. Plu-Bureau. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003 362(9382): 428-32. PMID: . Reason for Exclusion: DES

C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton and R. Hoover. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000 283(4): 485-91. PMID: . Reason for Exclusion: DES

M. B. Scharf, D. V. Berkowitz and K. Z. Reape. Effects of synthetic conjugated estrogens A on sleep quality in postmenopausal women with nocturnal diaphoresis and/or hot flushes: a pilot study. Fertil Steril 2007 88(3): 654-6. PMID: . Reason for Exclusion: NOP

F. Scheele, C. W. Burger and P. Kenemans. Postmenopausal hormone replacement in the woman with a reproductive risk factor for breast cancer. Maturitas 1999 33(3): 191-6. PMID: . Reason for Exclusion: PTU

K. Schenck-Gustafsson, M. Brincat, C. T. Erel, M. Gambacciani, I. Lambrinoudaki, M. H. Moen, F. Tremollieres, S. Vujovic, S. Rozenberg and M. Rees. EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas 2011 68(1): 94-7. PMID: . Reason for Exclusion: NCT

C. Schneider, S. S. Jick and C. R. Meier. Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009 12(5): 445-53. PMID: . Reason for Exclusion: PTU

C. Schneider, S. S. Jick and C. R. Meier. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric 2009 12(6): 514-24. PMID: . Reason for Exclusion: PTU

A. G. Schuurman, P. A. van den Brandt and R. A. Goldbohm. Exogenous hormone use and the risk of postmenopausal breast cancer: results from The Netherlands Cohort Study. Cancer Causes Control 1995 6(5): 416-24. PMID: . Reason for Exclusion: DES

H. E. Seaman, C. S. de Vries and R. D. Farmer. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum Reprod 2003 18(3): 522-6. PMID: . Reason for Exclusion: DES

G. Secreto, L. M. Chiechi, A. Amadori, R. Miceli, E. Venturelli, T. Valerio and E. Marubini. Soy isoflavones and melatonin for the relief of climacteric symptoms: a multicenter, double-blind, randomized study. Maturitas 2004 47(1): 11-20. PMID: . Reason for Exclusion: NRP

T. A. Sellers, P. J. Mink, J. R. Cerhan, W. Zheng, K. E. Anderson, L. H. Kushi and A. R. Folsom. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997 127(11): 973-80. PMID: . Reason for Exclusion: DES

N. R. Shah, J. Borenstein and R. W. Dubois. Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 2005 12(6): 668-78. PMID: . Reason for Exclusion: PTU

T. Shams, M. S. Setia, R. Hemmings, J. McCusker, M. Sewitch and A. Ciampi. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis. Altern Ther Health Med 2010 16(1): 36-44. PMID: . Reason for Exclusion: NRD

S. Shantakumar, M. B. Terry, A. Paykin, S. L. Teitelbaum, J. A. Britton, P. G. Moorman, S. B. Kritchevsky, A. I. Neugut and M. D. Gammon. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol 2007 165 Reason for Exclusion: PTU

J. A. Shapiro, N. S. Weiss, S. A. Beresford and L. F. Voigt. Menopausal hormone use and endometrial cancer, by tumor grade and invasion. Epidemiology 1998 9(1): 99-101. PMID: . Reason for Exclusion: DES

S. Shapiro, R. D. Farmer, A. O. Mueck, H. Seaman and J. C. Stevenson. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies: part 3. The Women's Health Initiative: unopposed estrogen. J Fam Plann Reprod Health Care 2011 37(4): 2 Reason for Exclusion: PTU

S. Shapiro, R. D. T. Farmer, A. O. Mueck, H. Seaman and J. C. Stevenson. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. Part 2. The Women's Health Initiative: Estrogen plus progestogen. Journal of Family Planning and Rep Reason for Exclusion: PTU

S. Shapiro. Recent epidemiological evidence relevant to the clinical management of the menopause. Climacteric 2007 10 Suppl 2(): 2-15. PMID: . Reason for Exclusion: NRD

S. Shapiro. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003 6(4): 302-10; discussion 310-3. PMID: . Reason for Exclusion: DES

S. Sharma. Hormone Replacement Therapy in menopause: current concerns and considerations. Kathmandu Univ Med J (KUMJ) 2003 1(4): 288-93. PMID: . Reason for Exclusion: NCT

W. Shen and V. Stearns. Treatment strategies for hot flushes. Expert Opin Pharmacother 2009 10(7): 1133-44. PMID: . Reason for Exclusion: NRD

J. E. Shepherd. Effects of estrogen on congnition mood, and degenerative brain diseases. J Am Pharm Assoc (Wash) 2001 41(2): 221-8. PMID: . Reason for Exclusion: NRD

S. Sherman, H. Miller, L. Nerurkar and I. Schiff. Research opportunities for reducing the burden of menopause-related symptoms. Am J Med 2005 118 Suppl 12B(): 166-71. PMID: . Reason for Exclusion: NRQ

B. Sherman, R. Wallace and J. Bean. Estrogen use and breast cancer. Interaction with body mass. Cancer 1983 51(8): 1527-31. PMID: . Reason for Exclusion: DES

A. M. Sherman, S. A. Shumaker, P. Sharp, D. M. Reboussin, C. Kancler, M. Walkup and D. M. Herrington. No effect of HRT on health-related quality of life in postmenopausal women with heart disease. Minerva Ginecol 2003 55(6): 511-7. PMID: . Reason for Exclusion: NRP

B. B. Sherwin and M. M. Gelfand. Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol 1985 151(2): 153-60. PMID: . Reason for Exclusion: NOP

B. B. Sherwin and M. M. Gelfand. Sex steroids and affect in the surgical menopause: a double-blind, cross-over study. Psychoneuroendocrinology 1985 10(3): 325-35. PMID: . Reason for Exclusion: NOP

B. B. Sherwin, M. M. Gelfand and W. Brender. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med 1985 47(4): 339-51. PMID: . Reason for Exclusion: NOP

B. B. Sherwin. Estrogen and mood in women. Endocrinologist 2005 15(3): 180-185. PMID: . Reason for Exclusion: NCT

B. B. Sherwin. Randomized clinical trials of combined estrogen-androgen preparations: effects on sexual functioning. Fertil Steril 2002 77 Suppl 4(): S49-54. PMID: . Reason for Exclusion: NRD

K. D. Shetty, W. B. Vogt and J. Bhattacharya. Hormone replacement therapy and cardiovascular health in the United States. Med Care 2009 47(5): 600-6. PMID: . Reason for Exclusion: NRP

J. L. Shifren, G. D. Braunstein, J. A. Simon, P. R. Casson, J. E. Buster, G. P. Redmond, R. E. Burki, E. S. Ginsburg, R. C. Rosen, S. R. Leiblum, K. E. Caramelli and N. A. Mazer. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Reason for Exclusion: NOP

B.C. Shin, M. S. Lee, E. J. Yang, H. S. Lim and E. Ernst. Maca (L. meyenii) for improving sexual function: a systematic review. BMC Complement Altern Med 2010 10(): 44. PMID: . Reason for Exclusion: NRD

M. G. Shlipak, D. A. Elmouchi, D. M. Herrington, F. Lin, D. Grady and M. A. Hlatky. The incidence of unrecognized myocardial infarction in women with coronary heart disease. Ann Intern Med 2001 134(11): 1043-7. PMID: . Reason for Exclusion: NRQ

L. P. Shulman. The adverse impact of hormone therapy discontinuation on bone health: Initiating a more balanced and comprehensive assessment of the impact and role of postmenopausal hormone therapy. Menopause 2011 18(11): 1152-1153. PMID: . Reason for Exclusion: NRQ

B. L. Sicat. Should postmenopausal hormone therapy be used to prevent osteoporosis?. Consultant Pharmacist 2004 19(8): 725-735. PMID: . Reason for Exclusion: PTU

S. S. Signorelli, S. Sciacchitano, M. Anzaldi, V. Fiore, S. Catanzaro, M. Simili and S. Neri. Effects of long-term hormone replacement therapy: results from a cohort study. J Endocrinol Invest 2011 34(3): 180-4. PMID: . Reason for Exclusion: NOP

M. Sillero-Arenas, M. Delgado-Rodriguez, R. Rodigues-Canteras, A. Bueno-Cavanillas and R. Galvez-Vargas. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992 79(2): 286-94. PMID: . Reason for Exclusion: PTU

L. A. Sim, L. McGovern, M. B. Elamin, B. A. Swiglo, P. J. Erwin and V. M. Montori. Effect on bone health of estrogen preparations in premenopausal women with anorexia nervosa: a systematic review and meta-analyses. Int J Eat Disord 2010 43(3): 218-25. PMID: . Reason for Exclusion: NRO

J. A. Simon, D. B. Hunninghake, S. K. Agarwal, F. Lin, J. A. Cauley, C. C. Ireland and J. H. Pickar. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study. Ann In Reason for Exclusion: DES

J. Simon, E. Klaiber, B. Wiita, A. Bowen and H. M. Yang. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause 1999 6(2): 138-46. PMID: . Reason for Exclusion: NOP

J. A. Simon, F. Lin, E. Vittinghoff and V. Bittner. The relation of postmenopausal hormone therapy to serum uric acid and the risk of coronary heart disease events: the Heart and Estrogen-Progestin Replacement Study (HERS). Ann Epidemiol 2006 16(2): 138-45. PMID: . Reason for Exclusion: NRQ

J. A. Simon, G. G. Nahum, H. Stanislaw and T. Gaines. The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation. Maturitas 2010 66(3): 277-84. PMID: . Reason for Exclusion: PTU

J. A. Simon, J. Hsia, J. A. Cauley, C. Richards, F. Harris, J. Fong, E. Barrett-Connor and S. B. Hulley. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001 103(5): 638-42. PMID: . Reason for Exclusion: DES

J. A. Simon, K. Z. Reape, S. Wininger and H. Hait. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. Fertil Steril 2008 Reason for Exclusion: NRO

J. Simon, L. Nachtigall, L. G. Ulrich, M. Eugster-Hausmann and R. Gut. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol 2010 116(4): 876-83. PMID: . Reason for Exclusion: PTU

J. Simon, L. Nachtigall, R. Gut, E. Lang, D. F. Archer and W. Utian. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008 112(5): 1053-60. PMID: . Reason for Exclusion: NRO

T. Simoncini and A. R. Genazzani. A review of the cardiovascular and breast actions of drospirenone in preclinical studies. Climacteric 2010 13(1): 22-33. PMID: . Reason for Exclusion: NCT

S. O. Skouby, F. Al-Azzawi, D. Barlow, J. Calaf-Alsina Erdogan Ertungealp, A. Gompel, A. Graziottin, D. Hudita, A. Pines, S. Rozenberg, G. Samsioe and J. C. Stevenson. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and Reason for Exclusion: NCT

T. E. Slanger, J. C. Chang-Claude, N. Obi, S. Kropp, J. Berger, E. Vettorazzi, W. Braendle, G. Bastert, S. Hentschel and D. Flesch-Janys. Menopausal hormone therapy and risk of clinical breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 2009 18(4): 1188-96. PMID: . Reason for Exclusion: PTU

N. L. Smith, S. R. Heckbert, R. N. Lemaitre, A. P. Reiner, T. Lumley, F. R. Rosendaal and B. M. Psaty. Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women. Arterioscler Thromb Vasc Biol 2006 26(12): 280 Reason for Exclusion: DES

N. L. Smith, S. R. Heckbert, R. N. Lemaitre, A. P. Reiner, T. Lumley, N. S. Weiss, E. B. Larson, F. R. Rosendaal and B. M. Psaty. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004 292(13): 1581-7. PMID: . Reason for Exclusion: DES

M. Snabes, J. Connor, D. Berry, J. Zborowski and W. White. Low cardiovascular event rate in post-menopausal women with increased cardiac risk: Findings from the ongoing blinded libigel(registered trademark) (Testosterone Gel) cardiovascular and breast cancer safety study. Reproductive Sciences 2010 17(3): 269A. PMID: . Reason for Exclusion: PTU

C. N. Soares, H. Joffe, R. Rubens, J. Caron, T. Roth and L. Cohen. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 2006 108(6): 1402-10. PMID: . Reason for Exclusion: NRF

C. N. Soares, M. E. Thase, A. Clayton, C. J. Guico-Pabia, K. Focht, Q. Jiang, S. G. Kornstein, P. T. Ninan and C. P. Kane. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram. CNS Drugs 2011 25(3): 227-38. PMID: . Reason for Exclusion: NRF

C. N. Soares. Escitalopram reduced hot flashes in non-depressed perimenopausal and postmenopausal women. Evidence-Based Medicine 2011 16(5): 159-160. PMID: . Reason for Exclusion: NRD

W. Somboonporn and S. R. Davis. Postmenopausal testosterone therapy and breast cancer risk. Maturitas 2004 49(4): 267-75. PMID: . Reason for Exclusion: NCT

W. Somboonporn, S. Davis, M. W. Seif and R. Bell. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005 (4): CD004509. PMID: . Reason for Exclusion: NRD

W. Somboonporn, S. Panna, T. Temtanakitpaisan, S. Kaewrudee and S. Soontrapa. Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 2011 (): . PMID: . Reason for Exclusion: NRD

Soy, black cohosh may have some benefit for menopause symptoms. Journal of Family Practice 2006 55(11): 939. PMID: . Reason for Exclusion: NRD

T. D. Spector, P. Brennan, P. A. Harris, J. W. Studd and A. J. Silman. Do current regimes of hormone replacement therapy protect against subsequent fractures?. Osteoporos Int 1992 2(5): 219-24. PMID: . Reason for Exclusion: DES

R. F. Spengler, E. A. Clarke, C. A. Woolever, A. M. Newman and R. W. Osborn. Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases. Am J Epidemiol 1981 114(4): 497-506. PMID: . Reason for Exclusion: DES

B. L. Sprague, A. Trentham-Dietz, K. M. Egan, L. Titus-Ernstoff, J. M. Hampton and P. A. Newcomb. Proportion of invasive breast cancer attributable to risk factors modifiable after menopause. Am J Epidemiol 2008 168(4): 404-11. PMID: . Reason for Exclusion: PTU

SSRIs ineffective for hot flashes. South African Family Practice 2005 47(3): 17. PMID: . Reason for Exclusion: DUP

J. A. Staffa, C. J. Newschaffer, J. K. Jones and V. Miller. Progestins and breast cancer: an epidemiologic review. Fertil Steril 1992 57(3): 473-91. PMID: . Reason for Exclusion: NRQ

C. Stahlberg, A. T. Pedersen, E. Lynge, Z. J. Andersen, N. Keiding, Y. A. Hundrup, E. B. Obel and B. Ottesen. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 2004 109(5): 721-7. PMID: . Reason for Exclusion: DES

C. Stahlberg, A. T. Pedersen, Z. J. Andersen, N. Keiding, Y. A. Hundrup, E. B. Obel, S. Moller, F. Rank, B. Ottesen and E. Lynge. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy. Br J Cancer 2004 91(4): 644-50. PMID:. Reason for Exclusion: DES

M. J. Stampfer and G. A. Colditz. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991 20(1): 47-63. PMID: . Reason for Exclusion: PTU

J. L. Stanford, L. A. Brinton, M. L. Berman, R. Mortel, L. B. Twiggs, R. J. Barrett, G. D. Wilbanks and R. N. Hoover. Oral contraceptives and endometrial cancer: do other risk factors modify the association?. Int J Cancer 1993 54(2): 243-8. PMID: . Reason for Exclusion: DES

J. L. Stanford, N. S. Weiss, L. F. Voigt, J. R. Daling, L. A. Habel and M. A. Rossing. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995 274(2): 137-42. PMID: . Reason for Exclusion: DES

E. D. Staren and S. Omer. Hormone replacement therapy in postmenopausal women. Am J Surg 2004 188(2): 136-49. PMID: . Reason for Exclusion: NCT

M. L. Stefanick, G. L. Anderson, K. L. Margolis, S. L. Hendrix, R. J. Rodabough, E. D. Paskett, D. S. Lane, F. A. Hubbell, A. R. Assaf, G. E. Sarto, R. S. Schenken, S. Yasmeen, L. Lessin and R. T. Chlebowski. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006 295(14): 1647-57. PMID: . Reason for Exclusion: DES

M. L. Stefanick. Postmenopausal hormone therapy and cardiovascular disease in women. Nutr Metab Cardiovasc Dis 2010 20(6): 451-8. PMID: . Reason for Exclusion: NCT

F. M. Steinberg, M. J. Murray, R. D. Lewis, M. A. Cramer, P. Amato, R. L. Young, S. Barnes, K. L. Konzelmann, J. G. Fischer, K. J. Ellis, R. J. Shypailo, J. K. Fraley, E. O. Smith and W. W. Wong. Clinical outcomes of a 2-y soy isoflavone supplementation in menopausal women. Am J C Reason for Exclusion: NRO

K. K. Steinberg, S. B. Thacker, S. J. Smith, D. F. Stroup, M. M. Zack, W. D. Flanders and R. L. Berkelman. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991 265(15): 1985-90. PMID: . Reason for Exclusion: PTU

K. Steinberg. Duration/dose of HRT and risk of breast cancer in the unselected populations: Data from meta-analysis. Obstetrical and Gynecological Survey 1998 53(10 SUPPL.): S13-S16. PMID: . Reason for Exclusion: PTU

A. Steingart, M. Cotterchio, N. Kreiger and M. Sloan. Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol 2003 32(6): 961-6. PMID: . Reason for Exclusion: NRP

K. A. Steingold, L. Laufer, R. J. Chetkowski, J. D. DeFazio, D. W. Matt, D. R. Meldrum and H. L. Judd. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985 61(4): 627-32. PMID: . Reason for Exclusion: NOP

J. C. Stevenson, H. N. Hodis, J. H. Pickar and R. A. Lobo. HRT and breast cancer risk: A realistic perspective. Climacteric 2011 14(6): 633-636. PMID: . Reason for Exclusion: NCT

C. Straczek, E. Oger, M. B. Yon de Jonage-Canonico, G. Plu-Bureau, J. Conard, G. Meyer, M. Alhenc-Gelas, H. Levesque, N. Trillot, M. T. Barrellier, D. Wahl, J. Emmerich and P. Y. Scarabin. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women. Reason for Exclusion: DES

D. O. Stram, Y. Liu, K. D. Henderson, J. Sullivan-Halley, J. Luo, T. Saxena, P. Reynolds, E. T. Chang, S. L. Neuhausen, P. L. Horn-Ross, L. Bernstein and G. Ursin. Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in Reason for Exclusion: PTU

B. L. Strom, R. Schinnar, A. L. Weber, G. Bunin, J. A. Berlin, M. Baumgarten, A. DeMichele, S. C. Rubin, M. Berlin, A. B. Troxel and T. R. Rebbeck. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 2006 164(8): 775-86. PMID: . Reason for Exclusion: DES

D. W. Sturdee. The menopausal hot flush--anything new?. Maturitas 2008 60(1): 42-9. PMID: . Reason for Exclusion: NRQ

J. Suckling, A. Lethaby and R. Kennedy. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006 (4): CD001500. PMID: . Reason for Exclusion: NRD

P. J. Sulak, P. Caubel and R. Lane. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy. Int J Fertil Womens Med 1999 44(6): 286-96. PMID: . Reason for Exclusion: NRO

J. M. Sullivan, R. Vander Zwaag, G. F. Lemp, J. P. Hughes, V. Maddock, F. W. Kroetz, K. B. Ramanathan and D. M. Mirvis. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988 108(3): 358-63. PMID: . Reason for Exclusion: DES

J. M. Sullivan. Hormone replacement in the secondary prevention of cardiovascular disease. Cardiovascular Risk Factors 1996 6(2): 94-98. PMID: . Reason for Exclusion: DES

R. Talamini, S. Franceschi, L. Dal Maso, E. Negri, E. Conti, R. Filiberti, M. Montella, O. Nanni and C. La Vecchia. The influence of reproductive and hormonal factors on the risk of colon and rectal cancer in women. Eur J Cancer 1998 34(7): 1070-6. PMID: . Reason for Exclusion: DES

R. M. Tamimi, S. E. Hankinson, W. Y. Chen, B. Rosner and G. A. Colditz. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006 166(14): 1483-9. PMID: . Reason for Exclusion: DES

R. Tamler and J. I. Mechanick. Dietary supplements and nutraceuticals in the management of endocrine disorders. Current Opinion in Endocrinology and Diabetes 2006 13(5): 425-430. PMID: . Reason for Exclusion: NRD

D. Tan, C. J. Haines, K. K. Limpaphayom, C. F. Holinka and M. K. Ausmanas. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. Reason for Exclusion: DUP

S. Tanaka, Y. Matsuyama, M. Shiraki and Y. Ohashi. Estimating the effects of time-varying treatments: incidence of fractures among postmenopausal Japanese women. Epidemiology 2007 18(5): 529-36. PMID: . Reason for Exclusion: PTU

A. Tavani, C. Braga, C. La Vecchia, E. Negri and S. Franceschi. Hormone replacement treatment and breast cancer risk: an age-specific analysis. Cancer Epidemiol Biomarkers Prev 1997 6(1): 11-4. PMID: . Reason for Exclusion: DES

A. Tavani, E. Negri and C. La Vecchia. Menstrual and reproductive factors and biliary tract cancers. Eur J Cancer Prev 1996 5(4): 241-7. PMID: . Reason for Exclusion: DES

H. J. Teede. Controversies in HRT. Aust Fam Physician 2002 31(5): 413-8. PMID: . Reason for Exclusion: NCT

C. B. Tempfer, E. K. Bentz, S. Leodolter, G. Tscherne, F. Reuss, H. S. Cross and J. C. Huber. Phytoestrogens in clinical practice: a review of the literature. Fertil Steril 2007 87(6): 1243-9. PMID: . Reason for Exclusion: NRD

B. Tengstrand. Oestrogen plus progestin significantly improves bone mineral density and reduces risk of fracture. Evidence-Based Healthcare 2004 8(2): 102-104. PMID: . Reason for Exclusion: DES

B. J. Tesch. Herbs commonly used by women: an evidence-based review. Dis Mon 2002 48(10): 671-96. PMID: . Reason for Exclusion: NCT

R. Teschke. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review. Menopause 2010 17(2): 426-40. PMID: . Reason for Exclusion: NRP

H. L. Thacker. Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women. Journal of Women's Health 2011 20(7): 1007-1016. PMID: . Reason for Exclusion: NRD

The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007 14(3 Pt 1): 355-69; quiz 370-1. PMID: . Reason for Exclusion: NRD

D. B. Thomas. Oral contraceptives and breast cancer: review of the epidemiologic literature. Contraception 1991 43(6): 597-642. PMID: . Reason for Exclusion: NRQ

E. A. Thompson. Alternative and complementary therapies for the menopause: a homeopathic approach. Maturitas 2010 66(4): 350-4. PMID: . Reason for Exclusion: NRD

A. Tjonneland, J. Christensen, B. L. Thomsen, A. Olsen, K. Overvad, M. Ewertz and L. Mellemkjaer. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 2004 100(11): 2328-37. PMID: . Reason for Exclusion: DES

S. Toh, S. Hernandez-Diaz, R. Logan, J. E. Rossouw and M. A. Hernan. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med 2010 152(4): 211-7. PMID: . Reason for Exclusion: PTU

C. A. Toles. The incidence of cardiovascular disease in menopausal women on hormone replacement therapy: a clinical evidence-based medicine review. J Natl Black Nurses Assoc 2007 18(2): 75-80. PMID: . Reason for Exclusion: PTU

K. A. Toulis, T. Tzellos, D. Kouvelas and D. G. Goulis. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin Ther 2009 31(2): 221-35. PMID: . Reason for Exclusion: NRD

K. Toulis, T. Tzellos, D. Kouvelas, C. Sardeli, G. Papazisis, M. Chourdakis and D. Goulis. Safety and tolerability of (alpha)2(delta) ligand gabapentin in treating hot flashes: An evidence-based systematic review and meta-analysis. Review of Clinical Pharmacology and Pharmacokinet Reason for Exclusion: NRD

B. J. Trock, L. Hilakivi-Clarke and R. Clarke. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 2006 98(7): 459-71. PMID: . Reason for Exclusion: NRP

P. Tuomikoski, T. S. Mikkola, M. J. Tikkanen and O. Ylikorkala. Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy. Climacteric 2010 13(5): 457-66. PMID: . Reason for Exclusion: NRQ

S. S. Tworoger, S. A. Missmer, R. L. Barbieri, W. C. Willett, G. A. Colditz and S. E. Hankinson. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J Natl Cancer Inst 2005 97(8): 595-602. PMID: . Reason for Exclusion: DES

L. Udoff, P. Langenberg and E. Y. Adashi. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995 86(2): 306-16. PMID: . Reason for Exclusion: NRD

E. M. Umland, C. Rinaldi, S. M. Parks and E. G. Boyce. The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. Ann Pharmacother 1999 33(12): 1315-28. PMID: . Reason for Exclusion: NRO

V. Unfer, M. L. Casini, L. Costabile, M. Mignosa, S. Gerli and G. C. Di Renzo. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril 2004 82(1): 145-8, quiz 265. PMID: . Reason for Exclusion: NRC

G. Ursin, C. C. Tseng, A. Paganini-Hill, S. Enger, P. C. Wan, S. Formenti, M. C. Pike and R. K. Ross. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer?. J Clin Oncol 2002 20(3): 699-706. PMID: . Reason for Exclusion: DES

T. Ushiroyama, A. Ikeda and M. Ueki. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition. J Med 2004 35(1-6): 151-62. PMID: . Reason for Exclusion: NRP

W. Utian, H. Yu, J. Bobula, S. Mirkin, S. Olivier and J. H. Pickar. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009 63(4): 329-35. PMID: . Reason for Exclusion: NRC

W. H. Utian, M. L. Gass and J. H. Pickar. Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women. Menopause 2004 11(3): 306-14. PMID: . Reason for Exclusion: NRO

W. H. Utian. The true clincal features of postmenopause and oophorectomy, and their response to oestrogen therapy. S Afr Med J 1972 46(23): 732-7. PMID: . Reason for Exclusion: NOP

D. V. Vakil, R. W. Morgan and M. Halliday. Exogenous estrogens and development of breast and endometrial cancer. Cancer Detect Prev 1983 6(4-5): 415-24. PMID: . Reason for Exclusion: DES

S. M. van Anders, A. B. Chernick, B. A. Chernick, E. Hampson and W. A. Fisher. Preliminary clinical experience with androgen administration for pre- and postmenopausal women with hypoactive sexual desire. J Sex Marital Ther 2005 31(3): 173-85. PMID: . Reason for Exclusion: NOP

F. E. van Leeuwen. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer. Acta Endocrinol (Copenh) 1991 125 Suppl 1(): 13-26. PMID: . Reason for Exclusion: NCT

T. P. van Staa, C. Cooper, D. Barlow and H. G. Leufkens. Individualizing the risks and benefits of postmenopausal hormone therapy. Menopause 2008 15(2): 374-81. PMID: . Reason for Exclusion: NRQ

P. Veerus, S. L. Hovi, K. Fischer, M. Rahu, M. Hakama and E. Hemminki. Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]. Maturitas 2006 55(2): 162-73. PMID: . Reason for Exclusion: NRF

V. Vega. Cardioprotective benefits of hormone replacement therapy. J Am Acad Nurse Pract 2001 13(2): 69-76; quiz 77-9. PMID: . Reason for Exclusion: PTU

L. S. Velentzis, M. M. Cantwell, C. Cardwell, M. R. Keshtgar, A. J. Leathem and J. V. Woodside. Lignans and breast cancer risk in pre- and post-menopausal women: meta-analyses of observational studies. Br J Cancer 2009 100(9): 1492-8. PMID: . Reason for Exclusion: NRP

P. Vestergaard, L. Mosekilde and B. Langdahl. Fracture prevention in postmenopausal women. Clin Evid (Online) 2011 2011(): . PMID: . Reason for Exclusion: PTU

P. Vestergaard. Postmenopausal hormone therapy. Current Women's Health Reviews 2006 2(4): 197-205. PMID: . Reason for Exclusion: NCT

M. R. Vickers, A. H. MacLennan, B. Lawton, D. Ford, J. Martin, S. K. Meredith, B. L. DeStavola, S. Rose, A. Dowell, H. C. Wilkes, J. H. Darbyshire and T. W. Meade. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a r. Reason for Exclusion: NRF

A. Vincent and L. A. Fitzpatrick. Soy isoflavones: are they useful in menopause?. Mayo Clin Proc 2000 75(11): 1174-84. PMID: . Reason for Exclusion: NRD

C. M. Viscoli, L. M. Brass, W. N. Kernan, P. M. Sarrel, S. Suissa and R. I. Horwitz. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001 345(17): 1243-9. PMID: . Reason for Exclusion: DES

C. M. Viscoli, L. M. Brass, W. N. Kernan, P. M. Sarrel, S. Suissa and R. I. Horwitz. Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST). Am J Obstet Gynecol 2005 192(2): 387-93. PMID: . Reason for Exclusion: DES

L. F. Voigt, N. S. Weiss, J. Chu, J. R. Daling, B. McKnight and G. van Belle. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991 338(8762): 274-7. PMID: . Reason for Exclusion: DES

L. F. Voigt, Q. Deng and N. S. Weiss. Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). Cancer Causes Control 1994 5(3): 227-33. PMID: . Reason for Exclusion: NRC

C. von Hagens, P. Schiller, B. Godbillon, J. Osburg, C. Klose, R. Limprecht and T. Strowitzki. Treating menopausal symptoms with a complex remedy or placebo: a randomized controlled trial. Climacteric 2011 (): . PMID: . Reason for Exclusion: NRC

E. M. Walker, A. I. Rodriguez, B. Kohn, R. M. Ball, J. Pegg, J. R. Pocock, R. Nunez, E. Peterson, S. Jakary and R. A. Levine. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled t Reason for Exclusion: NRP

M. P. Warren. A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol 2004 190(4): 1141-67. PMID: . Reason for Exclusion: PTU

S. Wassertheil-Smoller, S. L. Hendrix, M. Limacher, G. Heiss, C. Kooperberg, A. Baird, T. Kotchen, J. D. Curb, H. Black, J. E. Rossouw, A. Aragaki, M. Safford, E. Stein, S. Laowattana and W. J. Mysiw. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Reason for Exclusion: DES

L. E. Wehren, D. Hosking and M. C. Hochberg. Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis. Curr Med Res Opin 2004 20(4): 525-31. PMID: . Reason for Exclusion: PTU

E. Weiderpass, H. O. Adami, J. A. Baron, C. Magnusson, R. Bergstrom, A. Lindgren, N. Correia and I. Persson. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999 91(13): 1131-7. PMID: . Reason for Exclusion: DES

E. Weiderpass, J. A. Baron, H. O. Adami, C. Magnusson, A. Lindgren, R. Bergstrom, N. Correia and I. Persson. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999 353(9167): 1824-8. PMID: . Reason for Exclusion: DES

M. G. Weiner, K. Barnhart, D. Xie and R. L. Tannen. Hormone therapy and coronary heart disease in young women. Menopause 2008 15(1): 86-93. PMID: . Reason for Exclusion: PTU

A. L. Weinstein, M. C. Mahoney, P. C. Nasca, R. L. Hanson, M. C. Leske and A. O. Varma. Oestrogen replacement therapy and breast cancer risk: a case-control study. Int J Epidemiol 1993 22(5): 781-9. PMID: . Reason for Exclusion: DES

J. M. Weiss, B. S. Saltzman, J. A. Doherty, L. F. Voigt, C. Chen, S. A. Beresford, D. A. Hill and N. S. Weiss. Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. Am J Epidemiol 2006 164(1): 56-62. PMID: . Reason for Exclusion: DES

L. K. Weiss, R. T. Burkman, K. L. Cushing-Haugen, L. F. Voigt, M. S. Simon, J. R. Daling, S. A. Norman, L. Bernstein, G. Ursin, P. A. Marchbanks, B. L. Strom, J. A. Berlin, A. L. Weber, D. R. Doody, P. A. Wingo, J. A. McDonald, K. E. Malone, S. G. Folger and R. Spirtas. Hormone re Reason for Exclusion: DES

N. S. Weiss, V. T. Farewall, D. R. Szekely, D. R. English and N. Kiviat. Oestrogens and endometrial cancer: effect of other risk factors on the association. Maturitas 1980 2(3): 185-90. PMID: . Reason for Exclusion: DES

G. Wells, P. Tugwell, B. Shea, G. Guyatt, J. Peterson, N. Zytaruk, V. Robinson, D. Henry, D. O'Connell and A. Cranney. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosi Reason for Exclusion: PTU

A. J. Welton, M. R. Vickers, J. Kim, D. Ford, B. A. Lawton, A. H. MacLennan, S. K. Meredith, J. Martin and T. W. Meade. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008 337(): a1190. PMID: . Reason for Exclusion: DUP

F. K. Welty, K. S. Lee, N. S. Lew, M. Nasca and J. R. Zhou. The association between soy nut consumption and decreased menopausal symptoms. J Womens Health (Larchmt) 2007 16(3): 361-9. PMID: . Reason for Exclusion: NRF

A. M. Whelan, T. M. Jurgens and S. K. Bowles. Natural health products in the prevention and treatment of osteoporosis: systematic review of randomized controlled trials. Ann Pharmacother 2006 40(5): 836-49. PMID: . Reason for Exclusion: NRO

I. Wiklund, J. Holst, J. Karlberg, L. A. Mattsson, G. Samsioe, K. Sandin, M. Uvebrant and B. von Schoultz. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 1992 14(3): 211-24. PMID: . Reason for Exclusion: NRC

G. Williamson, P. Coppens, L. Serra-Majem and T. Dew. Review of the efficacy of green tea, isoflavones and aloe vera supplements based on randomised controlled trials. Food Funct 2011 (): . PMID: . Reason for Exclusion: NRD

P. S. Williamson-Hughes, B. D. Flickinger, M. J. Messina and M. W. Empie. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause 2006 13(5): 831-9. PMID: . Reason for Exclusion: NRD

D. M. Witt and T. R. Lousberg. Controversies surrounding estrogen use in postmenopausal women. Ann Pharmacother 1997 31(6): 745-55. PMID: . Reason for Exclusion: NCT

P. H. Wolf, J. H. Madans, F. F. Finucane, M. Higgins and J. C. Kleinman. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991 164(2): 489-94. PMID: . Reason for Exclusion: DES

V. C. Wong, C. E. Lim, X. Luo and W. S. Wong. Current alternative and complementary therapies used in menopause. Gynecol Endocrinol 2009 25(3): 166-74. PMID: . Reason for Exclusion: NRD

J. Woo, E. Lau, S. C. Ho, F. Cheng, C. Chan, A. S. Chan, C. J. Haines, T. Y. Chan, M. Li and A. Sham. Comparison of Pueraria lobata with hormone replacement therapy in treating the adverse health consequences of menopause. Menopause 2003 10(4): 352-61. PMID: . Reason for Exclusion: NRD

B. G. Wren. The effect of oestrogen on the female cardiovascular system. Med J Aust 1992 157(3): 204-8. PMID: . Reason for Exclusion: PTU

O. Wu, L. Robertson, P. Langhorne, S. Twaddle, G. D. Lowe, P. Clark, M. Greaves, I. D. Walker, I. Brenkel, L. Regan and I. A. Greer. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and E Reason for Exclusion: PTU

A. H. Wu, M. C. Yu, C. C. Tseng and M. C. Pike. Body size, hormone therapy and risk of breast cancer in Asian-American women. Int J Cancer 2007 120(4): 844-52. PMID: . Reason for Exclusion: PTU

F. Wu, R. Ames, J. Clearwater, M. C. Evans, G. Gamble and I. R. Reid. Prospective 10-year study of the determinants of bone density and bone loss in normal postmenopausal women, including the effect of hormone replacement therapy. Clin Endocrinol (Oxf) 2002 56(6): 703-11. PMID: . Reason for Exclusion: NOP

W. Wuttke, D. Seidlova-Wuttke and C. Gorkow. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 2003 44 Suppl 1(): S67-77. PMID: . Reason for Exclusion: NOP

W. Wuttke, K. Raus and C. Gorkow. Efficacy and tolerability of the Black cohosh (Actaea racemosa) ethanolic extract BNO 1055 on climacteric complaints: A double-blind, placebo- and conjugated estrogens-controlled study. Maturitas 2006 55(SUPPL. 1): S83-S91. PMID: . Reason for Exclusion: NOP

K. W. Wyrwich, D. I. Spratt, M. Gass, H. Yu and J. D. Bobula. Identifying meaningful differences in vasomotor symptoms among menopausal women. Menopause 2008 15(4 Pt 1): 698-705. PMID: . Reason for Exclusion: DUP

S. Xing, Y. Wu, J. Liu, R. Xu, Z. Zhang and Y. Wang. A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin. Chin Med J (Engl) 2003 116(4): 584-7. PMID: . Reason for Exclusion: NRO

T. Yasui, H. Uemura, M. Tezuka, M. Yamada, M. Irahara, M. Miura and T. Aono. Biological effects of hormone replacement therapy in relation to serum estradiol levels. Horm Res 2001 56(1-2): 38-44. PMID: . Reason for Exclusion: NOP

O. Ylikorkala and S. Rozenberg. Efficacy and tolerability of fully transdermal hormone replacement in sequential or continuous therapy at two doses of progestogen in postmenopausal women. Maturitas 2000 37(2): 83-93. PMID: . Reason for Exclusion: DUP

I. Yoles, Y. Yogev, Y. Frenkel, M. Hirsch, R. Nahum and B. Kaplan. Efficacy and safety of standard versus low-dose Femarelle (DT56a) for the treatment of menopausal symptoms. Clin Exp Obstet Gynecol 2004 31(2): 123-6. PMID: . Reason for Exclusion: NRC

M. E. Yurcheshen, T. Guttuso, Jr., M. McDermott, R. G. Holloway and M. Perlis. Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring model. J Womens Health (Larchmt) 2009 18(9): 1355-60. PMID: . Reason for Exclusion: NOP

E. Zaborowska, J. Brynhildsen, S. Damberg, M. Fredriksson, L. Lindh-Astrand, E. Nedstrand, Y. Wyon and M. Hammar. Effects of acupuncture, applied relaxation, estrogens and placebo on hot flushes in postmenopausal women: an analysis of two prospective, parallel, randomized studies. Reason for Exclusion: NOP

H. Zang, H. Shi and L. Speroff. Low-dose hormone therapy in postmenopausal women in China. Climacteric 2010 13(6): 544-52. PMID: . Reason for Exclusion: NCT

J. Zhou, F. Qu, R. Nan and D. Tang. The effect of chinese medicinal herbs in relieving menopausal symptoms in ovariectomized chinese women. Explore (NY) 2007 3(5): 478-84. PMID: . Reason for Exclusion: NRP

X. Zhu, J. Clarke, M. Proctor and Y. L. Liew. Chinese herbal medicine for menopausal symptoms. 2011 (): . PMID: . Reason for Exclusion: NCT

S. Ziaei, M. Moghasemi and S. Faghihzadeh. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric 2010 13(2): 147-56. PMID: . Reason for Exclusion: NRC

J. E. Zweifel and W. H. O'Brien. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997 22(3): 189-212. PMID: . Reason for Exclusion: NRD

Appendix C. Abstraction Forms

Table C-1. Key Question 1, Form 1. Study Characteristics

Variable Name	Variable Type	Answer Code	Answer Code Label
RefID	Text		
Author	Text		
Author followed by (d)			Refid contains a duplicate pop.
Author followed by (m)			Refid contains multiple public.
Author followed by (a)			Refid is a conference abstract
Author followed by (c)			Refid is from clinical registry
Year	Text		
Country	Text		
Number of sites	Text		
Country/Center Comments	Text		
Treatment	Checkbox	1	Hormone
		2	Non-hormone prescription
		3	Non-hormone non-prescription
KQ1	Radio	1	Yes
		2	No
KQ2	Radio	1	Yes
		2	No
KQ3	Radio	1	Yes
		2	No
Study design	Radio	1	RCT with placebo comparator
		2	RCT with active comparator
		3	Crossover with placebo comparator
		4	Crossover with active comparator
Follow-up in wks	Text		
Women with intact uterus?	Radio	1	Yes, whole study sample
		2	No, whole study sample
		3	Both included in study sample
		4	Unknown
Percentage with intact uterus	Text		
Presence of vaso symptoms required for inclusion?	Radio	1	Yes, only women with vaso symptoms included in study.
		2	No, women with and without vaso symptoms included in study.
		3	Uncertain
Subgroup analysis?	Radio	1	Yes
		2	No
Describe subgrp analysis	Text		

Variable Name	Variable Type	Answer Code	Answer Code Label
Vasomotor symptoms	Radio	1	Yes
		2	No
Sleep disturbance	Radio	1	Yes
		2	No
Psychological symptoms	Radio	1	Yes
		2	No
Urogenital atrophy	Radio	1	Yes
		2	No
Sexual function	Radio	1	Yes
		2	No
Quality of life	Radio	1	Yes
		2	No
Osteoporotic fractures	Radio	1	Yes
		2	No
Coronary heart disease	Radio	1	Yes
		2	No
Stroke	Radio	1	Yes
		2	No
Thromboembolism	Radio	1	Yes
		2	No
Breast cancer	Radio	1	Yes
		2	No
Endometrial cancer	Radio	1	Yes
		2	No
Ovarian cancer	Radio	1	Yes
		2	No
Colorectal cancer	Radio	1	Yes
		2	No
Cholecystitis	Radio	1	Yes
		2	No
Adverse events	Radio	1	Yes
		2	No
Potential Industry Involvement:			
Funding source	Checkbox	1	Manufacture-related
		2	Public source
		3	Not stated
Any authors with industry funding?	Radio	1	Yes
		2	No
		3	Not stated
Any mention of editorial service?	Radio	1	Yes
		2	No

Variable Name	Variable Type	Answer Code	Answer Code Label
Pooling Data:	Text	1	Mixtures
		2	black cohosh + St John's wort
		3	Single ingredient supplements
		4	Pueraria mirifica
		5	Combinations with isoflavones
	Radio	1	Total
		2	Moderate-to-Severe
	Radio	1	Hot flashes
		2	Vasomotor symptoms
		3	Climacteric symptoms
	Text		Min #/#days
	Text		Comment box

Table C-2. Key Question 1, Form 2. Study Arm Characteristics

Variable Name	Variable Type	Answer Code	Answer Code Label
Sample size, arm 1	Text		
Treatment, arm 1	Radio	1	Placebo
		2	Estrogen alone
		3	Estrogen and progestin combined
		4	Estrogen and progestin sequential
		5	Progestin alone
		6	Testosterone alone
		7	Testosterone and Estrogen combined
		8	Antidepressant
		9	Eszopiclone
		10	Clonidine
		11	Methyldopa
		12	Gabapentin, pregabalin
		13	Isoflavones, inc red clover, genistein, daidzein, equol
		14	Black cohosh (Cimicifuga racemosa)
		15	St John's wort (Hypericum perforatum)
		16	Ginseng
		17	Flax seed
		18	Vitamin E
		19	Dong quai (angelica sinensis)
		20	Dehydroepiandosterone (DHEA)
		21	Other
Other treatment description	Text		
Generic Drug name, arm 1	Text		

Variable Name	Variable Type	Answer Code	Answer Code Label
Trade Drug name, arm 1	Text		
Dose, arm 1	Text		
Dose category, arm 1	Radio	1	High
		2	Standard
		3	Low
		4	Ultra low
		5	Unknown
Mode of admin, arm 1	Radio	1	Oral
		2	Transdermal patch
		3	Vaginal cream
		4	Injection
		5	Dietary supplement
		6	Vaginal ring
		7	Intranasal spray
		8	Skin spray
		9	Vaginal ovule
		10	Vaginal gel
		11	Skin cream
		12	Skin gel
		13	Vaginal pessary/suppository
		14	Vaginal tablet
Mean age, arm 1	Text		
Age stand dev, arm 1	Text		
Lowest age, arm 1	Text		
Highest age, arm 1	Text		
Percent white, arm 1	Text		
Percent black, arm 1	Text		
Percent Hispanic, arm 1	Text		
Percent asian, arm 1	Text		
Percent other race, arm 1	Text		
Mean years since menopause, arm 1	Text		
Stand dev since menopause, arm 1	Text		
Mean months since last menstrual period, arm 1	Text		
Stand dev since last menstrual period, arm 1	Text		
Mean age at menopause, arm 1	Text		
Stand dev of age at menopause, arm 1	Text		
Percent previously using HRT	Text		
Mean BMI, arm 1	Text		
BMI stand dev, arm 1	Text		
Percent current smokers, arm 1	Text		
Percent former smokers, arm 1	Text		
Percent never smokers, arm 1	Text		

Variable Name	Variable Type	Answer Code	Answer Code Label
Comments (any characteristics sig different?)	Text		

Table C-3. Key Question 1, Form 3: Vasomotor Outcomes (estimating up to 3 different vasomotor outcomes reported in a single study)

Variable Name	Variable Type	Answer Code	Answer Code Label
Vasomotor scale, arm 1a	Radio	1	Greene vasomotor
		2	MENQOL vasomotor
		3	WHQ vasomotor
		4	Kupperman vasomotor
		5	Hot flashes
		6	Night sweats
		7	Hot flashes and night sweats
		8	Hot flash severity score
		9	Other
Vaso other scale description	Text		
Vaso frequency of measurements	Radio	1	Daily
		2	Weekly
		3	Monthly
Vaso symptom category	Radio	1	Total hot flashes
		2	Only moderate-severe hot flashes
Vaso baseline mean, arm 1a	Text		
Vaso baseline sd, arm 1a	Text		
Vaso baseline CI lower bound, arm 1a	Text		
Vaso baseline CI upper bound, arm 1a	Text		
Vaso 12-wk mean, arm 1a	Text		
Vaso 12-wk sd, arm 1a	Text		
Vaso 12-wk CI lower bound, arm 1a	Text		
Vaso 12-wk CI upper bound, arm 1a	Text		
Vaso 12-wk pre-post p-value, arm 1a	Text		
Vase 12-wk between grp p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso last mean, arm 1a	Text		
Vaso last sd, arm 1a	Text		
Vaso last CI lower bound, arm 1a	Text		
Vaso last CI upper bound, arm 1a	Text		
Vaso last pre-post p-value, arm 1a	Text		
Vaso last between grp p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Specify difference	*Radio*	*1*	*Difference in post-test from placebo (Not present for arm 1, but is for arm 2-6)*
		2	*Difference between changes (delta)*
Vaso difference from placebo, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*

Variable Name	Variable Type	Answer Code	Answer Code Label
Vaso diff CI lower bound, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso diff CI upper bound, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso diff p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso mean change score, arm 1a	Text		
Vaso mean change std dev, arm 1a	Text		
Vaso other outcome, arm 1a	Text		
Vaso comments, arm 1a	Text		
Vasomotor scale, arm 1b	Radio	1	Greene vasomotor
		2	MENQOL vasomotor
		3	WHQ vasomotor
		4	Kupperman vasomotor
		5	Hot flashes
		6	Night sweats
		7	Hot flashes and night sweats
		8	Hot flash severity score
		9	Other
Vaso other scale description, arm 1b	Text		
Vaso frequency of measurements	Radio	1	Daily
		2	Weekly
		3	Monthly
Vaso symptom category	Radio	1	Total hot flashes
		2	Only moderate-severe hot flashes
Vaso baseline mean, arm 1b	Text		
Vaso baseline sd, arm 1b	Text		
Vaso baseline CI lower bound, arm 1b	Text		
Vaso baseline CI upper bound, arm 1b	Text		
Vaso 12-wk mean, arm 1b	Text		
Vaso 12-wk sd, arm 1b	Text		
Vaso 12-wk pre-post p-value, arm 1b	Text		
Vaso 12-wk CI lower bound, arm 1b	Text		
Vaso 12-wk CI upper bound, arm 1b	Text		
Vaso 12-wk pre-post p-value, arm 1b	Text		
Vaso 12-wk between grp p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso last mean, arm 1b	Text		
Vaso last sd, arm 1b	Text		
Vaso last CI lower bound, arm 1b	Text		
Vaso last CI upper bound, arm 1b	Text		
Vaso last pre-post p-value, arm 1b	Text		
Vaso last between grp p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*

Variable Name	Variable Type	Answer Code	Answer Code Label
Specify difference	*Radio*	*1*	*Difference in post-test from placebo (Not present for arm 1, but is for arm 2-6)*
		2	*Difference between changes (delta)*
Vaso difference from placebo, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso diff CI lower bound, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso diff CI upper bound, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso diff p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso mean change score, arm 1b	Text		
Vaso mean change std dev, arm 1b	Text		
Vaso other outcome, arm 1b	Text		
Vaso comments, arm 1b	Text		
Vasomotor scale, arm 1c	Radio	1	Greene vasomotor
		2	MENQOL vasomotor
		3	WHQ vasomotor
		4	Kupperman vasomotor
		5	Hot flashes
		6	Night sweats
		7	Hot flashes and night sweats
		8	Hot flash severity score
		9	Other
Vaso other scale description, arm 1c	Text		
Vaso frequency of measurements	Radio	1	Daily
		2	Weekly
		3	Monthly
Vaso symptom category	Radio	1	Total hot flashes
		2	Only moderate-severe hot flashes
Vaso baseline mean, arm 1c	Text		
Vaso baseline sd, arm 1c	Text		
Vaso baseline CI lower bound, arm 1c	Text		
Vaso baseline CI upper bound, arm 1c	Text		
Vaso 12-wk mean, arm 1c	Text		
Vaso 12-wk sd, arm 1c	Text		
Vaso 12-wk CI lower bound, arm 1c	Text		
Vaso 12-wk CI upper bound, arm 1c	Text		
Vaso 12-wk pre-post p-value, arm 1c	Text		
Vaso 12-wk between grp p-value, arm 1c	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso last mean, arm 1c	Text		
Vaso last sd, arm 1c	Text		

Variable Name	Variable Type	Answer Code	Answer Code Label
Vaso last CI lower bound, arm 1c	Text		
Vaso last CI upper bound, arm 1c	Text		
Vaso last pre-post p-value, arm 1c	Text		
Vaso last between grp p-value, arm 1c	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Specify difference	*Radio*	*1*	*Difference in post-test from placebo (Not present for arm 1, but is for arm 2-6)*
		2	*Difference between changes (delta)*
Vaso difference from placebo, arm 1c	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso diff CI lower bound, arm 1c	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso diff CI upper bound, arm 1c	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso diff p-value, arm 1c	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Vaso mean change score, arm 1c	Text		
Vaso mean change p-value, arm 1c	Text		
Vaso other outcome, arm 1c	Text		
Vaso comments, arm 1c	Text		

Table C-4. Key Question 1, Form 4: Sleep Disturbance Outcomes (estimating up to 2 different sleep outcomes reported in a single study)

Variable Name	Variable Type	Answer Code	Answer Code Label
Sleep scale, arm 1a	Radio	1	WHI
		2	Other
		3	WHQ
Sleep other scale description, arm 1a	Text		
Sleep baseline mean, arm 1a	Text		
Sleep baseline sd, arm 1a	Text		
Sleep baseline CI lower bound, arm 1a	Text		
Sleep baseline CI upper bound, arm 1a	Text		
Sleep 12-wk mean, arm 1a	Text		
Sleep 12-wk sd, arm 1a	Text		
Sleep 12-wk CI lower bound, arm 1a	Text		
Sleep 12-wk CI upper bound, arm 1a	Text		
Sleep 12-wk pre-post p-value, arm 1a	Text		
Sleep 12-wk between grp p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sleep last mean, arm 1a	Text		
Sleep last sd, arm 1a	Text		
Sleep last CI lower bound, arm 1a	Text		
Sleep last CI upper bound, arm 1a	Text		
Sleep last pre-post p-value, arm 1a	Text		

Variable Name	Variable Type	Answer Code	Answer Code Label
Sleep last between grp p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Specify difference	*Radio*	*1*	*Difference in post-test from placebo (Not present for arm 1, but is for arm 2-6)*
		2	*Difference between changes (delta)*
Sleep difference from placebo, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sleep diff CI lower bound, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sleep diff CI upper bound, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sleep diff p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sleep mean change score, arm 1a	Text		
Sleep mean change std dev, arm 1a	Text		
Sleep other outcome, arm 1a	Text		
Sleep comments, arm 1a	Text		
Sleep scale, arm 1b	Radio	1	WHI
		2	Other
		3	WHQ
Sleep other scale description, arm 1b	Text		
Sleep baseline mean, arm 1b	Text		
Sleep baseline sd, arm 1b	Text		
Sleep baseline CI lower bound, arm 1b	Text		
Sleep baseline CI upper bound, arm 1b	Text		
Sleep 12-wk mean, arm 1b	Text		
Sleep 12-wk sd, arm 1b	Text		
Sleep 12-wk CI lower bound, arm 1b	Text		
Sleep 12-wk CI upper bound, arm 1b	Text		
Sleep 12-wk pre-post p-value, arm 1b	Text		
Sleep 12-wk between grp p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sleep last mean, arm 1b	Text		
Sleep last sd, arm 1b	Text		
Sleep last CI lower bound, arm 1b	Text		
Sleep last CI upper bound, arm 1b	Text		
Sleep last pre-post p-value, arm 1b	Text		
Sleep last between grp p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Specify difference	*Radio*	*1*	*Difference in post-test from placebo (Not present for arm 1, but is for arm 2-6)*
		2	*Difference between changes (delta)*
Sleep difference from placebo, arm 1b	*Text*		
Sleep diff CI lower bound, arm 1b	*Text*		

Variable Name	Variable Type	Answer Code	Answer Code Label
Sleep diff CI upper bound, arm 1b	*Text*		
Sleep diff p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sleep mean change score, arm 1b	Text		
Sleep mean change std dev, arm 1b	Text		
Sleep other outcome, arm 1b	Text		
Sleep comments, arm 1b	Text		

Table C-5. Key Question 1, Form 5: Psychological Outcomes (estimating up to 3 different psychological outcomes reported in a single study)

Variable Name	Variable Type	Answer Code	Answer Code Label
Psych scale, arm 1a	Radio	1	Greene psychological score
		2	Greene anxiety score
		3	Greene depression score
		4	WHQ anxiety score
		5	WHQ depression score
		6	Beck anxiety score
		7	Beck depression score
		8	MENQOL psychosocial score
		9	MQOL emotional score
		10	Hamilton anxiety score
		11	Hamilton depression score
		12	SF-36 mental health score
		13	CES-D depression score
		14	Other
Psych other scale description, arm 1a	Text		
Psych baseline mean, arm 1a	Text		
Psych baseline sd, arm 1a	Text		
Psych baseline CI lower bound, arm 1a	Text		
Psych baseline CI upper bound, arm 1a	Text		
Psych 12-wk mean, arm 1a	Text		
Psych 12-wk sd, arm 1a	Text		
Psych 12-wk CI lower bound, arm 1a	Text		
Psych 12-wk CI upper bound, arm 1a	Text		
Psych 12-wk pre-post p-value, arm 1a	Text		
Psych 12-wk between grp p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Psych last mean, arm 1a	Text		
Psych last sd, arm 1a	Text		
Psych last CI lower bound, arm 1a	Text		
Psych last CI upper bound, arm 1a	Text		
Psych last pre-post p-value, arm 1a	Text		
Psych last between grp p-value, arm 1a	*Text*		*(Not present for arm 1, but is for*

Variable Name	Variable Type	Answer Code	Answer Code Label
			arm 2-6)
Specify difference	*Radio*	*1*	*Difference in post-test from placebo (Not present for arm 1, but is for arm 2-6)*
		2	*Difference between changes (delta)*
Psych difference from placebo, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Psych diff CI lower bound, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Psych diff CI upper bound, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Psych diff p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Psych mean change score, arm 1a	Text		
Psych other outcome, arm 1a	Text		
Psych comments, arm 1a	Text		
Psych mean change std dev, arm 1a	Text		
Psych scale, arm 1b	Radio	1	Greene psychological score
		2	Greene anxiety score
		3	Greene depression score
		4	WHQ anxiety score
		5	WHQ depression score
		6	Beck anxiety score
		7	Beck depression score
		8	MENQOL psychosocial score
		9	MQOL emotional score
		10	Hamilton anxiety score
		11	Hamilton depression score
		12	SF-36 mental health score
		13	CES-D depression score
		14	Other
Psych other scale description, arm 1b	Text		
Psych baseline mean, arm 1b	Text		
Psych baseline sd, arm 1b	Text		
Psych baseline CI lower bound, arm 1b	Text		
Psych baseline CI upper bound, arm 1b	Text		
Psych 12-wk mean, arm 1b	Text		
Psych 12-wk sd, arm 1b	Text		
Psych 12-wk CI lower bound, arm 1b	Text		
Psych 12-wk CI upper bound, arm 1b	Text		
Psych 12-wk pre-post p-value, arm 1b	Text		
Psych 12-wk between grp p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*

Variable Name	Variable Type	Answer Code	Answer Code Label
Psych last mean, arm 1b	Text		
Psych last sd, arm 1b	Text		
Psych last CI lower bound, arm 1b	Text		
Psych last CI upper bound, arm 1b	Text		
Psych last pre-post p-value, arm 1b	Text		
Psych last between grp p-value, arm 1b	Text		
Specify difference	*Radio*	*1*	Difference in post-test from placebo *(Not present for arm 1, but is for arm 2-6)*
		2	Difference between changes (delta)
Psych difference from placebo, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Psych diff CI lower bound, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Psych diff CI upper bound, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Psych diff p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Psych mean change score, arm 1b	Text		
Psych mean change std dev, arm 1b	Text		
Psych other outcome, arm 1b	Text		
Psych comments, arm 1b	Text		
Psych scale, arm 1c	Radio	1	Greene psychological score
		2	Greene anxiety score
		3	Greene depression score
		4	WHQ anxiety score
		5	WHQ depression score
		6	Beck anxiety score
		7	Beck depression score
		8	MENQOL psychosocial score
		9	MQOL emotional score
		10	Hamilton anxiety score
		11	Hamilton depression score
		12	SF-36 mental health score
		13	CES-D depression score
		14	Other
Psych other scale description, arm 1c	Text		
Psych baseline mean, arm 1c	Text		
Psych baseline sd, arm 1c	Text		
Psych baseline CI lower bound, arm 1c	Text		
Psych baseline CI upper bound, arm 1c	Text		
Psych 12-wk mean, arm 1c	Text		
Psych 12-wk sd, arm 1c	Text		

Variable Name	Variable Type	Answer Code	Answer Code Label
Psych 12-wk CI lower bound, arm 1c	Text		
Psych 12-wk CI upper bound, arm 1c	Text		
Psych 12-wk pre-post p-value, arm 1c	Text		
Psych 12-wk between grp p-value, arm 1c	*Text*		
Psych last mean, arm 1c	Text		
Psych last sd, arm 1c	Text		
Psych last CI lower bound, arm 1c	Text		
Psych last CI upper bound, arm 1c	Text		
Psych last pre-post p-value, arm 1c	Text		
Psych last between grp p-value, arm 1c	Text		
Specify difference	*Radio*	*1*	Difference in post-test from placebo *(Not present for arm 1, but is for arm 2-6)*
		2	Difference between changes (delta)
Psych difference from placebo, arm 1c	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Psych diff CI lower bound, arm 1c	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Psych diff CI upper bound, arm 1c	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Psych diff p-value, arm 1c	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Psych mean change score, arm 1c	Text		
Psych mean change std dev, arm 1c	Text		
Psych other outcome, arm 1c	Text		
Psych comments, arm 1c	Text		

Table C-6. Key Question 1, Form 6: Urogenital Atrophy (estimating up to 2 QOL measures reported in a single study)

Variable Name	Variable Type	Answer Code	Answer Code Label
Urogenital atrophy scale, arm 1a	Radio	1	Vaginal dryness
		2	Vaginal atrophy
		3	Other
Urogen atrophy scale description, arm 1a	Text		
Urogen atrophy baseline percent, arm 1a	Text		
Urogen atrophy 12-wk percent, arm 1a	Text		
Urogen atrophy 12-wk CI lower bound, arm 1a	Text		
Urogen atrophy 12-wk CI upper bound, arm 1a	Text		
Urogen atrophy 12-wk pre-post p-value, arm 1a	Text		
Urogen atrophy 12-wk between grp p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Urogen atrophy last percent, arm 1a	Text		
Urogen atrophy last CI lower bound, arm 1a	Text		
Urogen atrophy last CI upper bound, arm 1a	Text		
Urogen atrophy last pre-post p-value, arm 1a	Text		

Variable Name	Variable Type	Answer Code	Answer Code Label
Urogen atrophy last between grp p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Specify difference	*Radio*	*1*	Difference in post-test from placebo *(Not present for arm 1, but is for arm 2-6)*
		2	Difference between changes (delta)
Urogen atrophy difference from placebo, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Urogen atrophy diff CI lower bound, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Urogen atrophy diff CI upper bound, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Urogen atrophy diff p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Urogen atrophy mean change score, arm 1a	Text		
Urogen atrophy mean change std dev, arm 1a	Text		
Urogen atrophy other outcome, arm 1a	Text		
Urogen atrophy comments, arm 1a	Text		
Urogenital atrophy scale, arm 1b	Radio	1	Vaginal dryness
		2	Vaginal atrophy
		3	Other
Urogen atrophy scale description, arm 1b	Text		
Urogen atrophy baseline percent, arm 1b	Text		
Urogen atrophy 12-wk percent, arm 1b	Text		
Urogen atrophy 12-wk CI lower bound, arm 1b	Text		
Urogen atrophy 12-wk CI upper bound, arm 1b	Text		
Urogen atrophy 12-wk pre-post p-value, arm 1b	Text		
Urogen atrophy 12-wk between grp p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Urogen atrophy last percent, arm 1b	Text		
Urogen atrophy last CI lower bound, arm 1b	Text		
Urogen atrophy last CI upper bound, arm 1b	Text		
Urogen atrophy last pre-post p-value, arm 1b	Text		
Urogen atrophy last between grp p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Specify difference	*Radio*	*1*	Difference in post-test from placebo *(Not present for arm 1, but is for arm 2-6)*
		2	Difference between changes (delta)
Urogen atrophy difference from placebo, arm 1b	*Text*		
Urogen atrophy diff CI lower bound, arm 1b	*Text*		
Urogen atrophy diff CI upper bound, arm 1b	*Text*		
Urogen atrophy diff p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Urogen atrophy mean change score, arm 1b	Text		
Urogen atrophy mean change std dev, arm 1b	Text		

Variable Name	Variable Type	Answer Code	Answer Code Label
Urogen atrophy other outcome, arm 1b	Text		
Urogen atrophy comments, arm 1b	Text		

Table C-7. Key Question 1, Form 7: Quality of Life Outcomes (estimating up to 2 QOL measures reported in a single study)

Variable Name	Variable Type	Answer Code	Answer Code Label
Quality of life scale, arm 1a	Radio	1	Greene total score
		2	MENQOL total score
		3	Kupperman total score
		4	MQOL overall qol
		5	WHQ total score
		6	SF-36 total score
		7	Other
QOL other scale description, arm 1a	Text		
QOL baseline mean, arm 1a	Text		
QOL baseline sd, arm 1a	Text		
QOL baseline CI lower bound, arm 1a	Text		
QOL baseline CI upper bound, arm 1a	Text		
QOL 12-wk mean, arm 1a	Text		
QOL 12-wk sd, arm 1a	Text		
QOL 12-wk CI lower bound, arm 1a	Text		
QOL 12-wk CI upper bound, arm 1a	Text		
QOL 12-wk pre-post p-value, arm 1a	Text		
QOL 12-wk between grp p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
QOL last mean, arm 1a	Text		
QOL last sd, arm 1a	Text		
QOL last CI lower bound, arm 1a	Text		
QOL last CI upper bound, arm 1a	Text		
QOL last pre-post p-value, arm 1a	Text		
QOL last between grp p-value, arm 1a	Text		
Specify difference	*Radio*	*1*	Difference in post-test from placebo *(Not present for arm 1, but is for arm 2-6)*
		2	Difference between changes (delta)
QOL difference from placebo, arm 1a	*Text*		
QOL diff CI lower bound, arm 1a	*Text*		
QOL diff CI upper bound, arm 1a	*Text*		
QOL diff p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
QOL mean change score, arm 1a	Text		
QOL mean change std dev, arm 1a	Text		
QOL other outcome, arm 1a	Text		

Variable Name	Variable Type	Answer Code	Answer Code Label
QOL comments, arm 1a	Text		
Quality of life scale, arm 1b	Radio	1	Greene total score
		2	MENQOL total score
		3	Kupperman total score
		4	MQOL overall qol
		5	WHQ total score
		6	SF-36 total score
		7	Other
QOL other scale description, arm 1b	Text		
QOL baseline mean, arm 1b	Text		
QOL baseline sd, arm 1b	Text		
QOL baseline CI lower bound, arm 1b	Text		
QOL baseline CI upper bound, arm 1b	Text		
QOL 12-wk mean, arm 1b	Text		
QOL 12-wk sd, arm 1b	Text		
QOL 12-wk CI lower bound, arm 1b	Text		
QOL 12-wk CI upper bound, arm 1b	Text		
QOL 12-wk pre-post p-value, arm 1b	Text		
QOL 12-wk between grp p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
QOL last mean, arm 1b	Text		
QOL last sd, arm 1b	Text		
QOL last CI lower bound, arm 1b	Text		
QOL last CI upper bound, arm 1b	Text		
QOL last pre-post p-value, arm 1b	Text		
QOL last between grp p-value, arm 1b	Text		
Specify difference	*Radio*	*1*	Difference in post-test from placebo *(Not present for arm 1, but is for arm 2-6)*
		2	Difference between changes (delta)
QOL difference from placebo, arm 1b	Text		
QOL diff CI lower bound, arm 1b	Text		
QOL diff CI upper bound, arm 1b	Text		
QOL diff p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
QOL mean change score, arm 1b	Text		
QOL mean change std dev, arm 1b	Text		
QOL other outcome, arm 1b	Text		
QOL comments, arm 1b	Text		

Table C-8. Key Question 1, Form 8: Sexual Function Outcomes (estimating up to 2 different sexual outcomes reported in a single study)

Variable Name	Variable Type	Answer Code	Answer Code Label
Sexual function scale, arm 1a	Radio	1	Greene sexual component score
		2	MENQOL sexual score
		3	MQOL sexual score
		4	WHQ sexual score
		5	McCoy sex scale
		6	Other
		7	Dyspareunia (pain during intercourse)
		8	Satisfying sexual episodes per week
		9	Total sexual episodes per week
Sexual function other scale description, arm 1a	Text		
Sexual function baseline mean, arm 1a	Text		
Sexual function baseline sd, arm 1a	Text		
Sexual function baseline CI lower bound, arm 1a	Text		
Sexual function baseline CI upper bound, arm 1a	Text		
Sexual function 12-wk mean, arm 1a	Text		
Sexual function 12-wk sd, arm 1a	Text		
Sexual function 12-wk CI lower bound, arm 1a	Text		
Sexual function 12-wk CI upper bound, arm 1a	Text		
Sexual function 12-wk pre-post p-value, arm 1a	Text		
Sexual function 12-wk between grp p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sexual function last mean, arm 1a	Text		
Sexual function last sd, arm 1a	Text		
Sexual function last CI lower bound, arm 1a	Text		
Sexual function last CI upper bound, arm 1a	Text		
Sexual function last pre-post p-value, arm 1a	Text		
Sexual function last between grp p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Specify difference	*Radio*	*1*	Difference in post-test from placebo *(Not present for arm 1, but is for arm 2-6)*
		2	Difference between changes (delta)
Sexual function difference from placebo, arm 1a	*Text*		
Sexual function diff CI lower bound, arm 1a	*Text*		
Sexual function diff CI upper bound, arm 1a	*Text*		
Sexual function diff p-value, arm 1a	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sexual function mean change score, arm 1a	Text		
Sexual function mean change std dev, arm 1a	Text		
Sexual function other outcome, arm 1a	Text		
Sexual function comments, arm 1a	Text		

Variable Name	Variable Type	Answer Code	Answer Code Label
Sexual function scale, arm 1b	Radio	1	Greene sexual component score
		2	MENQOL sexual score
		3	MQOL sexual score
		4	WHQ sexual score
		5	McCoy sex scale
		6	Other
		7	Dyspareunia (pain during intercourse)
		8	Satisfying sexual episodes per week
		9	Total sexual episodes per week
Sexual function other scale description, arm 1b	Text		
Sexual function baseline mean, arm 1b	Text		
Sexual function baseline sd, arm 1b	Text		
Sexual function baseline CI lower bound, arm 1b	Text		
Sexual function baseline CI upper bound, arm 1b	Text		
Sexual function 12-wk mean, arm 1b	Text		
Sexual function 12-wk sd, arm 1b	Text		
Sexual function 12-wk CI lower bound, arm 1b	Text		
Sexual function 12-wk CI upper bound, arm 1b	Text		
Sexual function 12-wk pre-post p-value, arm 1b	Text		
Sexual function 12-wk between grp p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sexual function last mean, arm 1b	Text		
Sexual function last sd, arm 1b	Text		
Sexual function last CI lower bound, arm 1b	Text		
Sexual function last CI upper bound, arm 1b	Text		
Sexual function last pre-post p-value, arm 1b	Text		
Sexual function last between grp p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Specify difference	*Radio*	*1*	Difference in post-test from placebo *(Not present for arm 1, but is for arm 2-6)*
		2	Difference between changes (delta)
Sexual function difference from placebo, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sexual function diff CI lower bound, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sexual function diff CI upper bound, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sexual function diff p-value, arm 1b	*Text*		*(Not present for arm 1, but is for arm 2-6)*
Sexual function mean change score, arm 1b	Text		
Sexual function mean change std dev, arm 1b	Text		
Sexual function other outcome, arm 1b	Text		

Variable Name	Variable Type	Answer Code	Answer Code Label
Sexual function comments, arm 1b	Text		

Table C-9. Key Question 1, Form 9: Study Quality

Variable Name	Variable Type	Answer Code	Answer Code Label
Was initial assembly of comparable groups: adequate randomization including equal distribution of potential confounders?	Radio	1	Yes
		2	No
		3	Uncertain
Were the researchers and subjects blinded to the study group assignment?	Radio	1	Yes
		2	No
		3	Uncertain
Was there adequate concealment of the study group assignments?	Radio	1	Yes
		2	No
		3	Uncertain
Was there maintenance of comparable groups (includes attrition, crossovers, adherence and contamination)?	Radio	1	Yes
		2	No
		3	Uncertain
Was there important differential loss to follow-up or overall high loss to follow-up?	Radio	1	Yes
		2	No
		3	Uncertain
Were measurements equal, reliable and valid (includes masking of outcome assessment)?	Radio	1	Yes
		2	No
		3	Uncertain
Were definitions of interventions clear?	Radio	1	Yes
		2	No
		3	Uncertain
Were all important outcomes considered and defined?	Radio	1	Yes
		2	No
		3	Uncertain
At analysis, was there adjustment for potential confounders (cohort studies) and intention-to-treat analysis (RCTs)?	Radio	1	Yes
		2	No
		3	Uncertain
Overall Quality Assessment	Radio	1	Good
		2	Fair
		3	Poor

Appendix D. Estrogen Dosing Categories

Mode of administration	Dose Category	17B-estradiol	Conjugated equine estrogen	Estradiol valerate	Estrone sulphate (estropipate or estrone piperazine)	Esterified estrogen	Ethinyl estradiol	Estradiol acetate
Oral	Ultra low	0.5mg	0.15mg 0.3mg	--	0.3mg	--	--	--
	Low	1.0mg	0.4mg	0.5mg	0.625mg	0.3mg	<0.010mg	--
	Standard	1.5mg 2mg	0.625mg	1mg	1.25mg 1.5mg	0.625mg	0.010mg	--
	High	4mg	1.25mg	2mg	2.5mg	1.25mg	>0.010mg	--
Transdermal Patch	Ultra low	0.025mg	--	--	--	--	--	--
	Low	0.0375mg	--	--	--	--	--	--
	Standard	0.05mg	--	--	--	--	--	--
	High	0.075mg 0.1mg	--	--	--	--	--	--
Vaginal Cream	Ultra low		--	--	--	--	--	--
	Low	0.1 mg	--	--	--	--	--	--
	Standard		0.625 mg	--	--	1.0 mg	--	--
	High	--	--	--	--	--	--	--
Vaginal Ring	Ultra low	--	--	--	--	--	--	--
	Low	0.0075mg	--	--	--	--	--	--
	Standard	--	--	--	--	--	--	--
	High	--	--	--	--	--	--	0.05 mg 0.10 mg
Topical (cream, spray, gel)	Ultra low	0.01% (gel) 0.03% (gel)	--	--	--	--	--	--
	Low	1.5 mg (spray) 0.04% (gel) 0.06% (gel) 0.10% (gel)	--	--	--	--	--	--
	Standard	0.05 mg (cream)	--	--	--	--	--	--
	High	--	--	--	--	--	--	--
Vaginal (pessary/suppository, tablet)	Ultra low	--	--	--	--	--	--	--
	Low	0.01 mg 0.0258 mg	--	--	--	--	--	--
	Standard	--	--	--	--	--	--	--
	High	--	--	--	--	--	--	--

Appendix E. Evidence Base for Key Question 1

Table E-1. Study characteristics for trials comparing hormone with placebo

1. Study	2. Country	3. Sites	4. Analyzed	5. Design	6. Study Arms	7. F/U (weeks)	8. Industry Funding	9. Editorial Assistance
Martin 1971	United States	2	165	RCT Plac Compare	3	12		No/NR
Campbell 1977	United Kingdom	1	136	Crossover	2	52		No/NR
Baumgardner 1978	United States	8	156	RCT Plac Compare	4	24		No/NR
Coope 1981	United Kingdom	1	55	Crossover	2	26		No/NR
Jensen 1983	Denmark	1	131	RCT Plac Compare	2	104		No/NR
Foidart 1991	Belgium	2	109	RCT Plac Compare	2	26		No/NR
Eriksen 1992	Denmark	NR	154	RCT Plac Compare	2	12		No/NR
Wiklund 1993	Sweden	15	223	RCT Plac Compare	2	12		No/NR
Derman 1995	United States	3	82	RCT Plac Compare	2	16	Yes	No/NR
Saletu 1995	Austria	1	64	RCT Plac Compare	2	12		No/NR
Good 1996	United States	NR	273	RCT Plac Compare	3	12		No/NR
Speroff (Study 1) 1996	United States	17	108	RCT Plac Compare	2	12	Yes	No/NR
Chung 1996	Hong Kong	1	83	Crossover	2	26		No/NR
Speroff (Study 2) 1996	United States	17	111	RCT Plac Compare	3	12	Yes	No/NR
Speroff (Study 3) 1996	United States	17	106	RCT Plac Compare	2	12	Yes	No/NR
Bacchi-Modena 1997	Italy	11	109	RCT Plac Compare	2	12		No/NR
Baerug 1998	Norway	5	119	RCT Plac Compare	3	12	Yes	No/NR
Bech 1998	Denmark	1	151	RCT Plac Compare	3	52		No/NR
de Vrijer 1999	Netherlands	16	254	RCT Plac Compare	3	12		No/NR
Leonetti 1999	United States	1	90	RCT Plac Compare	2	52	Yes	No/NR
Studd 1999	Multinational	63	355	RCT Plac Compare	5	12		No/NR
Polo-Kantola 1999	Finland	1	124	Crossover	2	12	Yes	No/NR
Casper 1999	Germany		67	RCT Plac Compare	2	24		No/NR
Cohen 1999	United States	Multi	259	RCT Plac Compare	2	12	Yes	No/NR
Rebar 2000	United States	25	204	RCT Plac Compare	2	104	Yes	No/NR
Speroff (Study 1) 2000	United States	11	219	RCT Plac Compare	5	16	Yes	No/NR
Rovati 2000	Italy	15	311	RCT Plac Compare	4	12	Yes	No/NR
Notelovitz 2000	United States	23	145	RCT Plac Compare	3	12		No/NR
Strickler 2000	United States	32	201	RCT Plac Compare	2	52	Yes	No/NR
Notelovitz 2000	United States	15	333	RCT Plac Compare	5	12	Yes	No/NR
DeAloysio 2000	Italy	1	156	RCT Plac Compare	3	12	Yes	No/NR
von Holst 2000	Germany	34	186	RCT Plac Compare	2	12		No/NR
Notelovitz 2000	United States	26	219	RCT Plac Compare	4	12	Yes	No/NR
Alexandersen 2000	Denmark	1	200	RCT Plac Compare	4	104	Yes	No/NR
Speroff (Study 2) 2000	United States	24	266	RCT Plac Compare	4	12	Yes	No/NR
Rigano 2001	Italy	1	362	RCT Plac Compare	2	26		No/NR

1. Study	2. Country	3. Sites	4. Analyzed	5. Design	6. Study Arms	7. F/U (weeks)	8. Industry Funding	9. Editorial Assistance
Utian (CEE alone arms) 2001	United States	57	117	RCT Plac Compare	4	52	Yes	No/NR
Simon 2001	United States	4	120	RCT Plac Compare	2	12	Yes	No/NR
Soares 2001	Brazil	2	50	RCT Plac Compare	2	12	Yes	No/NR
Utian (CEE/MPA arms) 2001	United States	57	152	RCT Plac Compare	5	52	Yes	No/NR
Rozenbaum 2002	France	21	165	RCT Plac Compare	3	12		No/NR
Shulman (Study 1) 2002	United States	32	293	RCT Plac Compare	3	12	Yes	No/NR
von Holst 2002	Germany	Multi	172	RCT Plac Compare	2	12		No/NR
Archer 2003	United States	11	221	RCT Plac Compare	3	12	Yes	No/NR
Vestergaard 2003	Denmark	Multi	1006	RCT Plac Compare	2	260		No/NR
Speroff 2003	United States	35	333	RCT Plac Compare	3	13	Yes	No/NR
Jirapinyo 2003	Thailand	1	120	RCT Plac Compare	2	52	Yes	No/NR
Haines 2003	Hong Kong	1	152	RCT Plac Compare	3	52	Yes	No/NR
Hays 2003	United States		16608	RCT Plac Compare	2	52		No/NR
Gambacciani 2003	Italy	1	50	RCT Plac Compare	2	12		No/NR
Gelfand 2003	Canada	18	119	RCT Plac Compare	2	12	Yes	No/NR
Wren 2003	Australia	1	80	RCT Plac Compare	2	12	Yes	No/NR
Simunic 2003	Croatia	15	1612	RCT Plac Compare	2	52		No/NR
Parsons 2003	United States	16	94	RCT Plac Compare	2	13	Yes	No/NR
Berlex (SIP) 2003	United States	NR	180	RCT Plac Compare	2	12		No/NR
Rudolph 2004	Germany	2	129	RCT Plac Compare	2	24	Yes	No/NR
Yang 2004	Taiwan	1	51	RCT Plac Compare	2	24		No/NR
Schurmann 2004	Multinational	19	225	RCT Plac Compare	4	16		No/NR
Utian 2004	United States	Multi	281	RCT Plac Compare	4	12	Yes	No/NR
Dessole 2004	Italy	NR	88	RCT Plac Compare	2	26		No/NR
Duramed (SIP) 2004	United States	NR	104	RCT Plac Compare	2	12		No/NR
Brunner 2005	United States		10739	RCT Plac Compare	2	52		No/NR
Onalan 2005	Turkey	1	210	RCT Plac Compare	3	52		No/NR
Bayer Healthcare (SIP) 2005	United States	NR	351	RCT Plac Compare	2	12		No/NR
Novartis (SIP) 2005	United States	NR	160	RCT Plac Compare	3	12		No/NR
Yaffe (d) 2006	United States	9	417	RCT Plac Compare	2	104	Yes	No/NR
Speroff (Study 1) 2006	United States	41	289	RCT Plac Compare	3	12	Yes	No/NR
Simon 2006	United States	37	200	RCT Plac Compare	2	12	Yes	No/NR
Diem (d) 2006	United States	9	417	RCT Plac Compare	2	104	Yes	No/NR
Nielsen 2006	Denmark	2	335	RCT Active Compare	3	104		No/NR
Osmanagaoglu 2006	Turkey	1	104	RCT Plac Compare	2	26		No/NR
Speroff (Study 2) 2006	United States	36	221	RCT Plac Compare	2	12	Yes	No/NR
Bachmann (d) 2007	United States	48	425	RCT Plac Compare	3	12	Yes	No/NR
Maki 2007	United States	19	180	RCT Plac Compare	2	17	Yes	No/NR
Endrikat 2007	Germany	31	324	RCT Plac Compare	2	12	Yes	No/NR
Lee 2007	South Korea	6	72	RCT Plac Compare	2	16	Yes	No/NR

1. Study	2. Country	3. Sites	4. Analyzed	5. Design	6. Study Arms	7. F/U (weeks)	8. Industry Funding	9. Editorial Assistance
Panay 2007	Multinational	Multi	575	RCT Plac Compare	3	24	Yes	No/NR
Simon 2007	Multinational	28	484	RCT Plac Compare	4	12	Yes	Yes
Pefanco 2007	United States	1	57	RCT Plac Compare	2	156	Yes	No/NR
Bayer Healthcare (SIP) 2007	United States	NR	165	RCT Plac Compare	2	12		No/NR
Buster (Study 1) 2008	United States	43	151	RCT Plac Compare	2	12	Yes	No/NR
Veerus 2008	Estonia	3	1823	RCT Plac Compare	4	187	Yes	No/NR
Davis 2008	Multinational	65	811	RCT Plac Compare	3	52	Yes	No/NR
Bachmann 2008	United States	9	230	RCT Plac Compare	3	12	Yes	No/NR
Huang (d) 2008	United States	9	417	RCT Plac Compare	2	104	Yes	No/NR
Welton 2008	Multinational	2	2130	RCT Plac Compare	2	52		No/NR
Buster (Study 2) 2008	United States	43	150	RCT Plac Compare	2	12	Yes	No/NR
Buster (Study 3) 2008	United States	43	153	RCT Plac Compare	2	12	Yes	No/NR
Simon (SIP) 2008	United States	42	248	RCT Plac Compare	2	12	Yes	No/NR
Benster 2009	United Kingdom	2	221	RCT Plac Compare	5	24	Yes	No/NR
Haines 2009	Multinational	Multi	160	RCT Plac Compare	2	12	Yes	Yes
Bachmann (d) 2009	United States	48	121	RCT Plac Compare	3	12	Yes	No/NR
Hedrick 2009	Multinational	48	495	RCT Plac Compare	4	12	Yes	No/NR
Baksu 2009	Turkey	1	132	RCT Plac Compare	4	52		No/NR
Bachmann (Study 1) 2009	Multinational	Multi	215	RCT Plac Compare	2	12	Yes	No/NR
Freedman 2009	United States	88	275	RCT Plac Compare	2	12	Yes	No/NR
Gast 2009	Multinational	25	285	RCT Plac Compare	2	24	Yes	Yes
Bachmann (Study 2) 2009		Multi	208	RCT Plac Compare	2	12	Yes	No/NR
Hassa 2010	Turkey	1	247	RCT Plac Compare	3	26		No/NR
Stevenson 2010	Multinational	15	313	RCT Plac Compare	3	13	Yes	No/NR
Raghunandan 2010	India	1	75	RCT Plac Compare	3	12		No/NR
Hedrick 2010	Multinational	48	488	RCT Plac Compare	4	12	Yes	No/NR
Liu 2011	Multinational	Multi	1029	RCT Plac Compare	6	12		No/NR
Lin 2011	China	9	244	RCT Plac Compare	2	16	Yes	Yes
Demetrio 2011	Brazil	1	66	RCT Plac Compare	2	24		No/NR
Liu 2012	United States	19	157	RCT Plac Compare	3	12	Yes	No/NR
Archer 2012	United States	78	351	RCT Plac Compare	3	12	Yes	Yes

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; MPA: medroxyprogesterone acetate; Multi: multicenter trial; NR: not reported; Plac: placebo; RCT: randomized controlled trial; (SIP); data came from a package insert

Table E-2. Study characteristics for trials comparing antidepressant with placebo

10. Study	11. Country	12. Sites	13. Analyzed	14. Design	15. Study Arms	16. F/U (weeks)	17. Industry Funding	18. Editorial Assistance

10. Study	11. Country	12. Sites	13. Analyzed	14. Design	15. Study Arms	16. F/U (weeks)	17. Industry Funding	18. Editorial Assistance
Suvanto-Luukkonen 2005	Finland	2	149	RCT Plac Compare	3	39	Yes	No/NR
Evans 2005	United States	1	80	RCT Plac Compare	2	12	Yes	No/NR
Kerwin 2007	United States	NR	87	Crossover	2	4	Yes	No/NR
Kalay 2007	Turkey	NR	50	RCT Plac Compare	2	8		No/NR
Speroff 2008	United States	37	620	RCT Plac Compare	5	12	Yes	No/NR
Soares 2008	Canada	NR	56	RCT Plac Compare	2	6	Yes	No/NR
Archer 2009	United States	32	541	RCT Plac Compare	3	26	Yes	Yes
Archer 2009	United States	34	452	RCT Plac Compare	3	12	Yes	Yes
Kornstein 2010	United States	37	372	RCT Plac Compare	2	8	Yes	Yes
Soares 2010	Multinational	72	461	RCT Active Compare	2	8	Yes	No/NR
Freeman 2011	United States	4	205	RCT Plac Compare	2	8		No/NR
Pfizer (c) 2011	Multinational	121	2118	RCT Plac Compare	2	52	Yes	No/NR
Bouchard 2012	Multinational	38	287	RCT Plac Compare	2	12	Yes	Yes

(c): data came from posted results on the clinical trial registry; F/U: followup NR: not reported; Plac: placebo; RCT: randomized controlled trial

Table E-3. Study characteristics for trials comparing other prescriptions with placebo

19. Study	20. Country	21. Sites	22. Analyzed	23. Design	24. Study Arms	25. F/U (weeks)	26. Industry Funding	27. Editorial Assistance
Clayden 1974	United Kingdom	18	85	Crossover	2	4		No/NR
Guttuso 2003	United States	1	59	RCT Plac Compare	2	12		No/NR
Butt 2008	Canada	NR	197	RCT Plac Compare	2	4	Yes	No/NR
Joffe 2010	United States	NR	59	Crossover	2	4	Yes	No/NR
Depomed (c) 2012	United States	45	532	RCT Plac Compare	3	12	Yes	No/NR
Depomed (c) 2012	United States	45	559	RCT Plac Compare	3	12	Yes	No/NR

(c): data came from posted results on the clinical trial registry; F/U: followup; NR: not reported; Plac: placebo; RCT: randomized controlled trial;

Table E-4. Study characteristics for trials comparing nonprescription nonhormone with placebo

28. Study	29. Country	30. Sites	31. Analyzed	32. Design	33. Study Arms	34. F/U (weeks)	35. Industry Funding	36. Editorial Assistance
Chenoy 1994	United Kingdom	2	56	RCT Plac Compare	2	26		No/NR
Murkies 1995	Australia	1	58	RCT Active Compare	2	12		No/NR
Hirata 1997	United States	1	71	RCT Plac Compare	2	24		No/NR
Albertazzi 1998	Italy	2	104	RCT Plac Compare	2	12	Yes	No/NR
Baber 1999	Australia	1	51	Crossover	2	12	Yes	No/NR
Wiklund 1999	Multinational	Multi	384	RCT Plac Compare	2	16	Yes	No/NR
Barnhart 1999	United States	1	60	RCT Plac Compare	2	12	Yes	No/NR

28. Study	29. Country	30. Sites	31. Analyzed	32. Design	33. Study Arms	34. F/U (weeks)	35. Industry Funding	36. Editorial Assistance
Upmalis 2000	United States	15	175	RCT Plac Compare	2	12	Yes	No/NR
Kotsopoulos 2000	Australia	NR	94	RCT Plac Compare	2	13		No/NR
Davis 2001	Australia	NR	55	RCT Plac Compare	2	12		No/NR
Faure 2002	France	1	75	RCT Plac Compare	2	16	Yes	No/NR
Han 2002	Brazil	1	80	RCT Plac Compare	2	22		No/NR
Tice 2003	United States	3	252	RCT Plac Compare	3	12	Yes	No/NR
Penotti 2003	Italy	1	62	RCT Plac Compare	2	26		No/NR
Burke 2003	United States	1	211	RCT Plac Compare	3	104	Yes	No/NR
Sammartino 2003	Italy	1	63	RCT Plac Compare	2	52		No/NR
Nahas 2004	Brazil	1	50	RCT Plac Compare	2	26	Yes	No/NR
Atkinson 2004	United Kingdom	1	205	RCT Plac Compare	2	52	Yes	No/NR
Hartley 2004	United Kingdom	1	57	RCT Plac Compare	2	12	Yes	No/NR
Winther 2005	Denmark	1	64	RCT Plac Compare	2	13	Yes	No/NR
Frei-Kleiner 2005	Switzerland	14	122	RCT Plac Compare	2	12	Yes	No/NR
Verhoeven 2005	Netherlands	11	124	RCT Plac Compare	2	12	Yes	No/NR
Kok 2005	Netherlands	NR	202	RCT Plac Compare	2	52	Yes	No/NR
Hidalgo 2005	Ecuador	2	106	Crossover	2	26		No/NR
Dodin 2005	Canada	1	179	RCT Plac Compare	2	52		No/NR
Osmers 2005	Germany	24	286	RCT Plac Compare	2	12		No/NR
Mucci 2006	Italy	Multi	89	RCT Plac Compare	2	24		No/NR
Heger (m) 2006	Ukraine	9	109	RCT Plac Compare	2	12	Yes	No/NR
Lewis 2006	Canada	1	99	RCT Plac Compare	3	16		No/NR
Uebelhack 2006	Germany	NR	301	RCT Plac Compare	2	16	Yes	No/NR
Sammartino 2006	Italy	1	75	RCT Plac Compare	2	12		No/NR
Casini 2006	Italy	3	154	Crossover	2	26		No/NR
Nahas 2007	Brazil	1	76	RCT Plac Compare	2	39	Yes	No/NR
Yang 2007	Taiwan	1	155	RCT Plac Compare	2	24	Yes	No/NR
Chung 2007	South Korea	Multi	77	RCT Plac Compare	2	12	Yes	No/NR
Cheng 2007	Sweden	NR	51	RCT Plac Compare	2	12		No/NR
Ho 2007	Hong Kong	1	176	RCT Plac Compare	2	26	Yes	No/NR
Cancellieri 2007	Italy	9	125	RCT Plac Compare	2	26		No/NR
Haines 2008	Hong Kong	1	84	RCT Plac Compare	2	26		No/NR
Jou 2008	Taiwan	2	96	RCT Plac Compare	3	26		No/NR
Khaodhiar 2008	United States	1	142	RCT Plac Compare	3	12	Yes	No/NR
Ferrari 2009	Italy	Multi	176	RCT Plac Compare	2	12		Yes
van der Sluijs 2009	Australia	5	92	RCT Plac Compare	2	16	Yes	No/NR
D'Anna (m) 2009	Italy	1	236	RCT Plac Compare	2	104		No/NR
van Die 2009	Australia	NR	100	RCT Plac Compare	2	16	Yes	No/NR
de Sousa-Munoz 2009	Brazil	1	84	RCT Plac Compare	2	16		No/NR
Labrie 2009	Multinational	Multi	216	RCT Plac Compare	4	12	Yes	No/NR

28. Study	29. Country	30. Sites	31. Analyzed	32. Design	33. Study Arms	34. F/U (weeks)	35. Industry Funding	36. Editorial Assistance
Panjari 2009	Australia	1	89	RCT Plac Compare	2	26		No/NR
Basaria 2009	United States	1	84	RCT Plac Compare	2	12		No/NR
Radhakrishnan 2009	India	1	85	RCT Plac Compare	2	26	Yes	No/NR
Lee 2010	South Korea	1	87	RCT Plac Compare	2	12	Yes	No/NR
Garcia 2010	Multinational	Multi	131	RCT Plac Compare	2	12	Yes	No/NR
Lipovac 2010	Austria	2	109	Crossover	2	12	Yes	No/NR
Shen 2010	United States	1	91	RCT Plac Compare	2	24		No/NR
Jassi 2010	India	NR	75	RCT Plac Compare	3	12		No/NR
Evans 2011	Canada	5	83	RCT Plac Compare	2	12	Yes	No/NR
Hsu 2011	Taiwan	2	50	RCT Plac Compare	2	52		No/NR
Andrikoula 2011	United Kingdom	1	70	RCT Plac Compare	2	12	Yes	No/NR
Levis 2011	United States	1	248	RCT Plac Compare	2	104		No/NR
Plotnikoff 2011	United States	1	178	RCT Plac Compare	3	13	Yes	No/NR
Chang 2011	United States	NR	64	RCT Plac Compare	2	12		No/NR
Auerbach 2012	Austria	NR	81	RCT Plac Compare	2	12	Yes	No/NR
Cianci 2012	Italy	Multi	120	RCT Plac Compare	2	12		No/NR
Kim 2012	South Korea	1	72	RCT Plac Compare	2	12	Yes	No/NR
Xia 2012	China	1	72	RCT Plac Compare	2	12		No/NR
Ye 2012	China	1	90	RCT Plac Compare	3	24	Yes	No/NR
Aso 2012	Japan	4	126	RCT Plac Compare	2	12	Yes	

F/U: followup; (m): trial contains data from multiple publications; Multi: multicenter trial; NR: not reported; Plac: placebo; RCT: randomized controlled trial

Table E-5. Study characteristics for trials comparing hormone and nonprescription nonhormone with placebo

37. Study	38. Country	39. Sites	40. Analyzed	41. Design	42. Study Arms	43. F/U (weeks)	44. Industry Funding	45. Editorial Assistance
Crisafulli 2004	Italy	1	90	RCT Plac Compare	3	52		No/NR
Newton 2006	United States	1	351	RCT Plac Compare	5	52		No/NR

Table E-6. Study characteristics for trials comparing hormone with hormone

46. Study	47. Country	48. Sites	49. Analyzed	50. Design	51. Study Arms	52. F/U (weeks)	53. Industry Funding	54. Editorial Assistance
Polvani 1991	Italy	17	373	RCT Active Compare	2	26		No/NR
Henriksson 1994	Multinational	9	157	RCT Active Compare	2	12		No/NR
Studd 1995	Multinational	19	204	RCT Active Compare	2	12		No/NR
Ayton 1996	Australia	3	194	RCT Active Compare	2	12	Yes	No/NR
Hilditch 1996	Canada	NR	74	RCT Active Compare	2	14	Yes	No/NR
Egarter 1996	Austria	Multi	101	RCT Active Compare	2	26	Yes	No/NR

46. Study	47. Country	48. Sites	49. Analyzed	50. Design	51. Study Arms	52. F/U (weeks)	53. Industry Funding	54. Editorial Assistance
Hirvonen 1997	Finland	1	120	RCT Active Compare	2	52		No/NR
Hirvonen 1997	Finland	1	173	RCT Active Compare	3	104	Yes	No/NR
Rozenberg 1997	Multinational	35	774	RCT Active Compare	5	52	Yes	No/NR
Al-Azzawi 1997	Netherlands	Multi	394	RCT Active Compare	3	28		No/NR
Lubbert 1997	Germany	469	2459	RCT Active Compare	2	12		No/NR
Barentsen 1997	Netherlands	12	165		2	12		Yes
Bachmann 1997	United States		196	RCT Active Compare	2	15	Yes	No/NR
Good 1999	United States	NR	321	RCT Active Compare	4	12	Yes	No/NR
Mattsson 2000	Multinational	Multi	659	RCT Active Compare	2	24	Yes	No/NR
Saure 2000	Denmark	Multi	376	RCT Active Compare	2	26		No/NR
Graser 2000	Multinational	49	581	RCT Active Compare	3	52	Yes	No/NR
Rioux 2000	Canada	6	159	RCT Active Compare	2	24	Yes	No/NR
Dugal 2000	Norway	Multi	96	RCT Active Compare	2	24		No/NR
Parsey 2000	United States	19	193	RCT Active Compare	2	12	Yes	No/NR
Meuwissen 2001	Netherlands	56	634	RCT Active Compare	2	52	Yes	No/NR
Lopes 2001	France	51	361		2	12		No/NR
Ozsoy 2002	Turkey	1	201	RCT Active Compare	2	24		No/NR
Loh 2002	Singapore	3	96	RCT Active Compare	2	26		No/NR
Buckler (d) 2003	United Kingdom	21	159	RCT Active Compare	2	24	Yes	No/NR
Al-Azzawi (d) 2003	United Kingdom	22	159	RCT Active Compare	2	24	Yes	No/NR
Lobo 2003	United States		218	RCT Active Compare	2	16	Yes	No/NR
Pornel 2005	Multinational	98	764	RCT Active Compare	2	52		No/NR
Gambacciani 2005	Multinational	4	850	RCT Active Compare	3	104		No/NR
Utian 2005	United States	33	248	RCT Active Compare	3	12	Yes	No/NR
Davis 2005	Multinational	2	120		2	16		No/NR
Raynaud 2005	France	Multi	405	RCT Active Compare	3	24		No/NR
Braunstein 2005	United States	39	446	RCT Plac Compare	4	24	Yes	No/NR
Simon 2005	Multinational	52	562	RCT Plac Compare	2	24	Yes	Yes
Weisberg 2005	Australia	4	185	RCT Active Compare	2	48	Yes	No/NR
Buster 2005	Multinational	53	532	RCT Plac Compare	2	24	Yes	Yes
Akhila 2006	India	1	88	RCT Active Compare	3	52		No/NR
Serrano 2006	Italy	4	114	RCT Active Compare	2	52		No/NR
Cieraad 2006	United Kingdom	29	189	RCT Active Compare	2	24		No/NR
Davis 2006	Multinational	15	76	RCT Plac Compare	2	24	Yes	No/NR
Long 2006	Taiwan	1	73	RCT Active Compare	2	12		No/NR
Shifren 2006	Multinational	58	549	RCT Active Compare	2	24	Yes	No/NR
Limpaphayom (m) 2006	Multinational	22	1028	RCT Active Compare	3	24	Yes	No/NR
Odabasi 2007	Turkey	1	61	RCT Active Compare	2	12		No/NR
Mattsson (d) 2007	Multinational	45	459	RCT Active Compare	3	52	Yes	No/NR
Pitkin (d) 2007	Multinational	45	459	RCT Active Compare	3	52	Yes	No/NR

46. Study	47. Country	48. Sites	49. Analyzed	50. Design	51. Study Arms	52. F/U (weeks)	53. Industry Funding	54. Editorial Assistance
Penteado 2008	Brazil	1	56	RCT Plac Compare	2	52	Yes	No/NR
Panay 2010	Multinational	17	272	RCT Plac Compare	2	24	Yes	No/NR

(d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; Multi: multicenter trial; NR: not reported; Plac: placebo; RCT: randomized controlled trial

Table E-7. Study characteristics for trials comparing hormone with nonprescription nonhormone

55. Study	56. Country	57. Sites	58. Analyzed	59. Design	60. Study Arms	61. F/U (weeks)	62. Industry Funding	63. Editorial Assistance
Nappi 2005	Italy	2	64	RCT Active Compare	2	13		No/NR
Nathorst-Boos 2006	Sweden	1	106	Crossover	2	26	Yes	No/NR
Kaari 2006	Brazil	1	69	RCT Active Compare	2	26	Yes	No/NR
Chandeying 2007	Thailand	1	60	RCT Active Compare	2	24		No/NR

F/U: followup; NR: not reported; Plac: placebo; RCT: randomized controlled trial

Table E-8. Study characteristics for trials comparing nonprescription nonhormone with nonprescription nonhormone

64. Study	65. Country	66. Sites	67. Analyzed	68. Design	69. Study Arms	70. F/U (weeks)	71. Industry Funding	72. Editorial Assistance
Liske 2002	Poland	4	149	RCT Active Compare	2	12		No/NR
Hidalgo 2006	Spain	Multi	925	RCT Active Compare	2	26		No/NR
Zervoudis (a) 2008	Greece	Multi	62	RCT Active Compare	2	52		No/NR
Agosta 2011	Italy	91	636	RCT Active Compare	2	12		No/NR
Le Donne 2011	Italy	1	62	RCT Active Compare	2	13		No/NR
Virojchaiwong 2011	Thailand	1	52	RCT Active Compare	2	26		No/NR

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; Multi: multicenter trial; NR: not reported; Plac: placebo; RCT: randomized controlled trial; (SIP); data came from a

Table E-9. Study characteristics for trials comparing nonprescription nonhormone with antidepressant

73. Study	74. Country	75. Sites	76. Analyzed	77. Design	78. Study Arms	79. F/U (weeks)	80. Industry Funding	81. Editorial Assistance
Oktem 2007	Turkey	1	80	RCT Active Compare	2	26		No/NR

(a): data came from a conference abstract; F/U: followup; Multi: multicenter trial; NR: not reported; Plac: placebo; RCT: randomized controlled trial

Table E-10. Age, BMI, and smoking status for trials comparing hormone with placebo

82. Study	83. Age, Mean (SD)	84. Range	85. BMI, Mean (SD)	86. Current	87. Former	88. Never
Martin 1971						
Campbell 1977						
Baumgardner 1978						
Coope 1981	48.3					
Jensen 1983	49.2	44 to 54				
Foidart 1991	54.4	32 to 66				
Eriksen 1992	58.4 (6.0)		23.8			
Wiklund 1993	52.6 (4.2)		24.6	29.1		
Derman 1995						
Saletu 1995	51.2 (3.3)					
Good 1996	50.9 (7.0)		25.6			
Speroff (Study 1) 1996						
Chung 1996	43.8 (4.9)					
Speroff (Study 2) 1996						
Speroff (Study 3) 1996						
Bacchi-Modena 1997	51.9 (4.0)	39 to 61				
Baerug 1998	51.3 (3.7)	45 to 61				
Bech 1998						
de Vrijer 1999	52.0	40 to 64				
Leonetti 1999	52.5 (3.9)		26.2 (4.3)			
Studd 1999	52.2 (3.7)					
Polo-Kantola 1999	56.4 (4.4)	47 to 65	26.9 (4.0)			
Casper 1999						
Cohen 1999	50.0			24		
Rebar 2000	51.2 (4.0)		25.7 (3.5)			
Speroff (Study 1) 2000	51.6 (3.9)			22.9	26.9	49.8
Rovati 2000	53.0 (4.4)		24.8	14.2		
Notelovitz 2000	49.5	28 to 63	26.1	38		
Strickler 2000	54.7 (3.5)		25.5 (3.5)			
Notelovitz 2000	51.1 (4.1)					
DeAloysio 2000	53.3 (4.0)					
von Holst 2000	53.5					
Notelovitz 2000	53.3 (5.6)		26.7 (5.5)	28		
Alexandersen 2000	59.2 (3.1)		25.4 (3.8)			
Speroff (Study 2) 2000	51.0 (4.1)			27.3	22.2	50
Rigano 2001						
Utian (CEE alone arms) 2001	52.0 (4.7)		24.4 (2.6)			
Simon 2001	48.6 (5.2)	38 to 66		29.8		
Soares 2001	49.8 (3.6)					
Utian (CEE/MPA arms) 2001	52.5 (4.9)		24.3 (2.8)			

82. Study	83. Age, Mean (SD)	84. Range	85. BMI, Mean (SD)	86. Current	87. Former	88. Never
Rozenbaum 2002	52.4 (5.1)		23.9 (3.6)			
Shulman (Study 1) 2002	52.0	43 to 68			28	72
von Holst 2002	53.3 (5.1)					66.9
Archer 2003	50.9 (6.4)					
Vestergaard 2003	49.8 (2.8)		25.2 (4.4)	44		
Speroff 2003	51.7 (7.1)	29 to 85	28.3	19		
Jirapinyo 2003	54.3 (4.3)		24.1 (3.4)			
Haines 2003						
Hays 2003	63.2 (7.1)		28.5 (5.8)			
Gambacciani 2003	54.3 (2.0)		24.3 (3.5)			
Gelfand 2003	52.6 (4.1)		25.4 (3.6)	5.9		
Wren 2003						
Simunic 2003	58.8 (7.0)					
Parsons 2003	59.1 (7.2)		27.8 (5.7)			
Berlex (SIP) 2003						
Rudolph 2004	56.1 (5.1)		25.4 (5.4)			
Yang 2004	53.2 (3.2)					
Schurmann 2004	53.6 (4.8)		26.2 (4.2)			
Utian 2004	51.1 (6.6)	26 to 65				
Dessole 2004	57.0 (4.5)		22.1 (4.7)			
Duramed (SIP) 2004						
Brunner 2005	63.6 (7.3)		30.1 (6.2)	10.5	38.4	51.1
Onalan 2005	52.1 (6.0)		25.5 (3.9)			
Bayer Healthcare (SIP) 2005						
Novartis (SIP) 2005						
Yaffe (d) 2006	66.7 (4.9)		28.1 (5.3)	6.9		
Speroff (Study 1) 2006	53.4 (4.5)	41 to 68	28.1			
Simon 2006	51.9 (6.0)	36 to 73				
Diem (d) 2006	66.7 (4.9)		28.1 (5.3)	6.9		
Nielsen 2006	52.7 (1.8)		25.2 (3.9)	28.8		
Osmanagaoglu 2006	50.5 (2.1)		25.0 (1.0)			
Speroff (Study 2) 2006	52.2 (7.0)	36 to 80	28.0			
Bachmann (d) 2007	52.7 (5.5)	40 to 71				
Maki 2007	52.2 (3.4)					
Endrikat 2007	56.2 (4.8)	40 to 68	26.6 (3.8)	11.4		
Lee 2007	52.0 (5.4)		23.6 (2.6)			
Panay 2007	55.5 (4.6)	44 to 65	25.2 (3.6)	18.2		
Simon 2007	54.4 (6.4)		26.2 (3.8)			
Pefanco 2007	75.6 (5.1)					
Bayer Healthcare (SIP) 2007						
Buster (Study 1) 2008	52.2 (6.0)	38 to 69	27.1 (4.5)			

82. Study	83. Age, Mean (SD)	84. Range	85. BMI, Mean (SD)	86. Current	87. Former	88. Never
Veerus 2008						
Davis 2008	54.3 (5.9)		27.2 (5.4)			
Bachmann 2008	57.9 (6.5)	46 to 79				
Huang (d) 2008	66.7 (4.9)		28.1 (5.3)	7		
Welton 2008						
Buster (Study 2) 2008	52.1 (6.9)	37 to 76	27.3 (4.5)			
Buster (Study 3) 2008	53.1 (6.9)	36 to 71	26.7 (4.0)			
Simon (SIP) 2008	58.7 (7.5)		27.1 (6.0)			
Benster 2009						
Haines 2009	52.4 (4.3)		24.0 (3.7)			
Bachmann (d) 2009	53.0 (5.8)	40 to 68				
Hedrick 2009	54.5 (6.8)		27.0 (4.0)			
Baksu 2009	50.1 (4.8)		26.7 (2.9)			
Bachmann (Study 1) 2009	57.8 (5.8)					
Freedman 2009	59.9 (6.7)		26.9 (4.9)			
Gast 2009	54.5	42 to 68				
Bachmann (Study 2) 2009	57.8 (5.6)					
Hassa 2010	50.2 (5.1)		28.4 (4.2)			
Stevenson 2010	53.7 (4.2)	45 to 66	26.4 (7.0)			
Raghunandan 2010	51.7 (6.0)		23.7 (0.6)			
Hedrick 2010						
Liu 2011						
Lin 2011	52.0 (3.7)		23.5 (2.8)	1.2		98.3
Demetrio 2011	50.4 (2.9)	45 to 56				
Liu 2012	54.1 (5.9)	33 to 66	28.5 (5.7)			
Archer 2012	53.7 (4.7)		28.1 (4.9)			

(a): data came from a conference abstract; BMI: body mass index; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; MPA: medroxyprogesterone acetate; SD: standard deviation; (SIP); data came from a

Table E-11. Age, BMI, and smoking status for trials comparing antidepressant with placebo

89. Study	90. Age, Mean (SD)	91. Range	92. BMI, Mean (SD)	93. Current	94. Former	95. Never
Suvanto-Luukkonen 2005	54.0	45 to 66		24.8		
Evans 2005	52.2 (5.5)			30.2		
Kerwin 2007	52.5 (5.1)			14.9		
Kalay 2007	52.6 (4.9)		28.0 (4.2)	22		
Speroff 2008	53.5 (4.8)	37 to 78	27.0 (4.6)			
Soares 2008	56.3 (2.7)					
Archer 2009	53.7 (5.0)		27.1 (4.6)			
Archer 2009	53.4 (4.8)	29 to 71	27.9 (5.0)			

89. Study	90. Age, Mean (SD)	91. Range	92. BMI, Mean (SD)	93. Current	94. Former	95. Never
Kornstein 2010	52.3 (6.3)	40 to 70				
Soares 2010	56.0 (6.0)					
Freeman 2011	53.9 (4.1)		29.1 (6.5)	22.9	28.8	48.3
Pfizer (c) 2011	53.8 (4.9)					
Bouchard 2012	54.0 (4.5)	40 to 66	26.0 (4.0)			

BMI: body mass index; (c): data came from posted results on the clinical trial registry; SD: standard deviation

Table E-12. Age, BMI, and smoking status for trials comparing other prescriptions with placebo

96. Study	97. Age, Mean (SD)	98. Range	99. BMI, Mean (SD)	100.Current	101.Former	102.Never
Clayden 1974						
Guttuso 2003	52.8 (3.4)					
Butt 2008	56.2 (4.6)		25.7 (4.5)	10.7		
Joffe 2010	52.2 (4.6)		27.6 (6.9)			
Depomed (c) 2012	52.9 (6.1)					
Depomed (c) 2012	53.2 (6.4)					

BMI: body mass index; (c): data came from posted results on the clinical trial registry; SD: standard deviation

Table E-13. Age, BMI, and smoking status for trials comparing nonprescription nonhormone with placebo

103.Study	104.Age, Mean (SD)	105.Range	106.BMI, Mean (SD)	107.Current	108.Former	109.Never
Chenoy 1994	54.0	45 to 67				
Murkies 1995	54.9 (5.5)		26.0 (3.8)			
Hirata 1997	52.4 (5.0)	44 to 69	24.4 (4.1)			
Albertazzi 1998	52.8 (3.3)	45 to 62	25.9 (3.8)			
Baber 1999						
Wiklund 1999	53.4 (4.0)					
Barnhart 1999	48.5 (2.5)					
Upmalis 2000	54.6 (4.5)					
Kotsopoulos 2000	59.5 (6.9)		25.5 (4.8)			
Davis 2001	55.2		25.9			
Faure 2002	53.4 (4.9)		24.9 (3.7)			
Han 2002	48.5 (7.6)			25		
Tice 2003	52.3 (3.1)		26.1 (4.9)	11.7		
Penotti 2003	52.5 (2.4)	49 to 58	23.2 (2.9)			
Burke 2003	50.8 (2.5)		27.1 (5.9)			
Sammartino 2003	51.8 (1.9)		25.3 (3.0)			
Nahas 2004	53.3 (5.2)		29.0 (5.2)			
Atkinson 2004	55.2 (4.8)		25.3 (3.7)			

103.Study	104.Age, Mean (SD)	105.Range	106.BMI, Mean (SD)	107.Current	108.Former	109.Never
Hartley 2004	57.9 (4.7)		25.2 (3.8)			
Winther 2005	51.4 (3.6)		26.6 (5.2)	20.4		
Frei-Kleiner 2005	52.4 (3.6)		24.7			
Verhoeven 2005	53.8 (4.8)		25.5 (2.9)	18.6		
Kok 2005	66.8 (4.7)		26.2 (3.7)	15.8	33.2	
Hidalgo 2005						
Dodin 2005	54.7 (4.3)		26.2 (4.6)	6.9		
Osmers 2005	54.5 (6.0)		25.2 (2.9)			
Mucci 2006	53.9 (5.9)		24.2 (3.4)			
Heger (m) 2006	48.9 (3.1)		25.9 (2.8)			
Lewis 2006	53.1 (3.2)	45 to 60	17.3 (2.8)	9.1	23.2	67.7
Uebelhack 2006	52.2 (4.3)	44 to 60	25.0 (3.5)			
Sammartino 2006	50.7 (1.8)		25.1 (3.0)			
Casini 2006						
Nahas 2007	55.7 (6.8)		29.1 (5.0)			
Yang 2007	46.8 (4.7)		24.1 (3.0)	2.9		
Chung 2007	50.7 (3.2)		22.6 (2.0)			
Cheng 2007	57.7 (4.6)		24.9 (3.1)			
Ho 2007	63.5 (5.9)		24.5 (3.3)			96.5
Cancellieri 2007	54.3 (4.7)		24.9 (3.6)			
Haines 2008	52.1 (4.8)		22.9 (3.1)			
Jou 2008	53.9 (3.5)		22.6 (2.8)			
Khaodhiar 2008	53.1 (5.2)		28.6 (5.2)		18.3	81.7
Ferrari 2009	54.1 (4.5)		24.5 (4.2)			
van der Sluijs 2009	55.7 (4.2)		25.6 (3.9)			
D'Anna (m) 2009	53.1 (2.1)		23.8 (3.6)			
van Die 2009	52.2 (4.0)		26.5 (4.7)			
de Sousa-Munoz 2009						
Labrie 2009	58.0	42 to 74				
Panjari 2009	54.5 (4.6)		25.6 (3.5)			
Basaria 2009	55.7 (8.8)	46 to 76	26.0 (5.2)	4.5		
Radhakrishnan 2009	48.9 (6.3)		25.5 (4.5)			
Lee 2010	53.0 (3.6)	45 to 60				
Garcia 2010	54.4 (3.6)	47 to 61	23.1 (3.7)			
Lipovac 2010	54.1 (7.1)		24.7 (3.9)			
Shen 2010	57.0 (6.5)		28.6 (5.2)			
Jassi 2010	51.1 (7.7)		23.4 (2.9)			
Evans 2011	53.5 (4.7)		26.0 (3.8)	21	22.2	56.8
Hsu 2011	52.5 (3.0)		23.8 (3.5)			
Andrikoula 2011	54.1 (7.1)		26.0 (7.1)			
Levis 2011	52.5 (3.3)		26.3 (3.3)			

103.Study	104.Age, Mean (SD)	105.Range	106.BMI, Mean (SD)	107.Current	108.Former	109.Never
Plotnikoff 2011	53.5 (3.2)					
Chang 2011	53.7 (5.8)	42 to 70	27.9 (5.0)			
Auerbach 2012	54.5 (7.5)		25.0 (3.8)			
Cianci 2012	55.0 (6.2)		25.6 (8.5)			
Kim 2012	54.0 (3.4)		22.2 (2.4)			
Xia 2012	50.5 (3.0)		25.2 (2.4)			
Ye 2012	52.3 (3.3)		22.6 (2.3)			
Aso 2012	53.5 (3.5)	45 to 60	21.5 (2.0)			

(a): data came from a conference abstract; BMI: body mass index; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; Multi: multicenter trial; NR: not reported; Plac: placebo; RCT: randomized controlled trial; SD: standard deviation; (SIP); data came from a

Table E-14. Age, BMI, and smoking status for trials comparing hormone and nonprescription nonhormone with placebo

110.Study	111.Age, Mean (SD)	112.Range	113.BMI, Mean (SD)	114.Current	115.Former	116.Never
Crisafulli 2004	51.7 (4.0)		23.7 (2.7)			
Newton 2006	52.2 (2.4)		28.6 (6.0)			

(a): data came from a conference abstract; BMI: body mass index; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; SD: standard deviation; (SIP); data came from a package insert

Table E-15. Age, BMI, and smoking status for trials comparing hormone with hormone

117.Study	118.Age, Mean (SD)	119.Range	120.BMI, Mean (SD)	121.Current	122.Former	123.Never
Polvani 1991						
Henriksson 1994	59.4 (6.7)	45 to 80		12.7		
Studd 1995	52.0 (4.8)	38 to 65	25.8			
Ayton 1996	59.5 (7.3)	36 to 86		12.7		
Hilditch 1996	56.4 (3.4)		24.6 (3.4)			
Egarter 1996	49.0	41 to 55				
Hirvonen 1997	56.3 (4.2)	46 to 65				
Hirvonen 1997	54.2 (5.4)	41 to 70		26		
Rozenberg 1997	52.8 (4.9)		24.8 (3.0)			
Al-Azzawi 1997						
Lubbert 1997	54.0 (7.0)					
Barentsen 1997						
Bachmann 1997	56.8	35 to 76				
Good 1999	50.4 (7.6)					
Mattsson 2000	51.1 (4.2)		25.2 (4.1)			
Saure 2000	49.0 (5.0)					
Graser 2000	54.1 (5.5)		25.3 (3.4)			
Rioux 2000	57.3 (7.4)					

117.Study	118.Age, Mean (SD)	119.Range	120.BMI, Mean (SD)	121.Current	122.Former	123.Never
Dugal 2000	58.8 (5.1)					
Parsey 2000	52.0 (4.9)					
Meuwissen 2001	52.9 (4.9)		25.2 (3.3)			
Lopes 2001	51.5 (4.5)		25.3 (4.3)			
Ozsoy 2002	50.6 (3.3)		23.3 (3.1)			
Loh 2002	53.7 (4.2)		23.0 (3.2)			
Buckler (d) 2003	51.5 (5.4)	31 to 63		25.6		
Al-Azzawi (d) 2003	51.5 (5.4)	31 to 63		25.6		
Lobo 2003	53.4 (5.7)	40 to 65	26.1 (5.0)			
Pornel 2005	52.7 (4.5)		25.1 (3.5)	24		
Gambacciani 2005	53.4 (4.4)		25.1 (3.4)	23.8		
Utian 2005	52.8 (6.6)	34 to 74	28.3			
Davis 2005	53.7 (4.0)	42 to 65		9.5		70
Raynaud 2005	52.5 (4.5)		24.3 (3.6)			
Braunstein 2005	49.3 (7.7)					
Simon 2005	49.1 (7.6)	26 to 70	27.9 (6.0)			
Weisberg 2005	57.9	46 to 81				
Buster 2005	48.9 (7.5)		27.6 (5.8)			
Akhila 2006						
Serrano 2006	52.2 (3.2)		25.0 (4.1)	19		
Cieraad 2006	49.1 (4.0)		26.1 (4.4)			
Davis 2006	50.1	30 to 66	24.4 (2.7)			
Long 2006	53.8 (6.7)					
Shifren 2006	53.9 (4.9)		25.8 (4.7)			
Limpaphayom (m) 2006	53.4 (5.0)		23.7 (3.4)			
Odabasi 2007	49.5 (3.1)		29.3 (3.5)			
Mattsson (d) 2007	51.4 (4.2)		24.7 (3.0)			
Pitkin (d) 2007	51.5 (4.1)		24.8 (3.0)			
Penteado 2008	52.1 (3.9)	42 to 60	27.3 (4.2)			
Panay 2010	56.6 (5.3)		26.5 (4.8)			

(a): data came from a conference abstract; BMI: body mass index; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; SD: standard deviation; (SIP); data came from a package insert

Table e-16. Age, BMI, and smoking status for trials comparing hormone with nonprescription nonhormone

124.Study	125.Age, Mean (SD)	126.Range	127.BMI, Mean (SD)	128.Current	129.Former	130.Never
Nappi 2005	50.7 (2.0)		22.4 (2.2)			
Nathorst-Boos 2006						
Kaari 2006	53.8 (5.3)		25.6 (3.8)			
Chandeying 2007	48.4 (5.0)	40 to 59		1.6		

BMI: body mass index; SD: standard deviation;

Table E-17. Age, BMI, and smoking status for trials comparing nonprescription nonhormone with nonprescription nonhormone

131.Study	132.Age, Mean (SD)	133.Range	134.BMI, Mean (SD)	135.Current	136.Former	137.Never
Liske 2002	50.0 (4.5)	42 to 60				
Hidalgo 2006						
Zervoudis (a) 2008						
Agosta 2011	53.1 (5.0)		25.2 (3.6)			
Le Donne 2011	58.8 (4.0)					
Virojchaiwong 2011	46.5 (4.4)		23.9 (3.9)			

(a): data came from a conference abstract; BMI: body mass index; SD: standard deviation; (SIP); data came from a package insert

Table E-18. Age, BMI, and smoking status for trials comparing nonprescription nonhormone with antidepressant

138.Study	139.Age, Mean (SD)	140.Range	141.BMI, Mean (SD)	142.Current	143.Former	144.Never
Oktem 2007	52.9 (6.0)		27.1 (3.8)	41.2		

BMI: body mass index; SD: standard deviation;

Table E-19. Racial makeup for trials comparing hormone with placebo

145.Study	146.White (%)	147.Black (%)	148.Hispanic (%)	149.Asian (%)	150.Other (%)	151.Not Classified (%)
Martin 1971						
Campbell 1977						
Baumgardner 1978						
Coope 1981						
Jensen 1983						
Foidart 1991						
Eriksen 1992						
Wiklund 1993						
Derman 1995						
Saletu 1995						
Good 1996	87.5	10.3			2.2	
Speroff (Study 1) 1996						
Chung 1996						
Speroff (Study 2) 1996						
Speroff (Study 3) 1996						
Bacchi-Modena 1997						

145.Study	146.White (%)	147.Black (%)	148.Hispanic (%)	149.Asian (%)	150.Other (%)	151.Not Classified (%)
Baerug 1998						
Bech 1998						
de Vrijer 1999						
Leonetti 1999	45.1					54.9
Studd 1999	100					
Polo-Kantola 1999						
Casper 1999						
Cohen 1999	83.5	13			3.5	
Rebar 2000						
Speroff (Study 1) 2000						
Rovati 2000						
Notelovitz 2000	82.6	8.3		2	6.7	0.4
Strickler 2000						
Notelovitz 2000						
DeAloysio 2000						
von Holst 2000						
Notelovitz 2000	87.7	4.3			8	
Alexandersen 2000						
Speroff (Study 2) 2000						
Rigano 2001						
Utian (CEE alone arms) 2001						
Simon 2001	68.6	27.4		0.8	3.2	
Soares 2001						
Utian (CEE/MPA arms) 2001						
Rozenbaum 2002	100					
Shulman (Study 1) 2002	80.6	13.3	4.4	0.7	1	
von Holst 2002						
Archer 2003	81.4	15.9		1.8	0.9	
Vestergaard 2003						
Speroff 2003	77.3	12	9	0.6	0.9	0.2
Jirapinyo 2003						
Haines 2003				100		
Hays 2003	83.9	6.8	5.3	2.2	1.8	
Gambacciani 2003						
Gelfand 2003	96.6	0.8		1.7	0.9	
Wren 2003						
Simunic 2003						
Parsons 2003	88.2	6.4	3.2	1.1	1.1	
Berlex (SIP) 2003						
Rudolph 2004						
Yang 2004						

145.Study	146.White (%)	147.Black (%)	148.Hispanic (%)	149.Asian (%)	150.Other (%)	151.Not Classified (%)
Schurmann 2004	100					
Utian 2004	81.2	17.4			1.4	
Dessole 2004	98.5					1.5
Duramed (SIP) 2004						
Brunner 2005	75.3	15.1	6.1	1.5	2	
Onalan 2005						
Bayer Healthcare (SIP) 2005						
Novartis (SIP) 2005						
Yaffe (d) 2006	92.3					7.7
Speroff (Study 1) 2006	78.1	8.7	12.5		0.7	
Simon 2006	75.5	19.5			5	
Diem (d) 2006	92.3					7.7
Nielsen 2006						
Osmanagaoglu 2006						
Speroff (Study 2) 2006	80.1	13.6	4.5		1.8	
Bachmann (d) 2007						
Maki 2007	81.7	9.5	6.1	1.1		1.6
Endrikat 2007						
Lee 2007				100		
Panay 2007	95	0.3		1	0.7	3
Simon 2007	84.5	9.7			5.8	
Pefanco 2007						
Bayer Healthcare (SIP) 2007						
Buster (Study 1) 2008	64.9	29.8	2.7	0.6	1.3	0.7
Veerus 2008						
Davis 2008	88.8	7.6	1.8	0.5	1.2	0.1
Bachmann 2008	92.2				7.8	
Huang (d) 2008	92.5					7.5
Welton 2008						
Buster (Study 2) 2008	74	22	2		2	
Buster (Study 3) 2008	71.2	21.6	4.6		2.6	
Simon (SIP) 2008	81.8	3.6	10.5	2.4	1.6	0.1
Benster 2009						
Haines 2009						
Bachmann (d) 2009						
Hedrick 2009	86.1	10.2		1.5	2.2	
Baksu 2009						
Bachmann (Study 1) 2009	91.6					8.4
Freedman 2009	86.6	5.5	6.5	0.7	0.7	
Gast 2009						
Bachmann (Study 2) 2009	92.8					7.2

145.Study	146.White (%)	147.Black (%)	148.Hispanic (%)	149.Asian (%)	150.Other (%)	151.Not Classified (%)
Hassa 2010						
Stevenson 2010						
Raghunandan 2010						
Hedrick 2010						
Liu 2011						
Lin 2011						
Demetrio 2011	79.9	6.3		3.1	10.7	
Liu 2012	66.9	14.6	16.6	0.6	1.3	
Archer 2012	80.6	17.7			1.7	

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; (SIP); data came from a package insert

TableE-20. Racial makeup for trials comparing antidepressant with placebo

152.Study	153.White (%)	154.Black (%)	155.Hispanic (%)	156.Asian (%)	157.Other (%)	158.Not Classified (%)
Suvanto-Luukkonen 2005						
Evans 2005	76.5	8.5		8.5	6.5	
Kerwin 2007	80.6		13.6		5.8	
Kalay 2007						
Speroff 2008	85.1	9.7			5.2	
Soares 2008	85.6	8.9	5.5			
Archer 2009	87.3	10.9			1.8	
Archer 2009	82.6	15.7			1.7	
Kornstein 2010	82.3	14.3			3.3	0.1
Soares 2010	80.5	7.9			11.5	0.1
Freeman 2011	49.8	46.3			3.9	
Pfizer (c) 2011						
Bouchard 2012	92.5	0.5			7	

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; (SIP); data came from a package insert

Table E-21. Racial makeup for trials comparing other prescriptions with placebo

159.Study	160.White (%)	161.Black (%)	162.Hispanic (%)	163.Asian (%)	164.Other (%)	165.Not Classified (%)
Clayden 1974						
Guttuso 2003	93.2	6.8				
Butt 2008	76.7				23.3	
Joffe 2010	71.2					28.8
Depomed (c) 2012	67.1	23.6	7	0.6	1.7	

159.Study	160.White (%)	161.Black (%)	162.Hispanic (%)	163.Asian (%)	164.Other (%)	165.Not Classified (%)
Depomed (c) 2012						

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; (SIP); data came from a package insert

Table E-22. Racial makeup for trials comparing nonprescription nonhormone with placebo

166.Study	167.White (%)	168.Black (%)	169.Hispanic (%)	170.Asian (%)	171.Other (%)	172.Not Classified (%)
Chenoy 1994						
Murkies 1995						
Hirata 1997	69	15.5	4.2	8.4		2.9
Albertazzi 1998						
Baber 1999						
Wiklund 1999						
Barnhart 1999						
Upmalis 2000	75.3	13.2			11.5	
Kotsopoulos 2000						
Davis 2001						
Faure 2002						
Han 2002	33.7	58.8		7.5		
Tice 2003	84.3	10			5.7	
Penotti 2003						
Burke 2003						
Sammartino 2003						
Nahas 2004						
Atkinson 2004						
Hartley 2004						
Winther 2005						
Frei-Kleiner 2005						
Verhoeven 2005						
Kok 2005						
Hidalgo 2005						
Dodin 2005						
Osmers 2005						
Mucci 2006						
Heger (m) 2006						
Lewis 2006						
Uebelhack 2006	100					
Sammartino 2006						
Casini 2006						
Nahas 2007						

166.Study	167.White (%)	168.Black (%)	169.Hispanic (%)	170.Asian (%)	171.Other (%)	172.Not Classified (%)
Yang 2007				100		
Chung 2007				45.5		54.5
Cheng 2007						
Ho 2007				100		
Cancellieri 2007						
Haines 2008				100		
Jou 2008				100		
Khaodhiar 2008	61.9	30.1			8	
Ferrari 2009						
van der Sluijs 2009						
D'Anna (m) 2009						
van Die 2009						
de Sousa-Munoz 2009						
Labrie 2009						
Panjari 2009						
Basaria 2009	79.6	9.7			10.7	
Radhakrishnan 2009						
Lee 2010						
Garcia 2010				21.4		78.6
Lipovac 2010						
Shen 2010						
Jassi 2010						
Evans 2011						
Hsu 2011						
Andrikoula 2011						
Levis 2011	22.6	9.6	66.1		1.6	0.1
Plotnikoff 2011	93.9					6.1
Chang 2011						
Auerbach 2012						
Cianci 2012						
Kim 2012						
Xia 2012						
Ye 2012						
Aso 2012				100		

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; (SIP); data came from a package insert

Table E-23. Racial makeup for trials comparing hormone and nonprescription nonhormone with placebo

173.Study	174.White (%)	175.Black (%)	176.Hispanic (%)	177.Asian (%)	178.Other (%)	179.Not Classified (%)

173.Study	174.White (%)	175.Black (%)	176.Hispanic (%)	177.Asian (%)	178.Other (%)	179.Not Classified (%)
Crisafulli 2004						
Newton 2006	93.2	2.5			4.3	

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; (SIP); data came from a package insert

Table E-24. Racial makeup for trials comparing hormone with hormone

180.Study	181.White (%)	182.Black (%)	183.Hispanic (%)	184.Asian (%)	185.Other (%)	186.Not Classified (%)
Polvani 1991						
Henriksson 1994						
Studd 1995	97.5				2.5	
Ayton 1996	66.5				1	32.5
Hilditch 1996						
Egarter 1996						
Hirvonen 1997						
Hirvonen 1997						
Rozenberg 1997						
Al-Azzawi 1997						
Lubbert 1997						
Barentsen 1997						
Bachmann 1997	85.6	6.7	6.1		1.6	
Good 1999	87.5	11.8			0.6	0.1
Mattsson 2000						
Saure 2000						
Graser 2000						
Rioux 2000						
Dugal 2000						
Parsey 2000	84	10.5	4.5		1	
Meuwissen 2001						
Lopes 2001	100					
Ozsoy 2002						
Loh 2002				100		
Buckler (d) 2003						
Al-Azzawi (d) 2003						
Lobo 2003	91.7	4.6	2.3		1.4	
Pornel 2005	99.2	0.3			0.5	
Gambacciani 2005	99.5	0.2			0.3	
Utian 2005	73.4				26.6	
Davis 2005						
Raynaud 2005						

180.Study	181.White (%)	182.Black (%)	183.Hispanic (%)	184.Asian (%)	185.Other (%)	186.Not Classified (%)
Braunstein 2005						
Simon 2005	88.6	8.5	2.5		0.4	
Weisberg 2005						
Buster 2005	90.3	5	3.5		1.2	
Akhila 2006						
Serrano 2006						
Cieraad 2006						
Davis 2006						
Long 2006						
Shifren 2006	93.8	3.5	2		0.7	
Limpaphayom (m) 2006				100		
Odabasi 2007						
Mattsson (d) 2007	99.4	0.3		0.3		
Pitkin (d) 2007						
Penteado 2008						
Panay 2010	98.6	0.7		0.7		

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; (SIP); data came from a package insert

Table E-25. Racial makeup for trials comparing hormone with nonprescription nonhormone

187.Study	188.White (%)	189.Black (%)	190.Hispanic (%)	191.Asian (%)	192.Other (%)	193.Not Classified (%)
Nappi 2005						
Nathorst-Boos 2006						
Kaari 2006						
Chandeying 2007						

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; (SIP); data came from a package insert

Table E-26. Racial makeup for trials comparing nonprescription nonhormone with nonprescription nonhormone

194.Study	195.White (%)	196.Black (%)	197.Hispanic (%)	198.Asian (%)	199.Other (%)	200.Not Classified (%)
Liske 2002						
Hidalgo 2006						
Zervoudis (a) 2008						
Agosta 2011						
Le Donne 2011						
Virojchaiwong 2011						

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; (SIP); data came from a package insert

Table E-27. Racial makeup for trials comparing nonprescription nonhormone with antidepressant

201.Study	202.White (%)	203.Black (%)	204.Hispanic (%)	205.Asian (%)	206.Other (%)	207.Not Classified (%)
Oktem 2007						

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; (SIP); data came from a package insert

Table E-28. Uterus status, age since menopause, and prior HRT use for trials comparing hormone with placebo

208.Study	209.Intact Uterus	210.(%)	211.Mean Age Menopause (SD)	212.Years Since Menopause (SD)	213.Prior HT (%)
Martin 1971	Mixed	56			
Campbell 1977	NR				
Baumgardner 1978	Mixed	63			
Coope 1981	Mixed	65.5			
Jensen 1983	NR			1.9	
Foidart 1991	Mixed	52.3			
Eriksen 1992	NR				
Wiklund 1993	All			3.1 (3.4)	31.8
Derman 1995	NR				
Saletu 1995	Mixed	71.9			
Good 1996	Mixed	43.6	43.0 (8.3)		
Speroff (Study 1) 1996	None				
Chung 1996	None		42.1 (8.0)	0.6 (1.5)	
Speroff (Study 2) 1996	None				
Speroff (Study 3) 1996	None				
Bacchi-Modena 1997	All			2.7	
Baerug 1998	NR		49.0 (3.3)	2.5 (2.9)	30.3
Bech 1998	NR				
de Vrijer 1999	Mixed	65		4.4	
Leonetti 1999	NR			3.2 (1.4)	
Studd 1999	NR			2.5 (1.8)	52.7
Polo-Kantola 1999	None				
Casper 1999	Mixed				
Cohen 1999	Mixed	81.5			
Rebar 2000	Mixed	67.6			
Speroff (Study 1) 2000	All			2.0 (1.6)	

208.Study	209.Intact Uterus	210.(%)	211.Mean Age Menopause (SD)	212.Years Since Menopause (SD)	213.Prior HT (%)
Rovati 2000	Mixed	71.1		3.5 (3.6)	
Notelovitz 2000	Mixed	30		5.9	49.7
Strickler 2000	NR			4.5 (1.9)	40.3
Notelovitz 2000	All			2.9 (2.8)	
DeAloysio 2000	Mixed	94.9		1.1 (1.1)	
von Holst 2000	None				
Notelovitz 2000	All			5.2 (4.9)	36.9
Alexandersen 2000	NR			9.3 (3.4)	
Speroff (Study 2) 2000	All			2.1 (1.2)	
Rigano 2001	All				
Utian (CEE alone arms) 2001	All		48.1 (4.7)	3.9 (3.5)	
Simon 2001	NR			7.2	
Soares 2001	NR			0.4 (0.4)	
Utian (CEE/MPA arms) 2001	All		48.2 (4.3)	4.2 (3.9)	
Rozenbaum 2002	Mixed	77.6	49.6 (3.9)	3.4 (3.1)	53.3
Shulman (Study 1) 2002	Mixed				
von Holst 2002	All				
Archer 2003	Mixed	76.9		10.2 (8.4)	62
Vestergaard 2003	Mixed	81		0.7 (0.6)	
Speroff 2003	Mixed	81			78.3
Jirapinyo 2003	All				
Haines 2003	None				
Hays 2003	All				26
Gambacciani 2003	NR			4.6 (3.0)	
Gelfand 2003	All			2.7 (3.0)	15.1
Wren 2003	NR				
Simunic 2003	All		49.9 (4.6)	9.2 (3.6)	
Parsons 2003	All			9.3 (6.7)	
Berlex (SIP) 2003	NR				
Rudolph 2004	Mixed			9.7 (8.0)	
Yang 2004	All		49.8 (3.2)	4.1 (0.9)	
Schurmann 2004	All				
Utian 2004	Mixed				
Dessole 2004	NR			7.2 (5.0)	
Duramed (SIP) 2004	NR				
Brunner 2005	None				48.4
Onalan 2005	All			4.4 (3.7)	
Bayer Healthcare (SIP) 2005	NR				
Novartis (SIP) 2005	NR				
Yaffe (d) 2006	All				

208.Study	209.Intact Uterus	210.(%)	211.Mean Age Menopause (SD)	212.Years Since Menopause (SD)	213.Prior HT (%)
Speroff (Study 1) 2006	Mixed	57			
Simon 2006	Mixed	50.5			
Diem (d) 2006	All			16.5 (7.1)	
Nielsen 2006	Mixed	94.3		2.2 (1.7)	6.6
Osmanagaoglu 2006	All				
Speroff (Study 2) 2006	Mixed	41			
Bachmann (d) 2007	Mixed	42.4	44.1 (8.0)	9.1 (8.2)	
Maki 2007	All			1.8 (0.8)	
Endrikat 2007	Mixed	67		4.6 (3.3)	
Lee 2007	Mixed				
Panay 2007	All				
Simon 2007	Mixed			8.7 (8.2)	81
Pefanco 2007	Mixed	68.4			
Bayer Healthcare (SIP) 2007	NR				
Buster (Study 1) 2008	Mixed	61.7			
Veerus 2008	NR				
Davis 2008	Mixed	55.9			
Bachmann 2008	Mixed	52.6		14.0 (8.6)	
Huang (d) 2008	All			16.5 (7.1)	
Welton 2008	Mixed				
Buster (Study 2) 2008	Mixed	61.7			
Buster (Study 3) 2008	Mixed	61.7			
Simon (SIP) 2008	Mixed	58.1		13.0 (9.3)	
Benster 2009	Mixed				
Haines 2009	Mixed	62.5		5.1 (5.1)	
Bachmann (d) 2009	Mixed	44.6		9.8 (8.6)	
Hedrick 2009	Mixed	47			
Baksu 2009	None				
Bachmann (Study 1) 2009	All			9.2 (6.2)	
Freedman 2009	Mixed	62.6		13.0 (8.8)	
Gast 2009	All			5.3	52.6
Bachmann (Study 2) 2009	All			5.3	
Hassa 2010	None				
Stevenson 2010	All			5.5 (4.6)	
Raghunandan 2010	Mixed			7.0 (1.5)	
Hedrick 2010	Mixed	48.4			
Liu 2011	Mixed				
Lin 2011	All			2.8 (3.0)	
Demetrio 2011	None			3.7	
Liu 2012	Mixed				

208.Study	209.Intact Uterus	210.(%)	211.Mean Age Menopause (SD)	212.Years Since Menopause (SD)	213.Prior HT (%)
Archer 2012	Mixed	65.4		8.5 (7.7)	

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; NR: not reported; SD: standard deviation; (SIP); data came from a package insert

Table E-29. Uterus status, age since menopause, and prior HRT use for trials comparing antidepressant with placebo

214.Study	215.Intact Uterus	216.(%)	217.Mean Age Menopause (SD)	218.Years Since Menopause (SD)	219.Prior HT (%)
Suvanto-Luukkonen 2005	All		50.0		35.5
Evans 2005	Mixed	79.2	47.5 (5.0)	4.5 (4.0)	
Kerwin 2007	NR				
Kalay 2007	Mixed			6.5 (4.2)	
Speroff 2008	Mixed	78.2		4.7 (4.5)	
Soares 2008	Mixed				
Archer 2009	Mixed	76.2			
Archer 2009	Mixed	79.9			
Kornstein 2010	Mixed				
Soares 2010	Mixed				
Freeman 2011	Mixed	75.6			
Pfizer (c) 2011	NR				
Bouchard 2012	All			5.5 (4.0)	

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; NR: not reported; SD: standard deviation; (SIP); data came from a package insert

Table E-30. Uterus status, age since menopause, and prior HRT use for trials comparing other prescriptions with placebo

220.Study	221.Intact Uterus	222.(%)	223.Mean Age Menopause (SD)	224.Years Since Menopause (SD)	225.Prior HT (%)
Clayden 1974	NR				
Guttuso 2003	Mixed	76.2		4.7 (5.0)	
Butt 2008	All			6.4 (6.1)	61.9
Joffe 2010	Mixed	86.2			
Depomed (c) 2012	Mixed				
Depomed (c) 2012	Mixed				

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; NR: not reported; SD: standard deviation; (SIP); data came from a package insert

Table E-31. Uterus status, age since menopause, and prior HRT use for trials comparing nonprescription nonhormone with placebo

226.Study	227.Intact Uterus	228.(%)	229.Mean Age Menopause (SD)	230.Years Since Menopause (SD)	231.Prior HT (%)
Chenoy 1994	NR				19.6
Murkies 1995	NR			5.7 (6.4)	
Hirata 1997	All			3.7 (3.2)	42.2
Albertazzi 1998	NR			3.9 (3.9)	
Baber 1999	NR				
Wiklund 1999	NR				
Barnhart 1999	NR				
Upmalis 2000	All				
Kotsopoulos 2000	NR				
Davis 2001	NR			5.2	49.1
Faure 2002	Mixed				
Han 2002	All			1.9 (1.6)	
Tice 2003	Mixed	93.7	49.1 (4.9)	3.3 (4.5)	
Penotti 2003	All			2.4 (1.4)	
Burke 2003	Mixed	73.4			85.3
Sammartino 2003	All			1.5	
Nahas 2004	NR		48.1 (3.5)	13.2 (1.6)	
Atkinson 2004	NR				
Hartley 2004	NR			7.8 (1.0)	
Winther 2005	Mixed	96.9		1.5 (1.4)	
Frei-Kleiner 2005	Mixed	81.1		3.2 (4.2)	
Verhoeven 2005	Mixed			4.0	41.1
Kok 2005	NR		48.5 (5.0)	18.6 (6.7)	22.4
Hidalgo 2005	Mixed				
Dodin 2005	Mixed	87		5.3	
Osmers 2005	Mixed	64			
Mucci 2006	NR			4.7 (5.2)	
Heger (m) 2006	NR				
Lewis 2006	All		49.5 (3.5)	3.7 (2.7)	37.4
Uebelhack 2006	Mixed	84.7			
Sammartino 2006	NR			1.3	
Casini 2006	All				
Nahas 2007	All		48.0 (3.6)	6.8 (4.5)	
Yang 2007	All				
Chung 2007	All				
Cheng 2007	NR			7.7 (4.6)	
Ho 2007	NR			13.8 (6.7)	
Cancellieri 2007	NR			2.8	
Haines 2008	Mixed		46.6 (5.2)	5.5 (3.8)	

226.Study	227.Intact Uterus	228.(%)	229.Mean Age Menopause (SD)	230.Years Since Menopause (SD)	231.Prior HT (%)
Jou 2008	NR		50.5 (5.5)		
Khaodhiar 2008	NR			5.1 (5.6)	
Ferrari 2009	Mixed			5.3 (5.2)	
van der Sluijs 2009	Mixed	81.5		5.8 (5.8)	54.4
D'Anna (m) 2009	Mixed	91.5		3.2 (1.7)	
van Die 2009	Mixed	83 (however all women experienced natural menopause)		4.1 (5.4)	32
de Sousa-Munoz 2009	Mixed				
Labrie 2009	NR				
Panjari 2009	Mixed	82	47.6 (6.3)	6.9 (6.5)	
Basaria 2009	Mixed	25		5.6 (6.0)	
Radhakrishnan 2009	Mixed	57		5.1 (4.8)	
Lee 2010	All		49.0 (2.8)		
Garcia 2010	All		49.2 (3.3)	5.1 (3.5)	
Lipovac 2010	Mixed	84.4			58.7
Shen 2010	NR			11.8 (8.3)	
Jassi 2010	Mixed			2.5 (1.2)	
Evans 2011	Mixed	66.3			
Hsu 2011	All			2.6 (1.4)	
Andrikoula 2011	NR		46.9 (4.8)		
Levis 2011	NR				
Plotnikoff 2011	Mixed	92.1			
Chang 2011	All			4.4	
Auerbach 2012	NR				
Cianci 2012	NR			5.3 (4.0)	
Kim 2012	NR		52.3 (3.1)		
Xia 2012	All				
Ye 2012	NR			2.6 (1.5)	
Aso 2012	All			3.7 (2.0)	

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; NR: not reported; SD: standard deviation; (SIP); data came from a package insert

Table E-32. Uterus status, age since menopause, and prior HRT use for trials comparing hormone and nonprescription nonhormone with placebo

232.Study	233.Intact Uterus	234.(%)	235.Mean Age Menopause (SD)	236.Years Since Menopause (SD)	237.Prior HT (%)
Crisafulli 2004	All			6.7 (4.3)	
Newton 2006	Mixed	89			40.1

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; NR: not reported; SD: standard deviation; (SIP); data came from a package insert

Table E-33. Uterus status, age since menopause, and prior HRT use for trials comparing hormone with hormone

238.Study	239.Intact Uterus	240.(%)	241.Mean Age Menopause (SD)	242.Years Since Menopause (SD)	243.Prior HT (%)
Polvani 1991	All				
Henriksson 1994	Mixed	87.2		9.8 (6.8)	47.2
Studd 1995	Mixed	99		4.4 (3.5)	
Ayton 1996	All			9.3 (7.3)	50.6
Hilditch 1996	All		50.1 (3.0)	3.5 (1.5)	
Egarter 1996	All				
Hirvonen 1997	NR		49.4 (3.6)		86.7
Hirvonen 1997	Mixed	59	47.9 (4.4)		65.3
Rozenberg 1997	All			4.6 (4.1)	69.8
Al-Azzawi 1997	None				
Lubbert 1997	Mixed	47.7			
Barentsen 1997	Mixed				
Bachmann 1997	Mixed	54		10.3	57.6
Good 1999	Mixed	45.8	42.5 (9.0)		
Mattsson 2000	Mixed	70.8	48.5 (4.1)	3.1 (2.8)	42
Saure 2000	All				34
Graser 2000	NR			5.7 (4.4)	
Rioux 2000	All			7.8 (7.1)	37
Dugal 2000	NR		49.5 (3.8)		26
Parsey 2000	Mixed	28.5			
Meuwissen 2001	All				56.3
Lopes 2001	NR			2.9 (2.9)	33.5
Ozsoy 2002	All		48.0 (4.0)	2.9 (2.7)	32.5
Loh 2002	NR			3.9 (7.0)	
Buckler (d) 2003	Mixed	55			
Al-Azzawi (d) 2003	Mixed	55.3			
Lobo 2003	Mixed			7.1 (6.0)	100
Pornel 2005	All			4.4 (4.0)	
Gambacciani 2005	All			1.2 (1.0)	
Utian 2005	Mixed	49.6			
Davis 2005	Mixed	73			58
Raynaud 2005	Mixed	22.5		3.8 (3.8)	
Braunstein 2005	None				
Simon 2005	None				
Weisberg 2005	All			3.7	
Buster 2005	None				
Akhila 2006	Mixed	30.6			

238.Study	239.Intact Uterus	240.(%)	241.Mean Age Menopause (SD)	242.Years Since Menopause (SD)	243.Prior HT (%)
Serrano 2006	All		50.1 (3.0)	1.9 (1.3)	
Cieraad 2006	All				
Davis 2006	None				100
Long 2006	None				
Shifren 2006	Mixed	68.5		6.2 (4.2)	100
Limpaphayom (m) 2006	All				
Odabasi 2007	All		46.8 (3.2)	2.7 (2.8)	
Mattsson (d) 2007	All		50.0 (4.2)	1.9 (0.6)	46.1
Pitkin (d) 2007	All		50.1 (4.1)	1.9 (0.6)	45.7
Penteado 2008	All			5.1 (4.6)	
Panay 2010	All				

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; NR: not reported; SD: standard deviation; (SIP); data came from a package insert

Table E-34. Uterus status, age since menopause, and prior HRT use for trials comparing hormone with nonprescription nonhormone

244.Study	245.Intact Uterus	246.(%)	247.Mean Age Menopause (SD)	248.Years Since Menopause (SD)	249.Prior HT (%)
Nappi 2005	All			0.8 (0.2)	
Nathorst-Boos 2006	All				
Kaari 2006	All		47.7 (5.0)	6.0	
Chandeying 2007	Mixed				

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; NR: not reported; SD: standard deviation; (SIP); data came from a package insert

Table E-35. Uterus status, age since menopause, and prior HRT use for trials comparing nonprescription nonhormone with nonprescription nonhormone

250.Study	251.Intact Uterus	252.(%)	253.Mean Age Menopause (SD)	254.Years Since Menopause (SD)	255.Prior HT (%)
Liske 2002	NR				
Hidalgo 2006	NR				
Zervoudis (a) 2008	NR				
Agosta 2011	Mixed	83.5			72
Le Donne 2011	NR		49.0 (2.8)		
Virojchaiwong 2011	None				

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; NR: not reported; SD: standard deviation; (SIP); data came from a package insert

Table E-36. Uterus status, age since menopause, and prior HRT use for trials comparing nonprescription nonhormone with antidepressant

256.Study	257.Intact Uterus	258.(%)	259.Mean Age Menopause (SD)	260.Years Since Menopause (SD)	261.Prior HT (%)
Oktem 2007	Mixed	75	46.8 (4.7)		40

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; NR: not reported; SD: standard deviation; (SIP); data came from a package insert

Table E-37. Reported outcomes for trials comparing hormone with placebo

262.Study	263.VMS Required	264.VMS	265.Sleep	266.Psychological	267.Urogenital	268.Sexual	269.QoL
Martin 1971	Yes	+					
Campbell 1977	No	+	+	+	+	+	
Baumgardner 1978	Yes	+					
Coope 1981	Uncertain	+		+			
Jensen 1983	Uncertain						+
Foidart 1991	Yes				+		+
Eriksen 1992	Uncertain				+	+	
Wiklund 1993	Uncertain	+	+	+		+	+
Derman 1995	Yes	+		+			+
Saletu 1995	Uncertain			+			+
Good 1996	Yes	+					
Speroff (Study 1) 1996	Yes	+					
Chung 1996	Uncertain	+	+		+		+
Speroff (Study 2) 1996	Yes	+					
Speroff (Study 3) 1996	Yes	+					
Bacchi-Modena 1997	Yes	+					+
Baerug 1998	Yes	+		+		+	+
Bech 1998	Uncertain	+	+	+	+		+
de Vrijer 1999	Yes	+					+
Leonetti 1999	No	+					
Studd 1999	Yes	+					+
Polo-Kantola 1999	Uncertain	+	+	+			
Casper 1999	Uncertain				+	+	
Cohen 1999	Yes	+					
Rebar 2000	Uncertain	+					+
Speroff (Study 1) 2000	Yes	+					
Rovati 2000	Yes	+					+
Notelovitz 2000	Yes	+					

262.Study	263.VMS Required	264.VMS	265.Sleep	266.Psychological	267.Urogenital	268.Sexual	269.QoL
Strickler 2000	Uncertain	+	+	+		+	+
Notelovitz 2000	Yes	+					
DeAloysio 2000	Yes	+					+
von Holst 2000	Yes	+			+		+
Notelovitz 2000	Yes	+					
Alexandersen 2000	Uncertain						+
Speroff (Study 2) 2000	Yes	+					
Rigano 2001	Yes						+
Utian (CEE alone arms) 2001	No	+					
Simon 2001	Yes	+					
Soares 2001	Uncertain			+			+
Utian (CEE/MPA arms) 2001	No	+					
Rozenbaum 2002	Yes	+		+	+		+
Shulman (Study 1) 2002	Yes	+			+		
von Holst 2002	Yes	+					+
Archer 2003	Yes	+					
Vestergaard 2003	No	+	+		+	+	
Speroff 2003	Yes	+		+	+	+	+
Jirapinyo 2003	No						+
Haines 2003	No			+			+
Hays 2003	No		+	+			+
Gambacciani 2003	Uncertain	+	+	+		+	
Gelfand 2003	Yes	+		+		+	+
Wren 2003	Yes	+		+		+	
Simunic 2003	Uncertain				+	+	
Parsons 2003	Uncertain				+	+	
Berlex (SIP) 2003	Uncertain	+					
Rudolph 2004	No			+			
Yang 2004	Uncertain	+		+		+	+
Schurmann 2004	Yes	+	+		+		
Utian 2004	Yes	+					
Dessole 2004	Uncertain				+	+	
Duramed (SIP) 2004	Uncertain	+					
Brunner 2005	No		+	+			+
Onalan 2005	No			+			
Bayer Healthcare (SIP) 2005	Yes	+					
Novartis (SIP) 2005	Uncertain	+					
Yaffe (d) 2006	Uncertain			+			
Speroff (Study 1) 2006	Yes	+					
Simon 2006	Yes	+					

262.Study	263.VMS Required	264.VMS	265.Sleep	266.Psychological	267.Urogenital	268.Sexual	269.QoL
Diem (d) 2006	No	+	+		+		
Nielsen 2006	Uncertain	+	+	+		+	
Osmanagaoglu 2006	Uncertain					+	
Speroff (Study 2) 2006	Yes	+					
Bachmann (d) 2007	Yes	+					
Maki 2007	No						
Endrikat 2007	Yes	+					
Lee 2007	Yes	+	+		+		
Panay 2007	Yes	+	+				+
Simon 2007	Yes	+		+	+	+	+
Pefanco 2007	Uncertain			+			
Bayer Healthcare (SIP) 2007	Uncertain	+					
Buster (Study 1) 2008	Yes	+					
Veerus 2008	Uncertain	+	+				+
Davis 2008	Uncertain					+	
Bachmann 2008	Uncertain				+		
Huang (d) 2008	Uncertain				+	+	
Welton 2008	No	+	+	+	+	+	+
Buster (Study 2) 2008	Yes	+					
Buster (Study 3) 2008	Yes	+					
Simon (SIP) 2008	Yes				+	+	
Benster 2009	Yes	+		+			
Haines 2009	Yes	+			+	+	+
Bachmann (d) 2009	Yes				+		
Hedrick 2009	Yes	+					
Baksu 2009	Uncertain	+	+	+			+
Bachmann (Study 1) 2009	Uncertain				+	+	
Freedman 2009	Uncertain				+	+	
Gast 2009	Uncertain	+				+	
Bachmann (Study 2) 2009	Uncertain				+	+	
Hassa 2010	Uncertain	+		+		+	+
Stevenson 2010	Yes	+					+
Raghunandan 2010	Uncertain				+	+	
Hedrick 2010	Yes						
Liu 2011	Yes	+					
Lin 2011	Yes	+	+		+		
Demetrio 2011	Yes			+			
Liu 2012	Yes	+					
Archer 2012	Yes	+					

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; QoL: quality of life; (SIP); data came from a package insert; VMS: vasomotor symptoms

Table E-38. Reported outcomes for trials comparing antidepressant with placebo

270.Study	271.VMS Required	272.VMS	273.Sleep	274.Psychological	275.Urogenital	276.Sexual	277.QoL
Suvanto-Luukkonen 2005	Uncertain	+	+	+			+
Evans 2005	Yes	+		+		+	
Kerwin 2007	Yes	+					
Kalay 2007	Yes	+		+			
Speroff 2008	Yes	+					
Soares 2008	Yes	+		+			
Archer 2009	Yes	+					+
Archer 2009	Yes	+					+
Kornstein 2010	No			+			
Soares 2010	Uncertain			+		+	+
Freeman 2011	Yes	+					
Pfizer (c) 2011	Yes	+		+		+	+
Bouchard 2012	Yes	+		+			+

(c): data came from posted results on the clinical trial registry; QoL: quality of life; VMS: vasomotor symptoms

Table E-39. Reported outcomes for trials comparing other prescriptions with placebo

278.Study	279.VMS Required	280.VMS	281.Sleep	282.Psychological	283.Urogenital	284.Sexual	285.QoL
Clayden 1974	Yes	+					
Guttuso 2003	Yes	+	+	+			
Butt 2008	Yes	+		+			
Joffe 2010	Uncertain	+	+	+			
Depomed (c) 2012	Yes	+					
Depomed (c) 2012	Yes	+					

(c): data came from posted results on the clinical trial registry; QoL: quality of life; VMS: vasomotor symptoms

Table E-40. Reported outcomes for trials comparing nonprescription nonhormone with placebo

286.Study	287.VMS Required	288.VMS	289.Sleep	290.Psychological	291.Urogenital	292.Sexual	293.QoL
Chenoy 1994	Yes	+					
Murkies 1995	Yes	+					+
Hirata 1997	Yes	+			+		+
Albertazzi 1998	Yes	+					

286.Study	287.VMS Required	288.VMS	289.Sleep	290.Psychological	291.Urogenital	292.Sexual	293.QoL
Baber 1999	Yes	+					+
Wiklund 1999	Yes	+	+	+		+	+
Barnhart 1999	No	+	+	+	+		+
Upmalis 2000	Yes	+					
Kotsopoulos 2000	Uncertain	+	+	+	+	+	
Davis 2001	Yes	+				+	
Faure 2002	Yes	+					
Han 2002	Yes	+	+				+
Tice 2003	Yes	+		+		+	
Penotti 2003	Yes	+					
Burke 2003	Yes	+					
Sammartino 2003	Yes						+
Nahas 2004	Yes	+					+
Atkinson 2004	No	+					
Hartley 2004	Uncertain	+	+	+		+	+
Winther 2005	Yes	+					+
Frei-Kleiner 2005	Yes	+					+
Verhoeven 2005	Yes	+					+
Kok 2005	No			+			+
Hidalgo 2005	Uncertain	+	+	+	+	+	+
Dodin 2005	No	+					+
Osmers 2005	Uncertain	+		+	+		+
Mucci 2006	Uncertain	+	+	+	+		
Heger (m) 2006	Yes	+	+	+	+	+	+
Lewis 2006	Uncertain	+		+		+	+
Uebelhack 2006	Yes	+		+	+		+
Sammartino 2006	Yes						+
Casini 2006	No			+			
Nahas 2007	Yes	+					
Yang 2007	Uncertain	+	+	+		+	
Chung 2007	Uncertain	+					+
Cheng 2007	Yes	+					
Ho 2007	No	+		+			
Cancellieri 2007	Uncertain						+
Haines 2008	Uncertain	+		+		+	
Jou 2008	Uncertain	+					+
Khaodhiar 2008	Yes	+					+
Ferrari 2009	Yes	+					+
van der Sluijs 2009	Yes	+		+		+	+
D'Anna (m) 2009	Yes	+					
van Die 2009	Yes	+	+	+		+	+

286.Study	287.VMS Required	288.VMS	289.Sleep	290.Psychological	291.Urogenital	292.Sexual	293.QoL
de Sousa-Munoz 2009	Yes			+			
Labrie 2009	Uncertain			+	+	+	+
Panjari 2009	Uncertain			+		+	+
Basaria 2009	Uncertain	+		+		+	
Radhakrishnan 2009	No	+					+
Lee 2010	Uncertain	+	+		+		+
Garcia 2010	Yes	+					
Lipovac 2010	Uncertain			+			
Shen 2010	Uncertain			+			
Jassi 2010	No	+	+	+			+
Evans 2011	Yes	+		+		+	+
Hsu 2011	Uncertain	+	+	+		+	+
Andrikoula 2011	Yes	+		+			+
Levis 2011	No						+
Plotnikoff 2011	Yes	+					
Chang 2011	Yes	+	+	+	+		+
Auerbach 2012	Yes	+	+	+	+		+
Cianci 2012	Uncertain	+			+		
Kim 2012	Yes	+					+
Xia 2012	Yes	+		+		+	
Ye 2012	Yes	+					+
Aso 2012	Yes	+					+

(m): trial contains data from multiple publications; QoL: quality of life; VMS: vasomotor symptoms

Table E-41. Reported outcomes for trials comparing hormone and nonprescription nonhormone with placebo

294.Study	295.VMS Required	296.VMS	297.Sleep	298.Psychological	299.Urogenital	300.Sexual	301.QoL
Crisafulli 2004	Uncertain	+					
Newton 2006	Yes	+					

QoL: quality of life; VMS: vasomotor symptoms

Table E-42. Reported outcomes for trials comparing hormone with hormone

302.Study	303.VMS Required	304.VMS	305.Sleep	306.Psychological	307.Urogenital	308.Sexual	309.QoL
Polvani 1991	Uncertain						+
Henriksson 1994	Uncertain				+	+	
Studd 1995	Yes	+					
Ayton 1996	Uncertain				+	+	
Hilditch 1996	Uncertain	+		+		+	

302.Study	303.VMS Required	304.VMS	305.Sleep	306.Psychological	307.Urogenital	308.Sexual	309.QoL
Egarter 1996	Yes						+
Hirvonen 1997	Uncertain	+					
Hirvonen 1997	No	+					
Rozenberg 1997	No	+					
Al-Azzawi 1997	Yes	+					
Lubbert 1997	Uncertain	+	+	+	+	+	+
Barentsen 1997	Uncertain				+	+	
Bachmann 1997	Uncertain				+		
Good 1999	Yes	+					
Mattsson 2000	Uncertain	+					+
Saure 2000	Yes	+		+			
Graser 2000	Yes						+
Rioux 2000	Uncertain				+		
Dugal 2000	Uncertain				+		
Parsey 2000	Yes	+					
Meuwissen 2001	Yes	+					+
Lopes 2001	Uncertain	+					+
Ozsoy 2002	Uncertain	+					+
Loh 2002	No	+		+		+	+
Buckler (d) 2003	Yes	+		+		+	+
Al-Azzawi (d) 2003	Yes	+			+	+	
Lobo 2003	Uncertain					+	
Pornel 2005	Yes	+	+				+
Gambacciani 2005	Yes	+		+			+
Utian 2005	Yes	+			+	+	
Davis 2005	Yes	+		+		+	+
Raynaud 2005	Yes	+					+
Braunstein 2005	Uncertain					+	
Simon 2005	Uncertain					+	
Weisberg 2005	Uncertain		+		+	+	
Buster 2005	Uncertain					+	
Akhila 2006	Uncertain	+		+	+		
Serrano 2006	No	+		+		+	
Cieraad 2006	Yes	+		+		+	
Davis 2006	No					+	
Long 2006	Uncertain				+	+	
Shifren 2006	Uncertain					+	
Limpaphayom (m) 2006	No	+	+	+	+	+	
Odabasi 2007	Uncertain	+		+	+		+
Mattsson (d) 2007	Yes	+					
Pitkin (d) 2007	Yes	+	+	+	+	+	+

302.Study	303.VMS Required	304.VMS	305.Sleep	306.Psychological	307.Urogenital	308.Sexual	309.QoL
Penteado 2008	Uncertain				+	+	
Panay 2010	Uncertain					+	

(d): duplicate patient population with other included article; (m): trial contains data from multiple publications; QoL: quality of life; VMS: vasomotor symptoms

Table E-43. Reported outcomes for trials comparing hormone with nonprescription nonhormone

310.Study	311.VMS Required	312.VMS	313.Sleep	314.Psychological	315.Urogenital	316.Sexual	317.QoL
Nappi 2005	Yes	+		+	+		
Nathorst-Boos 2006	Uncertain			+		+	
Kaari 2006	No	+					+
Chandeying 2007	Yes	+	+		+	+	+

QoL: quality of life; VMS: vasomotor symptoms

Table E-44. Reported outcomes for trials comparing nonprescription nonhormone with nonprescription nonhormone

318.Study	319.VMS Required	320.VMS	321.Sleep	322.Psychological	323.Urogenital	324.Sexual	325.QoL
Liske 2002	Yes			+			+
Hidalgo 2006	Yes	+	+				+
Zervoudis (a) 2008	Uncertain	+	+				
Agosta 2011	Yes	+	+	+	+		
Le Donne 2011	Uncertain				+		
Virojchaiwong 2011	Uncertain	+			+		+

(a): data came from a conference abstract; QoL: quality of life; VMS: vasomotor symptoms

Table E-45. Reported outcomes for trials comparing nonprescription nonhormone with antidepressant

326.Study	327.VMS Required	328.VMS	329.Sleep	330.Psychological	331.Urogenital	332.Sexual	333.QoL
Oktem 2007	Yes	+		+			+

QoL: quality of life; VMS: vasomotor symptoms

Table E-46. Therapies used in trials comparing hormone with placebo

334.Study	335.Arm	336.N	337.RxCat	338.Dose	339.Route	340.Generic	341.Trade	342.Est Dose
Martin 1971	1	56	Plac		Oral			
	2	53	EP seq	0.025 mg E + 1 mg P	Oral	mestranol + norethindrone		Standard
	3	56	EP seq	0.05 mg E + 1 mg P	Oral	mestranol + norethindrone		High
Campbell 1977	1	68	Plac		Oral			

334.Study	335.Arm	336.N	337.RxCat	338.Dose	339.Route	340.Generic	341.Trade	342.EstDose
	2	68	Est	1.25 mg	Oral	conjugated equine estrogens	Premarin	High
Baumgardner 1978	1	42	Plac		Oral			
	2	42	Est	0.1 mg	Oral	quinestrol	Estrovis	Low
	3	35	Est	0.2 mg	Oral	quinestrol	Estrovis	Standard
	4	37	Est	1.25 mg	Oral	conjugated estrogen	Premarin	High
Coope 1981	1	26	Plac		Oral			
	2	29	Est	0.3mg	Oral	piperazine estrone sulphate		UltraLow
Jensen 1983	1	90	Plac		Oral			
	2	41	EP seq	4 mg E + 1 mg P	Oral	estradiol + estriol + norethisterone acetate	Trisequens Forte	High
Foidart 1991	1	53	Plac		VagPes			
	2	56	Est	1 mg	VagPes	estriol	Ortho-Gynest-Depot	Low
Eriksen 1992	1	79	Plac		VagTab			
	2	75	Est	0.025 mg	VagTab	estradiol	Vagifem	Low
Wiklund 1993	1	111	Plac		Patch			
	2	112	Est	0.05 mg	Patch	estradiol		Standard
Derman 1995	1	42	Plac		Oral			
	2	40	EP seq	2 mg E + 1 mg P	Oral	estradiol + norethindrone acetate	Trisequens	Standard
Saletu 1995	1	32	Plac		Patch			
	2	32	Est	0.05 mg	Patch	estradiol	Estraderm	Standard
Good 1996	1	91	Plac		Patch			
	2	88	Est	0.05 mg	Patch	estradiol	Alora	Standard
	3	94	Est	0.10 mg	Patch	estradiol	Alora	High
Speroff (Study 1) 1996	1	54	Plac		Patch			
	2	54	Est	0.02 mg	Patch	estradiol	FemPatch	UltraLow
Chung 1996	1	40	Plac		Oral			
	2	43	Est	2mg	Oral	estradiol	Estrofem	Standard
Speroff (Study 2) 1996	1	37	Plac		Patch			
	2	37	Est	0.02 mg	Patch	estradiol	FemPatch	UltraLow
	3	37	Est	0.04 mg	Patch	estradiol	FemPatch	Low
Speroff (Study 3) 1996	1	53	Plac		Patch			
	2	53	Est	0.04 mg	Patch	estradiol	FemPatch	Low
Bacchi-Modena 1997	1	56	Plac		Patch			
	2	53	Est	0.05 mg	Patch	estradiol	Estraderm MX	Standard
Baerug 1998	1	41	Plac		Oral			
	2	38	EP comb	1mg E + 0.25mg P	Oral	estradiol + norethisterone acetate	Activelle	Low
	3	40	EP comb	1mg E + 0.5mg P	Oral	estradiol + norethisterone acetate	Activelle	Low
Bech 1998	1	51	Plac		Oral			

334.Study	335.Arm	336.N	337.RxCat	338.Dose	339.Route	340.Generic	341.Trade	342.Est Dose
	2	50	EP comb	2 mg E + 1 mg P	Oral	estradiol + norethisterone acetate	Kliogest	Standard
	3	50	EP seq	2 mg E + 1 mg P	Oral	estradiol + norethisterone acetate	Trisekvens (also Trisequens)	Standard
de Vrijer 1999	1	86	Plac		Patch			
	2	82	Est	0.05 mg	Patch	estradiol	Estraderm MX 50	Standard
	3	86	Est	0.10 mg	Patch	estradiol	Estraderm MX 100	High
Leonetti 1999	1	47	Plac		SknCrm			
	2	43	Prog	20 mg	SknCrm	progesterone		
Studd 1999	1	60	Plac		NasSpr			
	2	58	EP comb	0.1mg E + 5mg P	NasSpr	estradiol + medroxyprogesterone acetate	Aerodiol + medroxyprogesterone acetate	Low
	3	62	EP comb	0.20mg E + 5mg P	NasSpr	estradiol + medroxyprogesterone acetate	Aerodiol + medroxyprogesterone acetate	Low
	4	54	EP comb	0.30mg E + 5mg P	NasSpr	estradiol + medroxyprogesterone acetate	Aerodiol + medroxyprogesterone acetate	Standard
	5	62	EP comb	0.40mg E + 5mg P	NasSpr	estradiol + medroxyprogesterone acetate	Aerodiol + medroxyprogesterone acetate	High
Polo-Kantola 1999	1	62	Plac		SknGel			
	2	62	Est		SknGel	estradiol	Estrogel or Evorel	Standard
Casper 1999	1	34	Plac		VayRin			
	2	33	Est	0.0075 mg	VayRin	estradiol	Estring	Low
Cohen 1999	1	129	Plac		Patch			
	2	130	Est	0.0375mg	Patch	estradiol	Vivelle	Low
Rebar 2000	1	103	Plac		Oral			
	2	101	Est	0.3 mg	Oral	esterified estrogen	Estratab	Low
Speroff (Study 1) 2000	1	43	Plac		Oral			
	2	45	EP comb	0.001 mg EE + 0.2 mg NA	Oral	ethinyl estradiol (EE) + norethindrone acetate (NA)	FemHRT	UltraLow
	3	41	EP comb	0.0025 mg EE + 0.5 mg NA	Oral	ethinyl estradiol (EE) + norethindrone acetate (NA)	FemHRT	Low
	4	45	EP comb	0.005 mg EE + 1 mg NA	Oral	ethinyl estradiol (EE) + norethindrone acetate (NA)	FemHRT	Low
	5	45	EP comb	0.010 mg EE + 1 mg NA	Oral	ethinyl estradiol (EE) + norethindrone acetate (NA)	FemHRT	Standard
Rovati 2000	1	80	Plac		Patch			
	2	80	Est	0.025 mg	Patch	estradiol	Dermestril	UltraLow

334.Study	335.Arm	336.N	337.RxCat	338.Dose	339.Route	340.Generic	341.Trade	342.Est Dose
	3	77	Est	0.05 mg	Patch	estradiol	Dermestril	Standard
	4	74	Est	0.05 mg	Patch	estradiol	Dermestril	Standard
Notelovitz 2000	1	49	Plac		Oral			
	2	48	Est	1 mg	Oral	estradiol		Low
	3	48	Est	0.5 mg	Oral	estradiol		UltraLow
Strickler 2000	1	105	Plac		Oral			
	2	96	Est	0.625 mg	Oral	conjugated equine estrogens		Standard
Notelovitz 2000	1	66	Plac		Oral			
	2	68	Est	0.25 mg	Oral	estradiol		UltraLow
	3	64	Est	0.5 mg	Oral	estradiol		UltraLow
	4	67	Est	1.0 mg	Oral	estradiol		Low
	5	68	Est	2.0 mg	Oral	estradiol		Standard
DeAloysio 2000	1	52	Plac		Patch			
	2	52	Est	0.025 mg	Patch	estradiol	Dermestril	UltraLow
	3	52	Est	0.0375 mg	Patch	estradiol	Dermestril	Low
von Holst 2000	1	93	Plac		Patch			
	2	93	Est	0.05 mg	Patch	estradiol	Fem7	Standard
Notelovitz 2000	1	53	Plac		Patch			
	2	54	EP seq	0.050mg + 0.140mg	Patch	estradiol+ estradiol/norethindrone acetate	Vivelle + CombiPatch	Standard
	3	59	EP seq	0.050mg E + 0.250mg P	Patch	estradiol+ estradiol/norethindrone acetate	Vivelle + CombiPatch	Standard
	4	53	EP seq	0.050mg E + 0.400mg P	Patch	estradiol+ estradiol/norethindrone acetate	Vivelle + CombiPatch	Standard
Alexandersen 2000	1	50	Plac		Oral			
	2	50	EP seq	0.75mg E + 0.35mg P	Oral	piperazine estrone sulphate + norethisterone		Low
	3	50	EP seq	1.5mg E + 0.7mg P	Oral	piperazine estrone sulphate + norethisterone		Standard
	4	50	EP comb	2mg E + 1mg P	Oral	estradiol + norethisterone acetate		Standard
Speroff (Study 2) 2000	1	67	Plac		Oral			
	2	67	EP comb	0.0025 mg EE + 0.5 mg NA	Oral	ethinyl estradiol (EE) + norethindrone acetate (NA)	FemHRT	Low
	3	67	EP comb	0.005 mg EE + 1 mg NA	Oral	ethinyl estradiol (EE) + norethindrone acetate (NA)	FemHRT	Low
	4	65	EP comb	0.010 mg EE + 1 mg NA	Oral	ethinyl estradiol (EE) + norethindrone acetate (NA)	FemHRT	Standard
Rigano 2001	1	191	Plac					
	2	171	Est	0.05 mg	Patch	estradiol	Dermestril	Standard
Utian (CEE alone arms) 2001	1	28	Plac		Oral			
	2	30	Est	0.3mg	Oral	conjugated equine estrogen		UltraLow
	3	32	Est	0.45mg	Oral	conjugated equine estrogen		Low
	4	27	Est	0.625mg	Oral	conjugated equine estrogen		Standard
Simon 2001	1	48	Plac		Oral			

334.Study	335.Arm	336.N	337.RxCat	338.Dose	339.Route	340.Generic	341.Trade	342.Est Dose
	2	72	Est	0.625 mg	Oral	synthetic conjugated estrogen-A	Cenestin	Standard
Soares 2001	1	25	Plac		Patch			
	2	25	Est	0.1 mg	Patch	estradiol	Systen/Evorel	High
Utian (CEE/MPA arms) 2001	1	28	Plac		Oral			
	2	33	EP comb	0.3mg E + 1.5mg P	Oral	conjugated equine estrogen + medroxyprogesterone acetate		UltraLow
	3	29	EP comb	0.45mg E + 1.5mg P	Oral	conjugated equine estrogen + medroxyprogesterone acetate		Low
	4	28	EP comb	0.45mg E + 2.5mg P	Oral	conjugated equine estrogen + medroxyprogesterone acetate		Low
	5	34	EP comb	0.625mg E + 2.5mg P	Oral	conjugated equine estrogen + medroxyprogesterone acetate		Standard
Rozenbaum 2002	1	57	Plac		NasSpr			
	2	54	Est	0.15 mg	NasSpr	estradiol	Aerodiol	Low
	3	54	Est	0.30 mg	NasSpr	estradiol	Aerodiol	Standard
Shulman (Study 1) 2002	1	93	Plac		Patch			
	2	96	EP comb	0.045 mg E + 0.030 mg P	Patch	estradiol + levonorgestrel		Low
	3	104	EP comb	0.045 mg E + 0.040 mg P	Patch	estradiol + levonorgestrel		Low
von Holst 2002	1	88	Plac		Patch			
	2	84	EP seq	0.05 mg E + 0.01 mg P	Patch	estradiol + levonorogestrel	Fem7 Combi	Standard
Archer 2003	1	73	Plac		SknGel			
	2	75	Est	0.75 mg	SknGel	estradiol	EstroGel	Low
	3	73	Est	1.5 mg	SknGel	estradiol	EstroGel	Low
Vestergaard 2003	1	504	Plac		Oral			
	2	502	EP seq	2 mg E + 1 mg P	Oral	estradiol + norethisterone acetate	Trisequens	Standard
Speroff 2003	1	108	Plac		VayRin			
	2	113	EP comb	0.05 mg	VayRin	estradiol + progestin	Femring	High
	3	112	EP comb	0.10 mg	VayRin	estradiol + progestin	Femring	High
Jirapinyo 2003	1	60	Plac		Oral			
	2	60	EP comb	2 mg E + 1 mg P	Oral	estradiol + norethisterone acetate	Kliogest	Standard
Haines 2003	1	50	Plac		Oral			
	2	52	Est	1 mg	Oral	estradiol		Low
	3	50	Est	2 mg	Oral	estradiol		Standard
Hays 2003	1	8102	Plac		Oral			
	2	8506	EP comb	0.625mg E + 2.5mg P	Oral	conjugated equine estrogen + medroxyprogesterone acetate	Prempro	Standard
Gambacciani 2003	1	25	Plac		Oral			
	2	25	EP comb	1 mg E + 0.5 mg P	Oral	estradiol + norethisterone	Activelle	Low
Gelfand 2003	1	60	Plac		Oral			
	2	59	EP comb	1 mg E + 0.09 mg P	Oral	estradiol + norgestimate	Ortho-Prefest	Low
Wren 2003	1	42	Plac		SknCrm			
	2	38	Prog	32 mg	SknCrm	progesterone	Pro-Feme	
Simunic 2003	1	784	Plac		VagTab			

334.Study	335.Arm	336.N	337.RxCat	338.Dose	339.Route	340.Generic	341.Trade	342.Est Dose
	2	828	Est	0.025mg	VagTab	estradiol	Vagifem	Low
Parsons 2003	1	46	Plac		VagCrm		Replens (nonhormonal moisturizer)	
	2	48	Est	0.625 mg	VagCrm	conjugated estrogen	Premarin	Standard
Berlex (SIP) 2003	1	88	Plac		Patch			
	2	92	EP comb	.045 mg E + .03 mg P	Patch	Estradiol + Levonorgestrel	Climara Pro	Standard
Rudolph 2004	1	64	Plac		Oral			
	2	65	EP comb	2mg E + 2mg P	Oral	estradiol valerate + dienogest	Climodien/Lafamme	High
Yang 2004	1	25	Plac		Oral			
	2	26	EP comb	0.625mg E + 2.5mg P	Oral	conjugated estrogen + medroxyprogesterone acetate	Premelle	Standard
Schurmann 2004	1	61	Plac		Oral			
	2	55	EP comb	1mg E + 1mg P	Oral	estradiol + drospirenone		Low
	3	52	EP comb	1mg E + 2mg P	Oral	estradiol + drospirenone		Low
	4	57	EP comb	1mg E + 3mg P	Oral	estradiol + drospirenone		Low
Utian 2004	1	72	Plac		Oral			
	2	68	Est	0.3mg	Oral	synthetic conjugated estrogen	Enjuvia	UltraLow
	3	72	Est	0.625mg	Oral	synthetic conjugated estrogen	Enjuvia	Standard
	4	69	Est	1.25mg	Oral	synthetic conjugated estrogen	Enjuvia	High
Dessole 2004	1	44	Plac		VagOvu			
	2	44	Est	1mg	VagOvu	estriol	Colpogyn	Low
Duramed (SIP) 2004	1	51	Plac		Oral			
	2	53	Est	.45mg	Oral	synthetic conjugated estrogens	Cenestin	Low
Brunner 2005	1	5429	Plac		Oral			
	2	5310	Est	0.625 mg	Oral	conjugated equine estrogens	Premarin	Standard
Onalan 2005	1	54	Plac	1000 mg	Oral	calcium	Calcium Sandoz Forte	
	2	79	EP comb	0.625 mg E + 2.5 mg P	Oral	conjugated equine estrogen (CEE) + medroxyprogesterone acetate (MPA)	Premelle 2.5	Standard
	3	77	EP comb	0.625 mg E + 5.0 mg P	Oral	conjugated equine estrogen (CEE) + medroxyprogesterone acetate (MPA)	Premelle 5	Standard
Bayer Healthcare (SIP) 2005	1	176	Plac		Oral			
	2	175	EP comb	0.50 mg E + 0.25 mg P	Oral	estradiol + drospirenone	Angeliq	Low
Novartis (SIP) 2005	1	51	Plac		Patch			
	2	57	EP comb	0.05 mg E + 0.14 mg P	Patch	estradiol + norethindrone acetate	CombiPatch	Low
	3	52	EP comb	0.05 mg E + 0.25 mg P	Patch	estradiol + norethindrone acetate	CombiPatch	Low
Yaffe (d) 2006	1	209	Plac		Patch			
	2	208	Est	0.014mg	Patch	estradiol	Menostar	UltraLow
Speroff (Study 1) 2006	1	94	Plac		Oral			
	2	100	Est	0.9 mg	Oral	estradiol acetate	Femtrace	Standard

334.Study	335.Arm	336.N	337.RxCat	338.Dose	339.Route	340.Generic	341.Trade	342.EstDose
	3	95	Est	1.8 mg	Oral	estradiol acetate	Femtrace	High
Simon 2006	1	100	Plac		SknCrm			
	2	100	Est	2.5 mg/1g of cream	SknCrm	estradiol	Estrasorb	Low
Diem (d) 2006	1	209	Plac		Patch			
	2	208	Est	0.014 mg	Patch	estradiol	Menostar	UltraLow
Nielsen 2006	1	118	Plac		NasSpr			
	2	114	EP seq	0.15 mg E + 200mg P	NasSpr	estradiol (S21400) + progesterone	Aerodiol + progesterone	Low
	3	103	EP seq	0.30 mg E + 200 mg P	NasSpr	estradiol (S21400) + progesterone	Aerodiol + progesterone	Standard
Osmanagaoglu 2006	1	51	Plac		Oral			
	2	53	EP comb	2 mg E + 2 mg P	Oral	estradiol valerate (EV) + dienogest (P)	Climodien	High
Speroff (Study 2) 2006	1	108	Plac		Oral			
	2	113	Est	0.45 mg	Oral	estradiol acetate	Femtrace	Low
Bachmann (d) 2007	1	133	Plac		Patch			
	2	147	Est	0.014 mg	Patch	estradiol		UltraLow
	3	145	EP comb	0.023 mg E + 0.0075 mg P	Patch	estradiol + levonorgestrel		UltraLow
Maki 2007	1	91	Plac		Oral			
	2	89	EP comb	0.625mg E + 2.5mg P	Oral	conjugated equine estrogen + medroxyprogesterone acetate	Prempro	Standard
Endrikat 2007	1	162	Plac		Oral			
	2	162	EP comb	1mg E + 2mg P	Oral	estradiol valerate + dienogest		Standard
Lee 2007	1	37	Plac		Oral			
	2	35	EP comb	1 mg E + 2 mg P	Oral	estradiol + drospirenone		Low
Panay 2007	1	200	Plac		Oral			
	2	194	EP comb	0.5 mg E + 0.1 mg P	Oral	estradiol + norethisterone acetate		UltraLow
	3	181	EP comb	0.5 mg E + 0.25 mg P	Oral	estradiol + norethisterone acetate		UltraLow
Simon 2007	1	137	Plac		SknGel			
	2	136	Est	0.52 mg	SknGel	estradiol	Elestrin	Low
	3	142	Est	1.02 mg	SknGel	estradiol	Elestrin	Low
	4	69	Est	1.56 mg	SknGel	estradiol	Elestrin	Low
Pefanco 2007	1	25	Plac		Oral			
	2	32	EP seq	0.25mg + 100mg P	Oral	estradiol + progesterone		UltraLow
Bayer Healthcare (SIP) 2007	1	83	Plac		Patch			
	2	82	Est	.025 mg	Patch	estradiol	Climara	UltraLow
Buster (Study 1) 2008	1	75	Plac		SknSpr			
	2	76	Est	4.59 mg	SknSpr	estradiol	Evamist	Low
Veerus 2008	1	381	Plac		Oral			

334.Study	335.Arm	336.N	337.RxCat	338.Dose	339.Route	340.Generic	341.Trade	342.EstDose
	2	524	Plac					
	3	503	EP comb	0.625 mg + 2.5 mg	Oral	combined estrogens + medroxyprogestrone acetate		Standard
	4	415	EP comb	0.625 mg + 2.5 mg	Oral	combined estrogens + medroxyprogestrone acetate		Standard
Davis 2008	1	277	Plac		Patch			
	2	267	Test	0.15 mg	Patch			
	3	267	Test	0.30 mg	Patch			
Bachmann 2008	1	47	Plac		VagTab			
	2	92	Est	0.01 mg	VagTab	estradiol	Vagifem	Low
	3	91	Est	0.025 mg	VagTab	estradiol	Vagifem	Low
Huang (d) 2008	1	209	Plac		Patch			
	2	208	Est	0.014 mg	Patch	estradiol		UltraLow
Welton 2008	1	1087	Plac		Oral			
	2	1043	EP comb	0.625 E + 2.5/5.0 P	Oral	conjugated equine estrogen + medroxyprogesterone acetate	Prempro	Standard
Buster (Study 2) 2008	1	76	Plac		SknSpr			
	2	74	Est	3.06 mg	SknSpr	estradiol	Evamist	Low
Buster (Study 3) 2008	1	77	Plac		SknSpr			
	2	76	Est	1.53 mg	SknSpr	estradiol	Evamist	Low
Simon (SIP) 2008	1	123	Plac		Oral			
	2	125	Est	0.3 mg	Oral	synthetic conjugated estrogens	Enjuvia	Low
Benster 2009	1	43	Plac		SknCrm			
	2	46	Prog	5 mg	SknCrm	progestin	Progestelle	
	3	44	Prog	20 mg	SknCrm	progestin	Progestelle	
	4	43	Prog	40 mg	SknCrm	progestin	Progestelle	
	5	45	Prog	60 mg	SknCrm	progestin	Progestelle	
Haines 2009	1	80	Plac		Patch			
	2	80	Est	0.014 mg	Patch	estradiol		UltraLow
Bachmann (d) 2009	1	36	Plac		Patch			
	2	42	Est	0.014 mg	Patch	estradiol		UltraLow
	3	43	EP comb	0.023mg E + 0.0075mg P	Patch	estradiol + levonorgestrel		UltraLow
Hedrick 2009	1	125	Plac		SknGel			
	2	122	Est	0.25 mg	SknGel	estradiol	Divigel	Low
	3	123	Est	0.5 mg	SknGel	estradiol	Divigel	Low
	4	125	Est	1.0 mg	SknGel	estradiol	Divigel	Low
Baksu 2009	1	32	Plac		Oral			
	2	35	Est	0.625 mg	Oral	conjugated estrogen	Premarin	Standard
	3	33	Est	0.3 mg	NasSpr	estradiol hemihidrate	Aerodiol	Standard
	4	32	Est	1.5 mg	SknGel	estradiol hemihidrate	Estreva	Standard
Bachmann (Study	1	72	Plac		VagCrm			

334.Study	335.Arm	336.N	337.RxCat	338.Dose	339.Route	340.Generic	341.Trade	342.EstDose
1) 2009								
	2	143	Est	0.3 mg	VagCrm	conjugated estrogen		UltraLow
Freedman 2009	1	140	Plac		VagCrm			
	2	135	Est	0.179mg	VagCrm	synthetic conjugated estrogens-A		Standard
Gast 2009	1	141	Plac		Oral			
	2	144	EP comb	0.45 mg E + 1.5 mg MPA oral + 0.625 mg cream	Oral	conjugated estrogen + medroxyprogesterone acetate	Premarin	Low
Bachmann (Study 2) 2009	1	68	Plac		VagCrm			
	2	140	Est	0.3 mg	VagCrm	conjugated estrogen		Low
Hassa 2010	1	83	Plac		Injec			
	2	83	Est	0.625 mg	Oral	conjugated equine estrogen	Premarin	Standard
	3	81	Est	0.56 mg	Patch	estradiol	Climara	Standard
Stevenson 2010	1	127	Plac		Oral			
	2	124	EP comb	0.5 mg E + 2.5 mg D	Oral	estradiol and dydrogesterone		UltraLow
	3	62	EP comb	1 mg E + 5 mg D	Oral	estradiol and dydrogesterone		Low
Raghunandan 2010	1	25	Plac		VagCrm			
	2	25	Est	0.625 mg	VagCrm	conjugated equine estrogen	Premarin	Standard
	3	25	ET comb	0.625 mg E + 2% T	VagCrm	conjugated equine estrogen + testosterone	Premarin + testosterone	Standard
Hedrick 2010	1	124	Plac		SknGel			
	2	121	Est	0.25 mg	SknGel	estradiol	Divigel	Low
	3	119	Est	0.50 mg	SknGel	estradiol	Divigel	Low
	4	124	Est	1 mg	SknGel	estradiol	Divigel	Low
Liu 2011	1	168	Plac		Oral			
	2	172	Est	0.30 mg	Oral	esterified estrogen		Low
	3	172	ET comb	0.30 mg E + 0.30 mg MT	Oral	esterified estrogen + methyltestosterone		Low
	4	174	ET comb	0.30 mg E + 0.60 mg MT	Oral	esterified estrogen + methyltestosterone		Low
	5	168	Est	0.45 mg EE	Oral	esterified estrogen		Low
	6	175	Test	0.60 mg	Oral	methyltestosterone		
Lin 2011	1	61	Plac		Oral			
	2	183	EP comb	1 mg E + 2 mg P	Oral	estradiol + drospirenone		Low
Demetrio 2011	1	36	Plac		Oral			
	2	30	Est	0.625 mg	Oral	conjugated equine estrogen	Premarin	Standard
Liu 2012	1	52	Plac		Oral			
	2	53	Est	0.3mg	Oral	synthetic conjugated estrogen-B	Enjuvia	UltraLow
	3	52	Est	0.625mg	Oral	synthetic conjugated estrogen-B	Enjuvia	Standard
Archer 2012	1	114	Plac		SknGel			
	2	118	Est	0.27 mg	SknGel	Estradiol	EstroGel	Low
	3	119	Est	0.375 mg	SknGel	Estradiol	EstroGel	Low

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; (d): duplicate patient population with other included article; E: estrogen; EP comb: estrogen plus progestin; Est: estrogen alone; ET comb: estrogen plus testosterone; (m): trial contains data from multiple publications; NasSpr: nasal spray; P: progestin; Prog: progestin alone; Plac: placebo;

RxCat: treatment category; SD: standard deviation; (SIP); data came from a package insert; SknGel: skin gel; Test: testosterone alone; VagCrm: vaginal cream; VagOvu: vaginal ovule; VagPes: vaginal pessary; VagRin: vaginal ring; VagTab: vaginal tablet

Table E-47. Therapies used in trials comparing antidepressant with placebo

343.Study	344.Arm	345.N	346.RxCat	347.Dose	348.Route	349.Generic	350.Trade
Suvanto-Luukkonen 2005	1	50	Plac		Oral		
	2	50	Antide	10mg-30mg	Oral	fluoxetine	Seronil
	3	49	Antide	10mg-30mg	Oral	citalopram	Cipramil
Evans 2005	1	40	Plac		Oral		
	2	40	Antide	75mg	Oral	venlafaxine	Effexor XR
Kerwin 2007	1	41	Plac		Oral		
	2	46	Antide	50mg	Oral	sertraline	
Kalay 2007	1	25	Plac		Oral		
	2	25	Antide	10-40mg	Oral	citalopram	
Speroff 2008	1	77	Plac		Oral		
	2	141	Antide	50 mg	Oral	desvenlafaxine succinate	Pristiq
	3	145	Antide	100 mg	Oral	desvenlafaxine succinate	Pristiq
	4	137	Antide	150 mg	Oral	desvenlafaxine succinate	Pristiq
	5	120	Antide	200 mg	Oral	desvenlafaxine succinate	Pristiq
Soares 2008	1	28	Plac		Oral		
	2	28	Antide	12.5-25mg	Oral	paroxetine controlled release	
Archer 2009	1	180	Plac		Oral		
	2	182	Antide	100 mg	Oral	desvenlafaxine	
	3	179	Antide	150 mg	Oral	desvenlafaxine	
Archer 2009	1	151	Plac		Oral		
	2	150	Antide	100 mg	Oral	desvenlafaxine	
	3	151	Antide	150 mg	Oral	desvenlafaxine	
Kornstein 2010	1	125	Plac		Oral		
	2	247	Antide	100-200mg	Oral	devenlafaxine	Pristiq
Soares 2010	1	224	Antide	100 mg - 200 mg	Oral	desvenlafaxine	Pristiq
	2	237	Antide	10-20 mg	Oral	escitalopram	Lexapro
Freeman 2011	1	101	Plac		Oral		
	2	104	Antide	10-20mg	Oral	escitalopram	
Pfizer (c) 2011	1	1052	Plac		Oral		
	2	1066	Antide	100mg	Oral	desvenlafaxine	
Bouchard 2012	1	150	Plac		Oral		
	2	137	Antide	100 mg	Oral	desvenlafaxine	

Antide: antidepressant; Plac: placebo; RxCat: treatment category

Table E-48. Therapies used in trials comparing other prescriptions with placebo

351.Study	352.Arm	353.N	354.RxCat	355.Dose	356.Route	357.Generic	358.Trade
Clayden 1974	1	43	Plac		Oral		
	2	42	Clon	0.05-0.15mg	Oral	clonidine	
Guttuso 2003	1	29	Plac		Oral		
	2	30	Gab/Pre	900 mg	Oral	gabapentin	
Butt 2008	1	98	Plac		Oral		
	2	99	Gab/Pre	300mg	Oral	gabapentin	
Joffe 2010	1	29	Plac		Patch		
	2	30	Eszop	3mg	Patch		
Depomed (c) 2012	1	177	Plac		Oral		
	2	174	Gab/Pre	1200mg	Oral		
	3	181	Gab/Pre	1800mg	Oral		
Depomed (c) 2012	1	183	Plac		Oral		
	2	186	Gab/Pre	1200mg	Oral		
	3	190	Gab/Pre	1800mg	Oral		

(c): data came from posted results on the clinical trial registry; Clon: clonidine; Eszop: eszopiclone; Gab/Pre: gabapentin/pregabalin; Plac: placebo;

Table E-49. Therapies used in trials comparing nonprescription nonhormone with placebo

359.Study	360.Arm	361.N	362.RxCat	363.Dose	364.Route	365.Generic	366.Trade
Chenoy 1994	1	28	Plac		Oral		
	2	28	See Note	4000 mg primrose oil + 80 vitamin E	Oral		
Murkies 1995	1	30	Plac	45g	Suppl	unbleached wheat flour	
	2	28	Isofl	45g	Suppl	soy flour	
Hirata 1997	1	36	Plac		Oral		
	2	35	DongQ	4.5g	Oral	Angelica sinensis	
Albertazzi 1998	1	53	Plac		Suppl		
	2	51	Isofl	76 mg	Suppl	soy protein	Supro Brand
Baber 1999	1	26	Plac		Oral		
	2	25	Isofl	40 mg	Oral	isoflavone	Promensil
Wiklund 1999	1	191	Plac		Oral		
	2	193	Gins	200 mg	Oral		Ginsana G115
Barnhart 1999	1	30	Plac		Oral		
	2	30	DHEA	50mg	Oral		
Upmalis 2000	1	86	Plac		Oral		

359.Study	360.Arm	361.N	362.Rx Cat	363.Dose	364.Route	365.Generic	366.Trade
	2	89	Isofl	50mg	Oral	soy isoflavones	
Kotsopoulos 2000	1	50	Plac		Suppl	casein	
	2	44	Isofl	118 mg	Suppl		
Davis 2001	1	27	Plac		Suppl		
	2	28		See Note	Suppl		
Faure 2002	1	36	Plac		Oral		
	2	39	Isofl	70mg	Oral	soy isoflavones	Phytosoya
Han 2002	1	40	Plac		Oral		
	2	40	Isofl	100mg	Oral		
Tice 2003	1	85	Plac		Oral		
	2	83	Isofl	57.2 mg	Oral	isoflavones	Rimostil
	3	84	Isofl	82 mg	Oral	isoflavones	Promensil
Penotti 2003	1	34	Plac		Oral		
	2	28	Isofl	72mg	Oral	isoflavones	
Burke 2003	1	76	Plac		Suppl		
	2	70	Isofl	42 mg	Suppl	soy protein	
	3	65	Isofl	58 mg	Suppl	soy protein	
Sammartino 2003	1	31	Plac		Oral	calcium	
	2	32	Isofl	36 mg	Oral	genistein	
Nahas 2004	1	25	Plac		Oral		
	2	25	Isofl	60 mg	Oral	isoflavones	Isosoy
Atkinson 2004	1	103	Plac		Oral		
	2	102	Isofl	26mg biochanin A + 16mg formononetin + 1mg genistein + 0.5mg daidzein	Oral	red clover derivatives	Promensil
Hartley 2004	1	27	Plac		Oral		
	2	30	Gins	120 mg GK501 + 200 mg G115	Oral	GK501 + G115	Gincosan
Winther 2005	1	32	Plac		Oral		
	2	32	See Note	80 mg GC + 240 mg PI 82	Oral	GC Fem + PI 82	Femal
Frei-Kleiner 2005	1	41	Plac		Oral		
	2	81	B Coh	avg 42 mg (29-55 mg)	Oral		
Verhoeven 2005	1	64	Plac		Oral		
	2	60	See Note	50 mg Isoflavones + 8 mg deoxyacetein +1500 mg primrose oil + 0.00125 Vit D + 200 mg calcium	Oral	soy extract + black cohosh	
Kok 2005	1	102	Plac	36.5 g	Suppl		
	2	100	Isofl	52 mg genistein, 41 mg daidzein, 6 mg glycitein	Suppl		Solae soy protein
Hidalgo 2005	1	53	Plac		Oral		
	2	53	Isofl	80 mg	Oral	red clover isoflavone	

359.Study	360.Arm	361.N	362.Rx Cat	363.Dose	364.Route	365.Generic	366.Trade
Dodin 2005	1	94	Plac		Suppl	wheat germ	
	2	85	Flax	40g	Suppl	flax seed	
Osmers 2005	1	141	Plac		Oral		
	2	145	B Coh	40 mg	Oral	black cohosh	Remifemin
Mucci 2006	1	45	Plac		Oral		
	2	44	See Note	isoflavones: 60 mg; lactobacillus sporogenes: 500 million spores; magnolia extract: 60 mg; magnesium: 50 mg	Oral	isoflavones + lactobacillus sporogenes + magnolia extract + magnesium	
Heger (m) 2006	1	55	Plac		Oral		
	2	54	See Note	4 mg	Oral	rheum rhaponticum	Phytoestrol N
Lewis 2006	1	33	Plac		Suppl		
	2	33	Isofl	42 mg	Suppl	isoflavone	
	3	33	Flax	50 mg	Suppl	flaxseed	
Uebelhack 2006	1	150	Plac		Oral		
	2	151	See Note	3.75 mg Black Cohosh Native Extract + 70 mg St John's Wort Native Extract	Oral		Remifemin plus St John's wort
Sammartino 2006	1	39	Plac		Oral	calcium	
	2	36	See Note	60 mg I + 20 mg L + 1.25 c. racemosa	Oral		Euclim
Casini 2006	1	77	Plac		Oral		
	2	77	Isofl	60 mg	Oral	aglycone	
Nahas 2007	1	38	Plac		Oral		
	2	38	Isofl	100 mg	Oral	isoflavone	Glycine max AT
Yang 2007	1	75	Plac		Oral		
	2	80	See Note	200 mg	Oral	Maritime Pine Extract	Pycnogenol
Chung 2007	1	35	Plac		Oral		
	2	42	See Note	0.0364mL extract from Cimicifugae + 84 mg dried extract from Hypericum perforatum	Oral		Gyno-plus
Cheng 2007	1	25	Plac		Suppl		
	2	26	Isofl	60 mg	Suppl	isoflavones	
Ho 2007	1	91	Plac		Oral	starch	
	2	85	Isofl	80 mg	Oral	soy isoflavones	
Cancellieri 2007	1	65	Plac		Oral		
	2	60	Isofl	72 mg	Oral	soy beans, red clover, black cohosh	
Haines 2008	1	39	Plac		Oral		
	2	45	See	3 g	Oral		

359.Study	360.Arm	361.N	362.Rx Cat	363.Dose	364.Route	365.Generic	366.Trade
			Note				
Jou 2008	1	30	Plac		Suppl		
	2	34	Isofl	135 mg	Suppl	isoflavones	SoyLife
	3	32	Isofl	135 mg	Suppl	isoflavones	SoyLife
Khaodhiar 2008	1	45	Plac		Oral		
	2	48	Isofl	40 mg	Oral	daidzein-rich isoflavone aglycones	
	3	49	Isofl	60 mg	Oral	daidzein-rich isoflavone aglycones	
Ferrari 2009	1	94	Plac		Oral		
	2	82	Isofl	80 mg	Oral	isoflavones	Fisiogen/Zavital
van der Sluijs 2009	1	46	Plac		Oral		
	2	46	See Note	3820 mg	Oral		
D'Anna (m) 2009	1	117	Plac		Oral		
	2	119	Isofl	54 mg	Oral	isoflavone	
van Die 2009	1	50	Plac		Oral		
	2	50	See Note	900 mg H + 1000 mg V	Oral		
de Sousa-Munoz 2009	1	42	Plac		Oral		
	2	42	Isofl	120 mg	Oral	isoflavones	Isoflavin Beta
Labrie 2009	1	53	Plac		VagOvu		
	2	53	DHEA	3.25 mg	VagOvu	DHEA	Prasterone
	3	56	DHEA	6.5 mg	VagOvu	DHEA	Prasterone
	4	54	DHEA	13 mg	VagOvu	DHEA	Prasterone
Panjari 2009	1	43	Plac		Oral		
	2	46	DHEA	50 mg	Oral		
Basaria 2009	1	46	Plac		Suppl	casein protein	
	2	38	Isofl	160 mg	Suppl	isoflavones (soy protein)	
Radhakrishnan 2009	1	41	Plac		Oral	casein	
	2	44	Isofl	75 mg	Suppl	soy protein	
Lee 2010	1	44	Plac		Oral		
	2	43	Isofl	350 mg	Oral	isoflavone	Rexflavone
Garcia 2010	1	28	Plac		Oral		
	2	103	See Note	300 mg E. ulmoides +150 mg V radiata	Oral		Nutrafem
Lipovac 2010	1	59	Plac		Oral		
	2	50	Isofl	80 mg	Oral	red clover extract (MF11RCE)	

359.Study	360.Arm	361.N	362.Rx Cat	363.Dose	364.Route	365.Generic	366.Trade
Shen 2010	1	44	Plac	500 mg	Oral	starch	
	2	47	See Note	500 mg	Oral	green tea polyphenols	
Jassi 2010	1	25	Plac	30 g	Suppl	casein protein	
	2	25	Isofl	60 mg	Suppl	soy protein	
	3	25	Isofl	60 mg	Oral	soy isoflavones	
Evans 2011	1	42	Plac		Oral		
	2	41	Isofl	30 mg	Oral	genistein	geniVida
Hsu 2011	1	25	Plac		Suppl		
	2	25	See Note	24 mg	Suppl		
Andrikoula 2011	1	34	Plac		Oral		
	2	36		See Note	Oral		
Levis 2011	1	126	Plac		Oral		
	2	122	Isofl	200 mg	Oral	soy protein (genistein and daidzein)	Novasoy
Plotnikoff 2011	1	59	Plac		Oral		
	2	62	See Note	7.5g	Oral	keishibukuryogab (TU-025)	
	3	57	See Note	12.5g	Oral	keishibukuryogab (TU-025)	
Chang 2011	1	33	Plac		Oral		
	2	31	See Note	257.1 mg	Oral	cynanchum wilfordii + phlomis umbrosa +angelica gigas	EstroG-100
Auerbach 2012	1	38	Plac		Oral	sunflower oil	
	2	43	See Note	0.254 mg	Oral	pomegranate seed oil	PEKANA
Cianci 2012	1	60	Plac		Oral		
	2	60	Isofl	60 mg	Oral		
Kim 2012	1	36	Plac		Oral		
	2	36	Gins	3g	Oral	red ginseng	
Xia 2012	1	36	Plac		Oral		
	2	36	See Note	3500 mg	Oral	Du zhong + Bu gu zhi + Dan shen	Jiawei Quig'e Fang
Ye 2012	1	30	Plac		Oral		
	2	30	Isofl	84 mg	Oral	soy germ isoflavone	SoyLife EXTRA
	3	30	Isofl	126 mg	Oral	soy germ isoflavone	SoyLife EXTRA

359.Study	360.Arm	361.N	362.RxCat	363.Dose	364.Route	365.Generic	366.Trade
Aso 2012	1	60	Plac		Oral		
	2	66	Isofl	10mg	Oral	equol	

B coh: black cohosh; DHEA: Dehydroepiandrosterone; DongQ: dong quai; Gins: ginseng; Isofl: isoflavone; (m): trial contains data from multiple publications; Plac: placebo; Suppl: dietary supplement

Table E-50. Therapies used in trials comparing hormone and nonprescription nonhormone with placebo

367.Study	368.Arm	369.N	370.RxCat	371.Dose	372.Route	373.Generic	374.Trade	375.Est Dose
Crisafulli 2004	1	30	Plac		Oral			
	2	30	Isofl	54mg	Oral	genistein		
	3	30	EP comb	1mg E + 0.5mg P	Oral	estradiol + norethisterone acetate	Activelle	Low
Newton 2006	1	84	Plac		Oral			
	2	32	EP comb	0.625 mg E + 2.5 mg P	Oral	conjugated equine estrogen + medroxyprogesterone		Standard
	3	80	B Coh	160 mg	Oral	black cohosh		
	4	76	See Note	black cohosh: 200 mg; alfalfa: 400 mg; boron: 4 mg; chaste tree: 200 mg; dong quai: 400 mg; false unicorn: 200 mg; licorice: 200 mg; oats: 400 mg; pomegranate: 400 mg; ginseng: 400 mg	Oral	multibotanical	ProGyne	
	5	79	See Note	black cohosh: 200 mg; alfalfa: 400 mg; boron: 4 mg; chaste tree: 200 mg; dong quai: 400 mg; false unicorn: 200 mg; licorice: 200 mg; oats: 400 mg; pomegranate: 400 mg; ginseng: 400 mg	Oral	multibotanical	ProGyne	

B coh: black cohosh; EP comb: estrogen plus progestin combined; Isofl: isoflavone; Plac: placebo

Table E-51. Therapies used in trials comparing hormone with hormone

376.Study	377.Arm	378.N	379.RxCat	380.Dose	381.Route	382.Generic	383.Trade	384.Est Dose
Polvani 1991	1	170	EP seq	0.625 mg E + 10 mg P	Oral	conjugated equine estrogens + medroxyprogesterone acetate		Standard
	2	203	EP seq	0.05 mg E + 10 mg P	Patch	estradiol + medroxyprogesterone acetate		Standard
Henriksson 1994	1	106	Est	0.0095mg	VayRin	estradiol	Silastic	Low
	2	51	Est	0.5mg	VagPes	estriol	Ovesterin	Low
Studd 1995	1	104	EP seq	0.625 mg E + 20 mg P	Oral	conjugated estrogen + dydrogesterone	Premarin + Duphaston	Standard

376.Study	377.Arm	378.N	379.RxCat	380.Dose	381.Route	382.Generic	383.Trade	384.EstDose
	2	100	EP seq	0.05 mg E + 20 mg P	Patch	estradiol + dydrogesterone	Menorest + Duphaston	Standard
Ayton 1996	1	131	Est	0.0075mg	VayRin	estradiol	Estring	Low
	2	63	Est	0.625mg	VagCrm	conjugated estrogen	Premarin	Standard
Hilditch 1996	1	35	EP seq	0.625mg E + 10mg P	Oral	conjugated equine estrogen + medroxyprogesterone acetate	Premarin + Provera	Standard
	2	39	EP seq	0.014mg E + 10mg P	Patch	estradiol + medroxyprogesterone acetate	Estraderm + Provera	UltraLow
Egarter 1996	1	51	EP seq	2mg E + 10mg P	Oral	estradiol valerate + medroxyprogesterone acetate	Dilena or Divina	High
	2	50	EP seq	0.625mg E + 10mg P	Oral	conjugated estrogen + medrogestone	Premarin + Colpron	Standard
Hirvonen 1997	1	60	EP seq	1.0 mg E + 10 mg P	SknGel	estradiol + peroral dydrogesterone	Divigel + Terolut	Low
	2	60	EP seq	0.05 mg E + 10 mg P	Patch	estradiol + peroral dydrogesterone	Estraderm + Terolut	Standard
Hirvonen 1997	1	84	EP seq	1 mg E + 20 mg P	SknGel	estradiol + medroxyprogesterone acetate	Divigel + Provera	Low
	2	32	EP seq	2 mg E + 10 mg P	SknGel	estradiol + medroxyprogesterone acetate	Divigel + Provera	Standard
	3	57	EP seq	2 mg E + 10 mg P	Oral	estradiol valerate + medroxyprogesterone	Divina	High
Rozenberg 1997	1	153	EP comb	0.05 mg E + P (see comment)	Patch	estradiol + dydrogerterone or estradiol + norethisterone		Standard
	2	154	EP comb	0.05 mg E + 0.17 mg P	Patch	estradiol + norethisterone acetate		Standard
	3	158	EP comb	0.05 mg E + 0.35 P	Patch	estradiol + norethisterone acetate		Standard
	4	153	EP seq	0.05 mg E + 0.17 mg P	Patch	estradiol + norethisterone acetate		Standard
	5	156	EP seq	0.05 mg E + 0.35 mg P	Patch	estradiol + norethisterone acetate		Standard
Al-Azzawi 1997	1	129	Est	0.05 mg	Patch	estradiol	Estraderm	Standard
	2	134	Est	0.05 mg	Patch	estradiol	Lyrelle 50	Standard
	3	131	Est	0.08 mg	Patch	estradiol	Lyrelle 80	High
Lubbert 1997	1	1232	EP comb	0.05 mg E + ? mg P	Patch	estradiol + progestogen	Menorest + progestogen	Standard
	2	1227	EP seq	0.05 mg + ? mg P	Patch	estradiol + progestogen	Menorest + progestogen	Standard
Barentsen 1997	1	83	Est	0.0075mg	VayRin	estradiol	Estring	Low
	2	82	Est	0.5mg	VagCrm	estriol	Synapause	Low
Bachmann 1997	1	129	EP comb	0.0075mg	VayRin	estradiol + medroxyprogesterone	Estring	Low
	2	67	Est	0.625 mg	VagCrm	conjugated equine estrogen	Premarin	Standard
Good 1999	1	79	Est	0.625 mg	Oral	conjugated equine estrogen	Premarin	Standard
	2	82	Est	1.25 mg	Oral	conjugated equine estrogen	Premarin	High
	3	80	Est	0.05 mg	Patch	estradiol	Alora	Standard
	4	80	Est	0.1 mg	Patch	estradiol	Alora	High
Mattsson 2000	1	342	EP seq	2 mg E + 10 mg P	Oral	estradiol + dydrogesterone		Standard
	2	317	EP seq	0.3 mg E + 10 mg P	NasSpr	estradiol + dydrogesterone	Aerodiol	Standard
Saure 2000	1	186	EP seq	1.5 mg E + 0.15 P	Oral	estradiol (E2) + desogestrel	Liseta	Standard
	2	190	EP seq	2 mg E + 10 mg P	Oral	estradiol valerate + medroxyprogesterone acetate	Klimalet	High
Graser 2000	1	199	EP comb	2 mg E + 2 mg P	Oral	estradiol valerate + dienogest	Climodien	High

376.Study	377.Arm	378.N	379.RxCat	380.Dose	381.Route	382.Generic	383.Trade	384.Est Dose
	2	186	EP comb	2 mg E + 3 mg P	Oral	estradiol valerate + dienogest		High
	3	196	EP comb	2 mg E + 1 mg Estriol + 1.0 mg P	Oral	estradiol + estriol + norethisterone acetate	Kliogest	Standard
Rioux 2000	1	80	Est	0.025 mg	VagTab	estradiol	Vagifem	Low
	2	79	Est	1.25 mg	VagCrm	conjugated equine estrogen	Premarin	Standard
Dugal 2000	1	48	Est	0.025 mg	VagTab	estradiol	Vagifem	Low
	2	48	Est	0.5 mg	VagPes	estriol	Ovesterin	Low
Parsey 2000	1	95	Est	0.025mg	Patch	estradiol	Climara	UltraLow
	2	98	Est	0.3mg	Oral	conjugated equine estrogen	Premarin	UltraLow
Meuwissen 2001	1	314	EP seq	2mg E + 0.5mg P	Oral	estradiol valerate + norgestrel	Cyclocur	High
	2	320	EP seq	2mg E + 0.5mg P	Oral	estradiol + trimegestone		Standard
Lopes 2001	1	185	EP seq	0.05 mg E + 10 or 20 mg P	Patch	estradiol + dydrogesterone	Estraderm + dydrogesterone	Standard
	2	176	EP seq	0.3 mg E + 10 or 20 mg P	NasSpr	estradiol + dydrogesterone	Aerodiol + dydrogesterone	Standard
Ozsoy 2002	1	100	EP seq	2 mg E + 5 mg P	Oral	estradiol + medroxyprogesterone acetate		Standard
	2	101	EP seq	0.300 mg E + 5 mg P	NasSpr	estradiol + medroxyprogesterone acetate	Aerodiol + medroxyprogesterone acetate	Standard
Loh 2002	1	48	EP comb	1mg E + 0.5mg P	Oral	estradiol + norethisterone acetate		Low
	2	48	EP comb	2mg E + 1mg P	Oral	estradiol + norethisterone acetate		Standard
Buckler (d) 2003	1	75	EP seq	1 mg E + 1 mg P	Oral	estradiol + norethisterone	Elleste Solo + Micronor-HRT	Low
	2	84	EP seq	0.05 mg E + 1 mg P	VayRin	estradiol acetate + norethisterone	Menoring + Micronor-HRT	High
Al-Azzawi (d) 2003	1	75	EP seq	1mg + 1mg	Oral	estradiol + norethisterone	Elleste Solo + MicronorHRT	Low
	2	84	EP seq	0.050mg + 1mg	VayRin	estradiol acetate + norethisterone	Menoring + MicronorHRT	High
Lobo 2003	1	111	EP comb	0.625 mg	Oral	esterified estrogens	Estratab	Standard
	2	107	ET comb	0.625 mg E + 1.25 mg T	Oral	esterified estrogens + methyltestosterone	Estratest-HS	Standard
Pornel 2005	1	387	EP seq	1 mg E + 0.25 P	Oral	estradiol + trimegestone	Totelle	Low
	2	377	EP seq	1 mg E + 1 mg P	Oral	estradiol valerate + norethisterone	Climagest	Standard
Gambacciani 2005	1	432	EP comb	1 mg E + 0.125 mg P	Oral	estradiol + trimegestone		Low
	2	242	EP comb	1 mg E + 0.5 mg P	Oral	estradiol + norethisterone		Low
	3	176	EP comb	2 mg E + 1 mg P	Oral	estradiol + norethisterone		Standard
Utian 2005	1	79	EP comb	0.9 mg	Oral	estradiol acetate + progestin	Femtrace	Standard
	2	85	EP comb	0.625 mg	Oral	conjugated equine estrogens + progestin	Premarin	Standard
	3	84	EP comb	1 mg	Oral	estradiol + progestin	Estrace	Low
Davis 2005	1	60	Est	0.05 mg	Patch	estradiol	Estraderm	Standard
	2	60	Est	0.30 mg	NasSpr	estradiol	Aerodiol	Standard
Raynaud 2005	1	136	EP seq	0.05 mg + 1.2mg P	Patch	estradiol + norethisterone acetate	Oesclim + Milligynon	Standard
	2	134	EP seq	0.04 mg + 1.2mg P	Patch	estradiol + norethisterone acetate	Estrapatch + Milligynon	Low
	3	135	EP seq	0.06 mg E + 1.2m P	Patch	estradiol + norethisterone acetate	Estrapatch + Milligynon	High

376.Study	377.Arm	378.N	379.RxCat	380.Dose	381.Route	382.Generic	383.Trade	384.EstDose
Braunstein 2005	1	119	Est		Patch			
	2	106	ET comb	? mg E + 0.15 mg T	Patch	estrogen + testosterone		
	3	110	ET comb	? mg E + 0.3 mg T	Patch	estrogen + testosterone		
	4	111	ET comb	? mg E + 0.45 mg T	Patch	estrogen + testosterone		
Simon 2005	1	279	Est		Patch			
	2	283	Test	0.3 mg	Patch	testosterone		
Weisberg 2005	1	126	Est	0.008mg	VayRin	estradiol	ESTring	Low
	2	59	Est	0.025mg	VagTab	estradiol	Vagifem	Low
Buster 2005	1	266	Est		Patch			
	2	266	Test	0.3 mg	Patch	testosterone		
Akhila 2006	1	35	EP comb	0.625 mg E + 2.5 mg P	Oral	conjugated equine estrogen + depomedroxyprogesterone acetate	Premarin + MPA	Standard
	2	25	EP comb	1.5 mg E + 2.5 mg P	SknGel	estradiol + depomedroxyprogesterone acetate	Estrogel + MPA	Standard
	3	28	EP comb	0.05 mg E + 2.5 mg P	Patch	estradiol + depomedroxyprogesterone acetate	Estraderm + MPA	Standard
Serrano 2006	1	55	EP seq	0.625 mg E + 10 mg P	Oral	conjugated estrogens + medroxyprogesterone acetate	Premarin + medroxyprogesterone acetate	Standard
	2	59	EP seq	0.05 mg + 10 mg P	Patch	estradiol + medroxyprogesterone acetate	Climara + medroxyprogesterone acetate	Standard
Cieraad 2006	1	98	EP seq	1 mg E + 10 mg P	Oral	estradiol + dydrogesterone		Low
	2	91	EP seq	0.625 mg E + 0.15 mg P	Oral	conjugated equine estrogens + norgestrel		Standard
Davis 2006	1	39	Est		Patch			
	2	37	ET comb	?mg E + 0.3 mg T	Patch			
Long 2006	1	37	Est	0.625mg	Oral	conjugated equine estrogen		Standard
	2	36	Est	0.625mg/1g cream	VagCrm	conjugated equine estrogen	Premarin	Standard
Shifren 2006	1	273	EP comb	?mg E	Patch			
	2	276	ET comb	?mg E + 0.3 mg T	Patch	testosterone		
Limpaphayom (m) 2006	1	342	EP comb	0.3 mg E + 1.5 mg P	Oral	conjugated estrogens + medroxyprogesterone acetate		UltraLow
	2	342	EP comb	0.45 mg E + 1.5 mg P	Oral	conjugated estrogens + medroxyprogesterone acetate		Low
	3	344	EP comb	0.625 mg E + 2.5 mg P	Oral	conjugated estrogens + medroxyprogesterone acetate		Standard
Odabasi 2007	1	32	EP comb	0.3mg E + 90mg P	NasSpr	estradiol + progesterone	Aerodiol + Crinone	Standard
	2	29	EP comb	0.050mg E + 90mg P	Patch	estradiol + progesterone	Climara + Crinone	Standard
Mattsson (d) 2007	1	152	EP comb	1 mg E + 2.5 mg P	Oral	estradiol valerate + medroxyprogesterone acetate		Standard
	2	153	EP comb	1 mg E + 5 mg P	Oral	estradiol valerate + medroxyprogesterone acetate		Standard
	3	154	EP comb	2 mg E + 5 mg P	Oral	estradiol valerate + medroxyprogesterone acetate		High
Pitkin (d) 2007	1	152	EP comb	1 mg E + 2.5 mg P	Oral	estradiol valerate (E2V) + medroxyprogesterone acetate (MPA)		Standard
	2	153	EP comb	1 mg E + 5 mg P	Oral	estradiol valerate (E2V) + medroxyprogesterone acetate (MPA)		Standard
	3	154	EP comb	2 mg E + 5 mg P	Oral	estradiol valerate (E2V) + medroxyprogesterone acetate (MPA)		High
Penteado 2008	1	27	EP comb	0.625 mg E + 2.5 mg P	Oral	conjugated equine estrogens + medroxyprogesterone acetate		Standard
	2	29	ET comb	0.625 mg E + 2.5 mg P	Oral	conjugated equine estrogens + medroxyprogesterone acetate +		Standard

376.Study	377.Arm	378.N	379.RxCat	380.Dose	381.Route	382.Generic	383.Trade	384.Est Dose
				+ 2.0 mg T		methyltestosterone		
Panay 2010	1	142	Est		Patch			
	2	130	ET comb	0.30 mg	Patch			

(d): duplicate patient population with other included article; EP comb: estrogen plus progestin combined; EP seq: estrogen plus progestin sequential; Est: estrogen alone; ET comb: estrogen plus testosterone combine; (m): trial contains data from multiple publications; NasSpr: nasal spray; RxCat: treatment category; SknGel: skin gel; VagCrm: vaginal cream; VagOvu: vaginal ovule; VagPes: vaginal pessary; VagRin: vaginal ring; VagTab: vaginal tablet

Table E-52. Therapies used in trials comparing hormone with nonprescription nonhormone

385.Study	386.Arm	387.N	388.RxCat	389.Dose	390.Route	391.Generic	392.Trade	393.Est Dose
Nappi 2005	1	32	B Coh	40 mg	Oral		Remifemin	
	2	32	EP seq	0.00357mg E + 10 mg P	Patch	estradiol + dihydrogesterone	Estraderm + Dufaston	UltraLow
Nathorst-Boos 2006	1	53		EP comb	SknGel			
	2	53	See Note	10 mg	SknGel	testosterone	Testogel	Unknown
Kaari 2006	1	36	Est	0.625 mg	Oral	conjugated equine estrogens		Standard
	2	33	Isofl	120	Oral	glycoside + aglycone		
Chandeying 2007	1	30	EP comb	0.625mg E + 2.5mg P	Oral	conjugated equine estrogen + medroxyprogesterone acetate		Standard
	2	30	See Note	50mg	Oral			

B coh: black cohosh; EP comb: estrogen plus progestin combined; EP seq: estrogen plus progestin sequential; Est: estrogen alone;Isofl: isoflavone

Table E-53. Therapies used in trials comparing nonprescription nonhormone with nonprescription nonhormone

394.Study	395.Arm	396.N	397.RxCat	398.Dose	399.Route	400.Generic	401.Trade	402.Est Dose
Liske 2002	1	74	B Coh	39 mg	Oral		Remifemin	
	2	75	B Coh	127.3 mg	Oral		Remifemin	
Hidalgo 2006	1	478	See Note	60 mg I + 440 mg PO + 10 mg Vit E	Oral			
	2	447	See Note	120 mg I + 880 mg PO + 20 mg Vit E	Oral			
Zervoudis (a) 2008	1	31		See Note	Oral			
	2	31	Vit E	500 IU	Oral			
Agosta 2011	1	301	See Note	60 mg	Oral			
	2	335	See Note	60 mg	Oral			
Le Donne 2011	1	31	See Note	5 mg	VagPes			
	2	31	Isofl	0.097 mg	VagPes	genistein		
Virojchaiwong 2011	1	26	See Note	25 mg	Oral			
	2	26	See Note	50 mg	Oral	Pueraria mirifica		

(a): data came from a conference abstract; B coh: black cohosh; Isofl: isoflavone; IU: international unit; VagPes: vaginal pessary; VitE: vitamin E

Table E-54. Therapies used in trials comparing nonprescription nonhormone with antidepressant

403.Study	404.Arm	405.N	406.RxCat	407.Dose	408.Route	409.Generic	410.Trade	411.Est Dose
Oktem 2007	1	40	B Coh	40 mg	Oral		Remixin	
	2	40	Antide	20 mg	Oral	fluoxetine	Prozac HCl	

Antide: antidepressant; B coh: black cohosh

Table E-55. Study quality for trials comparing hormone with placebo

412.Study	413.Q1	414.Q2	415.Q3	416.Q4	417.Q5	418.Q6	419.Q7	420.Q8	421.Q9	422.Overall
Martin 1971	Unc	Yes	Unc	No	Yes	Yes	Yes	Yes	Unc	Poor
Campbell 1977	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Baumgardner 1978	Unc	Yes	Unc	Unc	Yes	Unc	Yes	Yes	Yes	Poor
Coope 1981	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Jensen 1983	Unc	Unc	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Foidart 1991	Unc	Unc	Unc	Unc	Unc	Yes	Yes	Yes	Unc	Poor
Eriksen 1992	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Wiklund 1993	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Derman 1995	Yes	Yes	Unc	No	Yes	Yes	Yes	Yes	Yes	Poor
Saletu 1995	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	No	Poor
Good 1996	Unc	Yes	Unc	No	Yes	Yes	Yes	Yes	Yes	Poor
Speroff (Study 1) 1996	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Poor
Chung 1996	Unc	Yes	Unc	No	Yes	Yes	Yes	Yes	Unc	Poor
Speroff (Study 2) 1996	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Unc	Poor
Speroff (Study 3) 1996	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No	Poor
Bacchi-Modena 1997	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Baerug 1998	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Bech 1998	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Unc	Poor
de Vrijer 1999	Unc	Unc	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Leonetti 1999	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Poor
Studd 1999	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Polo-Kantola 1999	Yes	Yes	Yes	Yes	No	Unc	Yes	Yes	No	Poor
Casper 1999	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	No	Poor
Cohen 1999	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Rebar 2000	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Unc	Poor
Speroff (Study 1) 2000	Unc	Yes	Unc	Unc	No	Unc	Yes	Yes	No	Poor
Rovati 2000	Yes	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Yes	Fair
Notelovitz 2000	Unc	Yes	Unc	Unc	Unc	Yes	Yes	Yes	Yes	Poor
Strickler 2000	Yes	Yes	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Poor
Notelovitz 2000	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Unc	Poor
DeAloysio 2000	Yes	Yes	Unc	No	Yes	Yes	Yes	Yes	Unc	Poor
von Holst 2000	Unc	Unc	Unc	Yes	No	Yes	Yes	Yes	Yes	Fair

412.Study	413.Q1	414.Q2	415.Q3	416.Q4	417.Q5	418.Q6	419.Q7	420.Q8	421.Q9	422.Overall
Notelovitz 2000	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Alexandersen 2000	Unc	No	Yes	No	Yes	Unc	Yes	Yes	Yes	Poor
Speroff (Study 2) 2000	Unc	Yes	Unc	Unc	No	Unc	Yes	Yes	Yes	Poor
Rigano 2001	No	Unc	Unc	Unc	Unc	Unc	Unc	Yes	Unc	Poor
Utian (CEE alone arms) 2001	Yes	Yes	Unc	No	Yes	Yes	Yes	Yes	No	Poor
Simon 2001	Unc	Yes	No	Yes	No	Yes	Yes	Yes	Yes	Fair
Soares 2001	Yes	Yes	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Poor
Utian (CEE/MPA arms) 2001	Yes	Yes	Unc	No	Yes	Yes	Yes	Yes	No	Poor
Rozenbaum 2002	Yes	Unc	Unc	Yes	No	Unc	Yes	Yes	Yes	Poor
Shulman (Study 1) 2002	Yes	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Fair
von Holst 2002	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Archer 2003	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Vestergaard 2003	No	No	No	Yes	No	Yes	Yes	Yes	Yes	Poor
Speroff 2003	Yes	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Yes	Fair
Jirapinyo 2003	Unc	Yes	Unc	No	Yes	Yes	Yes	Yes	No	Poor
Haines 2003	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Fair
Hays 2003	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Good
Gambacciani 2003	Unc	Unc	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Gelfand 2003	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Fair
Wren 2003	Unc	Unc	Unc	Yes	No	Unc	Yes	Yes	No	Poor
Simunic 2003	Yes	Yes	Unc	Unc	Unc	Yes	Yes	Yes	Unc	Poor
Parsons 2003	Yes	No	Yes	Yes	No	No	Yes	Yes	Unc	Poor
Berlex (SIP) 2003	Unc	Unc	Unc	Unc	Yes	Yes	Yes	Yes	Unc	Poor
Rudolph 2004	Yes	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Yes	Poor
Yang 2004	Unc	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Unc	Poor
Schurmann 2004	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Utian 2004	Yes	Yes	Unc	No	Yes	Yes	Yes	Yes	Yes	Poor
Dessole 2004	No	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Duramed (SIP) 2004	Unc	Unc	Unc	Unc	Unc	Yes	Yes	Yes	Yes	Poor
Brunner 2005	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Onalan 2005	Yes	Yes	Unc	Yes	Yes	Unc	Yes	Yes	Unc	Poor
Bayer Healthcare (SIP) 2005	Unc	Unc	Unc	Unc	Unc	Yes	Yes	Yes	Unc	Poor
Novartis (SIP) 2005	Unc	Unc	Unc	Unc	Unc	Yes	Yes	Yes	Unc	Poor
Yaffe (d) 2006	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Good
Speroff (Study 1) 2006	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Good
Simon 2006	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Diem (d) 2006	Unc	Yes	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Poor
Nielsen 2006	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Yes	Poor
Osmanagaoglu 2006	Unc	No	Unc	Unc	No	No	Yes	Yes	Unc	Poor
Speroff (Study 2) 2006	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Fair
Bachmann (d) 2007	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good

412.Study	413.Q1	414.Q2	415.Q3	416.Q4	417.Q5	418.Q6	419.Q7	420.Q8	421.Q9	422.Overall
Maki 2007	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Endrikat 2007	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Lee 2007	No	Yes	Unc	Yes	Yes	Yes	Yes	Yes	No	Poor
Panay 2007	No	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Simon 2007	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good
Pefanco 2007	Yes	Yes	No	Yes	Yes	Yes	Yes	Unc	Yes	Poor
Bayer Healthcare (SIP) 2007	Unc	Unc	Unc	Unc	Yes	Yes	Yes	Yes	Unc	Poor
Buster (Study 1) 2008	Yes	No	Unc	No	Yes	Yes	Yes	Yes	Yes	Poor
Veerus 2008	Unc	No	No	Unc	Unc	No	Yes	Yes	Yes	Poor
Davis 2008	Yes	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Yes	Poor
Bachmann 2008	No	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Good
Huang (d) 2008	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good
Welton 2008	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good
Buster (Study 2) 2008	Yes	No	Unc	No	Yes	Yes	Yes	Yes	Yes	Poor
Buster (Study 3) 2008	Yes	No	Unc	No	Yes	Yes	Yes	Yes	Yes	Poor
Simon (SIP) 2008	No	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Yes	Poor
Benster 2009	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Fair
Haines 2009	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Bachmann (d) 2009	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Hedrick 2009	Unc	Yes	Unc	Yes	No	No	Yes	Yes	Yes	Poor
Baksu 2009	Yes	No	No	Unc	No	No	Yes	Yes	Unc	Poor
Bachmann (Study 1) 2009	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Freedman 2009	No	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Gast 2009	Unc	Yes	Unc	No	Yes	Yes	Yes	Yes	Yes	Poor
Bachmann (Study 2) 2009	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Hassa 2010	Unc	No	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Stevenson 2010	Yes	Yes	Unc	Unc	Unc	Yes	Yes	Yes	Yes	Poor
Raghunandan 2010	Unc	Unc	Unc	Unc	Unc	Unc	Yes	Yes	Unc	Poor
Hedrick 2010	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Good
Liu 2011	Unc	Yes	Unc	Unc	Unc	Yes	Yes	Yes	Unc	Poor
Lin 2011	Unc	Yes	Unc	No	Yes	Yes	Yes	Yes	Yes	Poor
Demetrio 2011	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Liu 2012	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Archer 2012	Unc	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Unc	Poor

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; MPA: medroxyprogesterone acetate; (SIP); data came from a package insert; Unc: uncertain

Q1: Was initial assembly of comparable groups: adequate randomization including equal distribution of potential confounders?

Q2: Were the researchers and subjects blinded to the study group assignment?

Q3: Was there adequate concealment of the study group assignments?

Q4: Was there maintenance of comparable groups (includes attrition, crossovers, adherence and contamination)?

Q5: Was there important differential loss to follow-up or overall high loss to follow-up?

Q6: Were measurements equal, reliable and valid (includes masking of outcome assessment)?

Q7: Were definitions of interventions clear?

Q8: Were all important outcomes considered and defined?

Q9: At analysis, was there adjustment for potential confounders (cohort studies) and intention-to-treat analysis (RCTs)?

Q10: Overall Quality Asessment

Table E-56. Study quality for trials comparing antidepressant with placebo

423.Study	424.Q1	425.Q2	426.Q3	427.Q4	428.Q5	429.Q6	430.Q7	431.Q8	432.Q9	433.Overall
Suvanto-Luukkonen 2005	Unc	Yes	Yes	Unc	Yes	Yes	Yes	Yes	Unc	Poor
Evans 2005	Yes	Unc	Unc	Unc	Yes	Unc	Yes	Yes	Unc	Poor
Kerwin 2007	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Kalay 2007	Yes	No	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Speroff 2008	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good
Soares 2008	Yes	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Archer 2009	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Fair
Archer 2009	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good
Kornstein 2010	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	No	Poor
Soares 2010	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Good
Freeman 2011	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good
Pfizer (c) 2011	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	No	Poor
Bouchard 2012	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; MPA: medroxyprogesterone acetate; (SIP); data came from a package insert; Unc: uncertain

Q1: Was initial assembly of comparable groups: adequate randomization including equal distribution of potential confounders?

Q2: Were the researchers and subjects blinded to the study group assignment?

Q3: Was there adequate concealment of the study group assignments?

Q4: Was there maintenance of comparable groups (includes attrition, crossovers, adherence and contamination)?

Q5: Was there important differential loss to follow-up or overall high loss to follow-up?

Q6: Were measurements equal, reliable and valid (includes masking of outcome assessment)?

Q7: Were definitions of interventions clear?

Q8: Were all important outcomes considered and defined?

Q9: At analysis, was there adjustment for potential confounders (cohort studies) and intention-to-treat analysis (RCTs)?

Q10: Overall Quality Asessment

Table E-57. Study quality for trials comparing other prescriptions with placebo

434.Study	435.Q1	436.Q2	437.Q3	438.Q4	439.Q5	440.Q6	441.Q7	442.Q8	443.Q9	444.Overall
Clayden 1974	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Guttuso 2003	Unc	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Poor
Butt 2008	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Joffe 2010	Yes	Yes	Unc	Unc	Unc	Yes	Yes	Yes	Yes	Poor
Depomed (c) 2012	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Yes	Poor
Depomed (c) 2012	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Yes	Poor

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; MPA: medroxyprogesterone acetate; (SIP); data came from a package insert; Unc: uncertain

Q1: Was initial assembly of comparable groups: adequate randomization including equal distribution of potential confounders?

Q2: Were the researchers and subjects blinded to the study group assignment?

Q3: Was there adequate concealment of the study group assignments?

Q4: Was there maintenance of comparable groups (includes attrition, crossovers, adherence and contamination)?

Q5: Was there important differential loss to follow-up or overall high loss to follow-up?

Q6: Were measurements equal, reliable and valid (includes masking of outcome assessment)?

Q7: Were definitions of interventions clear?

Q8: Were all important outcomes considered and defined?

Q9: At analysis, was there adjustment for potential confounders (cohort studies) and intention-to-treat analysis (RCTs)?

Q10: Overall Quality Asessment

Table E-58. Study quality for trials comparing nonprescription nonhormone with placebo

445.Study	446.Q1	447.Q2	448.Q3	449.Q4	450.Q5	451.Q6	452.Q7	453.Q8	454.Q9	455.Overall
Chenoy 1994	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Yes	Poor
Murkies 1995	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Hirata 1997	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Albertazzi 1998	Yes	Yes	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Fair
Baber 1999	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Wiklund 1999	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Barnhart 1999	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Upmalis 2000	Unc	Yes	Unc	No	Yes	Unc	Yes	Yes	No	Poor
Kotsopoulos 2000	Unc	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Unc	Poor

445.Study	446.Q1	447.Q2	448.Q3	449.Q4	450.Q5	451.Q6	452.Q7	453.Q8	454.Q9	455.Overall
Davis 2001	Yes	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Unc	Poor
Faure 2002	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Yes	Poor
Han 2002	Yes	Yes	Yes	Unc	No	Yes	Yes	Yes	Yes	Good
Tice 2003	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good
Penotti 2003	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Unc	Poor
Burke 2003	No	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Sammartino 2003	Yes	No	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Nahas 2004	Unc	Yes	Unc	Unc	Unc	Yes	Yes	Yes	Unc	Poor
Atkinson 2004	Yes	Yes	Unc	Unc	No	Yes	Yes	Yes	No	Poor
Hartley 2004	Unc	Unc	Unc	Unc	No	Unc	Yes	Yes	No	Poor
Winther 2005	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Good
Frei-Kleiner 2005	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Verhoeven 2005	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Good
Kok 2005	Yes	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Yes	Poor
Hidalgo 2005	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Unc	Poor
Dodin 2005	Yes	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Fair
Osmers 2005	Unc	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Poor
Mucci 2006	Unc	Unc	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Heger (m) 2006	Yes	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Yes	Poor
Lewis 2006	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Good
Uebelhack 2006	Yes	Unc	Unc	Yes	No	Yes	Yes	Yes	Yes	Good
Sammartino 2006	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Fair
Casini 2006	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Nahas 2007	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Poor
Yang 2007	No	Yes	Unc	Yes	Yes	Yes	Yes	Yes	No	Poor
Chung 2007	No	Yes	Unc	Unc	No	Yes	Yes	Yes	No	Poor
Cheng 2007	Yes	Yes	Unc	Yes	Unc	Yes	Yes	Yes	No	Poor
Ho 2007	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Good
Cancellieri 2007	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Haines 2008	Yes	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Unc	Poor
Jou 2008	Yes	Yes	Unc	Unc	Unc	Yes	Yes	Yes	Unc	Poor
Khaodhiar 2008	Yes	Yes	Unc	No	No	Yes	Yes	Yes	No	Poor
Ferrari 2009	No	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Poor
van der Sluijs 2009	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good
D'Anna (m) 2009	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	No	Poor
van Die 2009	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good
de Sousa-Munoz 2009	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Labrie 2009	Unc	Unc	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Panjari 2009	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good
Basaria 2009	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good
Radhakrishnan 2009	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Unc	Poor

445.Study	446.Q1	447.Q2	448.Q3	449.Q4	450.Q5	451.Q6	452.Q7	453.Q8	454.Q9	455.Overall
Lee 2010	Unc	Yes	Yes	Unc	No	Yes	Yes	Yes	No	Poor
Garcia 2010	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Lipovac 2010	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Shen 2010	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Jassi 2010	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Evans 2011	No	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Hsu 2011	No	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Andrikoula 2011	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Unc	Poor
Levis 2011	Unc	Yes	Unc	No	Yes	Yes	Yes	Yes	No	Poor
Plotnikoff 2011	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good
Chang 2011	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Fair
Auerbach 2012	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	No	Poor
Cianci 2012	Yes	No	Unc	Unc	Unc	No	Yes	Yes	Unc	Poor
Kim 2012	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Fair
Xia 2012	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good
Ye 2012	Yes	No	No	Yes	No	No	Yes	Yes	Yes	Poor
Aso 2012	Yes	Yes	Unc	Unc	Yes	Yes	Yes	Yes	No	Poor

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; MPA: medroxyprogesterone acetate; (SIP); data came from a package insert; Unc: uncertain

Q1: Was initial assembly of comparable groups: adequate randomization including equal distribution of potential confounders?

Q2: Were the researchers and subjects blinded to the study group assignment?

Q3: Was there adequate concealment of the study group assignments?

Q4: Was there maintenance of comparable groups (includes attrition, crossovers, adherence and contamination)?

Q5: Was there important differential loss to follow-up or overall high loss to follow-up?

Q6: Were measurements equal, reliable and valid (includes masking of outcome assessment)?

Q7: Were definitions of interventions clear?

Q8: Were all important outcomes considered and defined?

Q9: At analysis, was there adjustment for potential confounders (cohort studies) and intention-to-treat analysis (RCTs)?

Q10: Overall Quality Asessment

Table E-59. Study quality for trials comparing hormone and nonprescription nonhormone with placebo

456.Study	457.Q1	458.Q2	459.Q3	460.Q4	461.Q5	462.Q6	463.Q7	464.Q8	465.Q9	466.Overall
Crisafulli 2004	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Newton 2006	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Good

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; MPA: medroxyprogesterone acetate; (SIP); data came from a package insert; Unc: uncertain

Q1: Was initial assembly of comparable groups: adequate randomization including equal distribution of potential confounders?

Q2: Were the researchers and subjects blinded to the study group assignment?

Q3: Was there adequate concealment of the study group assignments?

Q4: Was there maintenance of comparable groups (includes attrition, crossovers, adherence and contamination)?

Q5: Was there important differential loss to follow-up or overall high loss to follow-up?

Q6: Were measurements equal, reliable and valid (includes masking of outcome assessment)?

Q7: Were definitions of interventions clear?

Q8: Were all important outcomes considered and defined?

Q9: At analysis, was there adjustment for potential confounders (cohort studies) and intention-to-treat analysis (RCTs)?

Q10: Overall Quality Asessment

Table E-60. Study quality for trials comparing hormone with hormone

467.Study	468.Q1	469.Q2	470.Q3	471.Q4	472.Q5	473.Q6	474.Q7	475.Q8	476.Q9	477.Overall
Polvani 1991	Unc	No	No	No	Yes	Yes	Yes	Yes	No	Poor
Henriksson 1994	Unc	No	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Studd 1995	Unc	Unc	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Ayton 1996	Yes	No	No	Unc	No	Yes	Yes	Yes	Yes	Poor
Hilditch 1996	No	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Egarter 1996	No	No	No	Unc	No	No	Yes	Yes	Unc	Poor
Hirvonen 1997	Yes	No	No	Yes	No	No	Yes	Yes	Unc	Poor
Hirvonen 1997	Yes	No	No	No	Yes	Yes	Yes	No	Unc	Poor
Rozenberg 1997	Yes	No	No	Unc	Yes	Yes	Yes	Yes	Yes	Poor
Al-Azzawi 1997	Unc	No	No	Yes	No	No	Yes	Yes	Unc	Poor
Lubbert 1997	Yes	No	No	Yes	No	Yes	Yes	Yes	Yes	Poor
Barentsen 1997	Unc	No	No	Unc	No	Yes	Yes	Yes	Yes	Poor
Bachmann 1997	Yes	No	No	No	No	Unc	Yes	Yes	No	Poor
Good 1999	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Mattsson 2000	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Good
Saure 2000	Yes	Yes	Yes	Yes	No	Yes	Yes	Unc	Yes	Fair
Graser 2000	Unc	Yes	Unc	Unc	Unc	Yes	Yes	Yes	Yes	Poor
Rioux 2000	Yes	No	No	No	Yes	No	Yes	Yes	Unc	Poor
Dugal 2000	Unc	No	No	Unc	No	Unc	Yes	Yes	Yes	Poor
Parsey 2000	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Meuwissen 2001	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Yes	Poor

467.Study	468.Q1	469.Q2	470.Q3	471.Q4	472.Q5	473.Q6	474.Q7	475.Q8	476.Q9	477.Overall
Lopes 2001	Unc	No	No	Yes	No	Yes	Yes	Yes	Unc	Poor
Ozsoy 2002	No	No	No	Yes	No	Yes	Yes	Yes	Unc	Poor
Loh 2002	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Buckler (d) 2003	Yes	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Yes	Fair
Al-Azzawi (d) 2003	Yes	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Yes	Poor
Lobo 2003	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Pornel 2005	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	No	Poor
Gambacciani 2005	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Utian 2005	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Good
Davis 2005	Unc	No	No	Yes	No	Yes	Yes	Yes	Unc	Poor
Raynaud 2005	Unc	No	No	Unc	Yes	Unc	Yes	Yes	Yes	Poor
Braunstein 2005	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Yes	Poor
Simon 2005	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Weisberg 2005	No	No	No	Yes	Yes	Yes	Yes	Yes	Unc	Poor
Buster 2005	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor
Akhila 2006	Unc	Unc	Unc	Unc	Unc	Unc	Yes	Yes	Unc	Poor
Serrano 2006	Yes	No	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Cieraad 2006	Unc	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Yes	Poor
Davis 2006	Yes	Yes	Unc	Yes	Yes	Yes	Yes	Yes	Yes	Fair
Long 2006	Unc	No	Unc	Unc	Yes	Yes	Yes	Yes	No	Poor
Shifren 2006	Unc	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Yes	Poor
Limpaphayom (m) 2006	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Odabasi 2007	Unc	No	No	Unc	Yes	Yes	Yes	Yes	Unc	Poor
Mattsson (d) 2007	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Yes	Poor
Pitkin (d) 2007	Unc	Yes	Unc	Yes	No	Unc	Yes	Yes	Yes	Poor
Penteado 2008	Unc	Yes	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Panay 2010	Yes	Yes	Unc	Unc	Yes	Yes	Yes	Yes	Yes	Poor

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; MPA: medroxyprogesterone acetate; (SIP); data came from a package insert; Unc: uncertain

Q1: Was initial assembly of comparable groups: adequate randomization including equal distribution of potential confounders?

Q2: Were the researchers and subjects blinded to the study group assignment?

Q3: Was there adequate concealment of the study group assignments?

Q4: Was there maintenance of comparable groups (includes attrition, crossovers, adherence and contamination)?

Q5: Was there important differential loss to follow-up or overall high loss to follow-up?

Q6: Were measurements equal, reliable and valid (includes masking of outcome assessment)?

Q7: Were definitions of interventions clear?

Q8: Were all important outcomes considered and defined?

Q9: At analysis, was there adjustment for potential confounders (cohort studies) and intention-to-treat analysis (RCTs)?

Q10: Overall Quality Asessment

Table E-61. Study quality for trials comparing hormone with nonprescription nonhormone

478.Study	479.Q1	480.Q2	481.Q3	482.Q4	483.Q5	484.Q6	485.Q7	486.Q8	487.Q9	488.Overall
Nappi 2005	Yes	Unc	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Nathorst-Boos 2006	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Unc	Poor
Kaari 2006	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Unc	Poor
Chandeying 2007	Unc	No	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; MPA: medroxyprogesterone acetate; (SIP); data came from a package insert; Unc: uncertain

Q1: Was initial assembly of comparable groups: adequate randomization including equal distribution of potential confounders?

Q2: Were the researchers and subjects blinded to the study group assignment?

Q3: Was there adequate concealment of the study group assignments?

Q4: Was there maintenance of comparable groups (includes attrition, crossovers, adherence and contamination)?

Q5: Was there important differential loss to follow-up or overall high loss to follow-up?

Q6: Were measurements equal, reliable and valid (includes masking of outcome assessment)?

Q7: Were definitions of interventions clear?

Q8: Were all important outcomes considered and defined?

Q9: At analysis, was there adjustment for potential confounders (cohort studies) and intention-to-treat analysis (RCTs)?

Q10: Overall Quality Asessment

Table E-62. Study quality for trials comparing nonprescription nonhormone with nonprescription nonhormone

489.Study	490.Q1	491.Q2	492.Q3	493.Q4	494.Q5	495.Q6	496.Q7	497.Q8	498.Q9	499.Overall
Liske 2002	Yes	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Fair
Hidalgo 2006	Unc	No	No	Yes	No	Unc	Yes	Yes	Unc	Poor
Zervoudis (a) 2008	Unc	Unc	Unc	Unc	No	Unc	No	Yes	Unc	Poor
Agosta 2011	Unc	Unc	Unc	Yes	No	No	Yes	Yes	Unc	Poor
Le Donne 2011	Unc	Yes	Unc	Unc	No	Yes	Yes	Yes	Unc	Poor
Virojchaiwong 2011	No	Yes	Unc	Yes	No	Yes	Yes	Yes	Yes	Poor

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; MPA: medroxyprogesterone acetate; (SIP); data came from a package insert; Unc: uncertain

Q1: Was initial assembly of comparable groups: adequate randomization including equal distribution of potential confounders?

Q2: Were the researchers and subjects blinded to the study group assignment?

Q3: Was there adequate concealment of the study group assignments?

Q4: Was there maintenance of comparable groups (includes attrition, crossovers, adherence and contamination)?

Q5: Was there important differential loss to follow-up or overall high loss to follow-up?

Q6: Were measurements equal, reliable and valid (includes masking of outcome assessment)?

Q7: Were definitions of interventions clear?

Q8: Were all important outcomes considered and defined?

Q9: At analysis, was there adjustment for potential confounders (cohort studies) and intention-to-treat analysis (RCTs)?

Q10: Overall Quality Asessment

Table E-63. Study quality for trials comparing nonprescription nonhormone with antidepressant

500.Study	501.Q1	502.Q2	503.Q3	504.Q4	505.Q5	506.Q6	507.Q7	508.Q8	509.Q9	510.Overall
Oktem 2007	No	Unc	Unc	Yes	Yes	No	Yes	Yes	No	Poor

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; (m): trial contains data from multiple publications; MPA: medroxyprogesterone acetate; (SIP); data came from a package insert; Unc: uncertain

Q1: Was initial assembly of comparable groups: adequate randomization including equal distribution of potential confounders?

Q2: Were the researchers and subjects blinded to the study group assignment?

Q3: Was there adequate concealment of the study group assignments?

Q4: Was there maintenance of comparable groups (includes attrition, crossovers, adherence and contamination)?

Q5: Was there important differential loss to follow-up or overall high loss to follow-up?

Q6: Were measurements equal, reliable and valid (includes masking of outcome assessment)?

Q7: Were definitions of interventions clear?

Q8: Were all important outcomes considered and defined?

Q9: At analysis, was there adjustment for potential confounders (cohort studies) and intention-to-treat analysis (RCTs)?

Q10: Overall Quality Asessment

Appendix F. Vasomotor Symptom Plots

Table 1. Graphical depiction of point estimates of comparative standardized effect sizes. The range displayed is from -1 (left border of each cell) to 0 (cell center).

E-High							
-0.11	E-Standard						
-0.15	-0.04	E-Low/Ultralow					
-0.38	-0.27	-0.23	SSRI/SNRI				
-0.42	-0.31	-0.27	-0.04	Isoflavone			
-0.46	-0.35	-0.32	-0.08	-0.04	Gabap/Preg		
-0.58	-0.47	-0.43	-0.2	-0.16	-0.12	BlackCohosh	
-0.84	-0.74	-0.7	-0.47	-0.43	-0.38	-0.26	Placebo

Table 2. Expression of standardized effect sizes and credible intervals as odds ratios.

E-High							
0.82 (0.59 to 1.16)	E-Standard						
0.77 (0.53 to 1.10)	0.93 (0.72 to 1.20)	E-Low/Ultralow					
0.50 (0.28 to 0.92)	0.61 (0.36 to 1.05)	0.66 (0.39 to 1.12)	SSRI/SNRI				
0.47 (0.30 to 0.74)	0.57 (0.40 to 0.82)	0.61 (0.43 to 0.87)	0.93 (0.53 to 1.65)	Isoflavone			
0.43 (0.19 to 1.00)	0.53 (0.24 to 1.17)	0.56 (0.25 to 1.25)	0.86 (0.35 to 2.14)	0.92 (0.41 to 2.09)	Gabap/Preg		
0.35 (0.15 to 0.79)	0.42 (0.20 to 0.92)	0.45 (0.21 to 0.98)	0.69 (0.28 to 1.70)	0.74 (0.33 to 1.67)	0.81 (0.27 to 2.36)	Black Cohosh	
0.22 (0.15 to 0.31)	0.26 (0.21 to 0.33)	0.28 (0.23 to 0.35)	0.43 (0.26 to 0.70)	0.46 (0.34 to 0.62)	0.50 (0.23 to 1.08)	0.62 (0.29 to 1.32)	Placebo

Table 3. Numbers needed to treat based on 25 percent of placebo patients experiencing a reduction in hot flash frequency of 50 percent {Sloan 2001}

E-High							
26.2	E-Standard						
18.8	72.8	E-Low/Ultralow					
6.7	9.7	11.5	SSRI/SNRI				
6	8.4	9.7	73.6	Isoflavone			
5.4	7.2	8.2	34	65.3	Gabap/Preg		
4.2	5.2	5.8	13.3	16.8	23.4	Black Cohosh	
2.8	3.2	3.4	5.3	5.9	6.7	10	Placebo

Table 4. Difference between network result and calculable pairwise effect estimates (pooled random effect estimates or single trial effects if only available). The small differences reflect network consistency.

E-High							
0.04	E-Standard						
0.01	0.06	E-Low/Ultralow					
			SSRI/SNRI				
	-0.47	0.44		Isoflavone			
					Gabap/Preg		
	0.53	-0.21				Black Cohosh	
-0.12	0.05	0	-0.07	-0.02	-0.05	0	Placebo

Table 5 . Network result excluding black cohosh.

E-High						
-0.11 (-0.30 to 0.08)	E-Standard					
-0.14 (-0.34 to 0.06)	-0.03 (-0.17 to 0.11)	E-Low/Ultralow				
-0.37 (-0.71 to -0.04)	-0.27 (-0.57 to 0.04)	-0.23 (-0.53 to 0.06)	SSRI/SNRI			
-0.41 (-0.67 to -0.16)	-0.31 (-0.51 to -0.10)	-0.27 (-0.47 to -0.07)	-0.04 (-0.36 to 0.28)	Isoflavone		
-0.46 (-0.93 to 0.01)	-0.35 (-0.79 to 0.10)	-0.31 (-0.76 to 0.13)	-0.08 (-0.59 to 0.42)	-0.04 (-0.50 to 0.41)	Gabap/Preg	
-0.84 (-1.04 to -0.65)	-0.73 (-0.86 to -0.61)	-0.70 (-0.82 to -0.58)	-0.47 (-0.74 to -0.19)	-0.43 (-0.59 to -0.26)	-0.38 (-0.81 to 0.04)	Placebo

Table 6. Network result excluding 16 trials not specifying vasomotor symptoms as a primary outcome or symptom presence as an inclusion criterion.

E-High							
-0.10 (-0.30 to 0.10)	E-Standard						
-0.19 (-0.40 to 0.03)	-0.09 (-0.24 to 0.07)	E-Low/Ultralow					
-0.53 (-0.87 to -0.19)	-0.43 (-0.74 to -0.12)	-0.34 (-0.64 to -0.05)	SSRI/SNRI				
-0.43 (-0.70 to -0.16)	-0.33 (-0.55 to -0.10)	-0.24 (-0.46 to -0.03)	0.10 (-0.22 to 0.43)	Isoflavone			
-0.51 (-0.99 to -0.02)	-0.41 (-0.87 to 0.05)	-0.32 (-0.77 to 0.13)	0.02 (-0.49 to 0.54)	-0.08 (-0.55 to 0.39)	Gabap/Preg		
-0.57 (-1.01 to -0.13)	-0.47 (-0.89 to -0.06)	-0.39 (-0.79 to 0.02)	-0.04 (-0.49 to 0.41)	-0.15 (-0.58 to 0.29)	-0.07 (-0.66 to 0.52)	Black Cohosh	
-0.89 (-1.10 to -0.68)	-0.79 (-0.93 to -0.65)	-0.70 (-0.83 to -0.58)	-0.36 (-0.63 to -0.09)	-0.46 (-0.64 to -0.29)	-0.38 (-0.82 to 0.06)	-0.32 (-0.71 to 0.08)	Placebo

Figure 1. Vasomotor symptoms forest plot of pairwise comparisons—estrogen (high dose) compared with placebo.

Study	E–High Total	E–High Mean	E–High SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Martin 1971	56	–2.30	3.90	56	0.25	2.40	–0.78	[–1.17; –0.40]	10.6%
Campbell 1977	68	–35.00	60.66	68	0.00	60.66	–0.57	[–0.92; –0.23]	11.1%
Baumgardner 1978	37	0.30	0.75	42	0.64	0.74	–0.45	[–0.90; 0.00]	9.9%
Good 1996	94	–83.00	38.63	91	–64.00	39.89	–0.48	[–0.77; –0.19]	11.6%
de Vrijer 1999	86	0.40	3.14	86	5.70	3.14	–1.68	[–2.03; –1.33]	11.0%
Studd 1999	62	0.91	1.90	60	3.00	3.00	–0.83	[–1.20; –0.46]	10.8%
Speroff 2003	225	11.92	114.83	108	42.20	100.67	–0.27	[–0.50; –0.04]	12.3%
Utian 2004	69	12.40	26.30	72	47.50	49.80	–0.87	[–1.22; –0.53]	11.1%
Speroff (Study 1) 2006	95	6.70	80.59	94	46.70	60.82	–0.56	[–0.85; –0.27]	11.7%
Random effects model	**792**			**677**			**–0.72**	**[–0.99; –0.44]**	**100%**

Heterogeneity: tau–squared=0.1429



Figure 2. Vasomotor symptoms forest plot of pairwise comparisons—estrogen (standard dose) compared with placebo.

Study	E–Standard Total	E–Standard Mean	E–Standard SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Martin 1971	53	−2.00	3.70	56	0.25	2.40	−0.72	[−1.11; −0.33]	2.7%
Baumgardner 1978	35	0.20	0.97	42	0.64	0.74	−0.51	[−0.97; −0.06]	2.4%
Wiklund 1993	112	3.00	1.60	111	5.80	2.20	−1.45	[−1.75; −1.16]	3.0%
Derman 1995	40	4.50	3.70	42	9.40	4.50	−1.18	[−1.65; −0.70]	2.4%
Good 1996	88	−78.00	39.89	91	−64.00	39.89	−0.35	[−0.64; −0.05]	3.0%
Chung 1996	43	−0.41	0.49	40	−0.10	0.30	−0.75	[−1.19; −0.30]	2.5%
Bacchi−Modena 1997	53	2.90	4.26	56	7.10	4.26	−0.98	[−1.38; −0.58]	2.6%
Bech 1998	100	0.45	1.35	51	3.20	3.60	−1.16	[−1.52; −0.80]	2.8%
de Vrijer 1999	82	0.70	3.14	86	5.70	3.14	−1.59	[−1.93; −1.24]	2.8%
Studd 1999	119	1.24	1.92	60	3.00	3.00	−0.75	[−1.07; −0.43]	2.9%
Polo−Kantola 1999	62	0.31	1.47	62	1.20	1.47	−0.60	[−0.96; −0.24]	2.8%
Speroff (Study 1) 2000	45	4.90	37.98	43	21.00	23.59	−0.50	[−0.93; −0.08]	2.5%
Rovati 2000	151	0.45	1.08	80	3.80	3.65	−1.44	[−1.74; −1.14]	2.9%
Strickler 2000	96	2.03	0.39	105	2.71	1.44	−0.63	[−0.91; −0.35]	3.0%
Notelovitz 2000	68	3.00	43.33	66	28.20	21.25	−0.73	[−1.08; −0.38]	2.8%
von Holst 2000	93	11.80	12.90	93	19.40	25.90	−0.37	[−0.66; −0.08]	3.0%
Notelovitz 2000	166	1.63	2.86	53	6.30	4.10	−1.45	[−1.79; −1.12]	2.8%
Speroff (Study 2) 2000	65	7.90	92.62	67	39.80	60.86	−0.41	[−0.75; −0.06]	2.8%
Utian (CEE alone arms) 2001	27	−7.68	2.07	28	−4.00	1.08	−2.21	[−2.89; −1.53]	1.8%
Simon 2001	72	16.50	25.70	48	37.80	38.70	−0.67	[−1.05; −0.30]	2.7%
Utian (CEE/MPA arms) 2001	34	−8.40	4.13	28	−3.90	1.06	−1.41	[−1.98; −0.85]	2.1%
Rozenbaum 2002	54	−9.40	3.80	57	−5.20	3.90	−1.08	[−1.48; −0.68]	2.6%
von Holst 2002	84	9.30	13.45	88	17.10	13.45	−0.58	[−0.88; −0.27]	2.9%
Vestergaard 2003	502	0.48	0.90	504	0.83	1.10	−0.35	[−0.47; −0.22]	3.4%
Berlex (SIP) 2003	92	1.10	3.20	88	5.60	4.90	−1.09	[−1.40; −0.77]	2.9%
Yang 2004	26	0.60	1.10	25	0.80	1.10	−0.18	[−0.73; 0.37]	2.1%
Utian 2004	72	12.20	18.70	72	47.50	49.80	−0.93	[−1.28; −0.59]	2.8%
Newton 2006	32	−3.15	4.14	84	0.00	4.14	−0.76	[−1.18; −0.34]	2.6%
Speroff (Study 1) 2006	100	17.40	60.82	94	46.70	60.82	−0.48	[−0.77; −0.19]	3.0%
Nielsen 2006	103	−30.50	29.60	118	−2.30	21.60	−1.10	[−1.38; −0.81]	3.0%
Endrikat 2007	162	−6.40	7.31	162	−3.20	7.31	−0.44	[−0.66; −0.22]	3.2%
Veerus 2008	395	−0.33	0.47	371	−0.18	0.39	−0.33	[−0.48; −0.19]	3.4%
Welton 2008	1043	−15.00	35.31	1087	0.00	35.31	−0.42	[−0.51; −0.34]	3.5%
Baksu 2009	100	−0.24	0.80	32	0.32	0.93	−0.67	[−1.07; −0.26]	2.6%
Hassa 2010	164	1.15	0.68	83	1.40	0.64	−0.37	[−0.64; −0.11]	3.1%
Liu 2012	52	−4.70	7.07	52	0.00	6.26	−0.70	[−1.09; −0.30]	2.6%
Random effects model	**4585**			**4225**			**−0.79**	**[−0.92; −0.66]**	**100%**

Heterogeneity: tau−squared=0.1222



Figure 3. Vasomotor symptoms forest plot of pairwise comparisons—estrogen (low/ultralow dose) compared with placebo.

Study	E–Low Total	E–Low Mean	E–Low SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Baumgardner 1978	42	0.32	0.74	42	0.64	0.739	−0.43	[−0.86; 0.00]	2.0%
Coope 1981	29	4.30	20.86	26	15.60	20.860	−0.53	[−1.07; 0.01]	1.7%
Speroff (Study 1) 1996	54	13.40	24.44	54	21.50	24.443	−0.33	[−0.71; 0.05]	2.1%
Speroff (Study 2) 1996	74	12.90	25.11	37	29.80	23.720	−0.68	[−1.09; −0.28]	2.0%
Speroff (Study 3) 1996	53	9.40	40.28	53	35.90	40.282	−0.65	[−1.04; −0.26]	2.1%
Baerug 1998	78	7.46	13.86	41	67.00	62.000	−1.56	[−1.99; −1.13]	2.0%
Studd 1999	120	1.27	2.49	60	3.00	3.000	−0.65	[−0.96; −0.33]	2.2%
Cohen 1999	130	−9.30	2.30	129	−5.70	2.500	−1.49	[−1.77; −1.22]	2.3%
Rebar 2000	101	1.40	1.70	103	2.40	2.100	−0.52	[−0.80; −0.24]	2.3%
Speroff (Study 1) 2000	131	7.97	31.10	43	21.00	23.588	−0.44	[−0.79; −0.09]	2.2%
Rovati 2000	80	1.90	5.70	80	3.80	3.651	−0.39	[−0.71; −0.08]	2.2%
Notelovitz 2000	96	−10.05	3.14	49	−4.90	3.840	−1.51	[−1.90; −1.12]	2.1%
Notelovitz 2000	199	16.09	26.79	66	28.20	21.248	−0.47	[−0.75; −0.19]	2.3%
DeAloysio 2000	104	13.00	19.00	52	26.00	27.000	−0.59	[−0.93; −0.25]	2.2%
Speroff (Study 2) 2000	134	15.90	70.52	67	39.80	60.861	−0.35	[−0.65; −0.06]	2.3%
Utian (CEE alone arms) 2001	62	−6.90	1.89	28	−4.00	1.084	−1.71	[−2.22; −1.19]	1.8%
Utian (CEE/MPA arms) 2001	90	−9.02	2.47	28	−3.90	1.057	−2.29	[−2.81; −1.77]	1.8%
Rozenbaum 2002	54	−7.90	5.10	57	−5.20	3.900	−0.59	[−0.97; −0.21]	2.1%
Shulman (Study 1) 2002	200	−70.02	67.19	93	−37.70	70.512	−0.47	[−0.72; −0.22]	2.4%
Archer 2003	148	−8.84	5.88	73	−6.30	6.155	−0.42	[−0.71; −0.14]	2.3%
Gambacciani 2003	25	0.14	0.10	25	0.46	0.400	−1.08	[−1.68; −0.48]	1.6%
Gelfand 2003	59	1.60	0.77	60	3.90	1.600	−1.82	[−2.24; −1.39]	2.0%
Schurmann 2004	164	−85.98	21.11	61	−47.00	42.200	−1.37	[−1.69; −1.05]	2.2%
Crisafulli 2004	30	−64.00	55.30	30	−11.10	31.900	−1.16	[−1.71; −0.61]	1.7%
Utian 2004	68	30.70	47.70	72	47.50	49.800	−0.34	[−0.68; −0.01]	2.2%
Duramed (SIP) 2004	53	26.10	43.00	51	50.50	48.400	−0.53	[−0.92; −0.14]	2.1%
Bayer Healthcare (SIP) 2005	175	2.80	3.82	176	6.00	3.824	−0.84	[−1.05; −0.62]	2.4%
Novartis (SIP) 2005	109	−2.91	4.43	51	0.00	4.752	−0.64	[−0.98; −0.30]	2.2%
Simon 2006	100	−11.10	6.80	100	−7.20	5.400	−0.63	[−0.92; −0.35]	2.3%
Nielsen 2006	114	−25.10	29.70	118	−2.30	21.600	−0.88	[−1.15; −0.61]	2.3%
Speroff (Study 2) 2006	113	34.20	33.56	108	43.10	33.558	−0.26	[−0.53; 0.00]	2.3%
Bachmann (d) 2007	292	−45.10	51.63	133	−25.60	32.411	−0.42	[−0.63; −0.21]	2.4%
Lee 2007	35	3.90	22.22	37	25.00	22.224	−0.94	[−1.43; −0.45]	1.9%
Panay 2007	375	−58.67	65.19	200	−36.70	62.854	−0.34	[−0.51; −0.17]	2.5%
Simon 2007	347	−10.19	16.77	137	−6.10	12.589	−0.26	[−0.46; −0.06]	2.4%
Bayer Healthcare (SIP) 2007	82	−7.60	4.60	83	−6.00	9.700	−0.21	[−0.52; 0.10]	2.3%
Buster (Study 1) 2008	76	−8.40	4.50	75	−5.30	6.300	−0.56	[−0.89; −0.24]	2.2%
Buster (Study 2) 2008	74	−8.70	6.70	76	−6.20	5.800	−0.40	[−0.72; −0.07]	2.2%
Buster (Study 3) 2008	76	−8.10	4.00	77	−4.80	5.800	−0.66	[−0.98; −0.33]	2.2%
Haines 2009	80	−1.70	1.80	80	−1.50	1.900	−0.11	[−0.42; 0.20]	2.2%
Gast 2009	144	−0.42	0.21	141	−0.16	0.081	−1.61	[−1.87; −1.34]	2.3%
Stevenson 2010	186	−7.17	4.02	127	−5.50	4.400	−0.40	[−0.63; −0.17]	2.4%
Liu 2011	686	−9.10	8.66	168	−6.10	6.500	−0.36	[−0.53; −0.19]	2.5%
Lin 2011	183	−45.90	29.30	61	−27.50	28.100	−0.63	[−0.93; −0.34]	2.3%
Liu 2012	53	−3.60	6.26	52	0.00	6.264	−0.57	[−0.96; −0.18]	2.1%
Archer 2012	237	5.05	8.09	114	7.50	5.797	−0.33	[−0.55; −0.10]	2.4%
Random effects model	**5915**			**3594**			**−0.70**	**[−0.83; −0.58]**	**100%**

Heterogeneity: tau−squared=0.1529



Figure 4. Vasomotor symptoms forest plot of pairwise comparisons—SSRIs or SNRIs compared with placebo.

Study	SSRI SNRI Total	SSRI SNRI Mean	SSRI SNRI SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Suvanto–Luukkonen 2005	99	2.5	2.9	50	3.4	3.9	–0.29	[–0.63; 0.05]	8.7%
Evans 2005	40	31.3	24.0	40	52.3	24.0	–0.87	[–1.33; –0.41]	6.2%
Kalay 2007	25	4.5	2.0	25	6.8	1.0	–1.43	[–2.06; –0.81]	4.0%
Speroff 2008	145	3.7	3.9	77	5.6	5.2	–0.43	[–0.71; –0.15]	10.4%
Soares 2008	28	–6.1	5.5	28	–2.8	5.5	–0.59	[–1.12; –0.05]	5.1%
Archer 2009	361	3.9	5.0	180	5.6	4.7	–0.35	[–0.53; –0.17]	13.6%
Archer 2009	301	–7.0	4.2	151	–5.8	4.2	–0.30	[–0.50; –0.10]	13.1%
Freeman 2011	104	5.1	4.7	101	6.5	4.7	–0.30	[–0.57; –0.02]	10.6%
Pfizer (c) 2011	1066	–8.0	6.2	1052	–5.2	6.4	–0.44	[–0.53; –0.36]	16.3%
Bouchard 2012	137	–5.8	3.9	150	–5.8	3.8	0.00	[–0.23; 0.23]	11.9%
Random effects model	**2306**			**1854**			**–0.40**	**[–0.54; –0.26]**	**100%**

Heterogeneity: tau–squared=0.0306



Figure 5. Vasomotor symptoms forest plot of pairwise comparisons—isoflavones compared with placebo. Exluding Basari 2009 and Albertazzi 1998, SMD -0.29 (-0.39 to -0.19) tau^2=0.03.

Study	Isoflavone Total	Isoflavone Mean	Isoflavone SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Murkies 1995	28	3.50	3.20	30	4.00	3.30	−0.15	[−0.67; 0.36]	3.1%
Albertazzi 1998	51	5.88	1.04	53	7.48	1.04	−1.53	[−1.96; −1.09]	3.4%
Baber 1999	25	4.80	16.80	26	4.00	13.40	0.05	[−0.50; 0.60]	3.0%
Upmalis 2000	89	−2.30	1.16	86	−1.90	0.96	−0.37	[−0.67; −0.08]	3.9%
Kotsopoulos 2000	44	0.77	1.10	50	0.83	0.85	−0.06	[−0.47; 0.34]	3.5%
Faure 2002	39	3.90	4.30	36	7.00	7.10	−0.53	[−0.99; −0.07]	3.3%
Han 2002	40	8.20	3.20	40	9.90	2.50	−0.59	[−1.03; −0.14]	3.4%
Tice 2003	167	5.25	4.31	85	5.00	3.53	0.06	[−0.20; 0.32]	4.0%
Penotti 2003	28	5.50	3.80	34	4.00	3.70	0.40	[−0.11; 0.90]	3.1%
Burke 2003	135	1.05	0.86	76	1.20	0.87	−0.17	[−0.45; 0.11]	4.0%
Nahas 2004	25	3.00	2.10	25	5.20	2.50	−0.94	[−1.52; −0.35]	2.8%
Crisafulli 2004	30	−33.30	24.90	30	−11.10	31.90	−0.77	[−1.29; −0.24]	3.1%
Atkinson 2004	102	1.20	2.30	103	1.50	2.00	−0.14	[−0.41; 0.14]	4.0%
Lewis 2006	33	3.70	2.75	33	3.94	3.73	−0.07	[−0.56; 0.41]	3.2%
Nahas 2007	38	3.10	2.30	38	5.90	4.30	−0.80	[−1.27; −0.34]	3.3%
Cheng 2007	26	0.80	0.80	25	1.20	1.10	−0.41	[−0.97; 0.14]	3.0%
Ho 2007	85	0.24	0.59	91	0.23	0.54	0.02	[−0.28; 0.31]	3.9%
Jou 2008	66	1.50	2.61	30	1.30	2.20	0.08	[−0.35; 0.51]	3.4%
Khaodhiar 2008	97	3.90	1.77	45	4.50	1.05	−0.38	[−0.74; −0.02]	3.7%
Ferrari 2009	82	4.70	4.20	94	5.30	3.80	−0.15	[−0.45; 0.15]	3.9%
D'Anna (m) 2009	119	2.60	6.50	117	4.70	3.80	−0.39	[−0.65; −0.13]	4.0%
Basaria 2009	38	−1.80	0.64	46	−0.40	0.36	−2.74	[−3.34; −2.14]	2.8%
Radhakrishnan 2009	44	1.40	2.50	41	2.50	2.50	−0.44	[−0.87; −0.01]	3.4%
Lee 2010	43	−5.10	3.30	44	−3.90	3.00	−0.38	[−0.80; 0.05]	3.4%
Jassi 2010	50	4.90	3.85	25	6.40	3.60	−0.39	[−0.88; 0.09]	3.2%
Evans 2011	41	−5.20	4.42	42	−3.00	4.42	−0.49	[−0.93; −0.06]	3.4%
Cianci 2012	60	−0.94	1.05	60	−0.44	1.02	−0.48	[−0.84; −0.12]	3.7%
Ye 2012	60	8.45	9.40	30	12.30	8.90	−0.41	[−0.86; 0.03]	3.4%
Aso 2012	66	−1.90	1.80	60	−1.00	2.00	−0.47	[−0.83; −0.12]	3.7%
Random effects model	**1751**			**1495**			**−0.41**	**[−0.58; −0.25]**	**100%**

Heterogeneity: tau−squared=0.1546



Figure 6. Vasomotor symptoms forest plot of pairwise comparisons—gabapentin or pregabalin compared with placebo.

Study	Gabap Preg Total	Gabap Preg Mean	Gabap Preg SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Guttuso 2003	30	−44.6	31.5	29	−28.9	32.1	−0.49	[−1.01; 0.03]	4.7%
Butt 2008	99	4.5	3.3	98	6.5	4.5	−0.50	[−0.79; −0.22]	15.9%
Depomed (c) 2012	355	6.4	4.0	177	7.6	4.1	−0.31	[−0.49; −0.12]	38.8%
Depomed (c) 2012	376	5.0	5.7	183	6.6	5.6	−0.27	[−0.45; −0.10]	40.6%
Random effects model	**860**			**487**			**−0.33**	**[−0.45; −0.22]**	**100%**

Heterogeneity: tau−squared=0



Figure 7. Vasomotor symptoms forest plot of pairwise comparisons—black cohosh compared with placebo.

Study	Black Cohosh Total	Black Cohosh Mean	Black Cohosh SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Frei−Kleiner 2005	81	−0.07	0.19	41	0	0.19	−0.37	[−0.75; 0.00]	19%
Osmers 2005	145	−0.13	0.40	141	0	0.40	−0.32	[−0.55; −0.09]	51%
Newton 2006	80	−0.28	2.16	84	0	4.14	−0.08	[−0.39; 0.22]	30%
Random effects model	**306**			**266**			**−0.26**	**[−0.43; −0.09]**	**100%**

Heterogeneity: tau−squared=0



Figure 8. Vasomotor symptoms forest plot of pairwise comparisons—estrogen (high dose) compared with estrogen (standard dose).

Study	E–High Total	E–High Mean	E–High SD	E–Standard Total	E–Standard Mean	E–Standard SD	SMD	95% CI	Weight
Martin 1971	56	–2.30	3.90	53	–2.00	3.70	–0.08	[–0.45; 0.30]	7.2%
Baumgardner 1978	37	0.30	0.75	35	0.20	0.97	0.12	[–0.35; 0.58]	6.7%
Good 1996	94	–83.00	38.63	88	–78.00	39.89	–0.13	[–0.42; 0.16]	7.8%
Hirvonen 1997	57	–0.76	0.43	32	–0.80	0.40	0.10	[–0.33; 0.53]	6.9%
Al–Azzawi 1997	131	0.40	1.10	263	0.55	1.15	–0.13	[–0.34; 0.08]	8.2%
Good 1999	82	4.30	22.00	79	10.50	32.00	–0.23	[–0.54; 0.08]	7.7%
de Vrijer 1999	86	0.40	3.14	82	0.70	3.14	–0.10	[–0.40; 0.21]	7.7%
Studd 1999	62	0.91	1.90	119	1.24	1.92	–0.17	[–0.48; 0.14]	7.7%
Meuwissen 2001	314	0.80	1.83	320	0.32	1.83	0.26	[0.11; 0.42]	8.4%
Utian 2004	69	12.40	26.30	72	12.20	18.70	0.01	[–0.32; 0.34]	7.5%
Speroff (Study 1) 2006	95	6.70	80.59	100	17.40	60.82	–0.15	[–0.43; 0.13]	7.8%
Mattsson (d) 2007	154	11.50	2.88	305	16.05	4.03	–1.23	[–1.44; –1.02]	8.2%
Pitkin (d) 2007	154	–56.30	14.09	305	–53.85	13.47	–0.18	[–0.37; 0.02]	8.3%
Random effects model	**1391**			**1853**			**–0.15**	**[–0.40; 0.09]**	**100%**

Heterogeneity: tau–squared=0.1814



Figure 9. Vasomotor symptoms forest plot of pairwise comparisons—estrogen (high dose) compared with estrogen (low/ultralow dose).

Study	E–High Total	E–High Mean	E–High SD	E–Low Total	E–Low Mean	E–Low SD	SMD	95% CI	Weight
Baumgardner 1978	37	0.30	0.75	42	0.32	0.74	–0.02	[–0.46; 0.42]	12%
Hirvonen 1997	57	–0.76	0.43	84	–0.83	0.38	0.17	[–0.17; 0.51]	14%
Studd 1999	62	0.91	1.90	120	1.27	2.49	–0.16	[–0.46; 0.15]	15%
Saure 2000	190	–0.44	0.50	186	–0.51	0.50	0.14	[–0.06; 0.35]	17%
Buckler (d) 2003	84	–3.50	1.76	75	–3.20	1.61	–0.18	[–0.49; 0.14]	14%
Al–Azzawi (d) 2003	84	–48.20	14.13	75	–40.00	11.67	–0.63	[–0.95; –0.31]	14%
Utian 2004	69	12.40	26.30	68	30.70	47.70	–0.47	[–0.81; –0.13]	14%
Random effects model	**583**			**650**			**–0.16**	**[–0.39; 0.07]**	**100%**

Heterogeneity: tau–squared=0.0718



Figure 10. Vasomotor symptoms forest plot of pairwise comparisons—estrogen (standard dose) compared with estrogen (standard low/ultralow dose).

Study	E–Standard Total	E–Standard Mean	E–Standard SD	E–Low Total	E–Low Mean	E–Low SD	SMD	95% CI	Weight
Baumgardner 1978	35	0.20	0.965	42	0.32	0.74	−0.14	[−0.59; 0.31]	3.6%
Hilditch 1996	35	−1.80	0.500	39	−1.90	0.53	0.19	[−0.27; 0.65]	3.5%
Hirvonen 1997	60	−3.50	1.011	60	−4.38	1.65	0.64	[0.27; 1.01]	4.3%
Hirvonen 1997	32	−0.80	0.399	84	−0.83	0.38	0.07	[−0.34; 0.47]	3.9%
Studd 1999	119	1.24	1.920	120	1.27	2.49	−0.01	[−0.27; 0.24]	5.5%
Speroff (Study 1) 2000	45	4.90	37.977	131	7.97	31.10	−0.09	[−0.43; 0.25]	4.6%
Rovati 2000	151	0.45	1.080	80	1.90	5.70	−0.42	[−0.69; −0.14]	5.3%
Notelovitz 2000	68	3.00	43.330	199	16.09	26.79	−0.41	[−0.69; −0.13]	5.2%
Speroff (Study 2) 2000	65	7.90	92.616	134	15.90	70.52	−0.10	[−0.40; 0.19]	5.0%
Utian (CEE alone arms) 2001	27	−7.68	2.072	62	−6.90	1.89	−0.40	[−0.85; 0.06]	3.5%
Utian (CEE/MPA arms) 2001	34	−8.40	4.129	90	−9.02	2.47	0.20	[−0.19; 0.60]	4.0%
Rozenbaum 2002	54	−9.40	3.800	54	−7.90	5.10	−0.33	[−0.71; 0.05]	4.2%
Loh 2002	48	−2.10	3.800	48	−1.90	3.60	−0.05	[−0.45; 0.35]	4.0%
Utian 2004	72	12.20	18.700	68	30.70	47.70	−0.51	[−0.85; −0.18]	4.6%
Pornel 2005	377	0.29	1.200	387	0.23	1.20	0.05	[−0.09; 0.19]	6.6%
Utian 2005	164	−1.10	1.100	84	−1.30	1.20	0.18	[−0.09; 0.44]	5.4%
Raynaud 2005	136	−1.00	0.028	134	−0.97	0.17	−0.24	[−0.48; 0.00]	5.6%
Cieraad 2006	91	0.36	0.950	98	1.10	1.90	−0.49	[−0.77; −0.20]	5.1%
Nielsen 2006	103	−30.50	29.600	114	−25.10	29.70	−0.18	[−0.45; 0.09]	5.3%
Limpaphayom (m) 2006	344	−1.21	0.615	684	−1.32	0.67	0.17	[0.04; 0.30]	6.7%
Liu 2012	52	−4.70	7.073	53	−3.60	6.26	−0.16	[−0.55; 0.22]	4.1%
Random effects model	**2112**			**2765**			**−0.10**	**[−0.22; 0.02]**	**100%**

Heterogeneity: tau−squared=0.0491



Figure 11. Vasomotor symptoms forest plot of pairwise comparisons—ginseng compared with placebo.

Study	Ginseng Total	Ginseng Mean	Ginseng SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Wiklund 1999	193	5.6	2.0	191	5.8	1.9	−0.10	[−0.30; 0.10]	43%
Hartley 2004	30	1.1	0.3	27	1.3	0.2	−0.77	[−1.31; −0.23]	27%
Kim 2011	36	3.5	2.4	36	4.9	2.9	−0.52	[−0.99; −0.05]	30%
Random effects model	**259**			**254**			**−0.41**	**[−0.83; 0.02]**	**100%**

Heterogeneity: I−squared=70.6%, tau−squared=0.0963, p=0.0332



Appendix G. Quality of Life Plots

Table 7. Graphical depiction of point estimates of comparative standardized effect sizes. The range displayed is from 0 (center of each cell) to 1 (right of each cell).

E-Standard					
0.04	E-High				
0.16	0.11	E-Low/Ultralow			
0.34	0.30	0.19	SSRI/SNRI		
0.40	0.36	0.25	0.06	Isoflavone	
0.61	0.56	0.45	0.26	0.20	Placebo

Table 8. Standardized effect sizes and credible intervals as odds ratios.

E-Standard					
1.08 (0.71 to 1.63)	E-High				
1.32 (0.93 to 1.89)	1.23 (0.77 to 1.98)	E-Low/Ultralow			
1.86 (0.98 to 3.53)	1.72 (0.84 to 3.55)	1.40 (0.71 to 2.75)	SSRI/SNRI		
2.07 (1.36 to 3.14)	1.92 (1.13 to 3.29)	1.56 (0.98 to 2.50)	1.11 (0.57 to 2.19)	Isoflavone	
3.00 (2.30 to 3.92)	2.78 (1.82 to 4.26)	2.26 (1.62 to 3.17)	1.61 (0.90 to 2.90)	1.45 (1.04 to 2.02)	Placebo

Table 9. Difference between network result and calculable pairwise effect estimates (pooled random effect estimates or single trial effects if only available). The small differences reflect network consistency.

E-Standard					
-0.03	E-High				
0.03	0.21	E-Low/Ultralow			
			SSRI/SNRI		
				Isoflavone	
-0.02	-0.14	0.05	-0.01	0.03	Placebo

Figure 1. Forest plot estrogen (standard) versus placebo.

Study	Estrogen (Standard) Total	Mean	SD	Placebo Total	Mean	SD	SMD	95% CI	Weight
Wiklund 1993	112	18.80	8.70	111	6.70	10.10	1.28	[0.99; 1.57]	5.0%
Derman 1995	40	11.50	9.10	42	3.30	9.50	0.87	[0.42; 1.33]	4.0%
Saletu 1995	32	17.40	8.40	32	17.80	6.12	−0.05	[−0.54; 0.44]	3.8%
Chung 1996	41	3.80	7.99	40	1.70	8.53	0.25	[−0.19; 0.69]	4.1%
Bacchi−Modena 1997	53	9.00	13.88	56	0.00	13.88	0.64	[0.26; 1.03]	4.4%
Bech 1998	100	9.65	6.53	51	0.00	7.76	1.38	[1.01; 1.75]	4.5%
de Vrijer 1999	82	17.80	13.70	86	8.00	14.00	0.70	[0.39; 1.02]	4.9%
Studd 1999	54	17.66	5.44	60	9.10	6.74	1.38	[0.97; 1.79]	4.3%
Rovati 2000	151	21.19	8.25	80	11.10	7.50	1.26	[0.96; 1.55]	5.0%
Strickler 2000	96	0.25	1.35	105	0.00	1.53	0.17	[−0.11; 0.45]	5.1%
von Holst 2000	93	4.50	8.79	93	0.00	8.79	0.51	[0.22; 0.80]	5.0%
Rigano 2001	171	0.61	0.49	191	0.05	0.22	1.51	[1.28; 1.74]	5.3%
Rozenbaum 2002	54	19.20	9.60	57	12.20	9.10	0.74	[0.36; 1.13]	4.4%
von Holst 2002	84	5.60	9.21	88	0.00	9.21	0.61	[0.30; 0.91]	4.9%
Jirapinyo 2003	60	6.98	1.39	60	4.70	1.30	1.68	[1.27; 2.10]	4.2%
Haines 2003	50	5.10	8.42	50	2.30	8.36	0.33	[−0.06; 0.73]	4.4%
Hays 2003	8506	0.40	13.40	8102	0.70	13.50	−0.02	[−0.05; 0.01]	6.0%
Yang 2004	26	3.90	6.42	25	3.30	6.16	0.09	[−0.46; 0.64]	3.5%
Brunner 2005	5310	0.31	13.70	5429	0.37	14.20	0.00	[−0.04; 0.03]	6.0%
Welton 2008	1043	1.30	14.76	1087	0.90	13.20	0.03	[−0.06; 0.11]	5.9%
Hassa 2010	164	0.23	0.44	83	0.17	0.55	0.12	[−0.14; 0.39]	5.2%
Random effects model	**16322**			**15928**			**0.63**	**[0.47; 0.78]**	**100%**

Heterogeneity: I−squared=96.3%, tau−squared=0.1065, p<0.0001



Figure 2. Forest plot estrogen (high) versus placebo.

Study	E−High Total	Mean	SD	Placebo Total	Mean	SD	SMD	95% CI	Weight
Jensen 1983	41	4.1	6.5	90	0.0	6.5	0.63	[0.25; 1.01]	25%
de Vrijer 1999	86	18.1	14.3	86	8.0	14.0	0.71	[0.40; 1.02]	28%
Soares 2001	25	19.0	7.4	25	6.7	9.7	1.41	[0.78; 2.03]	15%
Speroff 2003	225	4.6	10.9	108	0.0	10.7	0.42	[0.19; 0.65]	32%
Random effects model	**377**			**309**			**0.70**	**[0.40; 1.01]**	**100%**

Heterogeneity: I−squared=67.3%, tau−squared=0.063, p=0.0272



Figure 3. Forest plot estrogen (low/ultralow) versus placebo.

Study	E–Low/Ultralow Total	Mean	SD	Placebo Total	Mean	SD	SMD	95% CI	Weight
Baerug 1998	78	50.8	114.8	41	0.0	127.1	0.42	[0.04; 0.81]	7.1%
Studd 1999	120	15.4	7.0	60	9.1	6.7	0.90	[0.58; 1.22]	8.1%
Rebar 2000	101	2.0	6.0	103	0.3	5.3	0.30	[0.03; 0.58]	8.9%
Rovati 2000	80	17.3	7.6	80	11.1	7.5	0.82	[0.50; 1.14]	8.1%
DeAloysio 2000	104	15.4	24.2	52	9.8	24.5	0.23	[–0.10; 0.56]	7.9%
Rozenbaum 2002	54	15.1	12.5	57	12.2	9.1	0.26	[–0.11; 0.64]	7.2%
Haines 2003	52	4.9	8.1	50	2.3	8.4	0.31	[–0.08; 0.71]	7.0%
Gelfand 2003	59	16.8	6.9	60	7.8	11.5	0.94	[0.56; 1.32]	7.1%
Panay 2007	375	4.5	13.2	200	0.0	13.8	0.33	[0.16; 0.50]	10.7%
Simon 2007	211	1.0	3.1	137	0.0	3.4	0.32	[0.10; 0.53]	9.9%
Haines 2009	80	1.0	1.3	80	1.0	1.1	0.00	[–0.31; 0.31]	8.3%
Stevenson 2010	186	8.3	7.8	127	7.4	7.0	0.12	[–0.10; 0.35]	9.8%
Random effects model	**1500**			**1047**			**0.40**	**[0.24; 0.56]**	**100%**

Heterogeneity: I–squared=71.2%, tau–squared=0.0521, p<0.0001



Figure 4. Forest plot isoflavone versus placebo.

Study	Isoflavone Total	Mean	SD	Placebo Total	Mean	SD	SMD	95% CI	Weight
Murkies 1995	28	5.30	5.4	30	3.40	5.5	0.34	[–0.17; 0.86]	3.7%
Baber 1999	25	4.40	29.4	26	4.09	44.7	0.01	[–0.54; 0.56]	3.4%
Nahas 2004	25	9.50	6.3	25	7.10	5.8	0.39	[–0.17; 0.95]	3.3%
Atkinson 2004	102	–0.90	4.1	103	–0.80	2.8	–0.03	[–0.30; 0.25]	8.0%
Kok 2005	100	–2.00	35.6	102	0.00	35.6	–0.06	[–0.33; 0.22]	7.9%
Lewis 2006	33	0.35	1.2	33	0.57	1.1	–0.19	[–0.68; 0.29]	4.1%
Ho 2007	85	–0.20	18.4	91	–3.00	20.6	0.14	[–0.15; 0.44]	7.4%
Cancellieri 2007	60	11.20	8.0	65	7.40	7.9	0.48	[0.12; 0.83]	6.1%
Jou 2008	66	14.60	16.5	30	11.70	13.6	0.18	[–0.25; 0.62]	4.8%
Khaodhiar 2008	97	8.76	42.4	45	0.00	53.8	0.19	[–0.17; 0.54]	6.1%
Ferrari 2009	82	5.90	9.3	94	7.40	7.4	–0.18	[–0.48; 0.12]	7.4%
Radhakrishnan 2009	44	5.90	4.9	41	2.80	5.2	0.61	[0.17; 1.05]	4.7%
Lee 2010	43	14.90	8.8	44	11.50	6.6	0.43	[0.01; 0.86]	4.9%
Jassi 2010	50	12.45	8.6	25	6.20	6.8	0.77	[0.27; 1.27]	3.9%
Evans 2011	41	6.30	8.2	42	5.20	10.6	0.12	[–0.32; 0.55]	4.8%
Levis 2011	122	0.73	5.2	126	0.34	6.6	0.07	[–0.18; 0.31]	8.7%
Ye 2012	60	10.80	4.8	30	10.20	5.4	0.12	[–0.32; 0.56]	4.7%
Aso 2012	66	3.10	5.2	60	1.60	4.9	0.29	[–0.06; 0.65]	6.2%
Random effects model	**1129**			**1012**			**0.17**	**[0.06; 0.29]**	**100%**

Heterogeneity: I–squared=40.1%, tau–squared=0.0237, p=0.0408



Figure 5. Forest plot SSRI/SNRI versus placebo.



Figure 6. Forest plot estrogen (high) versus estrogen (standard).



Figure 7. Forest plot estrogen (standard) versus estrogen (low/ultralow)



Figure 8. Forest plot black cohosh versus placebo.



Appendix H. Psychological Symptoms Plots

Figure 1. Effect of high dose estrogen compared with placebo on depression

Study	Estrogen (High) Total	Mean	SD	Placebo Total	Mean	SD	SMD	95% CI	Weight
Campbell 1977	68	−5.3	1.5	68	−3.9	1.1	−1.03	[−1.39; −0.67]	26%
Soares 2001	25	−10.5	13.8	25	0.0	13.8	−0.75	[−1.32; −0.17]	16%
Speroff 2003	225	−1.0	2.5	108	0.0	2.7	−0.41	[−0.64; −0.17]	32%
Rudolph 2004	65	−9.7	6.2	64	−6.4	7.7	−0.47	[−0.82; −0.12]	26%
Random effects model	**383**			**265**			**−0.64**	**[−0.94; −0.33]**	**100%**

Heterogeneity: I−squared=66.4%, tau−squared=0.0623, p=0.0303



Figure 2. Effect of high dose estrogen compared with placebo on anxiety

Study	Estrogen High Total	Mean	SD	Placebo Total	Mean	SD	SMD	95% CI	Weight
Speroff 2003	225	−0.85	2	108	0	1.7	−0.44	[−0.67; −0.21]	64%
Campbell 1977	68	−3.10	15	68	0	15.6	−0.20	[−0.54; 0.14]	36%
Random effects model	**293**			**176**			**−0.35**	**[−0.58; −0.13]**	**100%**

Heterogeneity: I−squared=24.3%, tau−squared=0.007, p=0.2505



Figure 3. Effect of standard dose estrogen compared with placebo on depression

Study	Estrogen (Standard) Total	Mean	SD	Placebo Total	Mean	SD	SMD	95% CI	Weight
Wiklund 1993	112	−3.100	4.80	111	−0.70	3.40	−0.57	[−0.84; −0.31]	10.1%
Derman 1995	40	−2.000	4.32	42	−0.10	6.22	−0.35	[−0.79; 0.09]	5.6%
Saletu 1995	32	−9.600	5.80	32	−10.30	6.12	0.12	[−0.37; 0.61]	4.7%
Bech 1998	100	−2.100	4.73	51	−0.30	5.68	−0.35	[−0.69; −0.01]	7.8%
Polo−Kantola 1999	62	−0.230	0.97	62	0.00	1.89	−0.15	[−0.50; 0.20]	7.5%
Hays 2003	8506	−0.100	1.80	8102	−0.10	1.80	0.00	[−0.03; 0.03]	19.1%
Yang 2004	26	−0.700	1.85	25	−0.40	1.51	−0.17	[−0.72; 0.38]	4.0%
Onalan 2005	156	−1.151	1.93	54	0.00	2.02	−0.59	[−0.90; −0.27]	8.5%
Welton 2008	1043	−0.008	0.13	1087	0.00	0.13	−0.06	[−0.15; 0.02]	17.7%
Hassa 2010	164	−0.080	0.40	83	−0.08	0.41	0.00	[−0.26; 0.27]	10.2%
Demetrio 2011	30	−6.000	6.27	36	−4.40	7.65	−0.22	[−0.71; 0.26]	4.8%
Random effects model	**10271**			**9685**			**−0.19**	**[−0.31; −0.07]**	**100%**

Heterogeneity: I−squared=74.5%, tau−squared=0.0205, p<0.0001



Figure 4. Effect of standard dose estrogen compared with placebo on anxiety

Study	Estrogen Standard Total	Mean	SD	Placebo Total	Mean	SD	SMD	95% CI	Weight
Hassa 2010	164	−0.039	0.33	83	0.01	0.37	−0.14	[−0.41; 0.12]	14.2%
Yang 2004	26	2.100	1.90	25	1.80	1.70	0.16	[−0.39; 0.71]	7.1%
Strickler 2000	96	−0.020	0.49	105	0.03	0.39	−0.11	[−0.39; 0.16]	13.8%
Polo−Kantola 1999	62	−0.040	0.25	62	0.00	0.27	−0.15	[−0.51; 0.20]	11.5%
Bech 1998	100	−2.500	3.75	51	−0.20	4.56	−0.57	[−0.91; −0.22]	11.8%
Wiklund 1993	112	−2.100	3.10	111	−0.80	2.60	−0.45	[−0.72; −0.19]	14.1%
Welton 2008	1043	−0.890	0.19	1087	−0.90	0.20	0.05	[−0.03; 0.14]	19.2%
Demetrio 2011	30	−4.200	4.95	36	−4.70	6.50	0.08	[−0.40; 0.57]	8.3%
Random effects model	**1633**			**1560**			**−0.16**	**[−0.34; 0.03]**	**100%**

Heterogeneity: I−squared=71.7%, tau−squared=0.0434, p=0.0008



Figure 5. Effect of standard dose estrogen compared with placebo on global mental health

Study	Estrogen (Standard) Total	Mean	SD	Placebo Total	Mean	SD	SMD	95% CI	Weight
Wiklund 1993	112	−13.5	21.0	111	−6.50	16.0	−0.37	[−0.64; −0.11]	6.3%
Derman 1995	40	−6.2	9.3	42	−0.90	10.9	−0.52	[−0.96; −0.08]	2.5%
Rozenbaum 2002	54	−25.2	24.2	57	−20.10	32.5	−0.18	[−0.55; 0.20]	3.4%
Haines 2003	50	−0.4	4.6	50	−0.60	4.6	0.04	[−0.35; 0.44]	3.1%
Hays 2003	8506	−0.6	12.1	8102	−0.70	12.4	0.01	[−0.02; 0.04]	38.0%
Yang 2004	26	3.3	3.0	25	3.00	2.6	0.11	[−0.44; 0.65]	1.7%
Brunner 2005	5310	−0.6	13.3	5429	−0.56	13.3	0.00	[−0.04; 0.03]	36.6%
Nielsen 2006	103	3.4	16.1	118	−0.10	14.8	0.23	[−0.04; 0.49]	6.3%
Demetrio 2011	30	43.6	21.6	36	54.60	28.7	−0.42	[−0.91; 0.07]	2.1%
Random effects model	**14231**			**13970**			**−0.03**	**[−0.10; 0.04]**	**100%**

Heterogeneity: I−squared=59.9%, tau−squared=0.0033, p=0.0105



Figure 6. Effect of low or ultralow dose estrogen compared with placebo on depression

Study	Estrogen (Low/Ultralow) Total	Mean	SD	Placebo Total	Mean	SD	SMD	95% CI	Weight
Coope 1981	29	2.00	7.53	26	0.00	9.11	0.24	[−0.29; 0.77]	34%
Gambacciani 2003	25	0.24	0.25	25	0.34	0.25	−0.39	[−0.95; 0.17]	31%
Pefanco 2007	32	0.00	3.46	25	0.00	3.61	0.00	[−0.52; 0.52]	35%
Random effects model	**86**			**76**			**−0.04**	**[−0.40; 0.31]**	**100%**

Heterogeneity: I−squared=23.1%, tau−squared=0.0226, p=0.2726



Figure 7. Effect of low or ultralow dose estrogen compared with placebo on anxiety

Study	Estrogen Low Ultralow Total	Mean	SD	Placebo Total	Mean	SD	SMD	95% CI	Weight
Gambacciani 2003	25	0.31	0.25	25	0.43	0.25	−0.47	[−1.04; 0.09]	14%
Nielsen 2006	114	0.50	12.60	118	1.60	10.80	−0.09	[−0.35; 0.16]	69%
Pefanco 2007	32	4.00	5.00	25	6.00	6.00	−0.36	[−0.89; 0.17]	16%
Random effects model	**171**			**168**			**−0.19**	**[−0.41; 0.02]**	**100%**

Heterogeneity: I−squared=0%, tau−squared=0, p=0.3846



Figure 8. Effect of low or ultralow dose estrogen compared with placebo on global mental health

Study	Estrogen (Low/Ultralow) Total	Mean	SD	Placebo Total	Mean	SD	SMD	95% CI	Weight
Baerug 1998	78	−0.44	0.49	41	0.0	0.2	−1.07	[−1.47; −0.66]	12%
Rozenbaum 2002	54	−20.40	25.70	57	−20.1	32.5	−0.01	[−0.38; 0.36]	13%
Haines 2003	52	−0.10	5.10	50	−0.6	4.6	0.10	[−0.29; 0.49]	12%
Gelfand 2003	59	2.40	1.50	60	2.9	1.6	−0.32	[−0.68; 0.04]	13%
Yaffe (d) 2006	208	−1.00	6.55	209	0.0	6.6	−0.15	[−0.34; 0.04]	18%
Nielsen 2006	114	−1.00	14.30	118	−0.1	14.8	−0.06	[−0.32; 0.20]	16%
Simon 2007	347	−0.48	1.95	137	0.0	1.7	−0.26	[−0.45; −0.06]	17%
Random effects model	**912**			**672**			**−0.24**	**[−0.45; −0.02]**	**100%**

Heterogeneity: I−squared=74.1%, tau−squared=0.0584, p=0.0008



Figure 9. Effect of isoflavones compared with placebo on depression

Study	Isoflavones Total	Mean	SD	Placebo Total	Mean	SD	SMD	95% CI	Weight
Kotsopoulos 2000	44	−0.08	0.77	50	0.02	0.89	−0.12	[−0.52; 0.29]	12%
Tice 2003	167	−0.25	2.30	85	0.00	2.43	−0.11	[−0.37; 0.15]	14%
Kok 2005	100	−0.20	3.23	102	0.00	3.23	−0.06	[−0.34; 0.21]	14%
Hidalgo 2005	53	−0.36	0.49	53	0.00	0.42	−0.78	[−1.18; −0.38]	12%
de Sousa−Munoz 2009	42	8.20	3.80	42	9.40	4.10	−0.30	[−0.73; 0.13]	12%
Lipovac 2010	50	1.50	2.10	59	5.20	3.70	−1.20	[−1.61; −0.79]	12%
Jassi 2010	50	−0.60	1.15	25	0.12	0.92	−0.66	[−1.15; −0.17]	11%
Evans 2011	41	−1.90	2.82	42	−1.40	3.65	−0.15	[−0.58; 0.28]	12%
Random effects model	**547**			**458**			**−0.41**	**[−0.69; −0.13]**	**100%**

Heterogeneity: I−squared=78.1%, tau−squared=0.1259, p<0.0001



Figure 10. Effect of isoflavones compared with placebo on anxiety

Study	Isoflavone Total	Isoflavone Mean	Isoflavone SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Kotsopoulos 2000	44	−0.12	0.99	50	−0.12	0.99	0.00	[−0.41; 0.41]	14%
Tice 2003	167	−0.95	0.49	85	−0.70	0.36	−0.56	[−0.82; −0.29]	16%
Hidalgo 2005	53	−0.38	0.50	53	0.00	0.32	−0.89	[−1.29; −0.49]	14%
Casini 2006	77	7.60	5.20	77	9.70	6.90	−0.34	[−0.66; −0.02]	15%
Lipovac 2010	50	2.40	2.53	59	8.05	4.76	−1.44	[−1.86; −1.01]	14%
Jassi 2010	50	−2.05	2.46	25	−1.00	2.49	−0.42	[−0.91; 0.06]	13%
Evans 2011	41	−1.80	2.76	42	−1.50	3.58	−0.09	[−0.52; 0.34]	14%
Random effects model	**482**			**391**			**−0.53**	**[−0.87; −0.20]**	**100%**

Heterogeneity: I−squared=81.8%, tau−squared=0.1635, p<0.0001



Figure 11. Effect of isoflavone compared with placebo on global mental health

Study	Isoflavone Total	Isoflavone Mean	Isoflavone SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Tice 2003	167	−0.5	4.4	85	0.0	4.4	−0.11	[−0.38; 0.15]	27.0%
Kok 2005	100	−2.2	13.8	102	0.0	13.8	−0.16	[−0.43; 0.12]	24.2%
Lewis 2006	33	1.7	1.4	33	2.1	1.7	−0.24	[−0.73; 0.24]	7.9%
Ho 2007	85	82.0	15.4	91	83.7	15.5	−0.11	[−0.41; 0.19]	21.1%
Basaria 2009	38	−0.6	25.3	46	0.0	25.3	−0.02	[−0.45; 0.41]	10.0%
Evans 2011	41	−3.6	5.2	42	−2.9	7.1	−0.11	[−0.54; 0.32]	9.9%
Random effects model	**464**			**399**			**−0.12**	**[−0.26; 0.01]**	**100%**

Heterogeneity: I−squared=0%, tau−squared=0, p=0.9912



Figure 22. Effect of SSRI/SNRI compared with placebo on depression

Study	SSRI/SNRI Total	SSRI/SNRI Mean	SSRI/SNRI SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Suvanto−Luukkonen 2005	99	7.1	8.5	50	9.7	10.1	−0.29	[−0.63; 0.06]	19%
Kornstein 2010	247	−12.6	7.2	125	−8.3	7.3	−0.59	[−0.81; −0.37]	31%
Pfizer (c) 2011	1066	−2.7	2.1	1052	−2.0	2.1	−0.33	[−0.42; −0.25]	50%
Random effects model	**1412**			**1227**			**−0.40**	**[−0.59; −0.22]**	**100%**

Heterogeneity: I−squared=59.1%, tau−squared=0.0149, p=0.0866



Figure 33. Effect of SSRI/SNRI compared with placebo on anxiety

Study	SSRI/SNRI Total	SSRI/SNRI Mean	SSRI/SNRI SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Kornstein 2010	247	−8.6	6.0	125	−5.9	6.1	−0.45	[−0.66; −0.23]	40%
Pfizer (c) 2011	1066	−3.2	2.3	1052	−2.7	2.4	−0.21	[−0.30; −0.13]	60%
Random effects model	**1313**			**1177**			**−0.31**	**[−0.53; −0.08]**	**100%**

Heterogeneity: I−squared=74%, tau−squared=0.0202, p=0.0498



Figure 14. Effect of SSRI/SNRI compared with placebo on global mental health

Study	SSRI/SNRI Total	SSRI/SNRI Mean	SSRI/SNRI SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Evans 2005	40	−8.7	13.1	40	0.0	13.1	−0.66	[−1.11; −0.21]	17%
Kalay 2007	25	−1.6	1.6	25	0.0	1.6	−0.98	[−1.56; −0.39]	12%
Pfizer (c) 2011	1066	−5.9	4.2	1052	−4.7	4.0	−0.29	[−0.38; −0.21]	40%
Bouchard 2012	137	−17.8	33.2	150	−13.5	31.8	−0.13	[−0.36; 0.10]	30%
Random effects model	**1268**			**1267**			**−0.39**	**[−0.63; −0.15]**	**100%**

Heterogeneity: I−squared=68.4%, tau−squared=0.0367, p=0.0233



Figure 45. Effect of gabapentin/pregabalin compared with placebo on global mental health

Study	Gabapentin/Pregabalin Total	Gabapentin/Pregabalin Mean	Gabapentin/Pregabalin SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Guttuso 2003	30	−4.4	10.2	29	−2.2	6.8	−0.25	[−0.76; 0.26]	23%
Butt 2008	99	2.4	1.3	98	2.7	1.6	−0.21	[−0.49; 0.07]	77%
Random effects model	**129**			**127**			**−0.22**	**[−0.46; 0.03]**	**100%**

Heterogeneity: I−squared=0%, tau−squared=0, p=0.8813



Appendix I. Sexual Function Plots

Figure 5. Pain during sex—vaginal estrogen compared with placebo

Study	Experimental Total	Experimental Mean	Experimental SD	Control Total	Control Mean	Control SD	SMD	95%–CI
Speroff 2003	112	−1.30	1.88	108	−0.800	5.66	−0.12	[−0.38; 0.15]
Bachmann (Study 1) 2009	143	−1.40	2.07	72	−0.400	2.07	−0.48	[−0.77; −0.19]
Freedman 2009	135	−1.80	1.81	140	−0.940	1.81	−0.48	[−0.71; −0.24]
Gast 2009	144	−2.50	5.15	141	−1.300	5.15	−0.23	[−0.47; 0.00]
Dessole 2004	44	−0.66	0.47	44	0.023	0.15	−1.92	[−2.43; −1.41]
Simunic 2003	828	−0.34	0.47	784	−0.109	0.31	−0.57	[−0.67; −0.47]
Parsons 2003	48	−0.11	0.31	46	−0.110	0.31	0.00	[−0.40; 0.41]
Casper 1999	33	−0.90	0.30	34	−0.450	0.50	−1.08	[−1.59; −0.56]
Eriksen 1992	75	−0.34	0.48	79	−0.214	0.41	−0.29	[−0.61; 0.02]
Bachmann (Study 2) 2009	140	−1.40	1.82	68	−0.700	1.82	−0.38	[−0.67; −0.09]
Random effects model	**1702**			**1516**			**−0.50**	**[−0.71; −0.29]**

Heterogeneity: I−squared=84.4%, tau−squared=0.09, p<0.0001



Figure 2. Pain during sex—oral estrogen compared with placebo

Study	Experimental Total	Experimental Mean	Experimental SD	Control Total	Control Mean	Control SD	SMD	95%–CI
Vestergaard 2003	502	−0.19	1.01	504	−0.065	1.01	−0.12	[−0.25; 0.00]
Campbell 1977	68	−3.50	0.82	68	−3.400	0.71	−0.13	[−0.47; 0.21]
Simon (SIP) 2008	125	−1.80	1.00	123	−0.750	0.95	−1.07	[−1.34; −0.81]
Random effects model	**695**			**695**			**−0.44**	**[−1.05; 0.17]**

Heterogeneity: I−squared=95.1%, tau−squared=0.2757, p<0.0001



Figure 3. Pain during sex—all estrogens compared with placebo

Study	Experimental Total	Experimental Mean	Experimental SD	Control Total	Control Mean	Control SD	SMD	95%–CI
Vestergaard 2003	502	−0.19	1.01	504	−0.065	1.01	−0.12	[−0.25; 0.00]
Speroff 2003	112	−1.30	1.88	108	−0.800	5.66	−0.12	[−0.38; 0.15]
Bachmann (Study 1) 2009	143	−1.40	2.07	72	−0.400	2.07	−0.48	[−0.77; −0.19]
Freedman 2009	135	−1.80	1.81	140	−0.940	1.81	−0.48	[−0.71; −0.24]
Gast 2009	144	−2.50	5.15	141	−1.300	5.15	−0.23	[−0.47; 0.00]
Dessole 2004	44	−0.66	0.47	44	0.023	0.15	−1.92	[−2.43; −1.41]
Simunic 2003	828	−0.34	0.47	784	−0.109	0.31	−0.57	[−0.67; −0.47]
Parsons 2003	48	−0.11	0.31	46	−0.110	0.31	0.00	[−0.40; 0.41]
Casper 1999	33	−0.90	0.30	34	−0.450	0.50	−1.08	[−1.59; −0.56]
Eriksen 1992	75	−0.34	0.48	79	−0.214	0.41	−0.29	[−0.61; 0.02]
Campbell 1977	68	−3.50	0.82	68	−3.400	0.71	−0.13	[−0.47; 0.21]
Bachmann (Study 2) 2009	140	−1.40	1.82	68	−0.700	1.82	−0.38	[−0.67; −0.09]
Simon (SIP) 2008	125	−1.80	1.00	123	−0.750	0.95	−1.07	[−1.34; −0.81]
Random effects model	**2397**			**2211**			**−0.49**	**[−0.69; −0.29]**

Heterogeneity: I−squared=89%, tau−squared=0.1091, p<0.0001



Figure 4. Global assessment of sexual function—all estrogens compared with placebo

Study	Estrogen Total	Estrogen Mean	Estrogen SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95%–CI
Wiklund 1993	112	1.50	2.50	111	0.40	1.70	0.51	[0.25; 0.78]
Gambacciani 2003	25	0.15	0.25	25	−0.02	0.25	0.67	[0.10; 1.24]
Gelfand 2003	59	1.40	1.30	60	0.60	2.04	0.46	[0.10; 0.83]
Nielsen 2006	217	4.70	20.70	118	−3.50	17.00	0.42	[0.19; 0.65]
Osmanagaoglu 2006	53	0.50	4.10	51	0.00	4.00	0.12	[−0.26; 0.51]
Simon 2007	211	0.73	3.28	137	−0.30	3.39	0.31	[0.09; 0.53]
Huang (d) 2008	208	3.80	26.50	209	1.10	25.50	0.10	[−0.09; 0.30]
Welton 2008	1043	0.08	0.38	1087	0.04	0.42	0.10	[0.01; 0.18]
Haines 2009	80	1.00	1.70	80	0.80	1.60	0.12	[−0.19; 0.43]
Raghunandan 2010	25	1.80	1.67	25	0.90	1.45	0.57	[0.00; 1.13]
Random effects model	**2033**			**1903**			**0.28**	**[0.16; 0.41]**

Heterogeneity: I−squared=60.4%, tau−squared=0.0214, p=0.0068



Figure 5. Mean difference in satisfying sexual episodes over 4 weeks—testosterone compared with placebo in women with intact uteri



Figure 6. Mean difference in satisfying sexual episodes over 4 weeks—testosterone compared with placebo in women with and without intact uteri/ovaries



Figure 7. Mean difference in satisfying sexual episodes over 4 weeks—testosterone compared with placebo (all trials)



Figure 8. Interest in sex—all estrogens compared with placebo



Figure 9. Interest in sex—isoflavones compared with placebo



Appendix J. Urogenital Atrophy Plots

Figure 1. Urogenital atrophy forest plot of pairwise comparisons—vaginal estrogens compared with placebo

Study	Experimental Total	Experimental Mean	Experimental SD	Control Total	Control Mean	Control SD	SMD	95%–CI
Foidart 1991	53	1.800	8.02	56	7.00	8.02	–0.64	[–1.03; –0.26]
Eriksen 1992	79	0.211	0.41	75	0.53	0.50	–0.70	[–1.03; –0.37]
Speroff 2003	108	0.800	2.15	225	1.10	2.07	–0.14	[–0.37; 0.09]
Simunic 2003	784	0.195	0.40	828	0.60	0.49	–0.91	[–1.02; –0.81]
Parsons 2003	46	5.000	31.00	48	12.90	23.90	–0.28	[–0.69; 0.12]
Dessole 2004	44	0.091	0.29	44	0.80	0.40	–2.00	[–2.51; –1.48]
Bachmann 2008	47	0.800	1.65	183	1.39	0.41	–0.72	[–1.04; –0.39]
Bachmann (Study 1) 2009	72	0.700	1.40	143	1.10	1.40	–0.28	[–0.57; 0.00]
Freedman 2009	140	1.200	1.01	135	1.60	1.01	–0.39	[–0.63; –0.16]
Bachmann (Study 2) 2009	68	0.800	7.61	140	1.10	7.61	–0.04	[–0.33; 0.25]
Raghunandan 2010	25	1.600	3.95	25	4.60	3.95	–0.75	[–1.32; –0.17]
Random effects model	**1466**			**1902**			**–0.60**	**[–0.86; –0.33]**

Heterogeneity: I–squared=90.1%, tau–squared=0.1685, p<0.0001



Figure 2. Urogenital atrophy forest plot of pairwise comparisons—nonvaginal estrogens compared with placebo

Study	Any Total	Any Mean	Any SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Campbell 1977	68	1.200	65.20	68	23.300	65.20	−0.34	[−0.68; 0.00]	4.5%
Chung 1996	40	0.020	0.14	43	0.240	0.43	−0.68	[−1.12; −0.23]	3.0%
Bech 1998	51	−0.200	4.25	100	0.550	10.25	−0.09	[−0.42; 0.25]	4.5%
von Holst 2000	93	0.800	1.50	93	1.300	2.00	−0.28	[−0.57; 0.01]	5.5%
Rozenbaum 2002	57	0.900	23.40	54	13.800	19.80	−0.59	[−0.97; −0.21]	3.8%
Vestergaard 2003	504	−0.150	1.29	502	0.060	1.29	−0.16	[−0.29; −0.04]	11.5%
Schurmann 2004	61	0.108	0.31	164	0.258	0.44	−0.37	[−0.67; −0.07]	5.4%
Diem (d) 2006	209	0.038	0.19	208	0.042	0.20	−0.02	[−0.21; 0.17]	8.6%
Lee 2007	37	0.135	0.34	35	0.400	0.49	−0.62	[−1.10; −0.15]	2.7%
Simon 2007	137	0.190	0.92	347	0.643	1.20	−0.40	[−0.60; −0.20]	8.3%
Simon (SIP) 2008	123	0.720	2.32	125	1.700	2.32	−0.42	[−0.67; −0.17]	6.5%
Huang (d) 2008	209	3.100	22.30	208	7.600	22.30	−0.20	[−0.39; −0.01]	8.6%
Welton 2008	1087	0.030	0.17	1043	0.100	0.30	−0.29	[−0.37; −0.20]	13.1%
Haines 2009	80	0.233	0.42	80	0.261	0.44	−0.06	[−0.37; 0.25]	5.1%
Bachmann (d) 2009	36	0.194	0.40	85	0.408	0.49	−0.46	[−0.85; −0.06]	3.6%
Lin 2011	61	0.174	0.38	183	0.456	0.50	−0.60	[−0.89; −0.30]	5.4%
Random effects model	**2853**			**3338**			**−0.30**	**[−0.39; −0.22]**	**100%**

Heterogeneity: tau−squared=0.0125



Figure 3. Urogenital atrophy forest plot of pairwise comparisons—isoflavones with placebo

Study	Isoflavone Total	Isoflavone Mean	Isoflavone SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Kotsopoulos 2000	50	0.150	0.28	44	0.35	0.13	−0.90	[−1.33; −0.47]	19%
Hidalgo 2005	53	0.057	0.23	53	0.41	0.49	−0.92	[−1.32; −0.52]	20%
Mucci 2006	45	39.100	59.10	44	72.10	59.10	−0.55	[−0.98; −0.13]	20%
Lee 2010	44	1.000	1.00	43	0.97	0.79	0.03	[−0.39; 0.45]	20%
Cianci 2012	60	9.500	49.10	60	34.80	49.10	−0.51	[−0.88; −0.15]	21%
Random effects model	**252**			**244**			**−0.57**	**[−0.90; −0.24]**	**100%**

Heterogeneity: tau−squared=0.0994



Appendix K. Sleep Plots

Figure 1. Sleep dysfunction forest plot of pairwise comparisons—estrogen (standard dose) compared with placebo

Study	E–Standard Total	E–Standard Mean	E–Standard SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Polo–Kantola 1990	62	0.710	1.007	62	0.100	1.007	0.60	[0.24; 0.96]	5.3%
Wiklund 1993	112	1.200	1.800	111	0.300	1.700	0.51	[0.25; 0.78]	7.3%
Chung 1996	43	0.020	0.140	40	0.070	0.255	–0.24	[–0.68; 0.19]	4.2%
Bech 1998	100	1.050	2.300	51	–0.100	1.531	0.55	[0.21; 0.89]	5.6%
Strickler 2000	96	0.130	0.065	105	0.040	0.045	1.60	[1.29; 1.92]	6.1%
Vestergaard 2003	502	–0.070	0.346	504	–0.100	0.346	0.09	[–0.04; 0.21]	11.1%
Hays 2003	8506	0.500	3.700	8102	0.100	3.600	0.11	[0.08; 0.14]	12.9%
Brunner 2005	5310	0.460	3.840	5429	0.070	3.880	0.10	[0.06; 0.14]	12.9%
Nielson 2006	103	8.200	17.700	118	–1.900	18.900	0.55	[0.28; 0.82]	7.2%
Veerus 2008	415	0.053	0.224	381	0.023	0.150	0.16	[0.02; 0.30]	10.7%
Welton 2008	1043	0.103	0.399	1087	0.046	0.399	0.14	[0.06; 0.23]	12.1%
Baksu 2009	100	0.277	0.902	32	–0.350	0.950	0.68	[0.28; 1.09]	4.6%
Random effects model	**16392**			**16022**			**0.33**	**[0.22; 0.44]**	**100%**

Heterogeneity: tau–squared=0.0231



Figure 6. Sleep dysfunction forest plot of pairwise comparisons—estrogen (low and ultralow dose) compared with placebo (excludes outlier Gambacciani 2003)

Study	E–Low/Ultralow Total	E–Low/Ultralow Mean	E–Low/Ultralow SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Schurmann 2004	164	0.586	0.493	61	0.239	0.426	0.73	[0.43; 1.03]	16%
Diem 2006	208	–0.007	0.083	209	0.009	0.094	–0.18	[–0.37; 0.01]	18%
Nielson 2006	114	8.100	21.200	118	–1.900	18.900	0.50	[0.24; 0.76]	17%
Lee 2007	35	0.486	0.500	37	0.136	0.343	0.81	[0.33; 1.29]	14%
Panay 2007	375	0.443	0.497	200	0.169	0.375	0.60	[0.42; 0.77]	18%
Lin 2011	183	0.537	0.499	61	0.459	0.498	0.16	[–0.13; 0.45]	17%
Random effects model	**1079**			**686**			**0.42**	**[0.09; 0.75]**	**100%**

Heterogeneity: tau–squared=0.1459



Figure 3. Sleep dysfunction forest plot of pairwise comparisons—any estrogen compared with placebo (excludes outlier Gambacciani 2003)

Study	Any Estrogen Total	Any Estrogen Mean	Any Estrogen SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Campbell 1977	68	18.800	28.595	68	2.300	28.595	0.57	[0.23; 0.92]	4.3%
Polo−Kantola 1990	62	0.710	1.007	62	0.100	1.007	0.60	[0.24; 0.96]	4.1%
Wiklund 1993	112	1.200	1.800	111	0.300	1.700	0.51	[0.25; 0.78]	5.3%
Chung 1996	43	0.020	0.140	40	0.070	0.255	−0.24	[−0.68; 0.19]	3.3%
Bech 1998	100	1.050	2.300	51	−0.100	1.531	0.55	[0.21; 0.89]	4.3%
Strickler 2000	96	0.130	0.065	105	0.040	0.045	1.60	[1.29; 1.92]	4.6%
Vestergaard 2003	502	−0.070	0.346	504	−0.100	0.346	0.09	[−0.04; 0.21]	7.4%
Hays 2003	8506	0.500	3.700	8102	0.100	3.600	0.11	[0.08; 0.14]	8.3%
Schurmann 2004	164	0.586	0.493	61	0.239	0.426	0.73	[0.43; 1.03]	4.8%
Brunner 2005	5310	0.460	3.840	5429	0.070	3.880	0.10	[0.06; 0.14]	8.2%
Diem 2006	208	−0.007	0.083	209	0.009	0.094	−0.18	[−0.37; 0.01]	6.4%
Nielson 2006	217	8.150	19.900	118	−1.900	18.900	0.51	[0.29; 0.74]	5.9%
Lee 2007	35	0.486	0.500	37	0.136	0.343	0.81	[0.33; 1.29]	2.9%
Panay 2007	375	0.443	0.497	200	0.169	0.375	0.60	[0.42; 0.77]	6.7%
Veerus 2008	415	0.053	0.224	381	0.023	0.150	0.16	[0.02; 0.30]	7.2%
Welton 2008	1043	0.103	0.399	1087	0.046	0.399	0.14	[0.06; 0.23]	7.9%
Baksu 2009	100	0.277	0.902	32	−0.350	0.950	0.68	[0.28; 1.09]	3.6%
Lin 2011	183	0.537	0.499	61	0.459	0.498	0.16	[−0.13; 0.45]	5.0%
Random effects model	**17539**			**16658**			**0.36**	**[0.26; 0.46]**	**100%**

Heterogeneity: tau−squared=0.0322



Figure 4. Sleep dysfunction forest plot of pairwise comparisons—isoflavones compared with placebo (excludes Jassi 2010)

Study	Isoflavone Total	Isoflavone Mean	Isoflavone SD	Placebo Total	Placebo Mean	Placebo SD	SMD	95% CI	Weight
Kotsopoulos 2000	44	−0.09	0.14	50	0.05	0.10	−1.16	[−1.60; −0.72]	20%
Han 2002	40	2.20	1.68	40	0.00	1.90	1.21	[0.74; 1.69]	20%
Hidalgo 2005	53	0.45	0.50	53	0.13	0.34	0.75	[0.35; 1.14]	20%
Mucci 2006	44	0.74	0.44	45	0.40	0.49	0.72	[0.29; 1.15]	20%
Lee 2010	43	1.49	2.08	44	1.03	1.92	0.23	[−0.19; 0.65]	20%
Random effects model	**224**			**232**			**0.35**	**[−0.43; 1.13]**	**100%**

Heterogeneity: tau−squared=0.7407



Figure 5. Sleep dysfunction forest plot of pairwise comparisons—standard versus low dose estrogen

Study	E–Standard Total	E–Standard Mean	E–Standard SD	E–Low/Ultralow Total	E–Low/Ultralow Mean	E–Low/Ultralow SD	SMD	95% CI	Weight
Pornel 2005	377	8.7	2.6	387	10.6	3.2	–0.65	[–0.79; –0.50]	34%
Nielson 2006	103	8.2	17.7	114	8.1	21.2	0.01	[–0.26; 0.27]	31%
Limpaphyom 2006	344	9.4	4.8	684	9.8	5.0	–0.07	[–0.20; 0.06]	34%
Random effects model	**824**			**1185**			**–0.24**	**[–0.67; 0.18]**	**100%**

Heterogeneity: tau–squared=0.1346



Appendix L. Quality Assessments from Nelson report

Table 10. Quality assessment for articles reporting long term effects of hormone therapies

Study/Trial	Adequate randomizationn	Adequate concealment	Groups similar at baseline	Comparable groups maintained	Eligibility criteria specified	Outcome assessors masked	Care provider maskedHE	Patient masked
Anderson 2003{Anderson, 2003 #688}/WHI estrogen plus progestin	Y	Y	Y	Compliance similar	Y	Y	Y	Y
Anderson 2004{Anderson, 2004 #682} /WHI estrogen only	Y	Y	Y	Y	Y	Y	Y	Y
Cherry 2002{Cherry, 2002 #677}/ESPRIT	Y	Y	Y	Greater noncompliance in treatment group	Y	Y	Y	Y
Chlebowski 2010{Chlebowski, 2010 #308}/WHI estrogen plus progestin	Y	Y	Y	Y	Y	Y	Y	Y
Cirillo 2005{Cirillo, 2005 #685}/WHI estrogen plus progestin	Y	Y	Y	Y	Y	Y	Y	Y
Heiss 2008{Heiss, 2008 #686}/WHI estrogen plus progestin	Y	Y	Y	Y	Y	Y	Y	Y
Hulley 2002{Hulley, 2002 #678}/HERS and HERS II	Y	Y	Y	Y	Y	Y	Y	Y
LaCroix 2011{LaCroix, 2011 #306}/WHI estrogen only	Y	Y	Y	Y	Y	Y	Y	Y
Rossouw 2002{Rossouw, 2002 #460}/WHI estrogen plus progestin	Y	Y	Y	Y	Y	Y	Y	Y

Table 11. Quality assessment for articles reporting long term effects of hormone therapies, cont.

Study/Trial	Attrition, crossovers, adherence, and contamination reported	Differential loss to followup	Intention to treat analysis	Post-randomization exclusions	Outcomes prespecified	Funding source	External validity	Study Quality
Anderson 2003/WHI estrogen/ progestin	Y	N	Y	Not reported	Y	National Heart, Lung, and Blood Institute, US Dept of Health and Human Services	Good	Fair

Anderson 2004 /WHI estrogen only	Y	N	Y	N	Y	National Heart, Lung, and Blood Institute, US Dept of Health and Human Services	Good	Fair
Cherry 2002/ESPRIT	Unclear	Unclear	Y	Not reported	Y	Schering AG	Fair	Fair
Chlebowski 2010/WHI estrogen/ progestin	Y	N	Y	N	Y	National Heart, Lung, and Blood Institute, US Dept of Health and Human Services	Good	Fair
Cirillo 2005/WHI estrogen/ progestin	Y	N	Y	N	Y	National Heart, Lung, and Blood Institute, US Dept of Health and Human Services	Good	Fair
Heiss 2008/WHI estrogen/ progestin	Y	N	Y	N	Y	National Heart, Lung, and Blood Institute, US Dept of Health and Human Services	Good	Fair
Hulley 2002/HERS and HERS II	Y	N	Y	Y	Y	Wyeth-Ayerst Research	Good/Fair	Fair
LaCroix 2011/WHI estrogen only	Y	N	Y	N	Y	National Heart, Lung, and Blood Institute, US Dept of Health and Human Services	Good	Fair
Rossouw 2002/WHI estrogen/ progestin	Y	N	Y	N	Y	National Heart, Lung, and Blood Institute, US Dept of Health and Human Services	Good	Fair

Appendix M. Short-term Adverse Effects for Nonhormone Therapies

Table M-1a. Short-term adverse effects for prescription nonhormone therapies used to treat menopausal symptoms

Study (Author, Year, Country)	Treatment (dose)	N	Total Adverse Events	Blood and Lymphatic System	Cardiac	Congenital, Familial and Genetic Disorders	Ear and Labyrinth Disorders	Eye	Endocrine Disorders	Gastrointestinal	General Disorders and Administration Site Conditions	Hepatobiliary Disorders	Immune System Disorders	Infections and Infestations
Archer, 2009, United States	placebo	180						0.0% to 1.1%		1.7% to 8.3%	0.6% to 5.0%			
	desvenlafaxine (100mg)	182						1.6% to 2.2%		4.9% to 45.1%	3.8% to 11.5%			
	desvenlafaxine (150mg)	179						5.0% to 6.1%		7.8% to 44.1%	5.0% to 17.3%			
Archer, 2009, United States	placebo	151	105							0.7% to 7.3%	4.0%			
	desvenlafaxine (100mg)	150	125					5.3%		6.0% to 28.7%	12.7%			
	desvenlafaxine (150mg)	151	128					0.7%		3.3% to 21.9%	11.3%			
Speroff, 2008, United states	placebo	77	67					0.0% to 1.3%		0.0% to 10.4%	0.0% to 9.1%			
	desvenlafaxine (50mg)	149	134					0.7% to 3.4%		4.7% to 27.5%	3.4% to 7.4%			
	desvenlafaxine (100mg)	155	146					2.6% to 5.8%		5.8% to 38.7%	5.2% to 19.4%			
	desvenlafaxine (150mg)	157	149					6.4% to 8.9%		5.7% to 47.8%	3.8% to 17.2%			
	desvenlafaxine (200mg)	151	147					6.0% to 6.6%		9.3% to 45.0%	7.3% to 15.2%			
Oktem, 2007, Turkey	black cohosh (40mg)	40	7							0.0% to 5.0%	2.5%			
	fluoxetine (20mg)	40	13							2.5% to 5.0%	5.0%			
Bouchard, 2012, Multinational	placebo	152	85		5.3%					2.6% to 4.6%	2.0%			
	desvenlafaxine (100mg)	158	116		4.4%			5.7%		10.1% to 31.0%	8.9%			
Depomed (c), 2012, United States	placebo	177	69		0.6%					0.6% to 4.0%	0.6% to 1.7%			4.0% to 5.6%
	gabapentin (1200mg)	174	150							0.6% to	5.2%			6.3% to

Study (Author, Year, Country)	Treatment (dose)	N	Total Adverse Events	Blood and Lymphatic System	Cardiac	Congenital, Familial and Genetic Disorders	Ear and Labyrinth Disorders	Eye	Endocrine Disorders	Gastrointestinal	General Disorders and Administration Site Conditions	Hepatobiliary Disorders	Immune System Disorders	Infections and Infestations
										6.9%				8.0%
	gabapentin (1800mg)	181	173							3.9% to 8.8%	5.0%			0.6% to 6.1%
Depomed (c), 2012, United States	placebo	183	31							1.6%				
	gabapentin (1200mg)	186	85							3.2%				
	gabapentin (1800mg)	190	72							7.4%	0.5%			
Pfizer (c), 2011, Mulitinational	placebo	1052	908	0.5% to 1.7%	0.1% to 3.2%	0.1% to 0.2%	0.9 %	0.1% to 7.6%	1.5 %	0.1% to 16.3%	0.7% to 17.0%	0.3%	3.5 %	0.1% to 31.3%
	desvenlafaxine (100mg)	1066	984	0.8% to 1.0%	0.1% to 3.3%	0.3%	4.0 %	0.2% to 15.7%	0.7 %	0.1% to 26.2%	0.1% to 23.5%	0.1% to 0.3%	2.9 %	0.1% to 38.5%
Freeman, 2011, United States	placebo	101	62							5.0% to 17.8%	9.9% to 13.9%			
	escitalopram (10mg)	104	54							9.6% to 10.6%	3.8% to 13.5%			
Butt, 2008, Canada	placebo	98					1.0 %				1.0%			
	gabapentin (300mg)	99					2.0 %	4.0%			1.0% to 2.0%			
Clayden, 1974, United Kingdom	placebo	43			16.3%					11.6% to 20.9%				
	clonidine (0.05 to 0.15mg)	42			9.5%					26.2% to 28.6%				
Soares, 2010, Multinational	escitalopram (10 to 20mg)	299								7.0% to 20.4%				
	desvenlafaxine (100 to 200mg)	296								8.8% to 27.7%				

Blood and Lymphatic System: Anaemia **Cardiac:** Acute Myocardial Infarction, Angina Pectoris, Atrial Fibrillation, Coronary Artery Occlusion, Palpitation, Coronary Artery Disease **Congenital, Familial and Genetic Disorders:** Cerebrovascular Arteriovenous Malformation, Carotid artery occlusion **Ear and Labyrinth Disorders:** Vertigo **Eye:** Glaucoma, Narrow Anterior Chamber Angle, Retinal Haemorrhage, Abnormal vision, Mydriasis **Gastrointestinal:** Abdominal Pain, Colitis Ischaemic, Diverticular Perforation, Gastrooesophageal Reflux Disease, Ileus, Ileus Paralytic, Lower Gastrotintestinal Hemorrhage, Stomatitis, Swollen Tongue, Upper Gastrointestinal Hemorrhage, Flatulence, Abdominal Hernia, Gastroesophageal reflux disease exacerbation, Constipation, Diarrhea, Dry mouth, Nausea, Vomiting, Anorexia, Dyspeptic Problems **General Disorders:** Chest Pain, Drug Therapeutic Incompatibility, Fatigue, Non-Cardiac Chest Pain, Chills, Asthenia, Tiredness **Hepatobiliary Disorders:** Biliary Dyskinesia, Cholecystitis **Infections and Infestations:** Cellulitis, Diverticulitis, Enterocolitis Viral, Escherichia Sepsis, Herpes Zoster, Laryngitis, Pneumonia, Pyelonephrities, Subcutaneous Abscess, Urinary Tract Infection, Nasopharyngitis, Upper Respiratory Tract Infection

Note: Blank cells indicate 0 adverse events

Table M-1b. Short-term adverse effects for prescription nonhormone therapies used to treat menopausal symptoms (continued)

Study (Author, Year, Country)	Treatment (dose)	N	Total Adverse Events	Investigations	Injury, poisoning and procedural complications	Metabolism/ Nutritional	Musculoskeletal	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Nervous System	Psychiatric Disorders	Renal/ Urinary	Reproductive System and Breast Disorders	Respiratory, Thoracic and Mediastinal Disorders	Skin and Subcutaneous Tissue	Vascular
Archer, 2009, United States	placebo	180				3.9%			2.2% to 10.0%						3.9%
	desvenlafaxine (100mg)	182				7.1%			8.2% to 19.2%						7.1%
	desvenlafaxine (150mg)	179				2.8%			11.2% to 22.9%						2.8%
Archer, 2009, United States	placebo	151	105						0.7% to 7.3%						1.3%
	desvenlafaxine (100mg)	150	125						9.3% to 12.7%						5.3%
	desvenlafaxine (150mg)	151	128						9.3% to 11.9%						4.0%
Speroff, 2008, United states	placebo	77	67			0.0% to 3.9%			0.0% to 10.4%					0.0% to 2.6%	1.3%
	desvenlafaxine (50mg)	149	134			2.7% to 4.0%			0.7% to 15.4%					1.3% to 6.0%	4.0%
	desvenlafaxine (100mg)	155	146			5.2% to 5.8%			2.6% to 19.4%					1.9% to 2.6%	5.2%
	desvenlafaxine (150mg)	157	149			2.5% to 7.6%			1.9% to 27.4%					1.3% to 2.5%	6.4%
	desvenlafaxine (200mg)	151	147			3.3% to 6.0%			1.3% to 27.2%					0.7% to 6.0%	7.9%
Oktem, 2007, Turkey	black cohosh (40mg)	40	7						0.0% to 2.5%					2.5%	
	fluoxetine (20mg)	40	13						2.5% to 7.5%					5.0%	
Bouchard, 2012, Multinational	placebo	152	85				0.7%		1.3% to 3.9%		0.7 %				
	desvenlafaxine (100mg)	158	116				3.8%		7.0% to 10.8%		0.6 %				
Depomed (c), 2012, United States	placebo	177	69	2.3%			5.1%		0.6% to 5.6%						
	gabapentin (1200mg)	174	150	2.9%			2.3%	0.6%	8.6% to 23.6%				0.6%		
	gabapentin (1800mg)	181	173	5.0%	0.6%		2.8%	0.6%	0.6% to 19.3%						
Depomed (c), 2012, United	placebo	183	31		0.5%				0.5% to 7.7%						

Study (Author, Year, Country)	Treatment (dose)	N	Total Adverse Events	Investigations	Injury, poisoning and procedural complications	Metabolism/ Nutritional	Musculoskeletal	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Nervous System	Psychiatric Disorders	Renal/ Urinary	Reproductive System and Breast Disorders	Respiratory, Thoracic and Mediastinal Disorders	Skin and Subcutaneous Tissue	Vascular
States	gabapentin (1200mg)	186	85		0.5%			0.5%	4.8% to 17.2%						
	gabapentin (1800mg)	190	72		0.5%				1.6% to 18.9%						
Pfizer (c), 2011, Mulitinational	placebo	1052	908	0.1% to 9.7%	0.1% to 20.2%	0.1% to 4.2%	0.2% to 34.2%	0.1% to 1.0%	0.1% to 24.9%	23.0%		0.1% to 11.8%	0.4% to 19.6%	0.1% to 11.5%	3.1% to 6.0%
	desvenlafaxine (100mg)	1066	984	0.1% to 12.4%	0.0% to 22.0%	0.2% to 7.1%	0.1% to 27.8%	0.1% to 1.4%	0.1% to 31.1%	0.2% to 43.8%	0.1 %	0.1% to 9.8%	0.1% to 25.3%	0.2% to 15.7%	3.6% to 10.1%
Freeman, 2011, United States	placebo	101	62	4.0%					6.9% to 10.9%					8.9%	
	escitalopram (10mg)	104	54	5.8%					2.9% to 8.7%					6.7%	
Butt, 2008, Canada	placebo	98							1.0% to 36.7%						
	gabapentin (300mg)	99							2.0% to 25.3%						
Clayden, 1974, United Kingdom	placebo	43					11.6%		51.2%			2.3%		9.3%	
	clonidine (0.05 to 0.15mg)	42					11.9%		52.4%			2.4%		16.7%	
Soares, 2010, Multinational	escitalopram (10 to 20mg)	299							9.4% to 28.4%					11.0%	
	desvenlafaxine (100 to 200mg)	296							11.1% to 25.7%					14.5%	

Investigations: Weight Increased, Blood Creatine Phosphokinase MB Increased, Blood Pressure Increased, Cardiac Stress Test Abnormal, Electrocardiogram T Wave Abnormal, Electrocardiogram T Wave Inversion, Electrocardiogram Abnormal **Injury, poisoning and procedural complications:** Overdose; Attempted Suicide, Accidental Overdose, Road Traffic Accident, Meniscus Lesion, Rib Fracture, Drug Toxicity, Hand Fracture, Injury, Intentional Overdose, Limb Injury, Patella Fracture, Radius Fracture, Traumatic Intracranial Hemorrhage, Ulna Fracture **Metabolism/Nutritional:** Weight Gain, Hypercholesteremia, Hyperlipemia, Hypokalaemia **Musculoskeletal and Connective Tissue:** Arthralgia, Back Pain, Bunion, Flank Pain, Foot Deformity, Intervertebral Disc Protrusion, Knee Deformity, Musculoskeletal Chest Pain, Osteoarthritis, Pain in Extremity **Neoplasms benign, malignant and unspecified (incl cysts and polyps):** Breast Cancer, Basal Cell Carcinoma, Carcinoid Tumor Pulmonary, Dermatofibrosarcoma, Lung Adenocarcinoma, Malignant Lung Neoplasm, Malignant Melanoma In Situ, Multiple Myeloma, Non-Small Cell Lung Cancer Stage III, Ovarian Cancer, Ovarian Cancer Recurrent, Pancreatic Carcinoma Metastatic, Squamous Cell Carcinoma of Skin, Thyroid Cancer, Transitional Cell Carcinoma, Uterine Leiomyoma **Nervous System**: Ageusia, Cerebral Hematoma, Cerebrovascular Disorder, Cervical Myelopathy, Confusion, Convulsion, Dizziness, Dysarthria, Headache, Hypoaesthesia, Insomnia, Irritability, Libido Decrease, Migraine, Nerve Compression, Nervousness, Paraesthesia, Presyncope, Sedation, Somnolence, Thinking Abnormal, Transient Ischemic Attack **Psychiatric Disorders:** Major Depression, Mental Status Changes **Reproductive System and Breast Disorders:** Endometrial Hyperplasia **Respiratory, Thoracic and Mediastinal Disorders:** Acute Resperatory Failure, Asthma, Chronic Obstructive Pulmonary Disease, Non-Cardiogenic Pulmonary Edema, Pulmonary Embolism, Pneumothorax **Renal/ Urinary:** Leukorrhea, Nephrolithiasis, Renal Failure Acute **Skin and Subcutaneous Tissue:** Sweating, Rash, Allergic Skin Reaction, Erythema, Pruritus **Vascular:** Hypertension

Note: Blank cells indicate 0 adverse events

Table M-2a.Short-term adverse effects for nonprescription nonhormone therapies used to treat menopausal symptoms

Study (Author, Year, Country)	Treatment (dose), n	N	Individuals with adverse events	Total Adverse Events	Blood and Lymphatic System	Cardiac	Ear and Labyrinth	Endocrine	Eye	Gastrointestinal	General Disorders and Administration Site Conditions	Immune	Infections
Evans, 2011, Canada	Placebo	42	33	79						0.0% to 14.3%			
	Genistein (30mg)	41	29	72						0.0% to 9.8%			
Garcia, 2010, Multinational	Placebo	31	9	34						6.5%	6.5%		3.2%
	Nutrafem [multibotanical]	103	43	109			1.0%			9.7%	5.8%	1.9%	1.9%
Chandeying, 2007, Thailand	CEE + MPA (0.625mg E + 2.5mg P)	30		34		3.3%				0.0% to 6.7%			
	Pueraria mirifica (50 mg)	30		31		6.7%				0.0% to 10.0%	3.3%		
Newton, 2006, United States	Placebo	84		67						15.5%	9.5%		
	CEE + MPA (0.625mg E + 2.5mg P)	32		41						12.5%	18.8%		
	Black cohosh (160 mg)	80		57						15.0%	15.0%		
	ProGyne multibotanical w/ black cohosh (200 mg) + 9 other ingredients	76		44						14.5%	9.2%		
	ProGyne multibotanical + dietary soy counseling	79		57						10.1%	15.2%		
Heger, 2006, Ukraine	Placebo	55	8										
	Phytoestrol N [rheum rhaponticum] (4 mg)	54	8			1.9%				1.9%			
Tice, 2003, United States	Placebo	85		33						3.5% to 4.7%			
	Rimostil (57.2 mg)	83		28						3.6% to 9.6%			
	Promensil (82 mg)	84		31						2.4% to 4.8%			
Albertazzi, 1998, Italy	Placebo	53		45						1.9% to 50.9%			
	Isoflavones [soy protein] (76 mg)	51		35						0.0% to 49.0%			
de Sousa-Munoz,	Placebo	42	7	16	2.4%					0.0% to 7.1%			

Study (Author, Year, Country)	Treatment (dose), n	N	Individuals with adverse events	Total Adverse Events	Blood and Lymphatic System	Cardiac	Ear and Labyrinth	Endocrine	Eye	Gastrointestinal	General Disorders and Administration Site Conditions	Immune	Infections
2009, Brazil	Isoflavones (120 mg)	42	12	22					2.4%	0.0% to 4.8%			
Uebelhack, 2006, Germany	Placebo	150		32	0.7%		0.7%		1.3%	0.7%			10.7%
	St. John's Wort (70 mg) + black cohosh (3.75 mg)	151		35					0.7%	0.7%	0.7%		11.9%
Kotsopoulos, 2000, Australia	Placebo	50		9						4.0%	12.0%	2.0%	
	Isoflavones [daidzein, genistein, glycitein] (118 mg)	44		10							15.9%		
Panjari, 2009, Australia	Placebo	43		24									
	DHEA (50 mg)	46		31									
Ho, 2007, Hong Kong	Placebo	91	43	68			1.1%	3.3%		3.3% to 11.0%	3.3%		
	Isoflavones [soy] (80 mg)	85	58	103			1.2%	2.4%	2.4%	3.5% to 16.5%	2.4%		
Osmers, 2005, Germany	Placebo	151		47	0.7%		0.7%			4.6%	0.7%		12.6%
	Remifemin [black cohosh] (40 mg)	153		50	0.7%	1.3%				5.2%	0.7%		8.5%
Levis, 2011, United States	Placebo	126	121		0.8% to 15.1%					9.5% to 42.9%			
	Novasoy [soy protein] (200 mg)	122	122		0.8% to 15.6%					17.2% to 52.5%			
Radhakrishnan, 2009, India	Placebo	41		27						0.0% to 34.1%	2.4%		
	Isoflavones [soy protein] (75 mg)	44		33						2.3% to 34.1%	6.8%		
Plotnikoff, 2011, United States	placebo	59								1.7%			
	keishibukuryogab (7.5g)	62								22.6%			
	keishibukuryogab (12.5g)	57								19.3%			

Blood and Lymphatic System: Anemia, Leukemia, Leg Edema **Cardiac:** Palpitation, Cardiomyopathy **Ear and Labyrinth:** Hearing **Endocrine:** Thyroid Eye: Blurred Vision, Swollen Eye **Gastrointestinal:** Anorexia, Bloating, Heartburn, Constipation, Diarrhea, Dry mouth, Nausea, Vomiting, Nausea/ Vomiting, Epigastric Pain, Stomach/GI Ache or Upset, Duodenal Ulcer, Flatulence **General Disorders and Administration Site Conditions:** Drowsiness/Tiredness, Weakness, Unpalatable/intolerable

Note: Blank cells indicate 0 adverse events

Table M-2b. Short-term adverse effects for nonprescription nonhormone therapies used to treat menopausal symptoms (continued)

Study (Author, Year, Country)	Treatment (dose), n	N	Individuals with adverse events	Total Adverse Events	Injury, Posoning, or Procedural Complications	Investigations	Metabolism/Nutritional	Musculoskeletal	Neoplasms	Nervous System	Psychiatric	Renal/ Urinary	Reproductive System/Breast	Respiratory and Thoracic	Skin and Subcutaneous Tissue	Surgical and Medical Procedures	Vascular	Other
Evans, 2011, Canada	Placebo	42	33	79						2.4%	2.4%		0.0% to 7.1%					
	Genistein (30mg)	41	29	72						0.0% to 2.4%		2.4%	2.4% to 9.8%		2.4%			
Garcia, 2010, Multinational	Placebo	31	9	34				12.9%		9.7%			3.2%	12.9 %	9.7%	3.2%		
	Nutrafem [multibotanical]	103	43	109		2.9%		9.7%		12.6%			1.0%	17.5 %	1.9%	1.9%		
Chandeying, 2007, Thailand	CEE + MPA (0.625mg E + 2.5mg P)	30		34			10.0%			0.0% to 6.7%		3.3%	0.0% to 30.0%	10.0 %	6.7%			3.3% to 6.7%
	Pueraria mirifica (50 mg)	30		31				3.3%		0.0% to 20.0%			6.7% to 16.7%	6.7%	3.3%			
Newton, 2006, United States	Placebo	84		67				11.9%		19.0%			3.6% to 20.2%					
	CEE + MPA (0.625mg E + 2.5mg P)	32		41				3.1%		18.8%			15.6% to 59.4%					
	Black cohosh (160 mg)	80		57				13.8%		15.0%			0.0% to 12.5%					
	ProGyne multibotanical w/ black cohosh (200 mg) + 9 other ingredients	76		44				11.8%		10.5%			1.3% to 10.5%					
	ProGyne multibotani	79		57				11.4%		15.2%			2.5% to 17.7%					

Study (Author, Year, Country)	Treatment (dose), n	N	Individuals with adverse events	Total Adverse Events	Injury, Posoning, or Procedural Complications	Investigations	Metabolism/Nutritional	Musculoskeletal	Neoplasms	Nervous System	Psychiatric	Renal/ Urinary	Reproductive System/Breast	Respiratory and Thoracic	Skin and Subcutaneous Tissue	Surgical and Medical Procedures	Vascular	Other
	cal + dietary soy counseling																	
Heger, 2006, Ukraine	Placebo	55	8				1.8%	1.8%				1.8%	0.0% to 3.6%	1.8%				1.8%
	Phytoestrol N [rheum rhaponticum] (4 mg)	54	8				1.9%	1.9%		1.9%			0.0% to 1.9%	1.9%				
Tice, 2003, United States	Placebo	85		33				15.3%		12.9%				16.5 %				
	Rimostil (57.2 mg)	83		28				18.1%		4.8%				12.0 %				
	Promensil (82 mg)	84		31				17.9%		6.0%				10.7 %				
Albertazzi, 1998, Italy	Placebo	53		45														17.0%
	Isoflavones [soy protein] (76 mg)	51		35														5.9%
de Sousa-Munoz, 2009, Brazil	Placebo	42	7	16			4.8%	7.1%		0.0% to 4.8%								
	Isoflavones (120 mg)	42	12	22			2.4%	4.8%		2.4% to 4.8%			2.4%					7.1%
Uebelhack, 2006, Germany	Placebo	150		32	1.3%	2.0%		3.3%					0.7%					
	St. John's Wort (70 mg) + black cohosh (3.75 mg)	151		35	1.3%	2.0%	1.3%	4.0%		0.7%								
Kotsopoulos, 2000, Australia	Placebo	50		9														
	Isoflavones [daidzein, genistein, glycitein] (118 mg)	44		10			2.3%											2.3%
Panjari,	Placebo	43		24														55.8%

Study (Author, Year, Country)	Treatment (dose), n	N	Individuals with adverse events	Total Adverse Events	Injury, Posoning, or Procedural Complications	Investigations	Metabolism/Nutritional	Musculoskeletal	Neoplasms	Nervous System	Psychiatric	Renal/ Urinary	Reproductive System/Breast	Respiratory and Thoracic	Skin and Subcutaneous Tissue	Surgical and Medical Procedures	Vascular	Other
2009, Australia	DHEA (50 mg)	46		31														4.3% to 56.5%
Ho, 2007, Hong Kong	Placebo	91	43	68			2.2% to 3.3%	4.4% to 8.8%	1.1%	4.4%			2.2%	2.2%	2.2%		1.1% to 2.2%	2.2% to 4.4%
	Isoflavones [soy] (80 mg)	85	58	103			3.5% to 7.1%	3.5% to 20.0%		1.2% to 9.4%			3.5% to 4.7%	2.4%	2.4%		1.2% to 4.7%	1.2% to 8.2%
Osmers, 2005, Germany	Placebo	151		47		3.3%		6.6%		3.3%	3.3%		2.6%	0.7%	2.0%		0.7%	
	Remifemin [black cohosh] (40 mg)	153		50	1.3%	3.9%	1.3%	9.8%		2.6%	1.3%	0.7%	2.6%		2.0%		0.7%	
Levis, 2011, United States	Placebo	126	121					0.8% to 5.6%	0.8%	34.1%		4.0%	4.8% to 23.8%	4.0%			4.0%	7.1% to 34.1%
	Novasoy [soy protein] (200 mg)	122	122					4.9% to 5.7%	0.8%	44.3%		5.7%	7.4% to 25.4%	5.7%			4.1%	2.5% to 32.0%
Radhakrishnan, 2009, India	Placebo	41		27											4.9%			
	Isoflavones [soy protein] (75 mg)	44		33											4.5%			
Plotnikoff, 2011, United States	placebo	59																
	keishibukuryogab (7.5g)	62																
	keishibukuryogab (12.5g)	57																

Immune: Immune Disorders, Allergies **Metabolism/Nutritional:** Appetite Increase, Weight Gain, Hunger **Musculoskeletal:** Musculoskeletal spasm/numbness, Fracture, Back Pain, Myalgia/ Arthralgia **Nervous System:** Dizziness, Insomnia, Headache, Nervous Disorders, Memory, Sole/Palm Numb, Intercostal Neuralgia, Tremors **Psychiatric:** Increased Emotionality **Renal/ Urinary:** Renal/ Urinary, UTI, Dysuria, Nocturia, Freq Urination **Reproductive System/Breast:** Breast soreness, Abnormal Mammogram, Reproductive System/Breast, Mastodynia, Cramps, Vaginal bleeding/Spotting, Vaginal Odor, Uterofibroma, Endometrium Dysplasia, Cervical Dysplasia, Pelvic Discomfort, Menstrual Disorder **Respiratory and Thoracic:** Upper RTI, Chest Discomfort **Skin and Subcutaneous Tissue:** Bruisability, Itching, Skin Disorders **Vascular:** Vascular Disorders, Hypertension, Hemorrhoids **Other:** Lower extremity weakness, Lower Extremity Tenderness, Abdominal pain, Acute Appendicitis, Sweating, Hand Sweats, Nonandrogeneic Aes, Increased Facial Hair, Hair Loss

Note: Blank cells indicate 0 adverse events

Appendix N. Effectiveness of Treatments for Menopausal Symptoms in Selected Subgroups

Vasomotor Symptoms

Table 12. Vasomotor outcomes by age subgroups

Rigano, 2001, Italy {Rigano, 2001 #103}

		Age 48-50		Age 51-53		Age 54-56	
Outcome	**Treatment**	**(N=163)**	**Subgroup N**	**(N=113)**	**Subgroup N**	**(N=86)**	**Subgroup N**
HFs (% without)	Placebo	14	75	61	61	17	55
	0.05 mg estradiol	80	88	62	52	100	31

Hedrick, 2010, Multinational{Hedrick, 201 #204}

		Age <50		Age 50-59		Age ≥60	
Outcome	**Treatment**	**(N=110)**	**Subgroup N**	**(N=277)**	**Subgroup N**	**(N=101)**	**Subgroup N**
Daily MSHFNS (mean change)	Placebo	-6.4	24	-5.1	77	-4.7	23
	0.25 mg estradiol	-8.5	21	-8.0[a]	73	-6.7	27
	0.50 mg estradiol	-6.7	29	-7.9[a]	68	-7.1	22
	1.0 mg estradiol	-9.3	36	-8.3[a]	59	-9.7[a]	29
Daily MSHFNS Severity Score (mean change)	Placebo	-0.8	24	-0.4	77	-0.4	23
	0.25 mg estradiol	-1.0	21	-0.7	73	-1.2[a]	27
	0.50 mg estradiol	-0.9	29	-1.0[b]	68	-1.1[c]	22
	1.0 mg estradiol	-1.2	36	-1.4[b]	59	-1.6[b]	29

Davis, 2001, Australia{Davis, 2001 #107}

		Age <55		Age ≥ 55	
Outcome	**Treatment**	**(N=NR)**	**Subgroup N**	**(N=NR)**	**Subgroup N**
MENQOL Vasomotor (difference in change from placebo)	Chinese medicinal herbs	-0.94 (95% CI: -1.7 to -0.14)	NR	0.51 (95% CI: -0.56 to 1.6)	NR

HFs: hot flashes; MENQOL: Menopause-specific Quality of Life; MSHF: moderate-to-severe hot flashes; MSHFNS: moderate-to-severe hot flashes and night sweats; N: number; NR: not reported; THFNS: total hot flashes and night sweats

a Difference from placebo: <0.01

b Difference from placebo: <0.001

c Difference from placebo: <0.05

Table 13. Vasomotor outcomes by BMI subgroups

Davis, 2001, Australia {Davis, 2001 #107}

		BMI ≤ 25		BMI 25	
Outcome	**Treatment**	**(N=NR)**	**Subgroup** N	**(N=NR)**	**Subgroup** N
MENQOL Vasomotor (difference in change from placebo)	Chinese medicinal herbs	-0.85 (95% CI: -1.6 to -0.08)	NR	0.42 (95% CI: -0.73 to 1.58)	NR
Daily THFNS (difference of mean % reduction)	Chinese medicinal herbs	7.1% (95% CI: -21.4% to 35.5%)	NR	26.2% (95% CI: -0.48% to 52.9%)	NR

Tice, 2003, United States {Tice, 2003 #78}

		BMI 25		BMI 25.1	
Outcome	**Treatment**	**(N=NR)**	**Subgroup** N	**(N=NR)**	**Subgroup** N
Weekly THF (% reduction at 12-weeks)	Placebo	40% (95% CI: 26 to 55%)	NR	32% (95% CI: 21 to 42%)	NR
	82mg isoflavones (Promensil)	30% (95% CI: 16 to 44%)	NR	49% (95% CI: 35 to 63%)	NR
	57.2mg isoflavones (Rimostil)	22% (95% CI: 7 to 37%)	NR	45% (95% CI: 32 to 59%)	NR

BMI: Body Mass Index; MENQOL: Menopause-specific Quality of Life; N: number; NR: not reported;THF: total hot flashes; THFNS: total hot flashes and night sweats

Table 14. Vasomotor outcomes by race subgroups

Freeman, 2011, United States{Freeman, 2011 #624}

		African American	White	Other
Outcome	**Treatment**	**(N=47)**	**(N=53)**	**(N=4)**
Daily THFNS (mean change)	10-20mg escitalopram	-0.48 95% CI: -3.0 to 2.0	-2.2 95% CI: -3.5 to -0.87	-2.3 95% CI: -7.8 to -3.2

CI: confidence interval; THFNS: total hot flashes and night sweats

Table 15. Vasomotor outcomes by severity of symptoms subgroups

Aso, 2012, Japan {Aso, 2012 #608}

			≤2 hot flashes/day		≥3 hot flashes/day	
Outcome	**Treatment**		**(N=64)**	**Subgroup** N	**(N=62)**	**Subgroup** N
Daily THF (mean)	Placebo	baseline:	1.6 (SD: 0.57)		4.4 (SD: 2.3)	
		12-week:	0.70	32	NR	34
		12-week mean change:	NR		-1.2 (SD: 2.9)	
	10 mg equol	baseline:	1.5 (SD: 0.57)		4.9 (SD: 2.3)	
		12-week:	0.59	32	NR	28
		12-week mean change:	NR		-2.9 (SD: 2.0)[a]	
Mattsson, 2007, Multinational{Mattsson, 2007 #32}						
			≥30 hot flashes at baseline		**<30 hot flashes at baseline**	
Outcome	**Treatment**		**(N=NR)**	**Subgroup** N	**(N=NR)**	**Subgroup** N
Weekly MSHF (mean)	1mg E2V 2.5mg MPA	baseline:	53.7		18.7	
		12-week:	5.3	NR	1.1	NR
		last:	2.6[b]		0.61[c]	
	1mg E2V 5mg MPA	baseline:	51.3		21.8	
		12-week:	4.5	NR	2.5	NR
		last:	4.9[b]		1.4[c]	
	2mg E2V 5mg MPA	baseline:	55.6		16.7	
		12-week:	3.2	NR	0.99	NR
		last:	2.3[b]		0.61[c]	
Maki, 2007, United States {Maki, 2007 #30}						
			asymptomatic at baseline		**symptomatic at baseline**	
Outcome	**Treatment**		**(N=81)**	**Subgroup** N	**(N=79)**	**Subgroup** N
Green vasomotor (mean change)	Placebo		-0.8	45	-1.6	38
	0.625mg CEE + 2.5mg MPA		-1.0	36	-2.8[e]	41
Diem, 2006, United States {Diem, 2006 #48}						
			very frequent vasomotor symptoms		**somewhat frequent vasomotor symptoms**	
Outcome	**Treatment**		**(N=9)**	**Subgroup** N	**(N=57)**	**Subgroup** N

Weekly THF	Placebo	baseline:	1.4%	3	14.4%	30
		2-year:	0.5%		8.2%	
	0.014mg estradiol (Menostar)	baseline:	2.9%	6	13.0%	27
		2-year:	0.5%[d]		7.4%[d]	

CEE: conjugated equine estrogen; E2V: estradiol valerate; MPA: medroxprogesterone acetate; N: number; NR: not reported;THF: total hot flashes; SD: standard deviation
a Difference from placebo p-value: 0.009
b pre-/post p-value at last: <0.001
c pre-/post p-value at last: <0.05
d Difference from placebo p-value: NS
e Difference from placebo p-value: 0.001

Table 16. Vasomotor outcomes by time since menopause subgroups

Baerug, 1998, Norway{Baerug, 1998 #96}								
			late perimenopausal		**post menopausal**			
Outcome	**Treatment**		**(N=NR)**	**Subgroup** N	**(N=NR)**	**Subgroup** N		
Weighted Weekly HFS (mean)	Placebo	baseline:	100.2	NR	124.5	NR		
		12-week:	38.0		79.3			
	1mg estradiol + 0.25mg NETA (Activelle)	baseline:	107.1	NR	126.9	NR		
		12-week:	1.4		10.8			
	1mg estradiol + 0.5mg NETA (Activelle)	baseline:	105.3	NR	127.5	NR		
		12-week:	1.2		7.4			

Davis, 2001, Australia {Davis, 2001 #107}					
		years amenorrhea		**years amenorrhea**	
Outcome	**Treatment**	**(N=NR)**	**Subgroup** N	**(N=NR)**	**Subgroup** N
MENQOL Vasomotor (difference in changes from placebo)	Chinese medicinal herbs	-0.31 (95% CI: -1.7 to 1.1)	NR	-0.09 (95% CI: -0.61 to 0.42)	NR
Daily THFNS (difference in changes from placebo)	Chinese medicinal herbs	4.8% (95% CI: -24.6 to 34.2%)	NR	26.8% (95% CI: 3.8% to 49.9%)	NR

Osmers, 2005, Germany{Osmers, 2005 #211}									
		early climacteric women		**late climacteric women**					
Outcome	**Treatment**	**(N=NR)**	**Subgroup** N	**(N=NR)**	**Subgroup** N				
MRS - HF (difference in changes from placebo)	40 mg black cohosh (Remifemin)	-0.11 (95% CI: -0.17 to -0.04)[a]	NR	-0.07 (95% CI: -0.13 to -0.02)[b]	NR				
Simon, 2001, United States {Simon, 2001 #106}									
		0 to ≤ mos since last menses		**6 to ≤12mos since last menses**		**12 to ≤36 mos since last menses**		**>36 mos since last menses**	
Outcome	**Treatment**	**(N=33)**	**Subgroup** N	**(N=7)**	**Subgroup** N	**(N=19)**	**Subgroup** N	**(N=58)**	**Subgroup** N
Daily MSHF (mean % reduction)	Placebo	-74.0 (SD: 31.0)	15	-27.9 (SD: 0)	1	-46.7 (SD: 40.9)	6	-53.1 (SD: 44.0)	25
	0.625 mg synthetic CE-A (Cenestin)	-77.5 (SD: 27.6)[c]	18	-82.6 (SD: 32.1)[c]	6	-85.2 (SD: 29.6)[d]	13	-80.1 (SD: 32.7)[d]	33

CE: conjugated estrogen; HFS: Hot flash Score; MENQOL: Menopause-specific Quality of Life; MRS – HF: Menopause Rating Scale – hot flashes; MSHF: Moderate-to-severe hot flashes; N: number; NR: not reported; NETA: norethisterone acetate; SD: standard deviation; THFNS: total hot flashes and night sweats
a Difference from placebo p-value: 0.002
b Difference from placebo p-value: 0.006
c Difference from placebo p-value: NS
d Difference from placebo p-value: <0.05

Table 17. Vasomotor outcomes by uterus status subgroups

Hedrick, 2010, Multinational{Hedrick, 2010 #204}					
		absent uterus		**intact uterus**	
Outcome	**Treatment**	**(N=259)**	**Subgroup** N	**(N=229)**	**Subgroup** N
Daily MSHFNS (mean change)	Placebo	-5.9	71	-4.4	53
	0.25mg estradiol (Divigel)	-8.8[a]	58	-7.0	63
	0.50mg estradiol (Divigel)	-7.0	62	-8.0[c]	57
	1mg estradiol (Divigel)	-9.7[b]	68	-8.0[c]	56

Daily MSHFNS Severity Score (mean change)	Placebo	-0.5	71	-0.4	53
	0.25mg estradiol (Divigel)	-0.8	58	-0.9[a]	63
	0.50mg estradiol (Divigel)	-0.8	62	-1.2[b]	57
	1mg estradiol (Divigel)	-1.4[b]	68	-1.4[b]	56

MSHFNS: moderate-to-severe hot flashes and night sweats; N: number
a Difference from placebo p-value: <0.05
b Difference from placebo p-value: <0.001
c Difference from placebo p-value: <0.01

Sexual Function

Table 18. Sexual function outcomes by age subgroups

Rigano, 2001, Italy {Rigano, 2001 #103}

		age 48-50		**age 51-53**		**age 54-56**	
Outcome	**Treatment**	**(N=163)**	**Subgroup N**	**(N=113)**	**Subgroup N**	**(N=86)**	**Subgroup N**
sexual activity (% reporting decrease)	Placebo	44%	75	62%	61	48%	55
	0.05mg estradiol	48%	88	75%	52	84%	31

Davis, 2001, Australia {Davis, 2001 #107}

		age < 55		**age ≥ 55**	
Outcome	**Treatment**	**(N=NR)**	**Subgroup N**	**(N=NR)**	**Subgroup N**
MENQOL sexual score (difference in changes from placebo)	Chinese medicinal herbs	-0.72 (95% CI: -2.8 to 1.4)	NR	-0.14 (95% CI: -1.3 to 1.0)	NR

MENQOL: Menopause-specific Quality of Life; N: number; NR: not reported; SD: standard deviation

Table 19. Sexual function outcomes by BMI subgroups

Davis, 2001, Australia {Davis, 2001 #107}

		BMI ≤ 25	**BMI > 25**
Outcome	**Treatment**	**(N=NR)**	**(N=NR)**
MENQOL sexual score (difference in changes from placebo)	Chinese medicinal herbs	-1.0 (95% CI:-2.7 to 0.65)	0.18 (95% CI: -1.5 to 1.8)

MENQOL: Menopause-specific Quality of Life; N: number; NR: not reported

Table 20. Sexual function outcomes by time since menopause subgroups

Davis, 2001, Australia{Davis, 2001 #107}

Outcome	Treatment	< 4 years amenorrhea (N=NR)	≥ 4 years amenorrhea (N=NR)
MENQOL sexual score (difference in changes from placebo)	Chinese medicinal herbs	0.52 (95% CI: -1.6 to 2.6)	-0.96 (95% CI: -2.1 to 0.16)

MENQOL: Menopause-specific Quality of Life; N: number; NR: not reported

Table 21. Sexual function outcomes by uterus status subgroups

Davis, 2008, Multinational{Davis, 2008 #165}

Outcome	Treatment		natural menopause (N=572)	Subgroup N	surgical menopause (N=199)	Subgroup N
frequency of satisfying sexual episodes per week (mean)	Placebo	baseline:	2.4 (SD: 2.8)	196	2.6 (SD: 2.5)	69
		last:	3.0 (SD: 4.2)		4.1 (SD: 4.2)	
	0.15mg testosterone	baseline:	2.8 (SD: 2.7)	187	3.1 (SD: 4.0)	65
		last:	4.0 (SD: 4.1)[a]		4.0 (SD: 4.8)[c]	
	0.30mg testosterone	baseline:	2.6 (SD: 2.8)	189	2.0 (SD: 2.4)	65
		last:	4.5 (SD: 5.5)[b]		4.4 (SD: 5.6)[c]	

N: number; SD: standard deviation
[a] difference from placebo p-value: 0.02
[b] difference from placebo p-value: <0.001
[c] difference from placebo p-value: NS

Psychological Symptoms

Table 22. Psychological outcomes by age subgroups

Davis, 2001, Australia {Davis, 2001 #107}

Outcome	Treatment	age < 55 years (N=NR)	age ≥ 55 years (N=NR)
MENQOL psychological score (difference in changes from placebo)	Chinese medicinal herbs	-0.22 (95% CI: -1.00 to 0.57)	0.10 (95% CI: -0.77 to 0.96)

MENQOL: Menopause-specific Quality of Life; N: number; NR: not reported

Table 23. Psychological outcomes by BMI subgroups

Davis, 2001, Australia {Davis, 2001 #107}

		BMI 25	**BMI 25**
Outcome	**Treatment**	**(N=NR)**	**(N=NR)**
MENQOL psychological score (difference in changes from placebo)	Chinese medicinal herbs	-0.17 (95% CI: -1.01 to 0.68)	0.13 (95% CI: -0.68 to 0.95)

MENQOL: Menopause-specific Quality of Life; N: number; NR: not reported

Table 24. Psychological outcomes by time since menopause subgroups

Davis, 2001, Australia {Davis, 2001 #107}

		years amenorrhea		**≥ years** amenorrhea	
Outcome	**Treatment**	**(N=NR)**	**Subgroup** N	**(N=NR)**	**Subgroup** N
MENQOL psychological score (difference in changes from placebo)	Chinese medicinal herbs	0.18 (95% CI: -0.81 to 1.2)	NR	-0.08 (95% CI: -0.70 to 0.54)	NR

Strickler, 2000, United States {Strickler, 2000 #111}

		years postmenopause		**years postmenopause**	
Outcome	**Treatment**	**(N=NR)**	**Subgroup** N	**(N=NR)**	**Subgroup** N
WHQ anxiety score (mean change)	Placebo	-0.02	NR	0.06	NR
	0.625mg CEE	-0.01[a]	NR	-0.02[b]	NR

Osmers, 2005, Germany{Osmers, 2005 #211}

		early climacteric women		**late climacteric women**	
Outcome	**Treatment**	**(N=NR)**	**Subgroup** N	**(N=NR)**	**Subgroup** N
MRS - Psyche subscale (Difference in changes from placebo)	40 mg black cohosh (Remifemin)	-0.04 (95% CI: -0.09 to 0.00)[c]	NR	-0.03 (95% CI: -0.06 to 0.00)[d]	NR

Kornstein, 2010, United States{Kornstein, 2010 #658}

		Perimenopausal women		**Postmenopausal women**	

Outcome	Treatment	(N=121)	Subgroup N	(N=251)	Subgroup N
Hamilton depression score (mean change)	Placebo	-7.0 (SD: 0.69)	37	-7.9 (SD: 0.69)	88
	10mg desvenlafaxine	-11.0[e]	84	-11.1[f]	163
	Difference from placebo	-4.1 (95% CI: -6.8 to -1.4)		-3.3 (95% CI: -5.1 to -1.5)	

CEE: conjugated equine estrogens; MENQOL: Menopause-specific Quality of Life; MRS: Menopause Rating Scale; N: number; NR: not reported; WHQ: Womens Health Questionnaire
a Between group p-value at last : 0.11
b Between group p-value at last : 0.24
c Difference in changes from placebo p-value: 0.048
d Difference in changes from placebo p-value: 0.08
e Pre/post p-value: 0.003
f Pre/post p-value<0.001

Table 25. Psychological outcomes by comorbidity subgroups

Rudolph, 2004, Germany{Rudolph, 2004 #62}

			without PMS or PND		with PMS or PND	
Outcome	**Treatment**		**(N=48)**	**Subgroup N**	**(N=17)**	**Subgroup N**
Hamilton depression score (mean)	2mg E2V 2mg dienogest	baseline:	17.9 (SD: 2.5)	48	21.7 (SD: 2.7)	17
		12-week:	11.2 (SD: 5.6)		14.5 (SD: 7.9)	
		last:	9.9 (SD: 6.5)		13.4 (SD: 8.7)[a]	

Strickler, 2000, United States{Strickler, 2000 #111}

		baseline anxiety 3.5		baseline anxiety 3.5	
Outcome	**Treatment**	**(N=NR)**	**Subgroup N**	**(N=NR)**	**Subgroup N**
WHQ anxiety score (mean change)	Placebo	0.19	NR	-0.05	NR
	0.625mg CEE	0.21[b]	NR	-0.15[c]	NR

CEE: conjugated equine estrogens; E2V: estradiol valerate; N: number; PMS: premenstrual syndrome; PND: postnatal depression; SD: standard deviation; WHQ: Women's Health Questionnaire
[a] Between group p-value at last: 0.0918
[b] Between treatment and placebo p-value at last: 0.67
[c] Between treatment and placebo p-value at last: 0.02

Quality of Life

Table 26. Quality of life outcomes for severity of symptom subgroups

Maki, 2007, United States{Maki, 2007 #30}

		asymptomatic		symptomatic	
Outcome	**Treatment**	**(N=81)**	**Subgroup** N	**(N=79)**	**Subgroup** N
GCS total score (mean change)	Placebo	-3.3	45	-3.6	38
	0.625mg CEE + 2.5mg MPA	-1.6	36	-6.4 [a]	41
Utian QOL score (mean change)	Placebo	3.5	45	-0.65	38
	0.625mg CEE + 2.5mg MPA	-1.3	36	5.7 [b]	41

CEE: conjugated equine estrogen; GCS: Greene Climacteric Scale; MPA: medroxyprogesterone acetate; N: number; QOL: quality of life

a Difference between asymptomatic and symptomatic change scores p-value: 0.10

b Difference between asymptomatic and symptomatic change scores p-value: 0.01

Table 27. Quality of life outcomes for time since menopause subgroups

Loh, 2002, Singapore{Loh, 2002 #98}

			years menopause	years menopause
Outcome	**Treatment**		**(N=NR)**	**(N=NR)**
KI total score	1 mg estradiol + 0.5 mg NETA	baseline mean:	12.5 (SD: 7.4)	13.3 (SD: 10.7)
		mean change:	-51.0 (SD: 72.0)	-7.8 (SD: 9.8)
	2 mg estradiol + 1 mg NETA	baseline mean:	15.2 (SD: 12.3)	13.2 (SD: 8.7)
		mean change:	-89.0 (SD: 12.0) [a]	-4.4 (SD: 9.3) [b]

Osmers, 2005, Germany{Osmers, 2005 #211}

			early climacteric women	late climacteric women
Outcome	**Treatment**		**(N=NR)**	**(N=NR)**
MRS total score	black cohosh	difference in changes from placebo:	-0.06 (95% CI:-0.10 to -0.03) [c]	-0.04 (95% CI:-0.07 to -0.02) [d]

CI: confidence interval; KI: Kupperman Index; MRS: Menopausal Rating Scale; N: number; NETA: norethindrone acetate; NR: not reported; SD: standard deviation

[a] Difference between groups p-value: 0.31

[b] Difference between groups p-value: 0.41

[c] Difference from placebo p-value: <0.001

[d] Difference from placebo p-value: 0.002

Sleep Dysfunction

Table 28.Sleep dysfunction outcomes by age subgroups

Rigano, 2001, Italy{Rigano, 2001 #103}

		age 48-50		age 51-53		age 54-56	
Outcome	**Treatment**	**(N=163)**	**Subgroup N**	**(N=113)**	**Subgroup N**	**(N=86)**	**Subgroup N**
No insomnia at 26 weeks [a]	Placebo	29%	75	46%	61	17%	55
	0.05mg estradiol	80%	88	62%	52	100%	31

N: number

[a] Unclear whether 100% of women had insomnia at baseline

Table 29. Sleep dysfunction outcomes by severity of symptoms subgroups

Diem, 2006, United States{Diem, 2006 #48}

			very frequent symptoms at baseline		somewhat frequent symptoms at baseline	
Outcome	**Treatment**		**(N=32)**	**Subgroup N**	**(N=114)**	**Subgroup N**
Self-reported troubled sleeping	Placebo	baseline:	7.2%	15	26.9%	56
		2 year:	6.0%		27.2%	
	0.014mg estradiol	baseline:	8.2%	17	27.9%	58
		2 year:	8.4% [a]		28.4% [a]	

N: number

[a] Difference from placebo p-value: NS

Urogenital Atrophy

Table 30. Urogenital outcomes by severity of symptom subgroups

Diem, 2006, United States{Diem, 2006 #48}

			very frequent symptoms at baseline		somewhat frequent symptoms at baseline	
Outcome	**Treatment**		**(N=55)**	**Subgroup N**	**(N=79)**	**Subgroup N**
Self-reported	Placebo	baseline:	14.9%	31	18.3%	38

vaginal dryness		2-year:	10.9%		18.5%	
	0.014mg estradiol (Menostar)	baseline:	11.5%		19.7%	41
		2-year:	10.6% [a]	24	16.4% [a]	

N: number

[a] Difference from placebo p-value: NS

Table 31. Urogenital outcomes by time since menopause subgroups

Osmers, 2005, Germany{Osmers, 2005 #211}

			early climacteric women	late climacteric women
Outcome	**Treatment**		**(N=NR)**	**(N=NR)**
MRS – atrophy	black cohosh (Remifemin)	difference in changes from placebo:	-0.07 (95% CI: -0.10 to -0.03) [a]	-0.05 (95% CI: -0.08 to -0.02) [b]

CI: confidence interval; MRS: Menopausal Rating Scale; N: number; NR: not reported

[a] Difference from placebo p-value: <0.001

[b] Difference from placebo p-value: 0.001

Appendix X. Completed Clinical Trials from federal registries

The following clinical trials are reported as complete, but no data or related publications could be found.

Trial	Status	Last Updated	Posted Study Results	N	Treatments	Duration	Estimated Study Completion Date
NCT00010712	Completed	8/17/2006	No	-	black cohosh	52 weeks	Jul-05
NCT00775242	Completed	8/21/2009	No	103	estradiol and progesterone injection	26 weeks?	Nov-08
NCT00799734	Completed	7/25/2011	No	108	chinese herbal medicine- Er-xian Decoction placebo	12 weeks	Jun-11
NCT00141570	Completed	1/29/2009	No	350	esterified estrogens and methyltestosterone	12 weeks	-
NCT00195455	Completed	12/17/2007	No	133	trimegestone estradiol	-	Mar-07
NCT00272935	Completed	1/8/2010	No	400	cenestin placebo	12 weeks	May-07
NCT00604825	Completed	10/13/2011	No	359	premarin placebo	12 weeks	Jul-08
NCT00141557	Terminated (lack of enrollment)	4/10/2008	No	133	esterified estrogens and methyltestosterone esterified estrogens	12 weeks	Mar-08
NCT00494208	Completed	5/12/2010	No	270	testosterone	60 weeks	Dec-09
NCT00338312	Completed	3/22/2010	No	610	placebo testosterone	52 weeks	Jul-06
NCT01080300	Completed	11/1/2011	No	600	gabapentin placebo	24 weeks	Sep-11
NCT00511953	Completed	6/6/2011	No	108	gabapentin placebo	13 weeks	Dec-07